2020 DIETARY GUIDELINES ADVISORY COMMITTEE

+ + + + +

PUBLIC MEETING

+ + + + -

WEDNESDAY JULY 10, 2019 DAY 1 OF 2

+ + + + +

The Dietary Guidelines Advisory Committee met in the Jefferson Auditorium, at the headquarters of the U.S. Department of Agriculture, 1400 Independence Avenue, S.W., Washington, D.C., at 9:00 a.m., Barbara Schneeman, Chair, presiding. The meeting allowed for public viewing, both in-person and by Web.

MEMBERS PRESENT

DR. BARBARA SCHNEEMAN, PhD, Chair
DR. RONALD KLEINMAN, MD, Vice Chair
DR. JAMY ARD, MD, Member
DR. REGAN BAILEY, PhD, MPH, RD, Member
DR. LYDIA BAZZANO, MD, PhD, Member
DR. CAROL BOUSHEY, PhD, MPH, RDN, Member
DR. SHARON DONOVAN, PhD, RD, Member
DR. HEATHER LEIDY, PhD, Member
DR. RICHARD MATTES, PhD, MPH, RD, Member
DR. TIMOTHY NAIMI, MD, MPH, Member
DR. RACHEL NOVOTNY, PhD, RDN, LD, Member
DR. JOAN SABATE, MD, DrPH, Member
DR. LINDA SNETSELAAR, PhD, RDN, LD, Member
DR. ELSIE TAVERAS, MD, MPH, RDN, LD, Member

C-O-N-T-E-N-T-S

Call to Order/Opening Remarks Eve Stoody, PhD	4
Chair Remarks/Agenda Barbara Schneeman, PhD	8
Data Analysis and Food Pattern Modeling Regan Bailey, PhD	20
Dietary Patterns Carol Boushey, PhD	60
Frequency of Eating Heather Leidy, PhD	94
Pregnancy and Lactation Subcommittee Sharon Donovan, PhD	140
Birth to 24 Months Subcommittee Elsie Taveras, MD	166
Beverages and Added Sugars Subcommittee Richard Mattes, PhD	210
Dietary Fats and Seafood Subcommittee	
Linda Snetselaar, PhD	243
Committee Discussion	257
Adjourn	276

1	P-R-O-C-E-E-D-I-N-G-S
2	(9:01 a.m.)
3	DR. STOODY: Good morning. I'm Eve
4	Stoody. I'm lead nutritionist of Nutrition
5	Guidance at USDA Center for Nutrition Policy and
6	Promotion and Designated Federal Officer to the
7	2020 Dietary Guidelines Advisory Committee.
8	I want to welcome everyone to the
9	second meeting of the Advisory Committee. We
10	have over 1,000 people who have registered for
11	this meeting with around 300 registered to attend
12	in-person and over 700 online. Thank you for
13	your interest in the dietary guidelines.
14	The meeting will be today from 9:00 to
15	4:30 and tomorrow from 8:30 to 12:30 and Dr.
16	Schneeman will do an overview of the agenda in
17	just a moment.
18	Now a few housekeeping items. For
19	those of you here in-person, you will notice that
20	each of us has a badge and you will need this
21	badge or a USDA badge in order to access the
22	halls of the building. So please keep your badge

visible at all times, and it designates to 1 2 Security that you are part of this group. You'll also notice that some of the badges say 3 4 staff. And if you have any questions, please see 5 a member of the staff. If you'd like any refreshments or lunch, the USDA cafeteria is --6 We're in Wing 5, take a right and it's at Wing 3. 7 8 This is a meeting of the committee and 9 all meetings of the full committee are open to the public. Fifteen of our 20 members are here 10 11 with us today. I do want to welcome in-person, 12 Drs. Donovan and Naimi who were not able to join 13 us for the first public meeting. Drs. Davis, 14 Dewey, Heymsfield, Mayer-Davis, and Stang were not able to join us today, but we do have a 15 16 quorum of members for today's deliberations. 17 Throughout your deliberations, we ask the members 18 to state your name prior to speaking so that 19 everyone can follow the conversation. 20 As a quick reminder, the 2020 Dietary 21 Guidelines Advisory Committee has been established to conduct an independent review of 22

current research on nutrition and health to be 1 2 considered by the Departments of Agriculture and Health and Human Services in the development of 3 the next addition of the Dietary Guidelines. 4 5 Specifically, the charge of the committee as outlined in its charter is to examine the 6 7 evidence on specific topics and questions 8 identified by the Departments. And these topics 9 and questions will be discussed throughout today's presentations. 10

11 The topics and questions were 12 identified by USDA and HHS following a process of 13 federal and public input and prioritized based on 14 four criteria; relevance and importance to developing public health guidance, potential 15 16 federal impact and avoiding duplication. Following its review, the Committee will develop 17 18 a report that outlines its science-based review 19 and recommendations to the Departments. And then 20 they will submit its report to the Secretaries of 21 Agriculture and Health and Human Services for 22 consideration as the Departments develop the next

addition of the Dietary Guidelines.

1

2	The Committee has the very important
3	role of describing the state of current nutrition
4	science. Each addition of the Dietary Guidelines
5	that USDA and HHS develop, in our partnership,
6	builds upon the previous addition with scientific
7	justification for changes informed by the
8	Committee's scientific report, along with input
9	from the public and federal agencies.
10	To give you a sense for where we are
11	in the process, this is the second of five
12	meetings of the Advisory Committee. The last
13	Committee meeting will be in March of next year.
14	And the Departments request the Committee's
15	report by May of 2020. And this is so that USDA
16	and HHS can meet our mandate to release the next
17	addition of the Dietary Guidelines within five
18	years, which means we need to release it by
19	December of 2020.
20	As you can see on this slide, there
21	are multiple opportunities for public input in
22	this process, including comments on the topics

and questions the committee is addressing. 1 Α 2 public call for nominations for committee membership, public comments throughout the 3 committee's deliberations, which is ongoing now. 4 And in spring of 2020, a call for comments on the 5 Committee's final scientific report once they 6 submit it to the Secretaries of USDA and HHS. 7 If you haven't done so already, please 8 9 save the dates for the remaining public meetings. During this meeting -- actually tomorrow and 10 during Meeting 4, there will be opportunity for 11 12 oral comments to the Committee from the public. Meeting 4 will be held outside of Washington D.C. 13 14 in Houston, Texas. And registration for each meeting will be announced about one month prior 15 16 to the meeting date at DietaryGuidelines.gov and 17 through our Listserv. So please do sign up for 18 our Listserv updates at DietaryGuidelines.gov if 19 you haven't already done so. 20 More information on the Committee, 21 including the protocols they will be discussing

today can be found at DietaryGuidelines.gov under

(202) 234-4433

22

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

Work Under Way. And we encourage you to follow along.

So with that, I'm now going to turn 3 4 the meeting over to the Committee, which is 5 chaired by Dr. Barbara Schneeman. Dr. Schneeman. CHAIR SCHNEEMAN: 6 Great. Thank you, 7 Eve. So my understanding is they will adjust the 8 microphones to make sure it's heard. So let me 9 know if there's a problem. So first of all, let me add my welcome 10 to that from USDA and HHS to the committee 11 12 It's great to see you all in-person members. 13 again. And also to the public who are either 14 here at USDA in the auditorium or watching 15 online. 16 My remarks -- this brief opening is 17 intended to review the agenda for today and 18 tomorrow so that we can focus -- I can focus then 19 on what we hope to achieve in this second public 20 meeting. And part of our goal then is to share 21 within the Committee, the tremendous amount of

22

1

2

Neal R. Gross and Co., Inc. Washington DC

work that has been done by the subcommittee since

(202) 234-4433

www.nealrgross.com

our first meeting. Most of today's meeting will 1 2 be reports of the work done by the subcommittees and then discussion by the full Committee. 3 So in the next several slides, I'll 4 5 provide you an orientation to the subcommittee presentations, defining key terms and elements of 6 7 the protocols, and describing the standard NESR criteria that apply across the various protocols. 8 9 So since Meeting 1, the subcommittees have met by teleconference frequently. 10 I think you were all promised a significant amount of 11 12 work at the first meeting and I think we've followed through on that and it won't change. 13 And so each Committee then has 14 discussed the specific questions that it will 15 16 address. They've received some additional 17 training on the approaches to examine the 18 evidence. And they've identified the order in 19 which they will develop their protocols for the 20 specific topics. And then they've actually 21 drafted protocols for some or all of its questions. And those are the ones that will be 22

brought to the full committee for discussion today.

3	So these are the subcommittee topic
4	areas. And I realize you probably can't read
5	that very well. But just to remind you, the
6	topic areas for the subcommittees are: dietary
7	patterns, pregnancy and lactation, birth to 24
8	months, beverages and added sugars, dietary fats
9	and seafood, and frequency of eating. And then
10	there's one cross-cutting working group on the
11	data analysis and food pattern modeling. And
12	that cuts across all of them.
13	So this gives you the subcommittee
14	members, but you'll get more details on that with
15	each subcommittee presentation. And also there
16	will be information on the USDA and HHS staff
17	that has supported the work of the Committee and
18	really helped the subcommittees make a tremendous
19	amount of progress since our first meeting.
20	So just as another reminder of the way
21	that the committee the Advisory Committee is
22	structuring its work. It's using one of three

Neal R. Gross and Co., Inc. Washington DC

1

2

www.nealrgross.com

approaches to examine the evidence; data 1 2 analysis, food pattern modeling, and the NESR systematic reviews. And those reviews are either 3 original reviews conducted by the Committee or 4 5 using and/or updating existing NESR systematic And again, for everything, there's 6 reviews. 7 always additional information at DietaryGuidelines.gov. 8

9 So for each approach that's used, there's a protocol that details how the 10 methodology is being applied to a specific 11 12 question. So the protocols then are a plan for 13 how one of the scientific approaches will be used 14 and there's a protocol for each question. And those protocols are created before the Committee 15 16 looks at the evidence. Again, to be objective in 17 how we approach each of the scientific questions. 18 Those protocols are posted online for the public 19 to view and better understand the approach that 20 the Committee is using. At this point, for this 21 meeting, we have 40 protocols that have been 22 drafted by the subcommittees for discussion

across the full committee today.

1

2	So to look at the components then of
3	the protocols, this just reminds you of the
4	various pieces of the protocol. There's an
5	analytic framework, inclusion/exclusion criteria,
6	the search strategy, and then the flow chart for
7	the literature search and screening. The
8	included articles/excluded articles with their
9	rationale.
10	So in our discussion of the
11	subcommittees today, we're really going to be
12	looking at the analytical framework and the
13	inclusion and exclusion criteria. With the goal
14	that we're trying to finalize these protocols so
15	that they can be implemented. And as they are
16	implemented, the protocols on-line will be
17	updated with the additional information.
18	So just then to look at those
19	components, the analytical framework defines the
20	core elements of the diet and health relationship
21	that's being examined. And it then serves as the
22	foundation for the rest of the systematic review

It informs the inclusion/exclusion process. criteria and the literature search. It directs the data extraction and risk of bias assessment. 4 And guides the strategy for synthesizing the evidence that the Committee will do in grading the conclusion.

7 So this next slide gives a template 8 that the committee members should be quite 9 familiar with by now. And you will see many more of them today. And just you'll see this template 10 11 over and over again. And it gives the key 12 components of the analytical framework. The 13 intervention or exposure and the comparator 14 that's being used. And the population of interest for the specific question that's being 15 16 examined. And it then has either and/or 17 intermediate outcomes or health outcomes, 18 depending on the nature of the question. And it 19 also then includes key factors that could impact the relationship; co-founders and other 20 21 covariates or other moderators.

22

(202) 234-4433

1

2

3

5

6

These analytical frameworks will also

include any key terms that need to be defined for 1 2 the specific question. And the subcommittees have really worked to try to make sure we have 3 some consistent terminology where appropriate. 4 5 But then of course each analytical framework has been tailored. And so I'm trying to cover the 6 7 general pieces so that the subcommittees can then 8 focus on how they've tailored the analytical 9 framework for their work.

So looking then at the inclusion and 10 exclusion criteria, these again are established 11 up-front so that they can be objective, 12 13 consistent, and transparent in identifying the articles that will be included in each review. 14 They're also looked at to make sure that they're 15 16 relevant for U.S. Federal policy, and standard criteria for the inclusion and exclusion criteria 17 18 are applied wherever possible.

However, some criteria do need to be
tailored to the specific review. And this just
gives some examples. Diet-related intervention,
exposures of interest, health outcome, endpoints

and/or intermediate outcomes, the dates of 1 2 publication, size of the study groups, study duration, age of the study participants. 3 Those are examples of things that might need to be 4 tailored to a specific protocol. 5 So then this slide is a reminder that 6 7 these are generally items that can be 8 standardized across the protocol. So in terms of 9 the study design, the kinds of studies that have been included in the -- will be included in the 10 11 systematic reviews and the types of studies that 12 will be excluded from the systematic reviews. 13 The focus is on peer-reviewed 14 publications, publications that are published in 15 English. And in terms of countries, we're 16 looking at very high or high human development. 17 So it's comparable to the U.S. population. And 18 obviously we're focused on studies that have been 19 conducted in humans. So the types of things that 20 dictate what studies get included. 21 Now where there might be more 22 tailoring within a particular protocol, looks at

the health status of study participants. 1 And 2 part of this is guided by the overall purpose of the Dietary Guidelines, which is to provide 3 recommendations about reducing risk for chronic 4 5 disease and promoting health in the general population. And we recognize that sometimes that 6 7 means including individuals who are at risk, but 8 these are not about management of disease or 9 treatment of disease.

10 So included are participants who are healthy, but it may include some subjects who are 11 12 at risk or might have been diagnosed with a 13 particular outcome. But it would exclude any 14 studies where the exclusive focus of the study was treatment or management of individuals who've 15 16 already been diagnosed or who have already been 17 designated as having the outcome of interest. 18 And we'll see that applied as appropriate across 19 the various protocols.

Likewise with infants, the focus is on full-term. But it can include some infants who are low birth weight, small for gestational age.

But it would exclude studies where that was the exclusive focus of the particular study. And again, we'll hear more detail on that as we go into individual protocols.

So of the protocols that we're going 5 to talk about today, 35 out of the 40 will be 6 7 focused on the systematic review protocols. So 8 that's the bulk of what we'll be hearing. But we 9 have five questions that will use the data analysis framework. And again, just like with 10 11 the systematic reviews, the data analysis also 12 develops a protocol for each of its questions.

And so the framework describes the 13 14 overall scope of the question, the plan details the data, and the subsequent analyses that are 15 16 included, and the analytical results. And so 17 today, our focus will be on the framework and on 18 the plan for those five questions. And again, as 19 the protocols are implemented, they will be 20 updated on the website.

21 So in today's agenda then, we'll be 22 going through the subcommittee presentations.

1

2

3

And we've allocated 45 minutes for each of the 1 2 subcommittees with the idea that we'll have a presentation from the subcommittee chair. 3 But then also have time for discussion amongst the 4 Committee to raise comments and ask questions. 5 And the order of the presentations will be the 6 7 Data Analysis and Food Pattern Modeling, the Dietary Patterns Subcommittee, the Frequency of 8 9 Eating, Pregnancy and Lactation, Birth to 24 Months, Beverages and Added Sugars, Dietary Fats 10 11 and Seafood. And this is the order that we've 12 projected. We've given you a tentative agenda. 13 However, the specific times may vary and be 14 subject to change based on the nature of the work and the discussion that we need to go through. 15 16 Oh and I should comment as well that 17 the Committee has the protocols in their 18 notebook, so you have the reference material in 19 front of you. But all of the protocols are 20 available online. So if anyone needs further 21 information, you can get that online. So each subcommittee will review its 22

It's going to describe the order its 1 work. 2 developing its protocols. Which questions it's dealing with now. Which questions it's left for 3 It will review the protocols themselves 4 future. 5 and how they've been tailored to address the question and address the topic that's been given 6 to it. And outline its next steps. And we're 7 8 asking that you keep the remarks at a high level, 9 so that there is time for discussion within the committee for the protocols. And again, you all 10 11 have them in your binders. 12 So just to remind you then for tomorrow's agenda, the focus will be on comments 13 14 from the public to the Advisory Committee. At 15 this point, since March, we've received 7,000 16 comments. And the public may have comments 17 specific to the 40 protocols that we are 18 discussing today. And we would encourage you to 19 submit those comments by Wednesday, July 24th. 20 Because part of the goal is to be able to start 21 implementing these protocols, so that the committee can complete its work in the time frame 22

2	But as a general observation, the
3	public comment period is open throughout the
4	Committee's work. So specific to the protocols,
5	it's helpful to get them sooner, rather than
6	later. But it's always open for comment.
7	So with that, let me just ask the
8	Committee, does anyone have a question or you
9	want to make another observation? Anything I
10	missed about where we need to go? Okay, they're
11	ready. Yes, so our first report then will be Dr.
12	Regan Bailey who is reporting for the cross-
13	cutting working group, the Data Analysis and Food
14	Pattern Modeling.
15	MEMBER BAILEY: Good morning,
16	everyone. So I'm here representing Working Group
17	7, which is comprised of the Jamie's; Dr. Jamy
18	Ard and Jamie Stang, Dr. Teresa Davis, Dr. Tim
19	Naimi, Dr. Schneeman, and supported by Dr.
20	Pannucci at the USDA.
21	Today we'll be describing the first
22	five questions that we will be tackling in order

of protocol development. And I'm not going to
 read them here at this point because we'll have a
 slide devoted to each question. The remaining
 questions that we have to address include
 beverages, added sugars, frequency of eating, and
 how those relate to achieving nutrient and food
 group intake recommendations.

We also have questions to answer 8 9 regarding food pattern modeling. So are changes to the food patterns needed based on the 10 relationships identified in your committee work 11 12 and the systematic reviews? Can food patterns 13 for those under two years of age be established? 14 And finally, food pattern modeling questions related to nutrient adequacy, the use of dietary 15 16 supplements and fortified foods, as well as added 17 sugars.

Before we begin, just a few key definitions. We'll be using the phrase, stage of life. And for data analysis and food pattern modeling, this can mean different things. The age groups for the definition of a stage of life

can differ based on the NHANES sampling weights 1 2 or by the dietary reference intakes. So the age groups are not perfectly aligned in all cases. 3 4 The term, socioeconomic status is a 5 broad term that we use to include income in dollars, poverty to income ratio, food security, 6 7 federal food assistance programs, and level of 8 education. 9 And finally, a RACC. This is the reference amount customarily consumed in one 10 occasion as determined by the FDA. And this is 11 represented on the nutrition facts label. 12 13 So our analytic framework, our 14 population is the U.S. population. So we'll be working with nationally representative survey 15 You'll see here in the blue boxes what 16 data. 17 we'll be talking about today as the B24 protocols 18 and analytic frameworks are still under 19 discussion. Broadly, children and adolescents 20 are defined 2 to 19. Adults 20 to 64. Older 21 adults 65 and older. And pregnant and lactating 22 women.

I'll use the term demographic 1 2 subgroups quite a bit to represent that we will have the data stratified by sex, by race, 3 4 ethnicity, socioeconomic status, and food 5 security status. The data sources that we have 6 7 available are What We Eat in America survey 8 component of the NHANES. This data can be 9 analyzed to get nutrient data on foods and beverages with the FNDDS. As Dr. Pannucci 10 11 described at our first meeting, we also have 12 what's called the FPED. This gives us data on 13 food groups and subgroups. As well as we have 14 the What We Eat in America food categories. So 15 these are foods as they are consumed, as well as 16 information on nutrient intakes from dietary 17 supplements, inclusive of antacids containing

19 So the first question is to describe 20 and evaluate current intakes of food groups and 21 nutrients. We'll be doing this looking at the 22 mean intakes of foods and subgroups, the usual

calcium or magnesium.

Neal R. Gross and Co., Inc. Washington DC

intake distributions, food category sources, food
 group intakes compared to existing
 recommendations and changes over time. And I'll
 be a little bit more granular on the upcoming
 slides.

In terms of looking at nutrient 6 7 intakes, we are first looking at nutrients from 8 foods and beverages alone. The most recent 9 iteration of the NHANES data, right now the dietary supplement data is not available. And so 10 11 we're starting with foods and beverages alone to 12 assess mean and usual intake distributions. We 13 will compare those usual intake distributions to 14 the dietary reference intakes. And we'll talk about that a little bit more in detail in 15 16 Question 3. Food category sources of these nutrients. And then changes that occur over 17 18 time.

19 Very similar for food groups. We're
20 looking at population averages. This is from
21 NHANES 2015/16. And in general, when we look at
22 the average or the mean intakes, we'll be looking

at 2015/'16. When we're looking at the 1 2 population distribution, we have four years of data from 2013 to 2016. So again, as I 3 4 mentioned, the percent meeting food group 5 recommendations and changes over time. And so for food group intakes, you'll see that here with 6 7 the What We Eat in America food group categories. 8 Similarly for nutrient intakes, we'll 9 have the population average. We'll have the usual intake distributions inclusive of foods and 10 11 beverages and total with dietary supplements. 12 Changes in intake of nutrients over time comparing 2009/'10 to '15/'16. And then food 13 14 category sources of those nutrients. The second question is to describe and 15 16 evaluate the prevalence of nutrition-related Right now, these are 17 chronic health conditions. 18 the nutrition-related chronic health conditions 19 under consideration. And I will not read these 20 as I again, will go through each of these in a 21 little bit more detail in upcoming slides. 22 The data sources that we have

Again, we have the NHANES data that 1 available. 2 includes the dietary data, laboratory, physical exam data. We also have the National Health 3 4 Interview Survey or NHIS. This is from 2017. We 5 have data from the National Vital Statistics System in 2017. We have the PRAMS data, the 6 7 Pregnancy Risk Assessment Monitoring System. As 8 well as the SEER data, which is a wonderful 9 repository of information on cancer registry statistics in the U.S. And this is from 2016. 10 11 In terms of the B to 24 group, we'll 12 be looking at the prevalence of low and high weight for length, length for age, and weight for 13 This will come from the NHANES data. We'll 14 age. also be characterizing the prevalence of low 15 16 birth weight among U.S. infants by race, 17 ethnicity, and the age of the mothers using the 18 National Vital Statistics. We have data 19 available from NHIS on children birth to four 20 years of age on the prevalence of food allergy. 21 Looking at children 2 to 19, we're interested in characterizing the prevalence of 22

underweight, overweight, obesity, and severe 1 2 obesity using the most recent NHANES data. As well as differences in the obesity prevalence by 3 those demographic characteristics that I 4 mentioned earlier; those four components. 5 And the degree of urbanization. We'll also be 6 7 looking at changes in obesity and severe obesity between 2007/'08 and 2015/'16. 8

9 For cardiovascular intermediate outcomes among children, we have the prevalence 10 of hypertension, high LDL, and low HDL by the 11 12 demographic subgroups, as well as by BMI status 13 from 2013 to 2016. For children, we have data on 14 leukemia from SEER. And from NHANES, we have data on pre-diabetes and type 2 diabetes from the 15 16 most recent survey cycles of NHANES.

For adults similar to children, we're interested in characterizing the prevalence of underweight, overweight, obesity, and severe obesity from NHANES. As well as waist circumference and waist circumference risk. And then examining obesity by the demographic

1

characteristics and level of urbanization.

2 In adults, we have data from NHANES on high triglycerides, high total cholesterol, low 3 LDL, high LDL, and the prevalence of 4 hypertension. So all of that data comes from the 5 physical exam in NHANES. From the National 6 Health Interview Survey, we also have the age-7 8 adjusted prevalence of hypertension, coronary 9 heart disease, and prevalence of stroke. For the Type 2 diabetes and pre-10 11 diabetes, we will be able to have this 12 information from 2013 through 2016 for adults. 13 We'll also have the prevalence of metabolic 14 syndrome. So we have the prevalence of each of 15 the five individual risk factors for metabolic 16 syndrome. But we will also have the 17 characteristic of metabolic syndrome based on 18 those five risk factors. 19 We have data on chronic liver disease 20 outcomes from NHIS 2017. We have age-adjusted 21 chronic liver disease and cirrhosis from the 22 National Vital Statistics System. As well as

> Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

1	high ALT and AST from NHANES 2013 to 2016.
2	We've talked as a committee about how
3	to use the ALT and AST with regards to data on
4	alcohol consumption. So we're exploring options
5	about characterizing high liver enzymes relative
6	to alcohol intake. So that's a little bit more
7	that we'll have to discuss with what data are
8	available and sample sizes.
9	These ten cancers are available to the
10	committee through the SEER 2016 data. And we'll
11	have information that is age-adjusted and sex
12	specific, both incidence and mortality.
13	For pregnant women, we'll have the
14	prevalence of gestational diabetes from the Vital
15	Statistics System, as well as the PRAMS data. We
16	will have information on pregnancy-induced
17	hypertension.
18	For older adults, we have information
19	on low bone mass and osteoporosis. This is at
20	the femoral neck and lumbar spine. As well as
21	the prevalence of reduced muscle strength. And
22	you'll see that all of these years don't

perfectly overlap. That's because NHANES doesn't collect the same information every year on every topic. So there's exceptions noted in the years throughout.

5 The third question is to describe and 6 evaluate the nutrients of public health concern. 7 There are no set definitions of what a nutrient 8 of public health concern is. In the National 9 Academy of Science's report and this working 10 group members agree that we should take what is 11 being called a three pronged approach.

12 So we'll look at the prevalence of 13 inadequate and excessive nutrient intakes 14 comparing current distributions to the dietary reference intakes. When available, we'll 15 16 consider biological endpoints or validated 17 surrogate endpoints such as biochemical indices 18 of a nutrient status with validated cut-points, 19 in addition to the dietary intake of nutrients. 20 And finally, we would consider the scientific 21 evidence on the relationship between nutrient 22 inadequacy and excess on clinical health

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

consequences.

1

2 A few more definitions. The dietary reference intakes as I'm sure you all know, 3 represent a set of reference values that are 4 5 established by the National Academies. We have 6 an acceptable -- I am so used to using the 7 acronym, so it's hard for me to actually say 8 these words. So it will be a little bit of an 9 alphabet soup. The AMDR, this is a recommended percent energy intake for macronutrients. 10 And so 11 we'll look below that and above that recommended 12 range, so AMDR.

13 The estimated average requirement or 14 EAR is what we use to estimate at the population 15 level, the risk of dietary inadequacy. When we don't have scientific data that is compelling 16 17 enough to establish an EAR, we have what is 18 called an adequate intake or an AI. And this is 19 the level that is assumed to ensure nutritional 20 adequacy. So in the absence of nutrients with an 21 EAR, we have only an adequate intake. And then we have the other end of the spectrum or the UL. 22

So this is the maximum daily amount that is 1 2 unlikely to cause adverse health consequences. With the release of the new report on 3 4 sodium and potassium, we have another term to 5 include in the DRIs. This is called the Chronic This is the lowest level Disease Risk Reduction. 6 of intake for which sufficient strength of 7 8 evidence exists to characterize a chronic disease 9 risk reduction. So right now, the CDRR is only available for sodium. That's just the most 10 recently updated sodium and potassium nutrients. 11 12 And then finally the term, nutrients 13 of public health concern. As I mentioned, this 14 has been a phrase that is used throughout the guidelines to represent a nutrient that is either 15 16 under-consumed or over-consumed relative to the DRI and linked in the literature with adverse 17 18 health outcomes in a general population or in a 19 population subgroup. 20 Here is the framework. Very similar 21 to some of the previous questions. We'll have

22

(202) 234-4433

Neal R. Gross and Co., Inc. Washington DC

nutrient intakes from total and from foods and

www.nealrgross.com

beverages alone. For nutrients with an EAR, 1 2 we'll use the cut-point method. There are some assumptions to the cut-point method that the 3 4 distributions of requirements are symmetrical. 5 That assumption is violated for menstruating women for the nutrient of iron. So the full 6 7 probability approach will be used for iron. 8 Again, comparing nutrients without an 9 EAR, we will look at those relative to the adequate intake. We will examine prevalence of 10 11 the population that exceeds the UL or the CDRR, 12 as well as people who are the prevalence inside or outside the AMDR. For added sugars and 13 14 saturated fat, we will use the 2015/2020 quidelines recommendations for less than 10 15 16 percent of total energy intake. 17 In terms of the data sources for the 18 other parameters, we have -- and I'll explain in 19 the next couple of slides -- laboratory data and exam data from NHANES, the nutrient intakes as I 20 21 described from What We Eat in America, and clinical health consequences that will be either 22

evidence from the systematic reviews that you are 1 2 all working on, as well as results from nutrition-related chronic health conditions. 3 So the analytic plan for ages 1 and 4 5 older, again looking at the usual intake distribution from foods and beverages and from 6 7 total inclusive of dietary supplements. In terms 8 of the biomarkers of nutrient status in children, 9 we would prefer to use the most recent survey But you'll see here there are exceptions 10 vears. 11 noted, both in what years that the samples are 12 collected and in what survey waves. So we have ferritin and transferrin. 13 14 We have low red blood cell folate, low serum folate, low serum copper, low serum zinc, and low 15 16 25 hydroxy Vitamin D. You'll see the survey 17 years associated unless otherwise noted. For 18 children 6 to 19 years from 2003 through 2006, we 19 have Vitamin A and carotenoids, Vitamin C, 20 Vitamin E, B12, and B6. 21 Very similar in adults, we have data on transferrin and ferritin. This is in women 22

1	who are to 20 to 49. We have low folate, both in
2	terms of serum and red blood cell. We have data
3	on unmetabolized folic acid in adults, copper,
4	zinc, Vitamin D. In addition to serum, B12, we
5	have elevated methylmalonic acid in 2013/'14.
6	And among pregnant women, we have the medium
7	urinary iodine concentration. Again, at the
8	bottom of this slide are the data on Vitamin A,
9	carotenoid CE, and B6.
10	So in terms of the next question which
11	is to describe and evaluate the current dietary
12	patterns on beverage consumption, this is really
13	going to be limited to data on the Healthy Eating
14	Index, both means and the component scores, as
15	well as food category contributions to total
16	intake. And this is a noted limitation. So we
17	don't have data on self-selected dietary
18	patterns. For example, are you a vegetarian? Do
19	you follow a specific dietary pattern? We really
20	have the Healthy Eating Index 2015 as how we will
21	evaluate dietary patterns based on the
22	availability of data.

1	In terms of beverage consumption,
2	we'll look at the types of beverages being
3	consumed, the percent consuming on a given day,
4	the volume variations in beverage consumption.
5	And then how those beverage types contribute to
6	energy, macronutrients, micronutrients, as well
7	as added sugar.
8	So a beverage pattern here can be
9	defined as the quantities, proportions,
10	varieties, and combinations of different
11	beverages in the diet. The definitions that are
12	being used are discrete beverage categories. So
13	that has been described to us as doing something
14	on purpose. Right? So these definitions are in
15	your binder. They're on the website. So I'm not
16	going to read those. But they include milk, 100
17	percent fruit juice, coffee, tea, diet beverages.
18	So diet beverages, this is where that
19	RACC definition comes into play. So a diet
20	beverages contains 40 calories or less per RACC.
21	So sweetened beverages on the other hand contain
22	more than 40 calories per RACC. And include
things like soft drinks, fruit drinks, and sports and energy drinks. Water in any type; tap, bottled, carbonated, enhanced, as long as it has less than 5 kcal per RACC, it is considered by definition to be water. And then alcoholic beverages inclusive of beer, wine, liquor, et cetera.

8 In terms of dietary patterns, as I 9 mentioned, we'll have the average HEI scores. 10 We'll have the distribution of HEI scores. We'll 11 be able to look at the population average change 12 in scores between 2003 and '04 and 2015/'16 and 13 the food category sources that contribute to 14 total energy intakes.

For beverages for two and older, we 15 16 have the percent who consumed. We have data on 17 sweetened beverage consumption, mean daily 18 beverage intake, and the percent mean energy of 19 selected nutrients. So the Federal Data Analysis 20 team has prepared data already, specifically on 21 carbohydrates, added sugars, protein, Vitamin C 22 and D, calcium, potassium, magnesium, phosphorus,

1

2

3

4

5

6

7

ĺ	
1	and caffeine. And once we identify the nutrients
2	of public health concern, we will also add those
3	to this list.
4	And then finally, the percent of daily beverage
5	calories consumed by those discrete types.
6	And I think this is our last question.
7	The question is how does dietary intake,
8	particularly dietary patterns track across life
9	changes from the introduction of foods, into
10	childhood through older adulthood. And it should
11	be noted that because we have the NHANES data to
12	address this question, it's not longitudinal. So
13	we don't have information on the same people and
14	how they're individual patterns change over time.
15	We can just look at life stages in certain years.
16	So that's a little bit of a limitation to
17	specifically address this question. The
18	introduction of foods is defined here. Any foods
19	that are complementary foods and beverages other
20	than human milk or infant formula.
21	On this slide, we have the analytical
22	framework. So we'll look at differences in food

category sources of nutrients across the 1 2 different life stages. Differences in mean food group intake. So for two and older, the percent 3 4 of each age group who meets the existing food 5 recommendations. And then differences in beverage categories and how they contribute to 6 7 energy and nutrient intakes across different life 8 stages.

9 Differences in food category contributions to energy intake across different 10 11 So for infants and toddlers life stages. 12 receiving human milk, energy intake will be limited to those complementary foods, not 13 inclusive of human milk or infant formula. 14 And 15 for two and older, food category contributions to 16 energy intake will also be assessed. We'll also 17 be able to compare differences in HEI 2015 for 18 those two and older. So you'll recall that 19 before this committee's work, there were no dietary guidelines for B to 24. So we don't have 20 21 a Healthy Eating Index to compare them to at 22 present.

1	Here's the analytic plan. Very
2	similar to the things that I mentioned before.
3	We have the food category sources. We have
4	population average intakes of food groups and
5	food subgroups. The percent of the population
6	that are meeting these recommendations, as well
7	as daily energy and nutrient intakes from
8	beverages across different life stages with the
9	same nutrients listed here as on the previous
10	slide. We also have the food category sources to
11	energy across different life stages. As well as
12	population average and component scores across
13	life stages.

So our next steps after we discuss 14 15 these five protocols will be to really have some 16 cross-cutting discussion with the B24 subgroup so 17 that we are all aligned on how the data and food 18 pattern modeling can best support the work of 19 your committee. We'll have cross-cutting 20 discussions with Beverages and Added Sugars on 21 the protocols specifically related to those 22 topics. We'll draft protocols for the frequency

of eating of course in conjunction with that 1 2 subgroup. And the plan is to have the information on nutrient intakes from dietary 3 4 supplements this fall so that we can compare how 5 foods and beverages relate to total intakes. And so how much is being contributed by dietary 6 7 supplements to answer some of those questions. 8 So our plan right now is to review the data 9 analysis results and then draft conclusion 10 statements.

11 So here are the members again of the 12 committee, as well as the support staff. And a 13 special thanks to the federal family that are the 14 Data Analysis Team who has already prepared a lot 15 of data for us. And will continue to develop the 16 data as we are requesting them. So thank you 17 very much.

Questions? I know that was a lot.
That was a lot for me and I'm a talker.
VICE CHAIR KLEINMAN: So Regan, one of
the questions that you brought up are the age
groupings because those are certainly going to

affect a lot of what the other committees are 1 2 talking about on many of the outcomes very, very, very dramatically between different age 3 4 categories. And some of them require a much 5 finer categorization of age then let's say DRI is much more specific than NHANES. 6 NHANES. So can you just elaborate a little bit more for 7 8 other members of the committee on how you're 9 thinking about that? 10 MEMBER BAILEY: So some of the

11 analysis has already been conducted. So we have 12 some that does have larger age groups; sometimes 13 two to 18 for example. We have the ability to 14 request data on smaller subgroups. And there are a lot of federal reports that already exist with 15 16 smaller subgroups. So I think we'll try to 17 cobble together some of what we have and what we 18 need, to get at what you're talking about. But I 19 think especially in terms of a B to 24 subgroup, 20 the changes that occur in eating are so dynamic 21 at that time that we'll have to probably have 22 smaller age groupings than maybe even the DRI.

1	VICE CHAIR KLEINMAN: But even
2	thinking about age 20 to age 60 so 65 and
3	older, okay?
4	MEMBER BAILEY: Yes.
5	VICE CHAIR KLEINMAN: But there's a
6	lot of difference there too.
7	MEMBER BAILEY: Yes.
8	VICE CHAIR KLEINMAN: I mean I think
9	we're just going to end up with a hell of a lot
10	of data and a lot of analyses specific
11	analyses. But I guess there's no other way to
12	think about it.
13	MEMBER BAILEY: Yes, I think so. And
14	I think that's something that we can put in our
15	recommendations that the federal government try
16	to align in terms of life stages. But in terms
17	of the work of the committee, I think we kind of
18	have our hands tied as to what's available and
19	what we can request. Even the term older adult,
20	is it 60? Is it 65? Is it 71+? A very hard
21	question to grapple with.
22	We won't comment on our specific ages,

but yes I --

1

2	VICE CHAIR KLEINMAN: It's like my
3	definition of a I'm a pediatrician. My
4	definition of a pediatric patient is anybody
5	who's younger or shorter than I am.
6	MEMBER BAILEY: Yes. Well even
7	including 18 year olds and 19 year olds and using
8	the term children is something that I think we
9	all agree, a 2-year-old is very different than a
10	19-year-old. Although they both have a lot of
11	emotional needs and issues. In terms of their
12	nutrition, yes, very different.
13	CHAIR SCHNEEMAN: And just be sure and
14	say your name for the transcript.
15	MEMBER TAVERAS: Elsie Taveras. I have
16	two questions. One, in the analytic plan for
17	adults 20 years and older, there's an examination
18	of chronic liver disease outcomes. Particularly
19	I was thinking of prevalence of high ALT and AST.
20	So is that not available for populations under
21	20? I'm wondering why that's not an outcome in
22	the pediatric

1	MEMBER BAILEY: Yes, I don't think we
2	considered it. It's certainly something that we
3	can look into. And that's why we have these
4	discussions. Because we were thinking about
5	fatty liver in terms of adults. But I think
6	that's a very salient point that if the data are
7	available in children, we should examine those as
8	well.
9	MEMBER TAVERAS: Yes. No, having seen
10	even 8 year olds with very high ALT and AST, I
11	would recommend that we try if the data's
12	available
13	(Simultaneous speaking.)
14	MEMBER BAILEY: Yes, if it's
15	available, we'll certainly add that.
16	MEMBER TAVERAS: to populations
17	under 20. And then the other question I had was
18	about the data sources. So do we not have any
19	data available from PedNSS or WIC, the
20	supplemental nutrition program for Women,
21	Infants, and Children? Because there's
22	surveillance data that they have on prevalence of

overweight and obesity among women -- among 1 2 pregnant lactating women and infants under five, I think. 3 4 MEMBER BAILEY: Okay, we can look into 5 that for sure. We've kind of thought mainly right now about the data that we've described to 6 7 But there are other federal resources that you. 8 can be utilized. 9 MEMBER TAVERAS: And my last question, 10 sweetened beverages, are we including flavored 11 milk in that definition? I see soft drinks, 12 fruit drinks and sport drinks. But I just want 13 to make sure that --14 MEMBER BAILEY: I'm going to punt that 15 one to Dr. Pannucci. But I think that the way 16 that the discrete beverage categories are 17 currently consumed is that it's milk as the base. 18 And that is not part of the sweetened beverage 19 category. But I would --20 CHAIR SCHNEEMAN: I'm just looking at 21 the slide on Page 19. 22 MEMBER BAILEY: Yes, I don't have the

1	slide in front of me.
2	CHAIR SCHNEEMAN: And milk says plain
3	and flavored milk, other milk dairy drinks, and
4	milk substitutes.
5	Yes please, Rachel.
6	MEMBER NOVOTNY: Rachel Novotny. I am
7	interested and this is perhaps a B24 question.
8	I know you said you're going to work with them.
9	But on the analytic plan for one and above, the
10	usual intake distributions that exclude infants
11	receiving human milk I guess I'm
12	MEMBER BAILEY: It's not excluding the
13	infants. It's excluding the data the
14	contributions from the infant formula or from
15	human milk. So it's not excluding the children.
16	It's just excluding those as a source of
17	nutrients.
18	MEMBER NOVOTNY: Yes, I guess but
19	that effectively excludes them. Correct? But
20	infants who would be receiving human milk I
21	guess what I'm getting at is I realize it's
22	difficult to estimate the volume in the milk.

You'd have to make an estimate. But I think the converse is that we end up with an assumption that the diet pattern of one and above excludes human milk.

5 MEMBER BAILEY: Yes and I think that's 6 something that we'll have to discuss as we 7 develop the B24 protocol. This is just kind of a 8 first pass at what we're thinking. I know that 9 the databases that are available to analyze human breast milk is an active area of investigation. 10 11 And you know, that the nutrient composition in 12 terms of fat and nutrients changes quite 13 dramatically. And so I think it's hard to 14 capture that with real accuracy. But I think 15 that's something that the B24 group -- that we'll 16 need to come together with the Data Analysis 17 working group to decide how to handle that 18 specifically. 19 MEMBER NOVOTNY: I would hope maybe we

20 could find a -- I think an estimate would be 21 better than assuming that.

MALE PARTICIPANT: You'll have to talk

Neal R. Gross and Co., Inc. Washington DC

22

1

2

3

4

1 up. 2 MEMBER NOVOTNY: Sorry, I'm thinking that an estimate might be a better norm to set. 3 4 AUDIENCE MEMBER 1: Louder! We can't 5 hear in the back at all. AUDIENCE MEMBER 2: We can't hear in 6 7 the middle either. 8 MEMBER NOVOTNY: Okay. 9 AUDIENCE MEMBER 3: You guys are whispering to yourselves. This is supposed to be 10 a public meeting. 11 12 MEMBER NOVOTNY: Okay, sorry. Okay. 13 So my suggestion is that we see if we can find an 14 estimate so that we can include a pattern of 15 infants who are breast fed in 1+ age group. And 16 it not reflect only those who are not breast-fed. 17 MEMBER BAILEY: And I just said that 18 is an active discussion that the working group on 19 Data Analysis and Food Pattern Modeling would 20 have with the B24 Committee to figure out how we can best estimate nutrient intakes in this 21 22 rapidly growing population changing, not growing.

1 Well they are growing too.

2	We apologize for the microphones. We
3	can hear each other up here, but we didn't
4	realize that we couldn't hear you. So it wasn't
5	intentional by any means.
6	CHAIR SCHNEEMAN: Okay, so we have
7	Rick Mattes and Sharon. Were you going to say
8	something also? Rick and then Sharon.
9	MEMBER MATTES: I'm Rick Mattes. So
10	I'm struck by the overlap or common goals for
11	what you're describing in both the Frequency of
12	Eating and the Beverages and Added Sugars
13	committees. And please take this it's
14	intended to be very constructive, rather than
15	So if we in the end your modeling
16	is going to be based on the large surveys, the
17	epidemiology and so on. The subcommittees the
18	other two subcommittees will be looking at
19	randomized control trials and so on. It won't
20	surprise me that in the end there is some
21	disparity between those the outcomes from the
22	two sources of data. How are we going to deal

Are we going to say -- we came up 1 with that? 2 with different answers based on the data set? Or do we say there is a hierarchy of science here 3 4 and the stronger science -- this is what we're 5 going to base on our recommendations on? If the 6 latter, maybe there's so much redundancy here, we 7 should be thinking about do we really need to do 8 the bazillion analyses you've got proposed there. 9 MEMBER BAILEY: I think what you will 10 identify in your systematic reviews will be 11 complementary to what we're doing. We will 12 identify for example added sugars. You might 13 come to a consensus statement on a recommendation 14 on added sugars. And then we would provide data on the prevalence of intake of sugar-sweetened 15 16 beverages for example. We wouldn't say that, 17 that necessarily is -- you know, trumps what you 18 found. The data are what the data are. And 19 that's this working group kind of just telling 20 you, these are the facts. Not ma'am, but mister. 21 And so I don't think that it's a lot 22 of overlap. You're identifying relationships

with health outcomes. And we are providing
 information on where Americans are at relative to
 those recommendations. So I think it's kind of
 more of a dovetail than overlap. But I'd love to
 hear other people's opinions.

This is Carol MEMBER BOUSHEY: 6 7 Boushey. It's real short. I wanted to reinforce 8 Because this really does help inform or that. 9 find out what might work well when we're looking at these randomized trials. 10 But you'll give us 11 the gauge as to where we can start from; either 12 up or down.

13 MEMBER DONOVAN: Sharon Donovan. So 14 I guess I just want to reiterate what Rachel and Elsie have said in terms of the B24 being a new 15 16 charter. That if we don't consider, you know, human milk and infant formula and also the B24 17 18 Committee is talking about some of these follow-19 on formulas that are actually fed to toddlers. 20 And we anticipate, particularly like iron and 21 other nutrient intakes will be quite different compared to one year olds who move to cow's milk. 22

1	So you know, whether it's trying to
2	get access to other data sets Because
3	otherwise, we're not going to be able to make any
4	sort of recommendations if we're just considering
5	non And you know, not many women not a
6	high percentage of women breast feed for longer
7	than a year, but it is recommended. So our
8	committees can work on that. But I think that we
9	really need to do the due diligence about
10	collecting that data and discussing because
11	with DRIs, we use average intakes and average
12	consumption to at least extrapolate requirements.
13	CHAIR SCHNEEMAN: One thing that I
14	would like to hear some discussion from the
15	committee members, you've presented a way of
16	looking at the nutrients of public health
17	concern. You had a diagram for that looking at
18	three components of nutrients of public health
19	concern. And I'm interested in whether other
20	committee members find that a useful approach for
21	going forward or had some questions or comments
22	about how we might define nutrients of public

health concern. It's on Page 13, if you're
 looking at the slides.

So just a reminder, 3 MEMBER BAILEY: 4 it's looking at those three prongs. One being 5 dietary intakes. Two being biochemical. And 6 three being clinical health consequences. Are 7 there any other ways that we can think about 8 collectively to identify what are nutrients of 9 public health concern? 10 CHAIR SCHNEEMAN: Dr. Ard, you look 11 like you were posed to say something. 12 MEMBER ARD: (No audible comment.) Well I take that to 13 CHAIR SCHNEEMAN: 14 indicate support for the approach that you've 15 proposed. So let me turn the question around. 16 Does anyone see a problem with taking that 17 approach? 18 MEMBER VAN HORN: Linda Van Horn. The 19 only thing I think, hearkening back to the discussion of the last round of the guidelines 20 21 related to dietary cholesterol. There was a

statement related to dietary cholesterol and that

Neal R. Gross and Co., Inc. Washington DC

22

no longer being a nutrient of concern. And there was a tremendous amount of confusion in the public as to what that meant. Everything from woohoo, let's eat eggs to maybe we should, you know, re-think what the role of dietary cholesterol is.

7 So my only point is that while I think 8 the definition and the criteria are good, if for 9 whatever reason this group should come up with another decision of that sort, I think we have to 10 11 be very explicit as to what that means and why 12 that was decided upon. So that we can establish, 13 you know, quite universally what is meant by that 14 decision.

15 CHAIR SCHNEEMAN: It sounds like
16 you're making sure we recognize all three
17 components. That it's not just one or the other,
18 but all three components. Great, thank you.
19 That's helpful.

20 MEMBER BOUSHEY: Linda, your comment 21 made me realize, the reality is every nutrient is 22 a public health concern. So we really need to be

1

2

3

4

5

6

careful when we actually label them that way and 1 2 how we write this up. Because we don't want anyone to think that there isn't any nutrient 3 4 that isn't important. 5 MEMBER MATTES: Rick Mattes. So it specifically says nutrients of concern, but there 6 7 are food constituents that are commonly consumed 8 with health implications. Do we want to talk 9 about phytochemicals and so on? MEMBER BAILEY: I think the reason 10 11 that it is labeled a nutrient is because one of 12 the -- we need to have a DRI for it in order to 13 compare it to a reference standard. And we need to have a validated biomarker. And so for a lot 14 of the phytonutrients and things like that, while 15 16 we recognize they exhibit a health effect. We 17 don't necessarily have that type of data that are 18 available to make the statement is my thinking 19 there. Yes, please. 20 CHAIR SCHNEEMAN: 21 MEMBER BAZZANO: Lydia Bazzano. Ι 22 just wanted to point out that the clinical health

consequences there are really the most -- I would say, you know, those are the things that we have to weigh most heavily. Because where we may not have data -- where we do have data, that's what needs to weigh the most heavily. And I understand that there may not be data for everything.

8 I'm being reminded CHAIR SCHNEEMAN: 9 to encourage everyone to be sure you speak up so 10 it's amplified well. Other questions or comments 11 about the presentation on the data analysis? 12 MEMBER NOVOTNY: Rachel Novotny. Ι 13 will speak as loudly as I can. Just raising the 14 question about the nutrients of public health concern makes me wonder whether as we go forward 15 16 or not for now because I think we have our 17 agenda, but whether we actually do want to think 18 about foods or food groups or food patterning of 19 public health concern in the future.

20 MEMBER SABATE: Joan Sabate. That's 21 also my concern. I think going back to these 22 nutrients of intake, biological endpoints, or

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6

7

clinical health outcomes, if we do not have 1 2 guidelines as far as some of the food constituencies, such as phytochemicals and so on 3 and so forth, that means that what you're giving 4 5 priority to some food constituencies called nutrients versus others that are not. 6 Because 7 ultimately all of them come from foods. So when we make in the hierarchy of 8 9 making decisions, are we going to just based on the nutrients for which we have guidelines and 10 not for the ones that we don't even though they 11 12 have influence on health? 13 And finally, I mean this committee is 14 trying to define nutrients of intake or is trying to guide the general public as far as what foods 15 16 to consume -- I mean what different proportions. 17 MEMBER NOVOTNY: Rachel Novotny. Just 18 to elaborate that again, I think also as we 19 communicate with the public about these things, 20 my feeling is that talking in nutrients has 21 contributed to turning to supplements rather than foods. So again, just to reiterate, I think as 22

we look for language for these things, I think as
 a food-based group, the more we can talk in
 foods, the better.

4 CHAIR SCHNEEMAN: So Regan, I know you 5 pointed to the fact that when it comes to looking 6 at data for dietary patterns, knowing what kind 7 of pattern are you following, we're limited in 8 terms of the type of data there. And it might 9 help to amplify how this relates to the 10 discussion that we're currently having.

11 MEMBER BAILEY: Yes, so right now what 12 we're limited to is the healthy -- Sorry, Regan 13 Bailey. So to address that, we have data on the 14 Healthy Eating Index only. And the data that Dr. Pannucci presented at the first meeting indicates 15 16 that most Americans or a high proportion of 17 Americans aren't doing that. We don't have data 18 on what they are doing. And that is something that I think really needs to be addressed for --19 I don't think can be addressed for this 20 21 committee, but certainly for future committees. 22 We have to know the current dietary patterns that

are being consumed, in addition to how they 1 2 relate to the Healthy Eating Index. So I think -- I really hear what 3 4 you're saying and I appreciate it. But at this current point, we're a little bit limited with 5 the data that we do have available to us 6 7 unfortunately. Don't shoot the messenger. 8 VICE CHAIR KLEINMAN: The messenger is 9 doing great. 10 CHAIR SCHNEEMAN: That may be the perfect introduction to our next subcommittee 11 12 So thank you very much, Regan. report. I think 13 that was very helpful. And I appreciate the comments from the committee. 14 It's been a 15 tremendous amount of work. 16 So our next subcommittee is to focus 17 on dietary patterns. And Carol Boushey, the 18 chair of that subcommittee will give the report. 19 Carol? 20 MEMBER BOUSHEY: Thank you. So I was 21 introduced as Carol Boushey. I can confirm that 22 I am. And I represent the Dietary Patterns

Subcommittee. And good, there are the slides. 1 2 And you can see the other members of the subcommittee up on the slides also. Okay, am I 3 hitting the wrong button? I was holding it 4 upside down. It does not work that way. 5 So for the next people, remember that. 6 7 The topic areas that the subcommittee 8 was tasked with are listed on this slide. The 9 first six have asterisks indicating that those 10 will be presented today. 11 As noted, we're the Dietary Patterns 12 Subcommittee. So the key definition that we are 13 using for dietary patterns in all the 2020 14 Advisory Committee reviews are the quantities, 15 proportions, variety, or combination of different 16 foods, drinks, and nutrients where available and 17 diets and the frequency with which they are 18 habitually consumed. 19 This definition was applied to all 20 analytical frameworks for the subcommittee, which 21 will be presented shortly and for the ones that

22

Neal R. Gross and Co., Inc. Washington DC

are not yet done. And this is an aspirational

www.nealrgross.com

definition that was developed by a panel of
 international experts for the existing NESR
 systematic reviews. And all information provided
 by studies about the dietary patterns tested or
 examined, including both foods and beverages,
 macro and micro-nutrients will be extracted from
 included articles.

8 So the two questions listed on this 9 slide, what is the relationship between dietary patterns consumed in all-cause mortality? 10 And 11 what is the relationship between dietary patterns 12 consumed and sarcopenia will be answered by 13 conducting original NESR systematic reviews. So these have never been done before. 14

15 The four questions listed on this 16 slide with outcomes of neurocognitive health; 17 growth size, body composition, and risk of 18 overweight and obesity; cardiovascular disease; 19 and Type 2 diabetes will be answered by updating 20 existing NESR systematic reviews.

The analytical framework that was brought up earlier is shown on this slide. And

illustrates the systematic review question 1 2 examining the relationship between dietary patterns and all-cause mortality. Do you think 3 we ran out of batteries already? 4 5 DR. STOODY: So it looks like the computer is shutting down, which is nice. 6 So 7 we'll just pause for one second and have IT come 8 set it back up. So if you'll just hold, so we 9 don't continue the discussion without the visual. 10 So one second. 11 (Long pause.) 12 MEMBER BOUSHEY: Thank you so much. 13 We'll get rocking and rolling here again. 14 So I'm going to start at the beginning of this slide. So you'll have heard this 15 16 sentence before. But just to make sure that 17 we're on the same page. 18 This is the analytical framework shown 19 on this slide. It illustrates the systematic 20 review question examining the relationship 21 between dietary patterns consumed and all-cause 22 mortality. The analytical framework provides a

foundation for the systematic review and helps to
 inform the development of the inclusion and the
 exclusion criteria.

The subcommittee defines all-cause 4 5 mortality as the total number of deaths from all causes during a specific time-period. 6 This is 7 the first analytical framework presented. The 8 others that you've seen today have been purely 9 demonstration frameworks. So for this presentation, we will add animation to point out 10 11 all the parts and pieces of the analytical 12 framework.

13 The intervention or exposure of 14 interest is consumption and/or adherence to a 15 dietary pattern. The comparators are consumption 16 of and/or adherence to a different dietary 17 pattern and different levels of consumption 18 and/or adherence to a dietary pattern. The 19 outcome of interest in this particular case is 20 all-cause, total mortality. 21

21 The population of interest for this 22 particular case; intervention, exposure and

outcomes is -- the population of interest for 1 2 interventions and outcomes are children through older adults, who are healthy and/or at risk for 3 chronic disease. For the question, the 4 subcommittee decided that infants and toddlers 5 from birth to 24 months were out of the scope. 6 7 Key confounders, which are factors 8 that may impact the relationship of interest in 9 this systematic review are shown on this slide. 10 And include sex, age, race, ethnicity, socioeconomic status, physical activity, 11 12 anthropometry, energy intake, and smoking. From 13 this point forward, the analytical frameworks will look like this and not have animation. 14 But they liked it so much, they did it twice. 15 16 Okay, the next framework should be 17 sarcopenia. It's coming. Yes, okay. The next 18 topical area is sarcopenia. This is the systematic review framework examining dietary 19 20 patterns consumed and sarcopenia. The 21 subcommittee discussed and applied a definition of sarcopenia based on the review of the 22

foundation for the National Institutes of Health Biomarkers, Consortium Sarcopenia project. As well as the consensus of three European working groups that converge to operationally define sarcopenia.

The definitions those groups presented 6 7 generally aligned on parameters of low skeletal 8 muscle or lean mass, low strength or weakness 9 and/or low muscle performance. That is mobility impairment, walking, speed, or function. 10 11 Therefore, the definition for sarcopenia applied 12 to this systematic review is progressive and generalized loss of skeletal muscle mass alone or 13 14 in conjunction with either or both low muscle strength and low muscle performance. 15

In this particular case, we have intermediate outcomes, which include low muscle mass, strength, and performance. And sarcopenia or severe sarcopenia as endpoint outcomes. The population of interest for the intervention exposure of dietary patterns includes adolescents, adults, and older adults who are

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

1	healthy and/or at risk for chronic disease. For
2	this question, the subcommittee decided that
3	infants and toddlers from birth to 24 months were
4	out of scope.
5	The population of interest for the
6	outcomes of sarcopenia includes adults and older
7	adults who are healthy and/or at risk of chronic
8	disease. The confounders are sex, age,
9	socioeconomic status, anthropometry, total energy
10	intake, dietary protein intake, physical
11	activity, and physical disability.
12	The next analytical framework is
13	dietary patterns and neurocognitive health. The
14	analytical framework here illustrates the
15	question examining the relationship between
16	dietary patterns consumed and neurocognitive
17	health. The outcomes include developmental
18	domains as specified on the right, academic
19	performance, attention deficit hyperactivity
20	disorder, autism spectrum disorder, cognitive
21	decline, and cognitive impairment and dementia,
22	Alzheimer's disease, anxiety, and depression.

The population of interest includes children through older adults who are healthy and/or who are at risk for chronic disease.

For this question, the subcommittee 4 excluded infants and toddlers because the Birth 5 to 24 Month Subcommittee will be completing this 6 The key confounders; sex, age, race, 7 review. ethnicity, socioeconomic status, anthropometry, 8 9 total energy intake, alcohol intake, smoking, physical activity, and family history of 10 neurocognitive disorders. 11

12 The next analytical framework focuses 13 on dietary patterns consumed and growth, size, 14 body composition, and risk of overweight and 15 obesity. The outcomes include weight and various 16 forms of weight, BMI, body composition and 17 distribution, percent fat mass, fat-free mass, 18 and incidents and prevalence of underweight, 19 failure to thrive, stunting, wasting, healthy 20 weight, overweight, and obesity. 21 The population of interest for the

22

1

2

3

intervention exposure and outcomes include

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

children through older adults who are healthy 1 2 and/or are at risk for chronic disease. For this question, again, the committee excludes infants 3 and toddlers and the Birth to 24 Months 4 5 Subcommittee will be handling this. Key confounders are sex, age, total energy intake, 6 7 physical activity, anthropometry at baseline, and smoking. 8

9 Cardiovascular disease is shown on this slide. 10 The analytical framework here 11 illustrates the review of dietary patterns 12 consumed and cardiovascular disease. The intermediate outcomes include total cholesterol, 13 14 low density lipoprotein, high density lipoprotein, triglycerides, and blood pressure. 15 16 The endpoint outcomes include cardiovascular 17 disease and specifications listed, stroke, venous 18 thrombosis, cardiovascular disease-related mortality. The population of interest here 19 includes children through older adults who are 20 21 healthy and/or are at risk for chronic disease. The key confounders are sex, age, energy intake, 22

physical activity, anthropometry, and smoking. 1 2 The Type 2 diabetes, that's the last analytical framework that we finished before this 3 meeting. And this illustrates the systematic 4 5 review for Type 2 diabetes and dietary patterns The intermediate outcomes include consumed. 6 7 hemoglobin A1c, glucose, insulin, and pre-8 The endpoint outcome is Type 2 diabetes. 9 The population of interest for the diabetes. 10 intervention exposure and outcomes includes 11 children through older adults who are healthy 12 and/or are at risk for chronic disease. 13 Key confounders as shown is sex, age, 14 total energy intake, physical activity, anthropometry, and smoking. The inclusion and 15 16 exclusion here, these criteria were outlined in 17 Dr. Schneeman's presentation. And so we will 18 apply all of the ones that she outlined clearly 19 in her presentation. And then inclusion and 20 exclusion criteria unique to the various analyses 21 that we are doing -- are starting here. 22 And so for the 2020 Advisory Committee

systematic reviews, examining dietary patterns 1 2 consumed, we'll apply all of the inclusion, exclusion criteria here for the intervention 3 exposure to operationalize the definition of 4 5 dietary patterns presented in this presentation. And studies that examine -- So these will be 6 7 studies that examine consumption and/or adherence 8 to dietary patterns such as, as an example, the 9 dietary approaches to stop hypertension, DASH. Α vegetarian or a vegan dietary pattern, a low 10 11 carbohydrate dietary pattern and high fat dietary 12 pattern will be considered. They'll be measured 13 or derived using a variety of approaches as specified in this inclusion criteria. 14 Studies must describe the dietary 15 16 pattern being tested or examined at a minimum 17 providing the foods and beverages consumed in the 18 pattern for inclusion. Studies that examine low

19 carbohydrate or high fat diets will be included 20 as long as they meet the percent specified as --21 and this is in the second row, as being the 22 criteria which is less than 45 percent of energy

from carbohydrate, for low carb, and are greater 1 2 than 35 percent energy from fat, which is high fat. And these are based on the AMDR. 3 And the exclusion criteria are studies 4 5 that do not provide a description of the dietary pattern or that they label the dietary pattern, 6 but they do not describe the foods and beverages 7 8 or the base pattern is solely on nutrients. So 9 this is a very food-oriented group. And studies that do not provide a description of the 10 11 macronutrient proportion examined or do not 12 examine the percentages specified for low 13 carbohydrate or high fat, if that is the pattern 14 that's being suggested. And then there are corresponding inclusions for the active 15 16 comparators.

So for some specifics for each of the outcomes that we're going to be looking at, for all cause mortality, it's studies that are reporting all-cause mortality. And then we'll exclude studies that report only one mortality or two because we're looking at mortality from all
1	causes. And then the inclusions for sarcopenia
2	were covered on the sarcopenia slide. We don't
3	have any exclusion criteria for the
4	neurocognitive health or for the growth size or
5	body composition, overweight and obesity. And
6	these inclusions were shown in the analytical
7	framework slides.
8	There are exclusions for CVD. And
9	that will exclude hypertensive disorders during
10	pregnancy and/or lactation. And for Type 2
11	diabetes, we'll exclude gestational diabetes
12	during pregnancy and/or lactation and Type 1
13	diabetes.
14	The dates of publications that we'll
15	be using are the reason they vary so much
16	so we have actually three different date ranges
17	has to do if it's a new you know, if it's a
18	brand new systematic review or an update of NESR.
19	So the date range of the publication for the new
20	systematic reviews will be January 2000 to May
21	2019.
22	The date range of publications to

update existing systematic reviews for the 1 2 neurocognitive health outcomes will be August 2014 to July 2019. And this is in addition to 3 the included articles published from 1980 to 4 5 2014. And an additional search will be done to capture outcomes that were not considered in the 6 existing review. 7 The neurological health 8 outcomes have had many changes in the labels. 9 And we want to catch all those changes in the labels that have occurred in current times. 10 11 The date range of the publication to 12 update the systematic reviews for growth and size and body composition in CVD and Type 2 diabetes 13 14 will be August 2013 to July 2019. And this is in addition to the included articles from the 15 16 previous systematic review of 1980 to 2014. So our next steps as we move forward, 17 18 we will develop next the protocols for the 19 questions of what is the relationship between 20 dietary patterns consumed and certain types of 21 cancer? And then, the next question will be what 22 is the relationship between dietary patterns

consumed and bone health? Then in addition, what we'll be doing as our next steps is implementing the protocols for all of the questions that were just presented. One, two, three, four, five, six of them.

So many thanks to the DGAC 6 7 subcommittee members for enthusiastically 8 participating in weekly meetings. And 9 appropriately the support people are displayed in the bottom box. And the reason I say that's 10 11 appropriate is because they represent the 12 foundation of this enterprise. They're tireless 13 in supporting all the activities or putting 14 together these efforts and really are 15 contributing to the success of the process. 16 So this slide represents the end and 17 being open for questions. 18 CHAIR SCHNEEMAN: Please. 19 MEMBER MATTES: Rick Mattes, one quick 20 question. For the key confounders for the 21 cardiovascular outcomes, did the committee consider sodium in there as something to 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

1	contemplate? I know it's a can of worms.
2	MEMBER BOUSHEY: We did. We did talk
3	about it. It's just it's so poorly measured.
4	What are your thoughts? Do you think we should
5	put it in?
6	MEMBER MATTES: I agree rarely is
7	there an adequate measurement of it. But it does
8	seem to be an issue that's very much on a lot of
9	the populations mind. And we have an opportunity
10	to evaluate the science and make a statement
11	here. I don't know.
12	MEMBER BOUSHEY: Yes, so we have
13	different and the other thing, because of
14	being hard to assess, it may not be present in
15	the paper. So we could put it in the confounders
16	that won't kill the paper.
17	MEMBER MATTES: Yes.
18	MEMBER BOUSHEY: Yes, okay. I'll make
19	a note of that.
20	CHAIR SCHNEEMAN: Yes, so that becomes
21	a good measure and something where you want the
22	data you want to know if sodium has been a

part of the study and reporting.

2	MEMBER NAIMI: Tim Naimi. Thanks for
3	that nice presentation. So you listed in terms
4	of the patterns, that we'd be considering the
5	DASH and vegetarian, vegan, low carb, high fat.
6	Are there other patterns that are going to be
7	included or is that the list or is that still up
8	for debate?
9	MEMBER BOUSHEY: Those are e.g's. It
10	shouldn't be i.e. They're e.g's, they're
11	examples. So really the number of patterns
12	available are very wide. And the most important
13	conditions is that we can identify what the foods
14	that comprise the pattern. But it doesn't even
15	have to have a name to make it in as a pattern.
16	And we will take both theoretically derived
17	patterns, as well as hypothetically derived
18	patterns. And I realize that was on this slide,
19	but I didn't say it out loud.
20	MEMBER LEIDY: Heather Leidy. Two
21	quick questions. One is a follow up to that.
22	And I know these are now examples. But I thought

I'd just bring it back up. In terms of a low carbohydrate diet, will there be ability to separate those out in terms of the other macro-4 nutrients? So there can be low carb high fat or low carb high protein? It sounds like all patterns are fair game.

7 But I guess my point is at the end of 8 the day, will they be grouped according to 9 certain dietary patterns that are listed like low carbohydrate diets? And that might actually be 10 11 very different, depending on the macro-nutrient 12 content.

13 Do you understand what I'm saying? So 14 there's a pattern that's low carbohydrate, but 15 There can be studies they're very different. 16 that define that. But then within that, they can 17 have very different macro-nutrient compositions. 18 And just maybe a point to consider that some 19 things maybe shouldn't be grouped in terms of a 20 generalized pattern.

You know, that's an 21 MEMBER BOUSHEY: 22 interesting point because we really are looking

1

2

3

5

at dietary patterns and they would all be 1 2 together. But that doesn't rule out that we might not look at them, you know, by different 3 And I haven't -- others here have been 4 types. 5 involved in this process before. And so I don't know when we start doing the analysis -- Linda, 6 7 Linda -- I've been waiting for an opportunity to 8 say that, you know this. So is that something 9 that once we get to the analytical part, that we can pull in parts and pieces and say what happens 10 11 if we take this one out? 12 MEMBER VAN HORN: Linda Van Horn. 13 I'll let the other Linda speak for herself. But 14 yes, I think this is definitely a topic that was 15 discussed in some of our calls, including the 16 sodium question, which of course is very much on 17 the hot button list at the moment. But I think 18 in some ways, this is reminiscent of the 19 discussion we just had earlier about nutrients of 20 concern. 21 MEMBER BOUSHEY: Yes. 22 MEMBER VAN HORN: I think we're in an

interesting point now in the fact that everyone 1 2 recognizes that eating patterns are more descriptive of someone's totality of intake. 3 But 4 I don't think there's any way you can separate an 5 eating pattern discussion from nutrients of And I think what we're experiencing 6 concern. 7 even as we're speaking is the fact that in many ways, the discussion about eating patterns really 8 9 has to incorporate, the concept at least of 10 nutrients, especially macro-nutrients, but even 11 micro-nutrients. 12 I was thinking as you were speaking 13 about carbohydrates, one of the nutrients of

14 concern in this country is low fiber intake. You 15 know, the U.S. public eats less than half of the 16 recommended amount of dietary fiber, which we all 17 know is derived in complex carbohydrates.

So my only point is here, I don't think we can eliminate from our consideration as we think about dietary patterns, the macronutrient or other distinguishing characteristics that really differentiates across these different 1 eating patterns.

2	MEMBER BOUSHEY: And I appreciate that
3	completely. Where I'm coming from actually is
4	we're creating now we're putting together the
5	structure for these reviews, right, these
6	systematic reviews. And in order to not be
7	biased then, we really would have to make these
8	decisions a priori. That's why I'm asking the
9	question. Is that you know, right now we're
10	lumping these all together. But what you're
11	saying and I am really open to it, is then we
12	a priori would need to somehow desegregate some
13	of these to capture what you were talking about
14	because that may be of importance. Because if we
15	put them all in and do it afterwards, that's not
16	following the rules. So that's why I was asking,
17	in the past, has this been done of desegregating
18	these exposures that you these studies that
19	you have found. That they met your criteria, but
20	now you're going to split them again.
21	MEMBER LEIDY: This is Heather again.
22	This is a follow up. I'm just thinking in terms

of the NESR search terms. It's hard to keep it 1 2 broad because if you're not having -- you know, for example in this case, our discussion has been 3 about everything but protein. So as an example, 4 5 if you don't search by high protein diets and you just go low carbohydrate diet, there's an 6 7 opportunity to actually miss some of those within 8 the NESR search criteria, which is something I 9 didn't think about. I guess maybe the search terms will come later on down the road. 10 I mean we're already really establishing that. 11 So 12 there's examples that are listed, but I'm just 13 not sure if that actually translates into all 14 encompassing search terms that will be able to pick up all these different dietary patterns. 15 16 MEMBER BOUSHEY: And that's actually 17 an interesting one to check on. 18 CHAIR SCHNEEMAN: I think it might be worthwhile if the staff could perhaps -- I know 19 20 you're sitting over there, but I can't see you. 21 Particularly this question on the search terms, I think it would be helpful. 22

(202) 234-4433

1	DR. ENGLISH: Yes, this is Laural
2	English. So to the first point earlier, I did
3	just want to touch on the fact that we will
4	extract all data that are reported to speak to
5	your concern about the other nutrients. So if
6	it's a low carbohydrate diet and they report the
7	nutrients the other macros, micros, we will
8	extract all information that is reported by the
9	article. And then we can group accordingly to
10	your earlier point in the evidence synthesis with
11	Mediterranean diets, low carbohydrate diet, et
12	cetera. So we can do that and plan to do that.
13	For the next question on the search
14	terms, we do develop a comprehensive search
15	strategy and there are MeSH terms in the PubMED
16	database. For example, ketogenetic diet, low
17	carbohydrate diet, we also add in key words. So
18	we have developed a comprehensive search and it
19	is peer reviewed by a second librarian. And then
20	we also have test papers that confirm that our
21	search is appropriate. So we believe it is
22	comprehensive to that.

1	MEMBER LEIDY: Another real quick
2	question. This is on I don't think you need
3	to go there, but on Slide 15, it's the Type 2
4	diabetes. And for me, just more of a
5	clarification. The endpoint outcome is Type 2
6	diabetes. And I wrestled with this in the
7	frequency of eating and so I thought I'd bring it
8	up.
9	I'm wondering what the outcome is. So
10	when you look at the cardiovascular disease,
11	there's parentheses with qualifiers in terms of
12	what that endpoint is. With Type 2 diabetes, I
13	understand what Type 2 diabetes is, but it's
14	generally identified as a certain HbA1c. And
15	HbA1c is actually an intermediate outcome. So
16	I'm just wondering what the Type 2 diabetes
17	endpoint outcome will be. Except that if
18	somebody has Type 2 diabetes, but is that the
19	only criteria? Or is it really based on
20	somebody's HbAlc and the changes of that?
21	It's a moot point, but it's an
22	intermediate right now. And it seems odd why it

isn't in the endpoint outcome. And I'm not a 1 2 medical doctor, but generally people are diagnosed with their HbAlc levels. And so that's 3 4 what I'm just trying to figure out why that's not an endpoint instead of an intermediate. 5 MEMBER BOUSHEY: Well that's a good 6 question. Yeah, that's a good question. 7 Jamy? 8 VICE CHAIR KLEINMAN: I mean I would 9 think it's both actually. And I think when they're searching, they're searching for the 10 11 health outcome Type 2 diabetes. But when looking at studies, they'll include studies that have 12 HbA1c's that are below the threshold for Type 2 13 14 diabetes. So one can follow that over time to a diagnosis of Type 2 diabetes. 15 I mean I'd ask the 16 staff, is that a correct interpretation? Yes, I 17 see head's bobbing yes. 18 DR. ENGLISH: Yes, this is Laural 19 English again. And yes, so to that point, it 20 would be diagnosed Type 2 diabetes. So if they 21 were looking at dietary patterns consumed in 22 those who were diagnosed with diabetes versus

those who did not, that's really to get at that. 1 2 But to your point, hemoglobin Alc, the other intermediate outcomes, we would be 3 extracting the data that are reported for those 4 continuous measures or the particular levels. 5 So it would be included pretty much as Dr. Kleinman 6 7 mentioned. CHAIR SCHNEEMAN: So Dr. Ard? I think 8 9 we had Dr. Ard and then Dr. Donovan. So I was just going to --10 MEMBER ARD: Jamy Ard, I was going to follow up on Heather's 11 12 question and point. And the answer that Laurel gave around the macro-nutrient distributions and 13 14 the dietary patterns associated with that. I think it will be important for us to 15 16 think about the categorization of those specific Because as we've 17 types of dietary patterns. 18 said, there's a wide range of what people define 19 as lower carbohydrate or lower fats. And 20 sometimes, I think it's probably just as 21 important to understand what was reduced in the 22 dietary intake, as well as what replaced it.

1	So in thinking about a lower
2	carbohydrate intake, I want to also know what
3	replaced the carbohydrate. Was that replaced by
4	fat intake or was that replaced by protein intake
5	and maybe even further. You could, you know, see
6	a branching of you know, well was that protein
7	mostly vegetable protein or animal protein?
8	Was that fat mostly saturated fat or unsaturated
9	fat?
10	So I think it will be important for us
11	in describing the results to, as best we can,
12	clarify what we mean when we say this is the
13	particular macro-nutrient dietary pattern. So
14	that we do avoid this sort of general lumping of,
15	well, it's just this. As we wouldn't necessarily
16	say, well, all vegetarian patterns are the same,
17	because there are different forms of vegetarian
18	patterns. And we would be specific to describe
19	well this is vegan or this is lacto-ovo, et
20	cetera.
21	So I think that will be important for
22	us to at least have a general working framework

of how we might want to categorize that. 1 And 2 then put the studies in those relevant boxes, to some extent. And it may not be at the level of, 3 4 well, this has to be less than 20 percent 5 carbohydrate or this has to be less than 100 grams per day of carbohydrate or to that extent. 6 7 But at least some general framework of 8 understanding not just what the reduced macro-9 nutrient was, but what replaced it. 10 MEMBER BOUSHEY: Yeah. 11 MEMBER SNETSELAAR: I just wanted to 12 piggyback on that just a bit. I think too and 13 we've discussed in our committee, the idea that 14 the Mediterranean diet has many different variations. And so this probably will be true of 15 16 all of the types of dietary patterns that we're looking at. I just wanted to add that. 17 18 MEMBER BOUSHEY: Yes, that's 19 absolutely right. But Jamy, we've got -- I 20 really appreciate what you said. Because we've 21 been really sensitive to the complexity of this. And I'm glad that this came up so that really 22

gives us additional guidance in moving forward. I think we'll be able to find all the papers, but it will be really somehow harmonizing them across the spectrum in some way that makes sense with regard to -- I mean really, what's available now is far more than what we had previously, I do believe.

So Sharon Donovan, 8 MEMBER DONOVAN: 9 this is more just a general comment. Because I noticed that your publication dates; one is May, 10 one is June, one is July. And it seems to me as 11 12 a committee we should decide what is the latest 13 date that we want all the systematic reviews to go to. We've talked about this because there's a 14 15 bunch of new -- from the pregnancy B 24 that were 16 just published, but they only went to January of So while I understand we'll be ruling 17 2017. 18 these, it seems like we should be consistent --19 or unless we can really justify why one should be 20 May, one should be June, and one should be July. Right. And actually 21 CHAIR SCHNEEMAN: 22 I have a feeling that when you're looking at the

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6

date, that's the furthest out date, the closest to now, the intent is to gather whatever is currently available. And perhaps the staff could comment on that. So May or June, I don't think there was an intent to make a difference there. It was probably when the protocol went into the box.

8 DR. ENGLISH: Yes. This is Laural 9 Yes, that's correct. And we wanted to again. get started as soon as possible after those two 10 11 first new -- the new questions were approved and 12 those protocols were approved. We did also 13 develop the search strategy and shared the search 14 strategy. And then conducted the search so that the staff could get going on literature search 15 and screening. 16

17 CHAIR SCHNEEMAN: But we will be
18 consistent in terms of we're trying to gather the
19 most current data.

20 DR. ENGLISH: Yes, and if there was 21 anything published after May, between May and 22 July for instance, we could do a secondary search

1

2

3

4

5

6

to make sure that there were no additional 1 2 publications that were missed between that time period. 3 4 MEMBER BOUSHEY: So is that something we should adopt across the board then? 5 Because I'm sure that's happening in every subcommittee. 6 7 CHAIR SCHNEEMAN: Oh absolutely. Yes, absolutely. 8 9 MEMBER BOUSHEY: Right, right. 10 VICE CHAIR KLEINMAN: Okay, we have one more report before we take a break at 11:45 11 12 And -- Oh, I'm sorry. for lunch. 13 MEMBER MATTES: Rick Mattes, and I'm 14 thinking about this issue of the patterning and macronutrients and so on a little further just in 15 16 case it helps your thinking as you go forward. 17 You could couch it in different ways. You could 18 talk about absolute level of each of those 19 nutrients. You could talk about proportion of 20 energy contributed by each of those nutrients. 21 You could talk about the amount relative to recommendations of each of those nutrients. 22 And

I don't know the right answer to that, but they 1 2 could well give you different answers. And so you may want to think that through to make your 3 4 decision. 5 CHAIR SCHNEEMAN: Thank you. So Dr. 6 Sabate had a comment as well. MEMBER SABATE: 7 Joan Sabate. I have 8 two comments to make. One is in line of what was 9 discussed before as far as what replaces carbohydrates, so foods coming from mainly 10 11 carbohydrates. And again since this is mainly a 12 committee that has to deal with foods. I think 13 besides whether it is protein or fat that is 14 replacing, I mean I think we at least have to capture -- I mean if the foods that are high in 15 16 protein and fats are coming from vegetables or 17 from animal intake. Because I mean there are --18 from the viewpoint, there are two ways, I mean to 19 accomplish a low carbohydrate diet. 20 The second point relates to a slide that is Number 13 that we discussed because I am 21

a member of this committee in which we relate the

22

dietary patterns with anthropometrics, particular overweight and obesity. And total energy intake is listed as a key confounder. I think listing as a key confounder may decrease the ability to connect, I mean dietary patterns and overweight and obesity.

7 I think before trying to use as a key confounder, we have to analyze as a mediator 8 9 because some of the dietary patterns may relate to the overweight and obesity mediating through 10 the total energy intake. Especially when we look 11 12 in descriptive epidemiology and how people, I 13 mean, consume these dietary patterns. So I think 14 that besides using as a key confounder, it has to be studied as a mediator between dietary patterns 15 16 and anthropometrics. Because it could be that 17 the connection is mainly through total dietary 18 intake.

19 MEMBER NAIMI: Tim Naimi. Just I 20 wanted to, in terms of consistency, you were 21 controlled for smoking as a confounder for all 22 these. And you controlled for alcohol

1

2

3

4

5

consumption for the neurocognitive health, but 1 2 not for overweight and obesity and cardiovascular disease and diabetes. And so I thought you 3 4 should probably be consistent one way or the 5 But I think it's an important potential other. source of calories and other possible effects. 6 7 MEMBER BOUSHEY: That's a good suggestion. 8 9 VICE CHAIR KLEINMAN: All right. I'm 10 so eager for lunch, I jumped to this last one. 11 So we are now at the third presentation. And we 12 will take a break for lunch at 11:45, so we have 13 plenty of time. And Dr. Heather Leidy's going to 14 present for the Frequency of Eating Subcommittee. 15 MEMBER LEIDY: I'm okay. I'm going to 16 try to use my slides. 17 CHAIR SCHNEEMAN: So Heather, you have 18 to really work at making sure you're heard. 19 Okay? 20 MEMBER LEIDY: Okay, sorry about that. 21 We have really short mics. And so I'm short, but not that short. So I'll just -- I'm sorry if you 22

couldn't hear my comments earlier. I usually have a big mouth.

3 So I will be presenting on behalf of 4 Steve Heymsfield who isn't able to be here today. 5 He is the chair of this committee. And then also 6 wanted to acknowledge Carol Boushey and then Rick 7 Mattes, as well as Ron Kleinman who were a part 8 of this committee as well.

9 And so it was pretty exciting to be a part of this subcommittee. These are new areas 10 11 of questioning that we were able to tackle. And 12 you'll quickly find we spent a substantial amount of time in the earlier weeks defining the topic 13 14 and working out the framework on the front end. And so as we go through the slides, if you have 15 16 clarifying questions, feel free to ask. And the 17 rest of the committee, happy to chime in with you 18 all too. I'm going to try to add some rationale 19 behind some of the things that we've selected 20 because they may seem a little -- not off, but 21 just different. And so I'll try to add some 22 context to that.

> Neal R. Gross and Co., Inc. Washington DC

1

1	And so our topics areas that we had
2	were the frequency of eating. And as you can see
3	the remainder, and Carol had already addressed
4	these with the previous topic. But just so
5	everybody's on the same page. You're really
6	looking at eating frequency and all-cause
7	mortality, growth, size, body composition,
8	overweight, and obesity, gestational weight gain,
9	postpartum weight loss, cardiovascular disease,
10	and Type 2 diabetes. And we are covering all of
11	the protocols today. And that's why they're in
12	an asterisk.
13	And so we really wanted to start with
14	identifying the key definitions. And so if you
15	have questions, feel free to raise them now
16	because it will help drive some of the rest of
17	the conversation.
18	And so eating frequency, we defined in
19	two manners. One is the number of daily eating
20	occasions. And then the second one is the timing
21	of daily eating occasions. And underneath that
22	then we have the timing of weekly eating

occasions, really identifying week day versus weekend. Meal skipping and then also fasting from a time restricted eating paradigm.

And so obviously now we have other 4 5 things to define. And so an eating occasion is any ingestive event. And thinking in terms of, 6 7 you know, what we know from the lay audience and 8 the U.S. American diet, as well as how studies 9 That includes preload, so that is are designed. 10 really anything before another eating occasion. So preloads, meals, and snacks. Within this 11 12 eating occasion, that includes all foods and/or 13 beverages. And then also whether they're caloric 14 or non-caloric.

Fasting was defined as an absence of 15 16 an eating event greater than eight hours during a 17 waking period in a 24-hour period. Again, we're 18 really trying to be sensitive to some of the more 19 recent research with time-restricted eating or 20 intermittent fasting, those types of concepts. 21 And so time-restricted eating, were really set 22 patterns of eating occasions throughout the day.

> Neal R. Gross and Co., Inc. Washington DC

1

2

1

And so that's how that was defined.

2 And then lastly, meals were dependent on timing throughout the day. So we're really 3 trying to get at, you know, what you typically 4 see as you know breakfast, lunch, dinner/supper. 5 And that's really around the morning, midday, and 6 7 evening eating occasions. Not that it's an elephant in the room, but you know, obviously 8 9 snacking is another component. Due to the fact that there really is no standard definition for 10 snacks, we felt the need not to include that as a 11 12 definition because it's just very variable. Ι 13 mean some base it on timing or energy or caloric 14 intake. And so we felt that because there's just no standardization, those eating occasions will 15 16 be included as eating occasions. But we just 17 felt that we shouldn't really define snacks. 18 The next piece then is well what 19 frequency of eating is not? Because that really 20 came in the discussion. And so two points here. 21 The first is that we are not addressing the 22 frequency of intake of single foods, beverages,

or categories of foods or beverages. 1 This is 2 really about when to eat, not what to eat. But even in a call yesterday or the 3 4 day before, it came up that, you know, there will be times that we can address other components --5 nutrients, micronutrient content, whatever. 6 But 7 the primary question within a study has to be the 8 frequency of eating. And then within that, we 9 can then look at different types of the foods that were included within that. But this is not 10 really specifically looking at single foods, like 11 12 the frequency of milk consumption or frequency of 13 seafood consumption, something like that. 14 And then the second point are studies that do not have eating occasions across the day. 15

16 And this really came about from this idea of meal 17 skipping and breakfast skipping or dinner or 18 whatever is in the research right now. But 19 you'll find that a lot of studies don't address 20 subsequent eating throughout the day. That it is 21 generally maybe if it's breakfast skipping, it's they assess lunch and that's it. And we really 22

(202) 234-4433

wanted to encompass with these outcomes, that I'll share here in a minute, that these studies really need to have eating occasions across the entire day to increase the quality of the study or to really adequately answer the question. And so those are the two points to keep in mind. Yes, for sure.

So this is Jamy. 8 MEMBER ARD: So can 9 you help me sort of figure -- or talk through how -- what's the difference between meal skipping 10 11 and time-restricted eating as you're 12 conceptualizing it? So if you're saying time-13 restricted eating is a set pattern of eating 14 occasions, and I skip breakfast every day, which one is that? Is that meal skipping or is that 15 16 just I don't start eating until noon? 17 MEMBER LEIDY: Sure. And feel free 18 for the rest of the committee to chime in. But 19 that really is encompassing both of those 20 aspects. Because there are studies that just 21 focus on breakfast skipping, which isn't really time-restricted eating. But some time-restricted 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6

eating components have a breakfast skipping 1 2 component. Or they just -- maybe they also have breakfast and lunch skipping. So I think what 3 we're trying to do is really include that all 4 5 So you know, it depends on how the together. NESR folks or how we compile the findings at the 6 But they can be separate, but they can also 7 end. be combined, depending on the study design. 8 9 MEMBER MATTES: Yes, I think the goal 10 here was to come up with terms that would be captured in a literature search. And it may 11 12 actually be very similar, but to make sure we 13 captured all the papers, we used both terms. 14 MEMBER LEIDY: Anybody else? VICE CHAIR KLEINMAN: I think also we 15 16 talked on the last call about intermittent 17 fasting for let's say religious reason or some 18 other purpose. And as long as that's not the 19 sole purpose of that study, then we would capture 20 those. So if for example, someone has a usual 21 consistent eating pattern, but fasts periodically 22 throughout the year, those will be captured. But

if they're fasting for four days, that's not the 1 2 kind of the study that we'll capture. And again, we 3 MEMBER LEIDY: Yes. 4 really had the mindset on the front end is you 5 know, intermittent fasting has changed to the definition of time-restricted eating. 6 But there 7 are still a number of studies that have never 8 been examined looking at every other day. And so 9 you know, when we look at that, we'll be able to capture that. But to your point, you know, it's 10 11 not a prolonged fasting period that we're trying 12 to capture. 13 MEMBER NOVOTNY: Rachel Novotny. I'm 14 wondering about water, especially with the frequency of consuming water throughout the day. 15 16 We may not find a lot of studies on that, but 17 just, what are your thoughts for handling water? 18 MEMBER LEIDY: Yes, so we had that 19 included in our definition that it's any eating 20 occasion, caloric or non-caloric. So even those 21 that are water and non-caloric will be included

22

Neal R. Gross and Co., Inc. Washington DC

in the analyses. Although as we all know, it's

very difficult -- many studies don't actually 1 2 assess water intake unless that's the only thing that they're changing. But that would be 3 4 included in our -- that would be captured in the 5 search terms in terms of -- because we're searching for any eating or drinking occasion. 6 7 And that would be included. 8 MEMBER NOVOTNY: So fasting with water 9 is not fasting in your definition. It's drinking 10 water. 11 In our definition, it MEMBER LEIDY: 12 would not be considered fasting because that 13 would be an ingestive event. But we also have 14 the caloric and non-caloric component to that. 15 Is that in agreement? Okay. 16 In terms of the inclusion and 17 exclusion criteria, these were the standard NESR 18 criteria used. So I won't go over this slide. 19 And we'll get to some of the things that are a little bit different with these research 20 21 questions. So I'll just go ahead and move on. 22 And so again, this is the analytical

framework. It's nice, we've only had one of 1 2 these so far. But in the afternoon, we're going to see quite a few, I would imagine. 3 The first 4 part is the intervention and exposure, which is 5 really the definitions that I just touched on. So I'm going to kind of go past that because the 6 7 inclusion/exclusion criteria are there. 8 In terms of the age of the study 9 participants, you can see here that it's children to older adults. And we are not focusing on 10 11 infants under the age of two. And that's in our 12 infants and toddlers. And so that's in the excluded criteria. And then in terms of the date 13 of publication, the committee also felt that 14 going from January of 2000 to the present was 15 16 also appropriate. But we did this for two 17 specific reasons and we thought long and hard 18 about this. 19 The first one is the methodology using 20 that we have is quite different now than it was 21 50 years ago in terms of some of the outcomes and 22 the methods of capturing eating frequency. And

so we felt to be consistent, 2000 and beyond 1 2 would be the best consistent data with that. And then the second piece too is --3 you know, it's interesting much like probably 4 5 dietary patterns. But eating frequency has a tendency to go through waves of research. 6 And so 7 I remember, I went back and looked last night to make sure, you know, some of the first big 8 9 studies that came out were like in the 1950s. And there were a cohort that came out. 10 And you didn't see it again until the '70s and then the 11 12 '90s. And so the challenge that we found is, you 13 know, this is the first time we've asked these 14 research questions. And so it would be nice to go back and look at the totality of the data. 15 16 The problem is as we know, eating 17 patterns and eating frequency has changed over 18 the past 50 years. Whereas, you know, 50 years 19 ago, three meals was the staple with very little 20 snacking. And so the control group there would 21 be far different than the control group from like 22 2000s on where there's -- you know, there's a lot

of meal skipping now and more eating occasions.
 And so that's why we felt it best to go from 2000
 to the present. Because that's the most
 consistency that we have with dietary patterns
 and our control comparators would be more
 consistent with that. So that's why we chose to
 go with 2000 and beyond.

In terms of the health status of the 8 9 study participants, again the NESR standard 10 criteria were included. Although, you know, this is more of an interesting thing, you know. 11 Based 12 on looking at the other presentations, I think 13 we're the only ones that included this. But we 14 actually excluded subjects who had post-bariatric 15 surgery. And our thinking on this was, you know, 16 when individuals go through post-bariatric 17 surgery, they would be healthy. Maybe overweight 18 or still obese, but you'd have a cohort of 19 healthy individuals so they should theoretically be included. 20

But as you know with post-bariatric
surgery, they are recommended or prescribed

smaller meals with more increased eating 1 2 frequency. And we felt that wasn't generalizable to the rest of the population. And so we chose 3 to include those in our exclusion criteria for 4 It seems a little weird that we 5 that reason. just added that on. But it really is because 6 7 they change their eating patterns.

8 In terms of dietary data collection, 9 this was also something I think that's unique to our committee. We wanted to have the highest 10 quality data that we could capture given that 11 12 this is the first time this question has been And so we -- I feel like this is probably 13 asked. 14 a little bit stricter than what you would think. But we chose a minimum of three days of dietary 15 16 data collection on at least two occasions. And 17 the intent of that was really to capture habitual 18 eating frequency or eating habits. That it wasn't just a single day. 19

And the other thing too with eating frequency, as an example with meal skipping, a lot of times you'll see that there's one eating

occasion, and then the data in these studies are 1 2 only captured at that next eating occasion. And so you don't get the rest of the entire day. 3 And it's really difficult to make recommendations 4 5 when you're not capturing, you know, over a 24hour period, as well as over the days to look at 6 habitual intake. And so that's why we chose the 7 8 three days of dietary data.

9 But as a note, because the question 10 that came up is the food frequency questionnaires 11 because they're done one time. But if you -- you 12 know, a lot of the ones that are validated are 13 over the last week or months or years. And so 14 the food frequency questionnaires would be 15 included within this data. This would be 16 acceptable because they are capturing over a 17 three day period. But we do want with the food 18 frequency questionnaires, there would be two 19 separate time points for those to be included. 20 Does that make sense so far? 21 And then in terms of the size of the

group, we chose 15 participants for studies using
a within subject analyses and then 30 1 2 participants for studies using between subject analyses or at least including a power 3 4 calculation. It wasn't and, it's or. And so if somebody -- if a group or research publication 5 has less than those, but have a power calculation 6 that adequately is powered based on a lower 7 sample size, we felt that was appropriate. Again, 8 9 our intent is really to increase the quality and to have enough power within a study to detect the 10 differences in the outcomes that they are 11 12 proposing.

Okay, so now we can get into the
actual questions. And all of these questions,
we're using the NESR system review to answer
those questions.

17 So the first one is what is the 18 relationship between frequency of eating and all-19 cause mortality? And what we've done here is 20 you'll see very similar framework. Some of the 21 ones that are in black in terms of the key 22 confounders, potential confounders, and potential

covariates are consistently used with other subcommittees. And then some of the ones are specifically for us. And then as we go along with each of the research questions, if something has changed, they're highlighted in red. So we'll kind of just work through this now.

And so the top piece, we've already 7 8 covered; the intervention exposure versus the 9 comparator. And the population is included In terms of the key confounders, again, 10 there. 11 we have sex, age, race/ethnicity. Total energy 12 intake is in italics, which is really difficult 13 to see. So I'm going to address that now. And 14 so this was an interesting one that came up. And 15 it's also to your point, Dr. Sabate.

Total energy intake is actually -- if you look at that, it's a key confounder, but it's also a potential covariate. Because we're trying to see whether it's a confounder or mediator. And so we felt that it was appropriate for these research questions with the frequency of eating to include it both ways. And so the only way

(202) 234-4433

1

2

3

4

5

6

that a study would be dinged is if they're not using it in one or the other manner. So that's why we went with it from that aspect.

We did include habitual eating 4 5 frequency, which I think is probably unique to our research questions. And again, there's a lot 6 of studies out there that will do eating 7 8 frequency studies. But baseline assessments are 9 not included. And we felt that it was critical to know when somebody's habitually fallen from an 10 eating pattern to know whether it's the change in 11 12 their habitual eating patterns versus just the 13 eating pattern itself. And so that's why we 14 wanted to include that as a key confounder.

15 And then we have smoking, 16 anthropometrics and menopausal status. In terms 17 of the potential confounders, we are I believe, 18 the only group that has socioeconomic status as a 19 potential confounder, not a key confounder. And 20 just given the research question, we felt that we 21 did not want that in the risk of bias as a key confounder. So it is included, but it's included 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

1

as a potential confounder.

2	We also have physical activity,
3	cultural practices, eating environment. So in
4	essence, who you eat with, where it is, whether
5	it's work, school, or you know, around an
6	exercise schedule. Thinking in terms of holiday
7	eating or seasonal eating. Sleep schedules,
8	trying to get shift work, dentition, hydration
9	status, pregnancy status, and pubertal status.
10	And so all of these potential key confounders, we
11	felt were important for the frequency of eating,
12	but not served as a key confounder.
13	And then lastly, the potential
14	covariates would be related to different aspects
15	of energy. And so we have diet energy density,
16	as well as the energy state of the diet. In
17	terms of energy, we were trying to think of it
18	two ways one with the diet and one from a
19	physiological energy. And so the first part we
20	wanted to use as a covariate is as I said, the
21	energy balance of total energy intake
22	I'm sorry, let me go back. Energy

Neal R. Gross and Co., Inc. Washington DC 112

www.nealrgross.com

state of the diet. So whether it's an energy 1 2 restriction diet or an energy surplus or an overfeed study. But then as well as thinking in 3 terms of energy from an energy balance, whether 4 5 somebody's in an energy-restricted state or an energy surplus state, thinking in energy intake 6 7 and energy expenditure. And then we also 8 included portion size macronutrient content, 9 location of eating occasion, habitual eating 10 frequency, and biochemical changes. 11 And again, you'll see again, some of 12 these are listed both ways. So as a key 13 confounder, as well as potential covariate to see 14 whether they are truly a confounder versus a mediator. And so that's why we have it as such. 15 16 And I don't think we've actually defined all-17 cause mortality, but that is the total number of 18 deaths from all causes during a specific time 19 period. 20 The next question that we had is what 21 is the relationship between the frequency of

22

(202) 234-4433

Neal R. Gross and Co., Inc. Washington DC

eating and growth, size, body composition, and

www.nealrgross.com

risk of overweight and obesity? And I'll only
highlight the changes that we had within this
versus the others. And so if you look at
obviously the endpoint outcomes were very similar
to what Dr. Boushey had presented with the
dietary patterns. So I'm not going to go into
that because they are identical.

8 Our key confounders here, the only 9 thing that we added as a key confounder was 10 physical activity. And that's really driven by 11 when you're thinking in terms of some of these 12 outcomes related to obesity. A lot of these 13 studies that have eating frequency also have a 14 physical activity or exercise component. And so we felt that even if they didn't have an exercise 15 16 component for these types of outcomes, it was 17 critical to have an assessment of their physical 18 activity or energy expenditure status. And so that's why that is a key confounder. 19

20 Potential confounders, same as the 21 previous one. Although we did add medication and 22 substance use. And this is related to any types

of substances or medications that would affect body composition or obesity status, those So we felt it was important for this aspects. 4 question to include those.

5 And then the potential covariates, the only thing that we added was a specialized diet 6 7 including all liquids diets. There are studies 8 that look at eating frequency and have diets that 9 are just all beverages. And so we felt that was 10 important because that's not very representative 11 of the population of who are consuming those.

12 The next question that we had Whoops. 13 is what is the relationship between frequency of 14 eating during pregnancy and gestational weight 15 qain. Whoops, sorry about that. There we go. 16 So it's pregnancy and gestational weight gain.

17 In terms of our intervention/exposure 18 versus comparator. The population was changed 19 obviously to women during pregnancy. Gestational 20 weight gain, I think this might be -- I don't 21 know if we've -- I guess we haven't heard it at this point. So it's change in maternal body 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

weight from baseline before and during pregnancy to a later time point during pregnancy and/or right before delivery. As well as weight gain in relationship to weight gain recommendations based on pre-pregnancy BMI. And as I said, the population is women during pregnancy.

The key confounders here, we did add 7 pre-pregnancy anthropometrics within that. 8 The 9 potential confounders very similar to previous, except we added the history of gestational 10 diabetes and history of gestational hypertension. 11 12 And just to make sure we're defining gestational 13 weight gain. That's a weight a woman gains 14 during pregnancy. And no changes to our potential covariates within this model. 15

16 The next one is what is the 17 relationship between the frequency of eating 18 during lactation and postpartum weight loss? 19 Within this, this is women during lactation, is 20 the population. And just a side note is that 21 women who are not lactating would not be included 22 within this. We're really focusing on women

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

1

during lactation.

2	Postpartum, the endpoint is changes in
3	weight from baseline postpartum to a later time
4	point during the postpartum period. And
5	postpartum weight retention if gestational weight
6	gain is controlled for. We're defining
7	postpartum weight retention as the amount of
8	weight that remains during the postpartum period
9	minus the woman's pre-pregnancy weight.
10	And we've added some key confounders,
11	a little bit different than the previous ones.
12	And that being pre-pregnancy anthropometrics and
13	gestational weight gain. But no differences in
14	potential confounders. And given a potential
15	covariate, we included the lactation duration
16	thinking that is a critical point in terms of how
17	long an individual woman has been lactating.
18	The next question is what is the
19	relationship between the frequency of eating and
20	cardiovascular disease? And within this model,
21	we have same things on the intervention/exposure
22	versus the comparator. In terms of the endpoint

outcomes, we have cardiovascular disease. And you can see those that are listed within that, as well as stroke, venous thrombosis, cardiovascular disease-related mortality. And then we also have 4 the intermediate outcomes listed here, which is very similar to the other subcommittees that have used that.

Key confounders and potential 8 9 confounders were similar to the previous ones. 10 In terms of potential covariates, those that are 11 highlighted in red were ones that we added for 12 this specific outcome of -- these outcomes of 13 interest. And that being dietary sodium and 14 potassium, as well as dietary fat composition.

And then the last research question is 15 16 what is the relationship between the frequency of 17 eating and the risk of Type 2 diabetes? Again, 18 very similar as what were previously discussed. 19 Endpoint is Type 2 diabetes. And we can see that 20 our intermediate outcomes here again are you 21 know, glucose, insulin, hemoglobin A1c, and pre-22 diabetes. Our key confounders, potential

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

5

6

confounders, and potential covariates are the
 same as the ones that are used previously. So
 I'm not going to list all those.

I'm quickly realizing though with our 4 5 group, we have a lot more of these than the So I'm not sure if we're maybe 6 dietary patterns. 7 being more specific or all encompassing. I'm not 8 sure how that works. But we do have quite a bit 9 that we're targeting. The nice part is these don't eliminate studies in terms of the potential 10 11 covariates or potential confounders. It's just 12 something that we're trying to keep an eye on as 13 we go forward. And I think this is probably 14 driven by the fact that this is the first time 15 these questions are being asked.

In terms of next steps, we will begin screening search results, extract data, and conduct risk of bias assessments, prepare the evidence synthesis, develop graded conclusion statements, and then document limitations and research recommendations.

22

And so with that, I just wanted to

acknowledge the members and the support staff. 1 2 It's been a really great opportunity working within this group, especially this support staff 3 4 have been overly helpful. When questions get 5 raised, it's great -- they come back with examples and things for us to consider. 6 And so 7 it's been a great opportunity. So with that, 8 I'll field any more questions if you all have 9 them. 10 MEMBER DONOVAN: Thanks, that was 11 great. The only thing I would add, on the 12 frequency of eating and postpartum weight loss, you have lactation duration, but you might also 13 14 want to consider exclusivity. So if a women is exclusively breast-feeding versus mixed feeding -15 16 - so if that's reported. 17 MEMBER NOVOTNY: I actually got 18 thinking about --Rachel Novotny -- whether you 19 might want to include monthly in frequency of eating. 20 I mean it would need further 21 elaboration. What I'm thinking about is lower income who change your eating patterns at the end 22

And eat less, start skipping 1 of the month. 2 meals. I'm not quite sure how you get at that. But it would be -- you would probably want 3 4 socioeconomic status or food security status with 5 that question. That's a really good 6 MEMBER LEIDY: And you know, the same was true with some 7 point. 8 of our terms that we were still -- as of 9 yesterday, still battling back and -- not battling, discussing back and forth. You know, 10 we have it within a 24-hour period. 11 But in 12 essence, if you're doing intermittent fasting and 13 it's every other day, it actually needs to be 14 extended to about 48 hours or if it's across the 15 week. 16 So we're not limiting studies based on 17 that. We're just trying to capture eating 18 patterns. And if it's longer than -- you know, I 19 think our minimum would be a 24-hour period. But 20 it would be great if we could extend that. And 21 you're exactly right. I mean eating patterns 22 across a month given SES status would be

critical, if those studies exist and if they
 actually have that.

MEMBER TAVERAS: Elsie Taveras. 3 4 Heather, I wonder if -- I saw sleep schedule. 5 But I wonder if sleep duration should also be included and frequency of eating and body 6 7 composition, gestational weight gain, and 8 postpartum weight loss. Duration as opposed to 9 just schedule. Right? Because you're thinking of -- I'm thinking of duration separate from 10 11 maybe circadian misaligned eating. So that was 12 one suggestion. And then I also wondered -- I didn't 13

14 see any mention as key confounders or potential 15 confounders of screen use. So frequency of 16 eating, especially if that eating is in front of 17 a screen and exposed to advertising. I just 18 wondered if the committee thought of how screens, 19 television viewing played into any of these 20 relationships.

21 MEMBER LEIDY: To answer your point 22 about the sleep, I think that's a critical

component. We put that in thinking of shift 1 2 workers. But then, you know, especially with breakfast skipping, there is some correlational 3 4 data that suggested that's related to sleep or 5 the sleep duration or the quality of sleep is potentially driving some of the meal responses. 6 7 And so something for us to think about to 8 include.

9 In terms of the screen use, to my 10 recollection, we didn't include that specifically. But we did talk about where or 11 12 when or who the eating occasion is with. So if 13 it is at home versus out at a restaurant or 14 something like that, that's included. But just because they're eating at home doesn't mean that 15 16 they're eating as a family unit. Or that they 17 don't have something else in terms of screen 18 time. So I think that's something that we should 19 probably think about capturing. We do have some 20 components of that, but not a specific statement 21 about screen time. That's a really good point. MEMBER DONOVAN: Sharon Donovan. 22 Ι

guess the comments about end of the month, it 1 2 also made me think that you have habitual eating patterns for both pregnancy and lactation. 3 And I think that women change their eating behaviors 4 5 and frequency during these periods of time. So I think it's okay to look within these time 6 7 periods, differences in eating frequency. But 8 I'm not sure you want habitual in as a key 9 confounder.

I think our intent was 10 MEMBER LEIDY: to capture -- Feel free to chime in. But it was 11 to capture what they were habitually consuming 12 13 before. So this would be pre-pregnancy. So it 14 depends on what we're qualifying as baseline. 15 But if they, you know, became pregnant, their 16 eating frequency may change. And then 17 postpartum, it may change as well.

And so we were trying to figure out just to capture that habitual period of time. Because if their eating patterns are most likely changing, but nobody has really quantified how they're changing. And so that's why we felt that

1	it was important. Again, not that it's going to
2	exclude a study. But that the quality of the
3	study will be evaluated a bit differently if
4	they've captured that versus if they haven't.
5	Rick, I don't know if you want to
6	MEMBER BAILEY: This is Regan Bailey.
7	Short mic here too. My question was surrounding
8	the diet assessment. I'm not sure that most of
9	the food frequency questionnaires capture that
10	rich contextual detail of timing and screens and
11	with whom you're eating, the way that a 24-hour
12	recall can. So are there any validated
13	questionnaires that assess purposeful versus
14	nonpurposeful skipping of meals or time-
15	restricted feeding that could be considered?
16	MEMBER LEIDY: There are.
17	MEMBER BAILEY: Okay.
18	MEMBER LEIDY: But that's a good
19	point. Again, we're thinking in terms of I
20	think we went in thinking highest or best quality
21	of research or data. And so thinking, you know,
22	three dietary recalls would capture that more

effectively than food frequency questionnaires. 1 2 They're still included, but the rating may be a little less. But there are questionnaires. 3 We've actually used them that look at screen time 4 and different components of that. So I think, 5 you know, food frequency questionnaires can also 6 7 capture time duration. They're just different questions. 8

9 So maybe we just need to think about 10 whether -- you know, right now, we just have food frequency questionnaires included. But you're 11 12 suggesting that we, you know, maybe call them something a little bit different if it's an 13 14 eating occasion questionnaire or something like I know breakfast skipping questionnaires -15 that. 16 - I quess we would need to define what a food frequency questionnaire is. And so we have that 17 18 generally, but what we think, I think as 19 nutritionists or dietitians, a food frequency 20 questionnaire might be different than some of 21 these other ones and they're just eating 22 questionnaires. And so I think maybe we need to

1 include that as well.

2	MEMBER BAILEY: Okay, thanks for that
3	clarity. The way that I understood it originally
4	was that a food frequency questionnaire would be
5	better than the recalls at getting habitual
6	intakes. So that really is helpful in terms of -
7	-
8	MEMBER LEIDY: I'm sorry, yes. The
9	only reason I brought that up is because our
10	first thought is well they wouldn't be included
11	because it's not three days. And then it's well
12	no, food frequency questionnaires, the ones that
13	are generally validated are longer term. But you
14	know, I think if we're rating them, most of us
15	the reason we included the three day minimum was
16	thinking of dietary recall assessments as the
17	first. But that we didn't want to exclude any
18	studies that have food frequency questionnaires
19	because some of them do get eating occasions.
20	MEMBER BAILEY: Okay.
21	MEMBER LEIDY: So yes, that's the tier
22	that we were thinking of.

1	MEMBER BAILEY: Great. And then just
2	a followup on that same slide. So a study that
3	has fewer than 15 people but a power calculation
4	that they are adequately powered would be
5	included.
6	MEMBER LEIDY: Correct.
7	MEMBER BAILEY: Okay, thank you.
8	MEMBER SABATE: Joan Sabate. I just
9	would like clarification on the number of daily
10	eating occasions. Because this is the exposure
11	for most of the outcomes that you are relating
12	to, and I put that as an example. Based on your
13	definitions, if somebody has a caloric intake of
14	1, 2, or 3 times a day, plus drinks water seven
15	times a day is the total number of eating
16	occasions of ten. Will this number of ten, will
17	be different than somebody that has just ten
18	small meals caloric meals a day? And will
19	both be the same number and will be related to
20	the outcomes by this numerical way?
21	MEMBER LEIDY: Go ahead.
22	MEMBER MATTES: Yes, we actually

thought about that some. So eating frequency can 1 2 affect total energy intake multiple ways. One is energy actually contributed by the eating event. 3 4 The other is by just changing the physiology --5 the behavior of the individual so that it alters subsequent intake. And so frequent consumption 6 7 of water may actually have an impact on the 8 energy value in foods selected when there is an 9 energy yielding consumption pattern event. So I think we want to count total in just the 10 frequencies to be able to capture both of those 11 12 ways frequency impacts intake.

13 MEMBER LEIDY: But I think, you know 14 -- so that's our search strategy. And then once the findings come in, I think we would comment on 15 16 whether those eating occasions had calories or 17 didn't or even the food form or those aspects. 18 So I don't think -- much like the dietary 19 patterns, I don't think we're going to -- you 20 know, once we see the studies in their totality, 21 you know, we may be able to pair some together. 22 But if there are very specific differences like

caloric content, then I think they need to be treated separately.

MEMBER SABATE: But I think this 3 4 should be stated from the beginning. Because one 5 thing is to have the number of frequent occasions. And another one is to -- besides 6 having the number, I mean to compute which ones 7 8 contribute calories versus which ones do not 9 contribute with calories, which is mainly water. Because it's a completely different approach, 10 11 especially in the context of intermittent fasting 12 and things of this sort. I'm not saying that 13 what you are saying isn't relevant, but it may 14 get the confusion between the two approaches that 15 I'm proposing. 16 MEMBER MATTES: So let me ask a 17 question. Would it change your interpretation if 18 multiple ingestive events were primarily water 19 versus a low calorie beverage? I think so --20 MEMBER SABATE:

21 definitely so.

1

2

MEMBER MATTES: So you think water is

Neal R. Gross and Co., Inc. Washington DC

a unique source of input? I mean what we're trying to capture is something about frequency, not source of nutrients, energy, or whatever. It's a behavior of how often something is ingested.

I think this is an MEMBER SABATE: 6 7 important question. I'm not saying what you're 8 proposing is irrelevant. But I'm just saying 9 that there is a big definition between a dietary pattern that includes two or three caloric eating 10 11 frequencies -- sorry, eating occasions versus 12 having ten occasions in which they are caloric 13 derived. I mean the one that is three plus 14 water, I mean many people -- I mean this is one pattern versus -- I will say we have to separate 15 16 the specific number whether it brings calories 17 into the frequent occasion or not is very 18 relevant.

MEMBER LEIDY: Except that our fundamental research -- the fundamental question of interest is really -- and that's why I put it back up -- it's the number of eating occasions

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

and the timing. The caloric content isn't --1 2 it's not answering that question. We've gone around about with that, it really is a separate 3 4 question because we're really just seeing about 5 timing, not so much the content within those. We will have that and we'll be able to document that 6 7 and look at you know, macronutrient content or 8 energy within each of those occasions. But that 9 first global definition is really about when to eat -- when or the number to eat versus the 10 caloric content within those. 11 12 It's a really good point and we've talked about that. But I think we felt that, 13 14 that was the truest definition of eating 15 frequency was just based on number and timing. 16 MEMBER MATTES: Yes, and water, we tend to think of it as essential but inert in 17 18 some ways. And it really isn't. I mean it 19 alters gastric emptying, GI transit time. It may 20 acutely influence appetitive sensations. It has 21 real physiological implications too. And so I think it's artificial to draw a line with that 22

1

kind of an event.

2	MEMBER LEIDY: But that's a really
3	good point. And that's something that we didn't
4	use as a key confounder. In that, there's a lot
5	of studies that don't capture or quantify water.
6	And there are others that do. So we need to
7	probably go back and be sensitive of that because
8	there are a number of studies that will be ad
9	libitum water consumption throughout the day or
10	that's not even stated in their strategy. And I
11	don't think we actually have that as a key
12	Covariate. And we might want to think about
13	putting that in. Because those studies that
14	focus on water will have it documented. Those
15	that don't, don't. And we're not really we're
16	not listing that as something of a point of
17	concern.
18	MEMBER VAN HORN: Linda Van Horn.
19	Just an important point to this discussion
20	relates to children. And we're probably all
21	familiar with the fact that, you know, appetite
22	regulation in children is something that's a

regulation in children is something that's a

Neal R. Gross and Co., Inc. Washington DC

great interest in prevention of obesity. 1 And the 2 type, as well as the amount of calories is important evidently. Especially for children 3 whose -- from the literature I've read and I'm 4 5 sure most of you have -- their ability when they're drinking a sugary beverage, for example, 6 7 to regulate their caloric intake in subsequent 8 meals is not the same as when they're consuming 9 either water or some other type of food. But the 10 sugar, you know, liquid candy so to speak has a -11 - doesn't seem to have the same impact in terms 12 of energy intake in subsequent meals, that it does with other foods. 13 14 So my only point is to recognize that children may have a different, you know, response 15 16 than adults. And it would be valuable to be able to separate that, if the data exists. 17 18 MEMBER LEIDY: Well and that's an 19 interesting point too because Rick and I are both 20 also on the Beverage Subcommittee. And so I 21 think that question will also -- that will be 22 more specifically addressed there with beverages.

Just a point that there's a lot of cross-talk
 with some of these. And I guess fortunately,
 we're on both.

VICE CHAIR KLEINMAN: Yes, and I was going to add that food patterns as well -- so beverage food patterns and food frequency all have to integrate the information that's being analyzed. And so I think that gets to the points that you're making, Linda, and others have made. Lydia?

11 MEMBER BAZZANO: Hi, Lydia Bazzano. 12 I just wanted to ask about -- the difference 13 between fasting and meal skipping is really the 14 intentionality. So you're capturing that in the 15 confounding or covariates more.

16 MEMBER LEIDY: Yes. And again, that 17 point was really just looking at our search terms 18 and what you typically see fasting not --19 overnight fasting. It's fasting across the day, 20 trying to target that intermittent fasting. And 21 then there's this other concept of meal skipping. And I think Jamy brought that up. A lot of those 22

(202) 234-4433

1	can be synonymous, but we want to just separate
2	them basically for the search strategy.
3	VICE CHAIR KLEINMAN: Well if there
4	are no other Oh Tim?
5	MEMBER MATTES: Can I just follow up
6	on Rachel's initial comment because I think it
7	was an interesting one about about the
8	possibility of a say a monthly cycle and eating
9	frequency. We talked about SES as a covariate.
10	What about something like food insecurity
11	Would that be better?
12	VICE CHAIR KLEINMAN: We talked about
13	that.
14	MEMBER NOVOTNY: Yes, I know. I was
15	trying to think about how it would be modeled to
16	whether that would be you know, I think we're
17	talking about a population the population,
18	which I think it is most relevant probably is a
19	food insecure one. But whether we would want to
20	in some way stratify by socioeconomic status too.
21	So I guess to be I would be inclusive in the
22	pole. So maybe include as possible confounders,

but consider possibly using a covariate -- one of 1 2 them as a covariate -- probably the food security 3 one. 4 VICE CHAIR KLEINMAN: I think we think 5 of those as an effect modifier potentially and so it would be a covariate. And I think it's a very 6 7 good idea to include it. 8 MEMBER LEIDY: Yes, it's a good thing 9 to add as well. VICE CHAIR KLEINMAN: Tim? 10 11 MEMBER NAIMI: I just wanted to return 12 to this theme one more time -- this issue about mediators versus confounders. And this very 13 14 important issue about whether we consider total energy intake as a mediator or confounder or 15 16 both. And my hope is that you present both. So 17 you have for example, total energy intake and 18 anthropometry as mostly kind of pitched as 19 confounders. And I understand that if you want 20 to isolate out the effects of frequency, then 21 that's appropriate. 22 But I would say for the public -- and

1	I think this is where we should consider what the
2	public if God forbid I was interested in
3	losing weight, I would want to know does fasting
4	help me lose weight? And then to me, it would be
5	a secondary question as to whether it's because
6	of reduced overall caloric intake because you
7	have fewer eating occasions or because of its
8	impact on metabolism.
9	So I think it would be nice to report
10	both of those things. But to consider like what
11	would the public find potentially most
12	interesting?
13	And then my other quick question was
14	again, to come back to alcohol. Is it part of
15	total energy intake? And even if it is, you
16	might want to control for patterning, which has,
17	you know, bodily impacts on cardiovascular
18	disease or diabetes. So that's not listed as a
19	confounder or potential confounder anywhere. So
20	just something to consider.
21	VICE CHAIR KLEINMAN: All right, are
22	there other questions or comments? Then I think

1	it may be getting close to time for an ingestive
2	event. So we will adjourn until 1 o'clock. And
3	that's it. Thank you all. Wonderful
4	presentations.
5	(Whereupon, the above-entitled matter
6	went off the record at 11:40 a.m. and resumed at
7	1:02 p.m.)
8	CHAIR SCHNEEMAN: So, I think we'll
9	get started again. Hopefully, everyone had an
10	enjoyable lunch. And we're going to continue
11	with our subcommittee reports. I'm going to turn
12	it back over to Dr. Kleinman.
13	VICE CHAIR KLEINMAN: Terrific. So,
14	our next report comes from the Pregnancy and
15	Lactation wait? Oh, yeah.
16	CHAIR SCHNEEMAN: I forgot one public
17	service announcement. Please be sure you speak
18	into the microphone, speak loudly, and say your
19	name before you start your comments. So, just to
20	help to make sure that we keep everything open.
21	Great. Sorry.
22	VICE CHAIR KLEINMAN: So, Ron

Kleinman. And the next report is going to come
 from the Pregnancy and Lactation Subcommittee.
 And Dr. Sharon Donovan is going to give us that
 report.
 MEMBER DONOVAN: Thank you, and good

afternoon. And I'm Sharon Donovan and I'm
presenting on behalf of the committee members
that you can see on this slide. Oh, I need the
advancer.

10 Okay, so the Pregnancy and Lactation 11 Subcommittee has three main topic areas. And the 12 first we're going to discuss is dietary patterns 13 during pregnancy and lactation.

And within this topic area, we will be conducting five new systematic reviews, which are shown on the left side of the screen. And the two that are in blue will be the ones that we're going to be discussing today.

We also have four existing reviews
that were done as part of the Pregnancy and Birth
to 24 Months project that many of you may have
seen. They were just recently published in AJCN.

1	For those who will be updating them,
2	because the last date that they were searched was
3	January 2017, so we'll be updating those
4	searches.
5	So, we began by focusing on the new
6	reviews. And then, as I mentioned today, we'll
7	do gestational weight gain and postpartum weight
8	loss.
9	So, the second two areas, two
10	questions, are second dietary supplements and
11	fortified foods, which, you can see the
12	dietary the nutrients that we'll be focusing
13	on, are folic acid, iron, B12, omega-3 fatty
14	acids, Vitamin D, and iodine.
15	And the committee decided to start
16	with folic acid and iron. So, those are the ones
17	we'll be presenting today.
18	For each of these nutrients there are
19	five health outcomes, which you can see on the
20	right side.
21	So, basically, these are up to 30
22	systematic reviews that we'll look at the effects

of supplements and fortified foods. 1 2 The final question relates to maternal diet and food allergies, and atopic, allergic 3 diseases. And we have not started on that one 4 5 yet. So, jumping right into dietary 6 patterns, so the two questions that we have is, 7 8 What is the relationship between dietary patterns 9 consumed during pregnancy and gestational weight gain, and dietary patterns during lactation and 10 11 postpartum weight loss? And so we'll be 12 conducting new systematic reviews. 13 So, just to remind you, we're using 14 the standard definition of dietary patterns that was presented earlier. 15 16 So, this is our first analytical 17 framework. So, I'll set this up for you. So, 18 this is looking at dietary patterns during 19 pregnancy and gestational weight gain. 20 So, the intervention and exposures and 21 the comparators, again, are consistent with how 22 Dietary Patterns subcommittee defines dietary

patterns.

2	So, we're looking at the key
3	confounders are shown below. And for all of the
4	ones that are in black, these are going to be
5	consistent for all of the dietary pattern
6	questions. And the ones that we've shown in blue
7	are specific to the outcome that we're
8	investigating.
9	So, as you can see, for this one,
10	which was related to pregnancy and gestational
11	weight gain, we have age, race, ethnicity,
12	socioeconomic status, physical activities,
13	smoking, parity, and anthropometry, which, in
14	this case, is pre-pregnancy BMI.
15	So then, the one specific for this are
16	history and diagnosis of gestational diabetes,
17	and gestational hypertension. So, from now on
18	I'm not going to repeat the ones that are in
19	black.
20	So, I think it was mentioned earlier,
21	the main outcomes for gestational weight gain
22	will be that change in maternal body weight from

baseline, either pre-pregnancy or early in 1 2 gestation, we'll be keeping track of that, and either right at delivery or near delivery. 3 And then we'll be comparing that 4 weight gain in relation to recommendations based 5 on pre-pregnancy BMI. 6 So, again, our population, as women 7 during pregnancy, they're healthy, or at risk for 8 9 chronic disease. So, the second analytical framework, 10 looking at dietary patterns consumed during 11 12 lactation, and postpartum weight loss. Again, what's different about this one 13 14 is we will be focusing in just on women during lactation. So, if women aren't lactating, then 15 16 their dietary patterns will be evaluated by the 17 Dietary Patterns Subcommittee. 18 So, we're looking now at change in 19 weight from baseline postpartum, so close to 20 delivery, we'll be recording that, and then 21 whatever the later time point postpartum. 22 So, again, we understand the papers to
be quite variable, but we'll be keeping track of 1 2 that. And then we'll look at postpartum 3 weight retention if gestational weight gain has 4 5 been accounted for. So, again, the only new confounder for 6 this will be breastfeeding. And what we mean by 7 8 breastfeeding is not only whether or not -- well, 9 obviously, this is lactation, so they will be breastfeeding. 10 11 But we'll be looking at are they 12 exclusively breastfeeding, or are they mixed 13 feeding. So, combining breast milk and infant 14 formula. Okav. So, our standard inclusion and 15 16 exclusion criteria are, we're using the standard NESR criteria. And then, in terms of dietary 17 18 patterns, we're using the ones that have been established for dietary patterns. 19 20 So, inclusion and exclusion 21 criteria -- again, either women during pregnancy 22 or women during lactation, only human studies.

1	And for temporality, we're looking
2	studies that assess outcome exposure prior to
3	outcome, and excluding those that assess outcome
4	prior to exposure. So, that's to control for
5	reverse causality.
6	Also, I should point out and this
7	is something that we're doing in a number is
8	that we're excluding studies in the case of
9	pregnancy, where they might have singleton and
10	multiple births, but they've combined that data.
11	So, they can have singleton or
12	multiple, but they have to have presented that
13	separately.
14	The same thing for postpartum. If
15	they have combined data for lactating and non-
16	lactating women together, then we're going to be
17	excluding those.
18	If there's a paper that has both and
19	they're reported separately, we'll include it,
20	but it's only the pooled data that will be
21	excluded.
22	Okay, so this is exclusion for health

And again, we've talked quite a bit 1 status. 2 about this, so we will include studies that enroll some or all mothers classified as 3 4 underweight or obese during pregnancy. That's 5 the only thing that sort of different there. We will enroll, again, studies for some mothers 6 7 maybe diagnosed with a disease which could 8 include obesity. 9 So, we will exclude studies that exclusively enroll women who give birth pre-term, 10 11 or they exclusively enroll women diagnosed with 12 either severe undernutrition or hospitalized with 13 an illness or injury. 14 So, we're really looking at healthy populations, or those at risk for chronic 15 16 disease. 17 Okay, so now, switching to the next 18 set of questions, which is the relationship 19 between nutrients from supplements and/or 20 fortified foods consumed before, during pregnancy 21 and lactation, and a specific health outcome. 22 So, we're really focusing again on

these nutrients, not necessarily in the foods, 1 2 but unless they're fortified foods or supplements. And again, the first two nutrients 3 we chose to focus on were folic acid and iron. 4 So, in terms of key definitions, this 5 is the definition for dietary supplements. 6 It is basically the definition from the Office of 7 Dietary Supplements. 8 9 But you can see that this does include not only nutrients, but potentially other dietary 10 11 ingredients. But again, we will be focusing on 12 the key nutrients, the six key nutrients that we 13 were assigned. 14 And then, in terms of fortification, again, we're using the FDA definition of 15 16 fortification, which was also used in the 2015 17 Dietary Guidelines, so again, trying to use 18 standardized, accepted definitions for 19 supplementation and fortification. 20 So, starting with our first question, 21 so this is the relationship between folic acid 22 from supplements and fortified foods. And in

this case we're looking at before, during 1 2 pregnancy and lactation, and all five outcomes. So, again, I'll just set up this 3 4 analytical framework. Again, we're looking at 5 exposure to folic acid from dietary supplements, which can be a single supplement or multiple, and 6 7 fortified foods, or a combination of supplements 8 and fortified foods. And then we'll be -- we 9 have comparators basically focusing on different levels of folate. 10 11 So, in this case, we're looking at --12 we've just decided for the before-pregnancy 13 exposure. In all cases, we're looking at six 14 months pre-pregnancy. So, we've set that as our time frame, and then during pregnancy and/or 15 16 lactation. 17 So, in terms of the markers of folate 18 status, we have folate, Vitamin B12, hemoglobin, 19 mean corpuscular volume, and red blood cell distribution width. 20 21 We chose not to include homocysteine, 22 because it's not a specific bio-marker for folate

status.

2	So, the key confounders are shown at
3	the bottom, and these will be used for all the
4	folic acid questions, with the addition of some
5	additional ones for certain outcomes.
6	So, this is looking at folic acid
7	before and during pregnancy on gestational
8	diabetes. Again, the intervention and
9	comparators are the same.
10	For the key confounders, we have added
11	in blue family history of diabetes or pre-
12	diabetes.
13	We have the intermediate outcomes.
14	This was discussed previously, so I guess based
15	on what we're deciding with diabetes in terms of
16	hemoglobin, A1C, or whether that will be
17	considered an intermediate, as well as an
18	outcome. So, we need to be consistent there.
19	But really, what we've tried to do for
20	our specific pregnancy and lactation outcomes is
21	mirror the criteria that are being used in other
22	outcomes, so that we're trying to be as

consistent as possible.

2 So, the next is basically looking at folic acid from supplements and fortified foods 3 on hypertensive disorders of pregnancy. So, same 4 intervention comparator. 5 Our intermediate outcomes are blood 6 7 pressure and proteinuria, and the health 8 outcomes, these hypertensive disorders of 9 pregnancy, were used in the criteria established by the American College of Obstetrics and 10 Gynecology, which were recently updated in 2019. 11 12 So, we're looking at eclampsia, pre-eclampsia, 13 and gestational hypertension. 14 The key confounders. The only addition here is diagnosis of gestational 15 16 diabetes, because there's some reports that between gestational diabetes and hypertensive 17 18 disorders during pregnancy. 19 The next is looking at human milk 20 composition. And the original question was human 21 milk composition and quantity. 22 And basically, the committee felt as

we discussed this, that there isn't really good 1 2 evidence for any of these micronutrients impacting the quantity of human milk, so we're 3 basically focusing on human milk composition. 4 So, very simple outcome, we're 5 basically just looking at folate in human milk. 6 7 And basically the same intervention comparators, 8 and no new key confounders for this outcome. 9 And then our last outcome for folic acid is basically looking at developmental 10 11 milestones, including neurocognitive development. 12 So, this is a little bit different because we're 13 actually not focusing as much on the mother. 14 We're focusing on the child. And basically our -- I'm sorry. 15 It 16 helps to advance the slide. 17 The developmental outcomes are similar 18 to what had been previously reported. We don't 19 have things like Alzheimer's, or some of the 20 longer-term outcomes. But we do include anxiety, 21 depression, autism, ADHD. 22 And because we know if we stayed

within the B-24, that there would be very few of 1 2 these measures that would be valid, other than developmental milestones. 3 We've actually considered both infants 4 and toddlers, and even children and adolescents. 5 So, we will be trying to expand that to be able 6 to capture more of these neurocognitive, 7 neurodevelopmental outcomes. 8 9 So, in terms of key confounders, we have added child sex, gestational age at 10 11 delivery, and breastfeeding. 12 So, in this case, whether or not the 13 child was breastfeeding, and also the duration 14 exclusivity. So really, we're kind of calling 15 this breastfeeding practices. 16 Okay, so overall, exclusion and 17 inclusion criteria, we're basically using the 18 standard criteria that Dr. Schneeman presented 19 this morning. 20 The types of studies. Again, we had 21 some discussion about this. Due in large part to 22 the fortification of the food supply with folate,

so we wanted to extend the searches back farther,
 back to 1980, rather than 2000.

And we also decided to include some 3 4 cross-sectional studies, and then controlled 5 before and after, so these could be studies that perhaps looked at human milk folate before the 6 fortification of the food supply and after, but 7 8 also, we felt in this case there would be very 9 few longitudinal studies on human milk composition. 10

So, we feel that cross-sectional
studies in folate intake are appropriate. So,
those are the only two differences there.

So, again, inclusion criteria, human participants only. There really isn't anything that's that different in terms of the inclusion criterial.

We will use studies, we will include mothers with obesity, being at risk of chronic disease, and we'll include studies where some of the children or the mothers may have gestational diabetes, hypertension, but exclude ones where

1 they're only diagnosed with those, and also 2 excluding pre-term infants. Okay, so I feel like I'm moving 3 4 through this pretty quickly. So, the next nutrient that we looked 5 at was iron. And so this, again, will be very 6 similar to folic acid, in terms of the 7 8 intervention and exposure. 9 And we had a long discussion about 10 this, but we actually decided to include only 11 iron from supplements, and not from fortified 12 foods. And the thinking is that in high and 13 14 very high-income countries, iron is more likely to come from supplements, rather than fortified 15 16 foods. 17 So, if you have comments, you can make 18 comments on that. But that was -- Kay Dewey was 19 one of the proponents of that. 20 Also, in terms of iron, we decided not 21 to look at human milk composition because all of 22 the minerals are tightly regulated at the level

of the mammary gland and there's a lot of 1 2 evidence that shows that iron supplementation has no impact on human milk iron content. 3 So, for iron we only have four 4 5 outcomes and we're not including a systematic review on iron from supplements and fortified 6 foods and milk iron. 7 8 So, again, these are going to be very 9 similar to the folate. This is looking at iron consumed before and during pregnancy and 10 11 lactation, and micronutrient status. So, basically, same intervention and 12 13 exposures. It's just in this case we're looking 14 at iron only from supplements. The outcomes will be iron status, 15 16 which will basically encompass however that was 17 reported in the manuscripts, so we didn't want to 18 list all of the options. They had diagnoses of 19 iron deficiency, iron deficiency anemia, and anemia. 20 21 The population -- again, women during 22 pregnancy and lactation -- and we will be looking

at iron supplementation up to six months prior to
 conception.

So, for all of the iron outcomes, the 3 4 only new key confounder that's consistent for all 5 of them is now baseline hemoglobin. So, we then -- the next analytical 6 7 framework is iron on gestational diabetes. So, 8 again, the intermediate outcomes and endpoint 9 outcomes will be the same as folic acid in The only new key 10 gestational diabetes. 11 confounders that we've added here is now family 12 history of diabetes and pre-diabetes, as well as 13 baseline hemoglobin. 14 So, the next is, again, iron and 15 hypertensive disorders during pregnancy. Aqain, same intermediate outcomes and health outcomes. 16 17 And the new key confounder in this case is

diagnosis of gestational diabetes. And then the
last one for this is looking at neurocognitive
development and the outcome.

21 So, again, very similar to folate in 22 terms of the outcomes, expanding the population

up to 18 years of age in the offspring, and now, 1 2 in addition to hemoglobin, bringing in child sex, gestational age of delivery, and breastfeeding. 3 So, for the iron and dietary 4 supplements, again, the standard criteria are 5 used for the overall NESR, as well as for folic 6 7 acid and health outcomes. So, basically, the next steps, after 8 9 incorporating any additional comments we receive at this meeting, is to go to our next set of 10 11 dietary patterns questions. 12 So, we've done the two on gestational 13 weight gain and postpartum weight retention. The 14 next are human milk composition and quantity, developmental milestones, and micronutrient 15 16 status. And then we will start on the next set 17 of analytical frameworks for dietary supplements 18 and fortified foods. 19 So, we haven't necessarily decided yet 20 on the order, but the next are B12, omega-3 fatty 21 acids, Vitamin D, and iodine. And then, for each of those four, we will likely be looking at 22

1	all five outcomes.
2	So, it's another 20 potential
3	systematic reviews. So, we have a lot of work
4	ahead of us.
5	So, I just would like to acknowledge
6	our committee members and our support staff, and
7	I would like everyone else to really say how
8	wonderful the support staff is and how hard
9	they're working.
10	And we have our weekly phone calls and
11	they're always prepared and very helpful when we
12	have questions. So, that's all we have.
13	VICE CHAIR KLEINMAN: Thank you very
14	much. We're open for questions or comments.
15	Linda?
16	MEMBER VAN HORN: Linda Van Horn.
17	First of all, I just want to congratulate your
18	group. That was a tremendous amount of work just
19	to get it organized. This is a topic area that
20	is so in need of this kind of scrutiny, and I
21	think you made a terrific start, as far as going
22	ahead with it.

1	Three things bear with me stuck
2	out to me as you were going through your list,
3	and I can see at the end you included one of
4	them, which was unsaturated fatty acids, and
5	three especially, related to neurocognitive
6	development, and possibly other aspects related
7	to even gestational diabetes, or things of that
8	sort.
9	CHAIR SCHNEEMAN: Linda?
10	MEMBER VAN HORN: Oh, sorry. Still
11	having trouble? Sorry. Okay.
12	And so, but two other things seem
13	important to me. One, the idea of only focusing
14	on supplemental iron to me, even in the developed
15	countries, seems potentially problematic.
16	Why? Because we have many women who
17	are attempting, at least, to become vegetarians
18	or semi-vegetarians, or what have you. And not
19	only that, we also have women who forego the
20	supplement, the dietary supplement, that's
21	recommended, because, frankly, they don't want to
22	be constipated.

1	And so, you know, at least in the work
2	that we've been doing over the last six years,
3	we've noticed that this is a trend, at least in
4	an industrialized country, with people who are
5	educated, but just basically don't take those
6	factors into consideration, in terms of a
7	recommended supplement.
8	So and especially since our food
9	supply now is so heavily fortified with iron in
10	various foods, it would just seem to me
11	unfortunate not to be able to really look at,
12	with or without supplemental iron, the impact on
13	your outcome.
14	So, I know that's a lot more work
15	maybe. But if it's possible, it would seem
16	relevant to be able to incorporate that if it is
17	possible.
18	And then the third thing sorry, one
19	more last thing, and that relates to gestational
20	hypertension and the concerns that, of course, we
21	have with preeclampsia and eclampsia, and
22	gestational diabetes, as well as hypertension,

the topic we raised earlier about sodium, and also calcium.

If you think about it, the DASH 3 4 diet -- I mean, wouldn't we want all pregnant 5 women to follow something like a DASH diet to reduce their risk for hypertension, as well as 6 7 obesity or excessive gestational weight gain. 8 So, as this set of guidelines will be 9 the launch for recommendations related to diet in pregnancy, as well as those first two years, I 10 11 just think if it's possible to be able to look at 12 some of those factors that could in fact be 13 influencing the common problems with pregnancy 14 related to gestational hypertension and diabetes, wouldn't we want to have a better sense of the 15 16 diet, the dietary pattern, that could help reduce 17 those risks. So -- sorry, that was my --18 MEMBER DONOVAN: No. I mean, those 19 were all --20 MEMBER VAN HORN: And others may 21 disagree. 22 MEMBER DONOVAN: No, they were good

1

And I think in terms of the supplemental 1 points. 2 iron and fortified -- iron from fortified foods, that was one of the original questions that we 3 4 qot. 5 So, I think we could consider changing 6 the search terms so we could get both of those, 7 and then be able to compare that. 8 The omega-3s. Again, with the omega-9 3s, we will be looking at all five outcomes with 10 that. 11 The last one I think is interesting, 12 because we don't have a question related to 13 dietary patterns in gestational -- well, but 14 actually, let me correct that. 15 So, that was one of the 16 previous -- let me see. Let me make sure I'm Because there were some of those 17 right. 18 systematic reviews that were done as part of the 19 pregnancy -- so yes, part of the pregnancy and 20 birth. 21 We have gestational diabetes, 22 hypertensive disorders during pregnancy, from

Neal R. Gross and Co., Inc. Washington DC

1	gestational age at birth and birth weight related
2	to dietary patterns. So, that's not one of our
3	new ones, but we will update that, so we will get
4	that.
5	VICE CHAIR KLEINMAN: Any other
6	comments or questions?
7	MEMBER BOUSHEY: Okay, I concur. I
8	just want to say, I concur
9	VICE CHAIR KLEINMAN: Say your name.
10	MEMBER BOUSHEY: Carol Boushey
11	concurs with Linda's comments thank you very
12	much so that because you said, I don't know
13	if others do. So, I'm letting you know, I do.
14	CHAIR SCHNEEMAN: I wanted to come
15	back on this point of iron and fortified foods.
16	And I'm not sure I fully understood the rationale
17	behind why you might do it, because I think iron
18	is part of the enrichment, so just like folic
19	acid is part of the enrichment. That's why it's
20	in fortified foods. It seems like the same logic
21	would hold for iron.
22	MEMBER DONOVAN: So, any other people

1	on the committee? Because I think I was not on
2	that call where this was discussed. And I
3	actually came back and asked. So, do you
4	remember some of the
5	(Off-mic comment.)
6	MEMBER DONOVAN: I think it's also
7	perhaps just because during pregnancy in
8	particular, I mean, the iron supplement level is
9	so high.
10	But again, I don't think it's a big
11	deal to just include that in the search terms.
12	It's not a new question. Right?
13	It was part of the original question
14	that we decided as a committee. But I will bring
15	it back and make that decision with the staff.
16	VICE CHAIR KLEINMAN: All right.
17	Either the post-ingested event coma is settling
18	in, or the questions have been asked. Anyway,
19	thank you very much, Sharon. That was a great
20	presentation.
21	So, we'll move on now to birth to
22	24 months. And Dr. Elsie Taveras is going to

present that. And she needs the clicker. 1 2 MEMBER TAVERAS: It's going to do much for the post-prandial. So, bear with me, please. 3 4 I'm Elsie Taveras. I am presenting 5 for the Birth to 24 Months Subcommittee. Our Chair, Kay Dewey, was not able to be here today, 6 7 but we have a number of our subcommittee 8 participants, including Sharon and Ron and Lydia. 9 So, I'm going to get started by telling you a little bit about the protocols that 10 we are going to discuss today. 11 12 We have eight protocols that we've 13 completed, and five additional protocols that are 14 yet to be completed. This slide shows the five topic areas 15 16 that we're presenting today that relate to 17 feeding human milk and infant formula. 18 So, you'll see that we're looking at 19 duration, frequency and volume of human milk or 20 infant formula, with growth, size and body 21 composition, with micronutrient status, with 22 developmental milestones, with food allergy,

atopic allergic diseases, and with long-term
 health outcomes.

And this slide shows the three topic 3 4 areas that relate to specific nutrients from 5 supplements and fortified foods. We'll be covering four specific nutrients: iron, 6 7 Vitamin D, Vitamin B12 and omega-3 fatty acids, 8 with three separate outcomes: nutrient status, 9 growth, size and body composition, and bone health. 10 11 And the five topic areas still to be 12 completed all relate to complementary feeding, 13 with micronutrient status, growth, size and body 14 composition, developmental milestones, food 15 allergy, and bone health. 16 So, let's begin by looking at the 17 protocols we've developed to examine human milk 18 and infant formula topics. And I'll warn you all 19 in advance that these are very complicated, with 20 a number of different comparators. So, bear with 21 me. 22 But also, I want to say ahead of time

1	that all of the protocols are available to the
2	committee, but also to the general audience and
3	on the Web.
4	So, our three human milk/infant
5	formula questions will be answered with new,
6	original, systematic reviews. And the three
7	questions that we will be asking are, what is the
8	relationship between the duration, frequency and
9	volume of exclusive human milk and/or infant
10	formula consumption, with growth, size and body
11	composition?
12	What is the relationship between
13	duration, frequency and volume of human milk
14	and/or infant formula consumption and
15	micronutrient status?
16	And what is the relationship between
17	the duration of exclusive human milk and/or
18	infant formula consumption and developmental
19	milestones, including neurocognitive development?
20	We have also two human milk/infant
21	formula questions that will be answered with
22	updates to existing systematic reviews similar to

the pregnancy and lactation reviews.

2	There are existing reviews on the
3	following two questions that we plan to update.
4	And the two questions that will be updated
5	through updating of existing systematic reviews
6	are the relationship between the duration of
7	exclusive human milk and/or infant formula
8	consumption, and food allergies and atopic
9	allergic diseases, and what is the relationship
10	between the duration of exclusive human milk or
11	infant formula consumption, and long-term health
12	outcomes?
13	We'll start, as we have with the other
13 14	We'll start, as we have with the other frameworks, with some key definitions.
13 14 15	We'll start, as we have with the other frameworks, with some key definitions. We defined human milk as mother's own
13 14 15 16	We'll start, as we have with the other frameworks, with some key definitions. We defined human milk as mother's own milk provided at the breast, or expressed and fed
13 14 15 16 17	We'll start, as we have with the other frameworks, with some key definitions. We defined human milk as mother's own milk provided at the breast, or expressed and fed fresh or after refrigeration or freezing, and we
13 14 15 16 17 18	We'll start, as we have with the other frameworks, with some key definitions. We defined human milk as mother's own milk provided at the breast, or expressed and fed fresh or after refrigeration or freezing, and we will not be examining donor milk.
13 14 15 16 17 18 19	We'll start, as we have with the other frameworks, with some key definitions. We defined human milk as mother's own milk provided at the breast, or expressed and fed fresh or after refrigeration or freezing, and we will not be examining donor milk. Infant formula is commercially-
13 14 15 16 17 18 19 20	We'll start, as we have with the other frameworks, with some key definitions. We defined human milk as mother's own milk provided at the breast, or expressed and fed fresh or after refrigeration or freezing, and we will not be examining donor milk. Infant formula is commercially- prepared infant formula, meeting FDA or
13 14 15 16 17 18 19 20 21	We'll start, as we have with the other frameworks, with some key definitions. We defined human milk as mother's own milk provided at the breast, or expressed and fed fresh or after refrigeration or freezing, and we will not be examining donor milk. Infant formula is commercially- prepared infant formula, meeting FDA or international food standards.
13 14 15 16 17 18 19 20 21 22	We'll start, as we have with the other frameworks, with some key definitions. We defined human milk as mother's own milk provided at the breast, or expressed and fed fresh or after refrigeration or freezing, and we will not be examining donor milk. Infant formula is commercially- prepared infant formula, meeting FDA or international food standards. And complementary foods and beverages

1	are foods and/or beverages other than human milk
2	or infant formula, provided to an infant or young
3	child, to provide nutrients and energy.
4	We also have definitions for feeding
5	methods, which you'll see throughout our analytic
6	frameworks.
7	The first is human milk feeding, which
8	is feeding human milk alone, or in combination
9	with infant formula and/or complementary foods or
10	beverages, such as cow's milk.
11	Exclusive human milk feeding, which is
12	feeding human milk alone, and not in combination
13	with infant formula and/or complementary foods or
14	beverages, such as cow's milk. This definition
15	is inclusive of the World Health Organization
16	definitions of exclusive and predominant
17	breastfeeding, which permit limited quantities of
18	drops or syrups containing vitamins, minerals, or
19	medicines, water and water-based drinks, such as
20	sweetened water and teas, fruit juice, oral
21	rehydration salt solutions, and ritual fluids.
22	Our definition for mixed feeding is

feeding human milk and infant formula, but not 1 2 complementary foods and beverages. And our definition for topping up is feeding infant 3 formula after human milk during a single feeding 4 5 session. So, I'm going to pause a bit. 6 And 7 similar to Carol, I have some animation, because 8 of the complexity of this analytic framework. 9 So, this is our analytic framework for a new systematic review on the relationship of 10 11 the duration, frequency and volume of human milk 12 and/or infant formula consumption, with growth, 13 size and body composition. 14 In the box on the left, you can see our comparators of interest are divided into two 15 16 groups -- I think I have several clickers -- the 17 top group being which is in red here, shows three 18 specific comparisons we want to use to examine 19 duration of human milk and/or infant formula 20 consumption. 21 These comparisons align with the first

feeding decisions that caregivers have to make.

22

A caregiver's first decision is whether or not to feed human milk, so we will examine comparisons of infants who ever consume human milk -- that is, any amount of human milk -- with infants who never consume human milk -- that is, completely or entirely formula-fed infants.

7 Among infants who are fed human milk, 8 subsequent decisions caregivers have to make are 9 how long to feed human milk at all, and how long 10 to feed it exclusively.

11 And therefore, the second comparison 12 that we are going to make is the comparison of 13 different durations of any human milk consumption 14 among infants who are human milk-fed, and consumption and comparison of different durations 15 16 of exclusive human milk consumption prior to the introduction of infant formula. 17 That's a 18 mouthful.

But essentially, our top group looks
at duration. And our bottom grouping then looks
at three specific exposures and comparators,
examining frequency and volume of human milk

1

2

3

4

5

and/or infant formula consumption.

2	So here, we want to examine
3	comparisons. First, comparisons of different
4	intensities or proportions or amounts of human
5	milk consumed by mixed-fed infants.
6	Next, we want to examine comparisons
7	of different intensities or proportions or
8	amounts of human milk consumed at the breast
9	versus by bottle in infants fed human milk as
10	their only source of milk.
11	And third, we want to examine
12	comparisons of consuming human milk or infant
13	formula, with consuming both human milk and
14	infant formula, during a single feeding session.
15	For example, topping up a human milk feeding with
16	infant formula.
17	We will examine all of these
18	comparisons in healthy infants and toddlers. Our
19	outcomes, as I mentioned earlier, is growth, size
20	and body composition outcomes that relate to
21	human milk and infant formula comparisons, and
22	they represent a range of outcomes that we will

look at and examine throughout the life span. 1 2 And finally, on this slide, very tiny at the bottom there are key confounders that 3 we've identified, and some of these are similar 4 throughout all of our slides: race/ethnicity, 5 socioeconomic status, types and amounts of 6 7 complementary foods and beverages and infant 8 formula, childhood diet, birth weight, fetal 9 growth, smoking, mode of delivery, and maternal body mass index. 10 11 Our next analytic framework is similar 12 in the examination of our interventions and 13 exposures, duration, frequency and volume, but looks at outcomes of micronutrient status. 14 Here, you'll observe that our 15 16 comparisons of interest are divided into the same 17 two groups as I showed in the previous slide for 18 growth, size and body composition. 19 The bottom grouping is a little bit 20 smaller than it was on the previous slide. We 21 retained the comparison of different intensities or proportions or amounts of human milk consumed 22

by mixed-fed infants.

2	However, we decided that the breast
3	versus bottle and the topping up comparisons, are
4	less relevant to examine in relation to the
5	micronutrient status outcomes you see on the
6	current slide.
7	In this case, our outcomes will
8	include micronutrient status in infants and
9	toddlers, specifically, iron, zinc, iodine,
10	Vitamins D and B12, and fatty acids.
11	This next analytic framework is for
12	the new systematic review on the relationship
13	between the duration of exclusive human milk or
14	infant formula consumption, and developmental
15	milestones, including neurocognitive development.
16	Here are comparators and sorry, our
17	intervention and exposures and comparators all
18	relate to duration of consumption.
19	Frequency and volume are not part of
20	this question. And therefore, the comparisons of
21	interest here include only the comparisons of
22	ever versus never consuming human milk and/or

different durations of any and exclusive human milk feeding.

In this slide, you will also notice 3 our outcomes of interest are developmental 4 milestones, including cognitive, 5 language/communication, movement/physical and 6 7 social-emotional developmental outcomes, as well 8 as a range of other outcomes, including academic 9 performance, attention deficit disorder, anxiety, depression, and autism spectrum disorder. 10 You'll notice also that these outcomes 11 12 will be examined in infants through adolescence. 13 That's our population for this analytic 14 framework. The next framework examines human milk 15 16 or infant formula consumption with food allergies 17 and atopic allergic diseases. 18 Similar to the previous slide, 19 frequency and volume are not part of this 20 question, and therefore, the comparisons of 21 interest are identical to the previous slide. 22 The outcomes of interest here are food

1

allergies, allergic rhinitis, and atopic 1 2 dermatitis, throughout the life span, and asthma, starting at two years of age. 3 And that was intentionally done so 4 that we are really capturing asthma, and not 5 transient, recurrent wheeze that happens prior to 6 the age of two. 7 Finally, this framework is to update 8 9 an existing systematic review on the relationship between the duration of exclusive human milk 10 11 and/or infant formula consumption, and long-term 12 health outcomes. 13 Again, you'll observe that frequency 14 and volume are not part of this question. And again, the comparisons of interest are identical 15 16 to the previous two slides. The outcomes of interest here include 17 18 a number of intermediate outcomes, including 19 intermediate cardiovascular disease outcomes and 20 intermediate diabetes outcomes, and a number of 21 endpoint health outcomes in both of those 22 categories.

1	Both of these endpoint health outcomes
2	will be examined among children through older
3	adults.
4	For inclusion and exclusion criteria,
5	for of the questions related to human milk or
6	infant formula consumption, we propose using the
7	standard inclusion and exclusion criteria that
8	were described by our committee chair for
9	publication status, language of publication,
10	study participants, and health status of
11	participants.
12	But we have number of ways that we are
13	tailoring the inclusion and exclusion criteria
14	for a few of the categories.
15	First, we propose including literature
16	published from 1980 to the present. This will
17	align with the existing systematic reviews that
18	have already been conducted, with examined the
19	literature back to 1980.
20	Additionally, 1980 was the year that
21	the US Congress passed the Infant Formula Act,
22	which established nutrient requirements for

commercial infant formulas in the US, and thus, 1 2 health effects associated with formula consumption before 1980 might be different. 3 So, that was the reason that we 4 tailored a bit the date of publication. 5 Second, we propose including studies 6 7 with at least 30 participants per group, or a 8 power analysis indicating that the study was 9 appropriately powered for the outcome of interest, and excluding studies with fewer than 10 11 30 participants per group with no power analysis. 12 You may have noticed that our age of 13 study participants varies across our analytic 14 frameworks. And we wanted to acknowledge and justify the variability in age and outcome across 15 16 the reviews. We want to look at studies that 17 18 examine human milk or infant formula consumption 19 in relation to growth, size, body composition, 20 atopic diseases, and long-term health outcomes, 21 throughout the life span. 22 So, you'll see that for those outcomes we are including -- the age of participants is throughout the life course. However, for asthma, for cardiovascular disease and diabetes outcomes, the age of study participants begins at age two years.

6 That's consistent with the existing 7 systematic reviews on human milk and infant 8 formula. These decisions were also made, as I 9 already mentioned, because an asthma diagnosis 10 under age two may actually represent transient, 11 recurrent wheeze, rather than asthma.

12 In addition, there is some uncertainty 13 regarding whether and how intermediate outcomes, 14 such as blood lipids in infants and toddlers, may 15 relate to subsequent cardio-metabolic risk.

We thought it was most important to address whether and how human milk or infant formula consumption may impact child development. And thus, we did not go beyond adolescence. And finally, we thought it was most important to examine nutrient status during the

22

(202) 234-4433

1

2

3

4

5

Neal R. Gross and Co., Inc. Washington DC

period of infancy and toddlerhood, when human
milk and infant formula are being consumed. 1 2 Finally, we proposed tailoring the standard criterion for country. Our inclusion 3 criteria for our analytic frameworks on infant 4 formula or human milk consumption will include 5 studies conducted in countries ranked as high or 6 7 very high in human development, and we will exclude studies conducted in countries ranked as 8 9 medium or lower human development. 10 So, with that I want to switch our focus to look at the protocols we've developed to 11 12 examine topics related to specific nutrients from supplements and fortified foods. 13 14 The approach to answer this next set of questions that examines specific nutrients 15 16 from supplements or fortified foods consumed 17 during -- between birth to 24 months, and 18 multiple health outcomes, will be original, 19 systematic reviews. 20 As noted on this slide, there are four 21 public health nutrients of interest for these questions, which are iron, Vitamin D, Vitamin B12 22

and omega-3 fatty acids. 1 2 So, four nutrients of interest, three outcomes of interest, which are nutrient status, 3 4 growth, size and body composition, and bone health, resulting in 12 analytic frameworks. 5 Again, some key definitions. 6 And I won't read these word-for-word. 7 These -- I know, 8 sorry, Gene. I know you really wanted me to read 9 these. These are the key definitions 10 11 discussed by our subcommittee, that are provided 12 on each analytic framework with this set of 13 questions. 14 The definition for dietary supplements is from the 1994 Dietary Supplement Health and 15 16 Education Act, is provided here on the slide. And the definition for fortification is as 17 18 defined by the US Food and Drug Administration, 19 and is also available online. 20 So, we'll start with our first 21 analytic framework examining nutrients, nutrient This next set of systematic review 22 status.

questions examine the relationship between a 1 2 specific nutrient -- in this case, iron -- from supplements and/or fortified foods, again, 3 consumed during infancy and toddlerhood, birth 4 through 24 months, and the specific nutrient 5 status outcomes. 6 7 The intervention or exposure of 8 interest in this next set of slides that you will 9 see, is consumption of a specific nutrient -again, here I'm showing iron -- from supplements 10 11 and/or fortified foods or beverages. 12 The comparators for consumption of the 13 nutrient from supplements are, consumption of the 14 specific nutrient at a different dosage or frequency, from supplements, and/or consumption 15 16 of the nutrient from fortified foods. 17 The population of interest for the 18 intervention/exposure, comparator and outcomes 19 include infants and toddlers, birth to 24 months, 20 who are healthy and/or at risk for chronic 21 diseases. The outcomes discussed by our 22

subcommittee as most relevant for iron
 consumption include iron status, including iron
 deficiency and anemia, zinc status and copper
 status.

5 And here, the key confounders are 6 similar to ones I have shown before, but in this 7 case include feeding practices, anthropometry at 8 birth or baseline, gestational age, prenatal 9 vitamin supplement use, and baseline nutrient 10 status.

So, similar to the previous slide,
this analytic framework is also examining
supplements -- sorry, a nutrient -- in this case,
Vitamin D, from supplements and/or fortified
foods consumed from birth to 24 months, and in
this case, Vitamin D nutrient status as the
outcome.

Again, our intervention or exposure of
interest and comparator is the specific nutrient
of interest, which here is Vitamin D.
The outcome of interest for this
framework is Vitamin D status and anemia. And

the same key confounders as the previous slide 1 2 are shown here, with the exception of the addition of sun exposure for Vitamin D. 3 Similar to the previous two slides of 4 5 iron and Vitamin D, this slide shows the analytic framework for Vitamin B12 and nutrient status. 6 And again, similar to the previous two 7 slides, the intervention or exposure of interest 8 9 and comparator relates here to the nutrient of Vitamin B12, the same population of interest as 10 presented on the previous slides. 11 12 The outcomes for nutrient status include Vitamin B12 and folate status. 13 And the 14 key confounders are all, similar to the previous slides, with the addition here of -- as a key 15 16 confounder, of maternal vegan diet. 17 And finally, this question examines 18 omega-3 fatty acids from supplements and/or 19 fortified foods, from birth to 24 months, with 20 the exposure or intervention of interest and 21 comparator being omega-3 fatty acids. 22 We are examining the same population

1	of interest as the previous slides. And here,
2	the outcome of interest is fatty acid status.
3	So, next we are this is the
4	analytic framework. And this is good. The next
5	series of slides are going to look very similar
6	as the previous four, with the specific nutrient,
7	so iron, Vitamin D, Vitamin B12, and omega-3
8	fatty acids.
9	But the next series of slides look at
10	growth, size and body composition. Again, the
11	slide I'm showing here shows iron and intake of
12	iron from supplements and/or fortified foods.
13	That's the intervention or exposure and
14	comparator.
15	The outcomes here are growth, size and
16	body composition outcomes. And these will be the
17	same for the next series of slides looking at
18	growth, size and body composition as the
19	outcomes.
20	The same population of interest for
21	both intervention exposure and outcome in this
22	slide is similar for the previous sets of

1

2	And our key confounders here include
3	key confounders that are similar in the previous
4	slides: sex, race/ethnicity, socioeconomic
5	status, parental education, feeding practices,
6	anthropometry at birth or baseline, and
7	gestational age.
8	I'll go fairly quickly through these
9	next slides, because really the only difference
10	in the next three slides is the nutrient of
11	interest.
12	In this case, it's Vitamin D. In the
13	next analytic framework it's Vitamin B12, and in
14	the next framework it's omega-3 fatty acids. In
15	all of those slides, the outcome is the same
16	growth, size and body composition.
17	And finally, the next four slides, all
18	similar to the previous eight, look at a specific
19	nutrient, but now shifting the outcome to bone
20	health.
21	And I'll pause for a minute to define
22	our outcomes our bone health outcomes. Here,

the outcomes include bone mass, bone mineral 1 2 density, bone mineral content, biomarkers of bone metabolism, rickets and fractures. 3 And so, what you'll see in the next 4 series of slides, this one shows the specific 5 nutrient of interest is iron. And the next 6 series of slides will show the specific nutrient 7 with the same bone health outcomes and the same 8 9 key confounders. So, for example, this next slide shows 10 Vitamin D as the specific nutrient of interest 11 12 from supplements and/or fortified foods, and the 13 outcome, again, in this slide, is bone health. 14 In this slide, the specific nutrient of interest is Vitamin D, and the outcomes are 15 16 the same. Sorry, that was supposed to be Vitamin B12. And the outcomes are the same, the 17 18 bone health outcomes. 19 And finally, the specific nutrient of interest in this final slide is omega-3 fatty 20 21 acids, with the same bone health outcomes as the previous slides. 22

1	Our inclusion and exclusion criteria
2	that we propose will be the standard criteria for
3	the criteria, or for the categories shown here on
4	this slide. But in the upcoming slides, I'll
5	illustrate, again, where we are tailoring the
6	inclusion and exclusion criteria for this set of
7	questions.
8	So, first, the criteria shown here for
9	the intervention/exposures correspond to what was
10	illustrated on all of the analytic frameworks.
11	Specifically, for inclusion criteria, we will
12	include studies that specify the dosage amount
13	and fortification level received of each of the
14	specific nutrients.
15	We'll also include studies that
16	examine animal products that contained added
17	nutrients as a result of feeding the animal a
18	specialized diet.
19	Follow-up formula will be considered
20	as a fortified food or beverage. The
21	subcommittee discussed the interest in examining
22	evidence of follow-up formula, but recognized the

lack of an accepted definition, and potential
 overlap with infant formula.

There are no name or claim requirements for toddler milks, and there's a wide variation and statement of identity for what a follow-on formula is.

For exclusion criteria, studies that do not specify the dosage amount or fortification level received or the specific nutrient, will be excluded, as well as studies that vary nutrients other than the nutrient of interest, without controlling for that variation.

We also propose tailoring, similar to the previous set of analytic frameworks, the age of study participants, for bone health outcomes the age will include only children and adolescents ages two to 12 years.

We also are proposing to tailor the sources of foods, beverages or nutrients. For the sources of these we -- given the age of intervention and exposure, and that it is birth to 24 months, we will consider studies in which

1 infant formula is examined, as long as it meets 2 the FDA or international standards. Our next steps are to implement the 3 4 protocols that we discussed today, eight in 5 total, followed by developing the remaining protocols, which all relate to complementary 6 7 feeding. 8 We also plan to meet with the Data 9 Analysis and Food Pattern Modeling, Cross-cutting 10 Working Group, to discuss assessing food group 11 and nutrient intakes among children birth to 12 24 months. I want to acknowledge our subcommittee 13 14 members and the overwhelming amount of work and support that we get from the USDA staff. 15 It's 16 been an incredible amount of work, as Sharon 17 mentioned, developing these protocols, and many 18 more to come. 19 And it wouldn't be possible without 20 all the help that we get from the staff, so thank 21 you. 22 VICE CHAIR KLEINMAN: Thank you very

1	much, Elsie. We're open for questions and
2	comments. This is a new topic and a lot of work
3	has been done by the Birth to 24 Committee
4	working on it before we got to it. But a lot of
5	work continues. Questions? Comments? Rachel?
6	MEMBER NOVOTNY: Thank you. That was
7	really great to see how much you've broken down
8	the human milk piece. I appreciate that.
9	I have a question and it's part
10	relating back to our earlier conversations. And
11	I think I understand at least somewhat your
12	rationale for the definitions of complementary
13	feeding and exclusive breastfeeding. But I'm
14	thinking specifically again about water.
15	And I know that typically we have
16	thought of complementary feeding as beginning to
17	add new foods and often around complexity of
18	nutrients. But also, different types of ways of
19	eating.
20	And so, I'm thinking again about the
21	definition of complementary foods is to provide
22	nutrients and energy. So, presumably, water is

1	not a complementary food. And then, the
2	predominant feeding would include water in your
3	definition of exclusive breastfeeding.
4	So, I guess I would like to be able to
5	pull away the predominant feeding from the
6	exclusive breastfeeding, not necessarily for all
7	analyses, but perhaps for some that have to do
8	with eating patterns around when things besides
9	the breast have been introduced, or the human
10	milk have been introduced.
11	And then, similarly on the
12	complementary foods, I wonder if we want water as
13	a pattern, or as a food, to be able to be
14	identified.
15	So, I'm not positive of the answer,
16	but I think it's an inconsistency that will
17	evolve with our other approaches. And I think
18	this first has to hang together as a B24
19	question.
20	But I think even as a B24 question,
21	there might be some reasons to be able to pull
22	those things out to keep it together or apart.

Í	
1	MEMBER TAVERAS: But you're right,
2	Rachel, that the definition of complementary
3	foods and beverages does not include water.
4	And that also is consistent with the
5	World Health Organization definition, that allows
6	water in the definition of predominant
7	breastfeeding and exclusive breast milk feeding.
8	But is your question about whether
9	I don't think your question is whether water
10	should be. It's how water is
11	MEMBER NOVOTNY: Whether it could be
12	identified
13	MEMBER TAVERAS: It could be
14	identified.
15	MEMBER NOVOTNY: in that setting,
16	so that it could be pulled out. And I think
17	there was a time when we were more strict with
18	exclusive breastfeeding.
19	And for some of our questions about
20	habits around food and drink, it might be
21	useful to be able to pull it apart and similarly
22	with the complementary.

1	MEMBER TAVERAS: It's a good point I
2	will - it will depend on how much it's being
3	reported. I think it was a good point even in
4	the adult studies, about the lack of studies
5	actually saying how much water is consumed.
6	And I suspect that we might run into
7	the same issue in the Birth to 24 Month group.
8	VICE CHAIR KLEINMAN: I mean, I think
9	until the WHO did come up with that broader
10	definition of exclusive breastfeeding, water was
11	not included, nor was anything else.
12	But then, along came a couple of
13	things. One, recommendations to supplement with
14	Vitamin D and iron in the exclusively breastfed
15	infant, and a struggle to help families
16	understand how you call something exclusive, but
17	yet you supplement.
18	And then, I think the other
19	consideration is hydration at that age and how
20	you ensure adequate hydration, which can, by and
21	large, be assured through exclusive
22	breastfeeding, but occasionally requires water,

1 particularly during the first few weeks 2 postpartum, when bilirubin metabolism is an issue. 3 4 So, there's nothing very clean about 5 this, and it does pose some challenges to us. 6 And I suppose we -- I mean, we can ask the question whether water intake can be identified. 7 8 But I don't think we're going to get a clean set 9 of outcomes based on information about water intake. 10 11 Juice and other things, that -- and 12 teas, I think that's where you get into 13 predominant. And that makes it even more 14 challenging for us. And I suspect many of us 15 would just as soon consider that complementary 16 feeding. 17 But in an effort to be consistent with 18 worldwide recommendations and common practices, 19 that's why it's lumped together. 20 So, I don't think I'm shedding any 21 light on this, but I'm just trying to say why it's more --22

1	MEMBER NOVOTNY: But maybe we can just
2	code whether it's exclusive or predominant if
3	it's identified. And that would give the
4	potential to do an exclusive analysis.
5	VICE CHAIR KLEINMAN: Yeah. Thank
6	you.
7	CHAIR SCHNEEMAN: This is Barbara
8	Schneeman. I'm wondering if we also want to ask
9	the staff about pulling out that kind of
10	information.
11	It sounds like you're coming to the
12	fact that it needs to be data that's collected if
13	it's available
14	MEMBER TAVERAS: If it's available.
15	CHAIR SCHNEEMAN: Yeah. And so, I
16	don't know if the staff wants to comment on that.
17	MS. GUNGOR: Sure. This is Darcy
18	Gungor. And this definition came about actually
19	during the Pregnancy and Birth to 24 Months
20	project and sort of has been carried over into
21	this one.
22	And I think there was just an

acknowledgment among experts of that team, and 1 2 now of this team, that there are sometimes not great definitions and great parameters and 3 4 descriptions of what is fed to infants. 5 And so, I think the intention was to sort of capture the spectrum of full 6 7 breastfeeding, both exclusive and predominant, but we absolutely extract as much data and as 8 9 many definitions as are provided in every research article, in terms of the feeding 10 11 exposures. 12 And so, if there are clear definitions 13 of predominant versus exclusivity in what's fed 14 and when, all of those data are pulled, and we can certainly present it in that way. 15 16 CHAIR SCHNEEMAN: And, Darcy, 17 including water? Because I think that was the --18 MS. GUNGOR: If it's presented, it would be available for you to look at. 19 Yeah. 20 (Off-mic comment.) MEMBER BOUSHEY: Hi. This is Carol 21 22 Boushey, and that was really -- that was

1	fantastic. There was so much to go through.
2	Looking at weeds here, and it really
3	is, in that first grouping, I guess I had thought
4	that there would be something on parent
5	education.
6	In the second group, parent education
7	is listed in your key confounders, but it isn't
8	in the first group. And so I was curious as to
9	what made these two concepts so different that
10	parent education wouldn't be listed as a
11	confounder?
12	MEMBER TAVERAS: That's a very good
13	question. I don't
14	MEMBER BOUSHEY: Oh, okay. Well good.
15	Take it back to the group.
16	MEMBER TAVERAS: I'll look to the
17	staff. Was that an omission, maybe?
18	MS. GUNGOR: Is the question whether
19	there is parent education on the framework for
20	growth, size and body composition?
21	MEMBER TAVERAS: As a key confounder.
22	MS. GUNGOR: Yeah, I think that would

be picked up as a part of socioeconomic status, 1 2 perhaps? I think we tended to --MEMBER BOUSHEY: Socioeconomic status 3 4 is in the other group also. That's why it kind 5 of jumped out at me. 6 MS. GUNGOR: Yeah, that's a great 7 point. 8 MEMBER BOUSHEY: So --9 MS. GUNGOR: I think that the --10 MEMBER TAVERAS: Yeah. No, that's a 11 good point. 12 MS. GUNGOR: -- the distinction, when 13 it was put on sort of down the road for the 14 developmental milestones, I think was to make sure that that specific indicator was there as 15 16 well. But we can certainly bring that back to 17 the team. 18 MEMBER BOUSHEY: And then, this is 19 also minor. The race/ethnicity, when that's 20 listed, is that for the parent, or is that for 21 the child? 22 MEMBER TAVERAS: That's a good

1 question. 2 MEMBER BOUSHEY: Because we do -these are mixed. You know, they're mixed parent 3 4 and they're mixed child. So, I just wasn't 5 clear. It's a good question. 6 MS. GUNGOR: 7 think the intention is to extract it for the 8 infant. But I think if it's presented for the 9 level of the parent, I think we would extract that as well. 10 11 So, I mean, I just --MEMBER BOUSHEY: 12 I mean you can pick what you want. I just want to be clear on that. 13 14 MEMBER BAILEY: Elsie, again, great Lots of information. 15 iob. 16 CHAIR SCHNEEMAN: This is Regan 17 Bailey. 18 MEMBER BAILEY: Sorry, Regan Bailey. 19 Short microphone, tall person. When you have the 20 nutrient status, does that need to be more clear in terms of biomarkers? Are you -- what is 21

22 status? Ι

1	MEMBER TAVERAS: So, where we expect
2	to have actual biomarkers, we made note of it.
3	So, I can pull them up, but in several of them,
4	particularly for the bone health outcomes, we
5	included biomarkers.
6	But I don't think we if there were
7	biomarkers for every single outcome. Is that
8	what you're asking, Regan?
9	MEMBER BAILEY: Yeah, I was just
10	asking for like Vitamin D status. Is that
11	serum 25 hydroxy D? Is that dietary intakes?
12	MEMBER TAVERAS: Yeah. So here we
13	didn't include the exact biomarker. But yes,
14	where available, we plan to include biomarker
15	status as well, as our for-short status,
16	essentially.
17	CHAIR SCHNEEMAN: I guess just to
18	follow up on that question, because I was curious
19	about the same thing, because there's a
20	difference in looking at intake versus looking at
21	status from a clinical biomarker.
22	So, is the aim to look at a

biochemical or clinical status marker? 1 2 MEMBER TAVERAS: Yes, if it's available. 3 4 CHAIR SCHNEEMAN: Oh, okay. And then, 5 I know you also had fatty acid status. And so, I was interested in knowing what do you think would 6 7 be included in that? 8 So, that's a good MEMBER TAVERAS: 9 question, because we didn't have a list for the fatty acid outcomes there. 10 MS. ENGLISH: Yeah. 11 This is --12 MEMBER TAVERAS: And biomarkers. MS. ENGLISH: Yeah. This is Laurel 13 14 English. I just wanted to add on there that we do have some more specific examples included in 15 the inclusion/exclusion criteria that's posted 16 17 online in the protocols. 18 But as a typical standard approach, we 19 extract anything that is reported. So, for the 20 example of fatty acid status, we would certainly 21 extract omega-3s, omega-6, omega-9. I think the subcommittee discussed red blood cell membrane. 22

1	So, if it's reported, we will
2	certainly extract it and it would be available
3	for the evidence that this is.
4	MEMBER DONOVAN: Yeah, this is Sharon
5	Donovan. I recall the same conversation, because
6	these are all so zero to two years of age. So, a
7	lot of the standard markers that we might expect
8	in adults may not be available.
9	So, I think the idea was whatever in
10	the paper that they're reporting as their iron
11	status marker, and then we'll basically pull it
12	all. And then, in the analysis phase we'll need
13	to go through that.
14	But it also talks about like some of
15	the bone markers may not necessarily be validated
16	in this age. So, you know, we the issue with
17	this whole area is that the amount of evidence
18	may not be very deep.
19	So, we're trying to cast the net
20	widely, at least at this point, in terms of
21	but this is really status, we were thinking
22	primarily biomarkers, because we're going to be

collecting the intake, and then we're looking at 1 2 the effect on whatever the health outcome is. Can I just ask a 3 MEMBER NOVOTNY: 4 question. And I feel kind of stupid because I'm 5 on the committee, but I can't remember the conversation around when we looked at specific, 6 7 like omega-3 fatty acids in growth, size and body 8 composition, when we looked at human milk 9 feeding, we looked longer than just B24. But for all of the specific nutrients 10 11 on growth, size and body composition, we were only talking about birth to 24 months. 12 For bone, 13 we're going farther. 14 But I'm just thinking that some of the aspects on growth may not play out yet in the 15 16 first two years. So, I think the committee 17 should maybe reconsider for just mainly for 18 those -- the bone and the growth for growing 19 longer. 20 MEMBER TAVERAS: No, I agree. For 21 bone and growth for sure. For bone it's already 22 MEMBER DONOVAN:

1	through 18. But for some reason, for the it's
2	there for the human milk but not for the specific
3	nutrients on growth and size and body
4	composition.
5	VICE CHAIR KLEINMAN: Linda.
6	MEMBER VAN HORN: Just quickly. First
7	of all, adding my compliments and accolades to
8	the work that's been done, two quick things. One
9	relates to, I'm so happy to see inclusion of mode
10	of delivery.
11	I think as we're looking at a rapidly
12	escalating interest in the microbiome and
13	understanding the differences, in terms of
14	C-section versus vaginal delivery as it affects
15	the microbiome, it's of interest to consider that
16	aspect, not only I think I saw it in one
17	slide, but I didn't see it in the others.
18	And of course, only if it's available.
19	And it may be or may not. So, that was one
20	comment. The other, in the interest of both
21	Vitamin D and also bone health, I was surprised
22	that there was no mention of dietary calcium or

Neal R. Gross and Co., Inc. Washington DC

1 sources of calcium.

2	And my concern is related to the large
3	number of moms who really don't understand the
4	difference between dairy milk and plant-based
5	milks, and how different those can be in terms of
6	source and bioavailability of dietary calcium.
7	So, I just, again, it may not be
8	available. But again, with the end in mind, it
9	would be
10	MEMBER TAVERAS: Right, good to
11	include it.
12	MEMBER VAN HORN: good to consider
13	it. Yeah.
14	MEMBER TAVERAS: No, that's a good
15	point.
16	VICE CHAIR KLEINMAN: Rachel?
17	MEMBER NOVOTNY: Rachel Novotny. Just
18	wondered about the rationale for the very high
19	development countries. I assume it's more and
20	longer human milk feeding. But wonder if you had
21	anything more to say?
22	MEMBER TAVERAS: The very high what?

1 Sorry? 2 MEMBER NOVOTNY: Human development level of inclusion criteria of your population. 3 4 MEMBER TAVERAS: So, it's partly to be 5 consistent with the existing reviews. Is that right? 6 7 VICE CHAIR KLEINMAN: Yeah, it was 8 meant to be representative of the US population, 9 rather than globally. 10 MEMBER NOVOTNY: Okay. I thought it went one level down. 11 12 VICE CHAIR KLEINMAN: It's very high 13 and high. 14 MEMBER NOVOTNY: And most of the rest are just high, are they not? 15 16 VICE CHAIR KLEINMAN: No, they're 17 both. 18 MEMBER NOVOTNY: Oh, they're both. 19 Okay. 20 MEMBER TAVERAS: The very high and 21 high is one of the general standard criteria, and was what was used for the existing reviews. 22

I have just one other 1 MEMBER BOUSHEY: 2 little small thing. Carol Boushey. And thanks for bringing up calcium. That's where I was 3 4 going next, but I won't say that now. But what I 5 will share is that having the older ages for the bone is a great idea. 6 7 But in the analytical framework, those 8 higher ages aren't included. So, you want to 9 make sure those get in there. 10 MEMBER TAVERAS: Thank you for 11 pointing that out. 12 VICE CHAIR KLEINMAN: All right, I 13 think that we've exhausted that topic, for the 14 moment anyway. So, turn it over to you, Barbara. 15 CHAIR SCHNEEMAN: Right. So, we're 16 actually -- if you advance the slides, we're 17 scheduled to have a break at 2:30 that hopefully 18 no one will object if we give you all ten extra 19 minutes. 20 We do try to hold to the time schedule 21 as much as possible because we know that people are watching online and various other ways. 22 So,

1	why don't we break now. And then we'll expect
2	you back at 2:45.
3	(Whereupon, the above-entitled matter
4	went off the record at 2:21 p.m. and resumed at
5	2:47 p.m.)
6	CHAIR SCHNEEMAN: I will, once again,
7	remind the Committee members, please make every
8	effort to say your name and speak as directly
9	into the microphone as you possibly can. So, it
10	helps both with the transcription as well as
11	people hearing who are participating either
12	online or in the room. So, that would be great.
13	So, we are ready for our next two
14	subcommittee presentations. And so our next one
15	is the beverage beverages and added sugars
16	subcommittee and Rick, I believe you are going to
17	do the presentation for that.
18	MEMBER MATTES: Right. Thank you.
19	CHAIR SCHNEEMAN: Microphone.
20	MEMBER MATTES: Okay. Yep, got the
21	mic on. Okay, so here's the list of Committee
22	members and, as you can see, that Beth is

I

actually the subcommittee chair, but since she is 1 2 not here I'm sitting in for her. I think if we were to run this 3 presentation through iThenticate, relative to 4 what's already been done, we would be expelled 5 for plagiarism. 6 7 (Laughter.) MEMBER MATTES: We've already covered 8 9 much of this, but we will go through it, just so it is on record and clear. 10 CHAIR SCHNEEMAN: But this is 11 12 government, so ---13 MEMBER MATTES: Right. Right, right. 14 Okay, so, our questions fall into three primary topic areas. And the first is the role of non-15 16 alcoholic beverages and consumption on a number of different outcomes, including, anthropometric 17 18 measures and each of those is assessed across the 19 life span, but also, the role of non-alcoholic 20 beverages during pregnancy and effects on birth 21 weight, standardized for gestational age and sex, 22 as well as gestational weight gain. And then,

the third question under this topic area concerns 1 2 non-alcoholic beverage consumption during lactation and its effects on postpartum weight 3 4 loss and still --- still, oh, there we go, sorry about that. And human milk composition and 5 quantity. 6 7 So the subcommittee has worked through 8 the first four of these -- they are the ones 9 highlighted with the asterisk. The one that we 10 haven't gotten to yet is human milk composition and quantity. 11 12 The second topic area is added sugars 13 and is largely parallel to the way we have handled the beverages question -- some small

14 differences in terms of the general population. 15 16 We've added questions related to risk for 17 cardiovascular disease and type 2 diabetes and 18 for the analysis concerning pregnancy. We have 19 taken out birth weight but retained gestational 20 weight gain. And then for lactation, the impact 21 on milk composition and quantity is removed, but postpartum weight loss is retained. 22

1	Alcohol will be the third main area
2	and again, we haven't gotten there yet and the
3	questions there are defined here, but since we
4	haven't gotten to them, I won't belabor those.
5	Whoops, sorry about that.
6	So, the four questions that we will
7	present in a little bit more detail are listed
8	here. The way we will be approaching them is
9	through the NESR systematic reviews.
10	We do have a couple of definitions
11	that are probably worth specifying. We are using
12	the same definition of beverage pattern, but I do
13	want to, kind of, emphasize the orientation here,
14	because pattern can evoke many different
15	concepts, it can be circadian, infradian,
16	seasonal, cultural, nutrient and so on. And
17	different subcommittees are indeed, picking up on
18	them in different facets, so the frequency of
19	eating group will be looking more at temporal
20	patterns, the dietary pattern group will be
21	looking more at sources.
22	So our focus here really is primarily

on quantity, on portion size, and as Regan 1 2 pointed out first thing this morning, we will definitely have to work across subcommittees to 3 integrate all of this as we go forward. 4 Our definition of gestational weight 5 gain is drawn from the CDC and is pretty 6 straightforward -- women -- the weight women gain 7 during pregnancy and the IOM 2009 definition is 8 9 used for post-partum weight retention. It is the amount of weight that remains -- interesting 10 choice of words -- during the post-partum period, 11 12 minus the woman's pre-pregnancy weight. 13 Okay. We are the beverage group, so 14 it's incumbent on us to define beverages in a bit more detail than some of the other groups have 15 16 ventured into. And we have defined ten discrete 17 -- no, I shouldn't say that -- we have defined 18 ten categories. They are not as discrete as one 19 might hope, but, so one large cluster is milk or 20 dairy products, and as you can see on the slide, 21 so under milk there are gradations based on fat 22 content, under flavored milks there is flavor

added, but it is also still gradations of fat 1 2 content. And then there is dairy drinks and substitutes. A lot of these plant-based milk-3 4 like beverages, milk shakes and that sort of 5 thing. And then we get to the non-alcoholic 6 7 beverage sources and one category there are 8 hundred percent juices and they can either be 9 fruit or vegetable. For diet beverages, I want to take a 10 11 little bit of an opportunity -- or a side track 12 here -- it includes low calorie, sweetened. Now 13 it says here, high intensity sweetened. We've 14 talked about thinking of our questions in the context of the population and communicating 15 16 messages and so on. I would like to put in a 17 statement that we consider -- rather than calling 18 them high intensity sweeteners, we have an 19 opportunity here to try to standardize language 20 in this field. High intensity, I would argue, is 21 really not the right word because nothing is sweeter than nine percent sucrose. These things 22

aren't sweeter than plain old sugar. It is just 1 2 you can get to that level of sweetness at a much lower concentration. So it really isn't an 3 4 appropriate term. They aren't artificial because 5 stevia is not artificial. We could call them high potency but that sort of medical-izes it and 6 7 I don't think that's desirable. They are not 8 non-caloric because aspartame is caloric. 9 So, I would argue that we adopt the terminology of low calorie sweetener. 10 It 11 probably conveys most clearly to consumers what 12 the primary goal of their use may be and it's as 13 fitting a description as I think we are going to 14 come up. So, we do include beverages with low 15 16 calorie sweeteners in them, but also in that 17 category are beverages that have just been 18 diluted with water. 19 And then, obviously a very big issue 20 amongst consumers is sweetened beverages. And 21 there we have soft drinks, fruit drinks, sports 22 beverages and then other items that -- specialty
1	teas and coffees, smoothies and so on.
2	Nutritional beverages would include
3	meal replacement products, smoothies that have a
4	specific, intentional nutrient content, protein
5	shakes, and then other what we are calling
6	functional drinks beverages that somebody
7	believes contains something that has some special
8	physiological impact. Right?
9	And then we have, clearly, coffee and
10	tea that can be either sweetened or unsweetened.
11	Plain water, which could be subdivided
12	by tap or bottle and then flavor, or enhanced
13	water, so, with gas in it or some flavoring.
14	Relevant to the discussion we've been
15	having about water do we include it, do we not
16	include it let me, also, just take this
17	opportunity to just point out that any beverage
18	is almost entirely water. All right. On a
19	weight basis there is no beverage that isn't
20	mostly water. And it is really just a gradation.
21	So if we consider water sort of the vehicle or
22	the most elemental of things that we drink, we

1	can add a little odor to it, or we can add a
2	little gas to it and I don't know to what degree
3	you think that fundamentally changes it. We can
4	add a low calorie sweetener to it to what
5	degree does that change it? We can add an actual
6	sweetener to it, or some fat to it, or some
7	protein to it. We can make it more or less
8	viscous as we go on. It is just a continuum
9	and we have to decide where we want to draw the
10	line in that continuum, and it may be this is one
11	of those issues we identify and say, next,
12	dietary guidelines committee think about it.
13	(Laughter.)
14	MEMBER MATTES: Okay. Then so this
15	is our first analytical framework and it has to
16	do with growth, size, body composition, risk of
17	overweight and obesity. And we have taken those
18	ten beverage categories and put them in the first
19	box as our intervention exposure and the
20	comparator will be the consumption of any one of
21	those relative to a different type of beverage, a
22	different amount of that same beverage, compared

1	to a beverage with different nutrient content, a
2	different sensory property or a different
3	physical form so gradation in viscosity, for
4	example. There are quite a few studies out there
5	comparing beverages to a solid food even within
6	the same so a juice compared to a whole fruit,
7	or a vegetable compared to a blended vegetable
8	and so on.

9 And I think it is important to have 10 these distinctions because it does, in fact, 11 allow us to compare across categories to see to 12 what degree is it -- is whatever health outcome 13 we are measuring, really due to the fact of delivery system -- it's a beverage -- relative to 14 15 what property it also conveys. Is it just a 16 delivery system for nutrients -- and is the 17 nutrients, is it the sensory thing -- is it 18 really something special about sweetened 19 beverages that has a health impact, or is it just something about the vehicle that changes how we 20 21 react to sweetness?

22

(202) 234-4433

So by having broken this down as

discretely as we have, we can, I think, get much 1 2 deeper into the question of where the actual impact lies -- where the mechanism lies. 3 So our outcomes on this one are the 4 5 same as a number of other groups have identified the anthropometric sorts of indices, which 6 7 primarily fall into various measures of adiposity. Our key confounders are sex, age, 8 9 race, ethnicity, sociodemographic status, total 10 energy intake and anthropometric measurements pre-period of time that we are studying so that 11 12 we can see what effect of a change of beverage 13 consumption may have had. 14 One thing we don't have in here, and I noticed nobody else, sort of, raised questions 15 16 about what their subcommittee included or didn't 17 include, but I want to throw it out so that ---18 it sort of dawned on me that we didn't include customary beverage intake on this one. We do on 19 20 some others, and again, if we want to look at

22

21

what effect a change in beverage intake has had

we may want to include that so we -- as we talk

about it -- I think we ought to consider that. 1 2 The second analytical framework focuses on birth weight. We have the same 3 exposures and comparators. The difference here 4 5 is in the outcome. So obviously we are looking at birth weight and relative to age, length, 6 gestational age and sex. And in this framework 7 8 the intervention is on the woman -- on the mother 9 --- and the outcome is on the infant. So it is a distinction here that is different from the other 10 11 analyses that we have undertaken. 12 The third analytical framework is 13 gestational weight gain. Again, the same 14 intervention, same comparator, the outcomes, though are gestational weight gain and weight 15 16 gain in relation to recommendations based on pre-17 pregnancy and BMI. 18 The primary population here is the 19 woman -- the pregnant woman -- and the key 20 confounders are maternal age, race, ethnicity, 21 socioeconomic status, pre-pregnancy beverage 22 intake, pre-pregnancy BMI, smoking. And once

again, we have gestational diabetes in several of the other analytical frameworks, but we didn't include it in this one. It seems to me relevant if we are looking at gestational weight gain. So we may want to consider that during the discussion period, as well.

7 Our final analytical framework is on 8 postpartum weight loss -- same intervention, 9 same comparator. The outcomes here though are 10 change in weight from baseline to some later time 11 point during the postpartum period and post-12 partum weight retention if gestational weight 13 gain is controlled.

14 The key confounders are maternal age, race, ethnicity, socioeconomic status, pre-15 16 pregnancy beverage intake, pre-pregnancy BMI, 17 gestational weight gain is used here, smoking, 18 and breast feeding status. And the one that we 19 don't have here, again, is gestational diabetes 20 that may be relevant that we can discuss 21 momentarily.

22

1

2

3

4

5

6

In terms of inclusion and exclusion

criteria, we are using the same standard criteria
 that have been described multiple times before.
 For the upper part we have tailored a few of
 them. We are setting a date going forward for
 which papers to include of January 2000 and it
 will go through the end of June 2019.

7 In terms of study duration, we decided 8 that we should set a minimum of eight weeks. The 9 rationale being that a lot of our outcomes are weight-related and it just takes time to measure 10 a change in body weight that is something other 11 12 than a transient shift in fluid balance. And 13 even eight weeks is probably truly a minimum, but 14 we were afraid of losing too many papers if we went too much further than that. 15

In terms of inclusion and exclusion, in terms of study participants, the inclusion criteria, as I mentioned, we will be looking over the lifespan so those categories are defined on this slide. And I think are consistent with some of the other groups, though, I guess not all. And, by definition the complement is

we will not be looking at beverage consumption in 1 2 infants and toddlers. In terms of birth weight we will only 3 be looking at humans, excluding animal trials. 4 And gestational weight gain we will be 5 looking at females who are pregnant, capable of 6 7 becoming pregnant, and then their offspring. And consistent, I think with the 8 9 exclusion criteria that Sharon outlined for their subcommittee, we will be excluding protocols that 10 don't uniquely identify outcomes for single 11 12 versus multiple pregnancies. And for women who 13 are in hospitals for reasons other than their 14 pregnancy. And then for postpartum weight loss we 15 16 have added postpartum women who are lactating as 17 inclusion criteria and obviously, those that 18 aren't will be excluded. 19 And finally for inclusion and 20 exclusion, with regard to health status, we will 21 be including studies that enrolled participants 22 who are healthy in the general population, and

people who may have a health condition but aren't targeted because of their health condition, to be included in the trial. We will be excluding studies that exclusively enroll participants who are -- including individuals with obesity as the target group.

7 In terms of postpartum weight loss, what we are including that is a variation on the 8 9 theme, are studies that enroll mothers with infants born full term and studies that enroll 10 11 some mothers with infants who are born full term, but may also have low birth weight, or low --12 13 small for gestational age -- offspring. And for 14 this one we actually will exclude studies that exclusively enroll pre-term infants, but also 15 16 studies that exclusively enroll mothers with 17 obesity, which is a difference from the other 18 analytical models.

19 Next steps will be to finish our
20 analysis in the general population focusing on
21 human milk composition and quantity -- whoops,
22 sorry --- so the last question in that category.

Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6

1	Then we will move on to the added sugars category
2	and you can see listed there the different
3	outcomes we'll be focusing on and then finally
4	alcohol.
5	And we do want to thank the staff's
6	outstanding job in keeping us on track and
7	providing us with the information we needed to
8	give our advice. So, I will stop there.
9	CHAIR SCHNEEMAN: So, we canthis is
10	Barbara we can take some questions or comments
11	or I think you threw out a few things that sounds
12	like you would like input on. And particularly
13	from, I think the B through 24 and the pregnancy
14	and lactation groups.
15	MEMBER DONOVAN: For the questions
16	that you had about this is Sharon Donovan
17	the gestational diabetes. I think it might make
18	sense to add that to your confounders. And I
19	understand the question with postpartum weight
20	retention is, you know, what is the impact of
21	beverage intake during lactation and postpartum
22	weight loss? But to me, it would be

I

interesting, just beverage intake postpartum and 1 2 I understand it is a different question, but I think that women who aren't breast feeding might 3 4 choose to start to drink more alcohol, for example, or make different dietary choices. 5 So, but I understand we were given the 6 7 questions to address, but you will have studies, I think, that have non-lactating women in them. 8 9 MEMBER MATTES: Yes, that is a good I wouldn't be surprised if, in some of 10 point. 11 those papers they are the comparison group. So, 12 we might be able to pick up some of that information. 13 14 Rachel Novotny. Yes, MEMBER NOVOTNY: 15 on the gestational diabetes. I think, though, 16 the question may be a bit of harmonization I think we were taking this 17 amongst our groups. 18 -- correct me if I'm wrong -- approach, a very 19 minimalist approach, of things that would exclude 20 studies from, you know, from their ranking. So 21 maybe we need another box for some things that we want to consider in analysis, but that maybe 22

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

1	wouldn't necessarily ding the study. And I am
2	not sure where that is a must-include.
3	MEMBER MATTES: Actually, could I ask
4	the staff because when we were working on
5	these models, there was a third box, for a while
6	and it kind of disappeared. Can you comment on
7	that?
8	DR. KINGSHIPP: Sure. This is
9	Brittany Kingshipp. So we do have a supplemental
10	document it is not part of the formal analytic
11	frameworks that you have shown that we have a
12	list of additional Covariates that will be
13	considered. So for instance if a study presents
14	information on for instance, gestational
15	diabetes, like you all were talking about we
16	would pull that information and present it to
17	you, but it wouldn't be considered in the list of
18	key confounders the confounders that actually
19	are considered in the risk of bias when we are
20	assessing these studies. And so, it is just a,
21	just kind of a tier down from those lists that
22	are on the analytic framework, but something that

1

we would still be considering.

2 MEMBER ARD: Jamy Ard. So, to continue on that point, I think it might be 3 useful to --when there are similar outcomes or 4 populations, we might want to really sort of 5 compare -- which confounders do we really believe 6 are key? So, for example, like I've looked at 7 parity. Parity is included for pregnancy- and 8 9 lactation-related outcomes, but not frequency of 10 eating in sugar sweetened beverage when it comes to gestational weight gain. And so, I would want 11 12 to say, okay, if we are going to say it is key 13 for gestational weight gain in this one 14 particular question, do we have a rationale for not including it in others, or should it be, when 15 16 it comes to gestational weight gain, parity is 17 something that we are going to consider across 18 all of the particular questions? 19 So it might be good for us to just 20 have a grid or something that we can share across 21 committees to make sure that we are at least 22 consistent in our rationale. And it's, right

now, it feels sort of haphazard, like, oh yes, I 1 2 thought about this one. What about it? But we could probably harmonize that a little bit. 3 4 CHAIR SCHNEEMAN: Yes, this is Barbara And Jamy, I think that is a good 5 Schneeman. Certainly one of the points here is 6 point. 7 making sure we all know what is going on with 8 each of the subcommittees and looking for exactly 9 those kind of items. So, it is probably a bit of homework to make sure if something is relevant in 10 11 one area, we're consistent across. It's a verv 12 good point. Tim? Tim Naimi. 13 MEMBER NAIMI: I don't 14 know if it was in our other box, but physical activity is another key covariant in most ---15 16 physical activity is a key covariant, key 17 confounder, for a lot of the other groups and I'm 18 not sure if it was in our other box that 19 disappeared or whether it is just an omission. Ι 20 don't know if anyone remembers. 21 MEMBER MATTES: I will let Brittany 22 give the real answer, but I'm pretty sure it is

in the other box. 1 2 DR. KINGSHIPP: Yes, you are correct. MEMBER MATTES: We decided that it 3 4 wouldn't be in a lot of the papers, and so if we 5 put it as a key confounder we would be downgrading a lot of relevant papers. 6 But I think it is ---7 8 DR. KINGSHIPP: That is correct, yes. 9 **MEMBER MATTES:** -- yep. 10 CHAIR SCHNEEMAN: And going forward 11 it's probably important to make sure we have 12 those other boxes visible as part of the 13 protocols, as well. So, Heidi? 14 Same type of thing, but MEMBER LEIDY: I think the grid will really help. But I was 15 16 thinking that, you know, with our sugar sweetened 17 -- or the beverages one, we also have the 18 criteria for the eight weeks, for when looking at 19 changes in obesity-related outcomes. But I don't 20 think that we have it in the eating frequency --21 and there may not be in the other ones. So I 22 think having a grid like that and then having a

discussions in terms of what we should 1 2 standardize I think would be great. And that is just another one that came to mind. 3 CHAIR SCHNEEMAN: So, Eve, I'm going 4 5 to -- hopefully that is something that we can work with staff to put together going forward. 6 7 Great. Eve is nodding her head yes, for the 8 record. 9 MEMBER SABATE: Joan Sabate. As far as 10 the analytical frame -- as far as the analytical 11 framework between the beverages and the growth 12 size, body composition and risk of overweight and 13 obesity, one of the key confounders is total 14 energy intake. This is, I assume, total energy intake for the whole diet. And then, if that is 15 16 the case, I mean, how are we going to distinguish 17 between the beverages that carry energy versus 18 the ones that they do not? And how are we going 19 to, you know, do this, as far as you want to 20 answer the question, if carrying energy into the 21 beverages versus not, has an impact on the outcomes of interest regardless of the other 22

1

components of the diet?

2	MEMBER MATTES: Yeah, we definitely
3	spent some time talking about this. The issue is
4	I don't think there are a lot of papers that will
5	differentiate the beverage contribution to total
6	daily energy intake. But we're looking at
7	primarily intervention kinds of studies. What we
8	will see is: to what degree did the addition or
9	subtraction of a particular beverage have an
10	impact on the health outcome?
11	So we want to know what the energy
12	intake was prior to the intervention to be able
13	to determine what impact the change in beverage
14	consumption had. That was the rationale for
15	putting it in there.
16	If we had data on beverage energy
17	intake prior to the intervention, that would be
18	wonderful. But I don't think it's reported very
19	often.
20	MEMBER SABATE: Would you be able to
21	answer the question if energy beverages versus
22	beverages that has no calories, I mean, has an

impact on the outcomes of interest? 1 2 MEMBER MATTES: If what happens -- if the mechanism of, say, weight gain with beverage 3 4 consumption is due to lack of compensation for 5 that energy, then it would be essential to know the pre-energy intake to be able to assess that. 6 MEMBER SABATE: 7 Yes. But what about 8 during the intervention? That's one thing. 9 And the second thing is: are you going also to consider study designs other than 10 11 intervention studies? 12 MEMBER NAIMI: I think they're 13 primarily intervention studies in our bailiwick. 14 They're actually in your slides, the 15 kinds of studies we're going to. 16 CHAIR SCHNEEMAN: Right. So yes, the inclusion criteria for the studies is the same as 17 18 for all of the -- that's the standard protocol. 19 So if you just go back to --20 MEMBER SABATE: So once you took the 21 studies, particular studies, how are you going to 22

1	CHAIR SCHNEEMAN: Right, it's just the
2	quality of the evidence varies by the type of
3	MEMBER SABATE: Correct.
4	CHAIR SCHNEEMAN: study. So we're
5	not pulling out something as only looking at one
6	type of study here. It's the same inclusion
7	criteria.
8	MEMBER SABATE: But if the adjustment
9	is just for the total energy intake, then you
10	will not be able to see the difference between
11	one versus the other. Because, I mean, you don't
12	take into consideration the energy that is
13	carried on the beverage.
14	MEMBER MATTES: If it's an
15	intervention study where the intervention is a
16	manipulation of the beverage, then we need a
17	baseline to be able to determine what that change
18	in beverage what impact that change in
19	beverage intake had.
20	So that maybe I'm missing your
21	point, but it seems to me we need that
22	information in order to draw a conclusion about

1 the role of the beverage.

2	MEMBER SABATE: Yes. But on an
3	epidemiological study, for instance, I mean if
4	you adjust for the total energy intake, the
5	energy of the beverage is included in the
6	adjustment.
7	MEMBER NAIMI: Well, I think you're
8	are you alluding to the fact that I think you're
9	thinking primarily of intervention studies
10	MEMBER SABATE: That's correct.
11	MEMBER NAIMI: in which case you'd
12	like to know the baseline.
13	But I think you're thinking of
14	something which I was concerned about, which is
15	if you're looking at an epidemiological study,
16	you would actually like to be able to control for
17	the non-beverage calorie intake of the person,
18	you know, over the study period to isolate out
19	the effect of the beverage as opposed to all of
20	the so I think it depends on the study design.
21	MEMBER SABATE: Correct. Yes.
22	MEMBER MATTES: I think for this

committee, it's drawing primarily from clinical 1 2 intervention. So I think the point I've been making is relevant, but to the point of 3 epidemiological trials, I actually think that 4 5 your group is more likely to answer that question. 6 7 (Laughter.) MEMBER BAILEY: Can't put this one on 8 9 me, Mattes. So we'll have the nationally 10 11 representative survey data that we can look at 12 the contribution that beverages make towards 13 total energy intake. But we don't have beverage 14 intake in some sort of exposure controlling for 15 energy intake. 16 So, we will have prevalence estimates, 17 and means, and distributions, and contributions, 18 but not necessarily controlling for it, the words 19 you're saying, yeah. 20 MEMBER MATTES: So it's the complement 21 of studies that will give us the answer I think. Yeah. 22

1	MEMBER SABATE: No, but one thing is
2	a descriptive of what the American population is
3	doing. Another thing is in a longitudinal study,
4	not an intervention, a short intervention. And
5	to answer the question, the consumption of a non-
6	calorie beverage versus one calorie beverage has
7	an effect on obesity, I mean this is a very valid
8	question that is within I think the scope of this
9	committee.
10	CHAIR SCHNEEMAN: So Carol, did you
11	want to say something?
12	So I yeah, okay.
13	MEMBER BAZZANO: This is Lydia
14	Bazzano. I was just going to point out that, you
15	know, in most nutritional epidemiology and with
16	the longitudinal designs, we take into account
17	total energy intake. And it's just that if there
18	is measurement error around that, I don't
19	necessarily know if you could pluck out the part
20	of the beverage specifically in order to get that
21	information.
22	But you can look at whether the

beverage as a whole seems to contribute to the outcome.

CHAIR SCHNEEMAN: So Dr. Sabate, my understanding is you're -- are you trying to make sure that we account for beverages that have calories and beverages that don't have calories? Is that part of what you want to make sure we want to account for?

9 MEMBER SABATE: I wasn't aware that 10 the subcommittee was only looking or majorly 11 looking at the interventional studies. I think 12 there is some part of the literature that is 13 trying to also look at these from a longitudinal 14 perspective.

15 So put in simple terms, if somebody 16 has zero energy coming from the beverages that 17 this person consumed versus another individual 18 has 50 percent of their daily calories coming 19 from beverages, if we adjust for total energy 20 intake while making the two beverages equal, 21 therefore is not going to be any effect, just by mathematical definition. 22

(202) 234-4433

1

2

So what I'm saying is one thing is to 1 2 adjust for the diet other than beverage, and another thing is to take away the effect of the 3 energy in the beverage that may have on the 4 I don't know. Probably Timothy can 5 outcome. explain it better. 6 7 MEMBER MATTES: Well, if you take the 8 example of somebody who took 100 percent of their 9 calories from sugared soda, let's say, and then you control for their total energy intake, you 10 11 will over-control. You will basically -- so the 12 more that, the more that somebody's total 13 calories come from beverages, and then you 14 control for total energy, or over-controlling and you're basically controlling away the -- you're 15 16 trying to isolate the effect of a beverage, so 17 you would like to control for energy intake from 18 things other than that beverage, or at least 19 other than beverages to distill out that in a 20 longitudinal or epidemiological study as opposed 21 to a intervention study.

22

CHAIR SCHNEEMAN: So it sounds like

1	this is a factor that will come into play when
2	we're looking at the observational data.
3	MEMBER BOUSHEY: So if you do find
4	some longitudinal studies that address this, then
5	you can or you will only limit it to
6	interventions.
7	MEMBER MATTES: I understand your
8	point. It's well taken. I'm not sure that we
9	have included longitudinal studies in the array
10	of terms that we are going to be looking at.
11	So if that's something we should
12	change, that's something we should change.
13	DR. KINGSHIPP: Rick, can I clarify?
14	MEMBER MATTES: Yeah, please.
15	DR. KINGSHIPP: Just from the staff
16	perspective. And so it is correct that the
17	slides that Dr. Schneeman presented earlier, the
18	standard criteria, are being used for these
19	beverage consumption questions. So we will be
20	including any prospective/retrospective cohort
21	trials. So in that case we might have
22	observational longitudinal data.

1	It is true that we are also including
2	experimental studies, RCTs, that sort of thing.
3	So I mean we haven't got into them yet, so we
4	don't yet know what the proportions and breakdown
5	will be, but both types of study designs will be
6	included.
7	MEMBER NAIMI: Okay. Good. Thank you.
8	And just to make a general point, I
9	mean of course intervention studies are good
10	because they can be well, carefully controlled.
11	But they're good for determining short-term
12	effects.
13	And as you mentioned, Rick, the
14	ability to look at an impact on something like
15	weight, you know, oftentimes a longitudinal study
16	which can go over years or even decades may be
17	more relevant.
18	So I expect we'll have both kinds of
19	studies to look at, but I don't know. We'll see.
20	CHAIR SCHNEEMAN: So, I think we have
21	Dr. Sabate's comments about what's needed in
22	terms of the observational data. Okay? Great.

Thank you.

1

2	So we have one more subcommittee to go
3	through. So I want to be sure we have time to do
4	that. So that is the Dietary Fats and Seafood,
5	and Dr. Snetselaar.
6	MEMBER SNETSELAAR: Thank you.
7	My subcommittee on Dietary Fats and
8	Seafood, I have Regan Bailey, Joan Sabate, and
9	Linda Van Horn. So thank you so much for being a
10	part of the committee. Also Barbara Schneeman
11	was the Advisory Committee chair rep.
12	So for our particular subcommittee, we
13	have two topics areas: dietary fats, and seafood.
14	And there were three seafood questions,
15	specifically on seafood intake during pregnancy
16	and lactation, and childhood and neurocognitive
17	and cardiovascular outcomes.
18	And then our second topic on dietary
19	fats included all-cause mortality, cancer,
20	cardiovascular disease, and neurocognitive
21	development and health.
22	And I am including here some key

ĺ	
1	acronyms so that just as I'm going through the
2	slides these will be familiar.
3	You've heard them probably already
4	today: N-3, N-6, PUFAs, MUFAs, EPA, DHA, CVD,
5	and methylmercury.
6	And these are our seafood questions.
7	I'm not going to read through them in detail
8	because I will be showing you the analytic
9	framework for each one. The systematic review
10	protocols that our subcommittee will develop will
11	answer these three questions on seafood
12	consumption and health.
13	We began with a definition of seafood
14	that was taken from the 2015-2020 Dietary
15	Guidelines for Americans, definitions for
16	seafood. And that definition includes marine
17	animals and okay, one more. There we go.
18	So seafood is defined as marine
19	animals that live in the sea and in freshwater
20	lakes and rivers. And it includes, for example,
21	salmon, tuna, trout and tilapia. And the
22	shellfish examples would be shrimp, crab, and

oysters.

1

2	And then we are also going to be
3	looking at seafood in terms of the
4	characteristics. And as you see here, type,
5	source is very important; the amount and
6	frequency of intake; and then the timing of
7	exposure.
8	And this is our first analytic
9	framework, our first question. And that is: what
10	is the relationship between seafood consumption
11	during pregnancy and lactation and neurocognitive
12	development of the infant?
13	And I'm going to be going through
14	separate elements within this analytic framework
15	in the next few minutes.
16	So this first slide is focusing on the
17	box that includes intervention and exposure
18	versus comparators. And we will be looking at
19	seafood consumption as it was defined earlier.
20	And the seafood consumption will examine studies
21	that look at types, sources, amounts of seafood
22	consumed, or different frequency and timing of

1

seafood consumption.

2	And then here highlighted are
3	populations that we are considering. They
4	include looking at infants, toddlers, children,
5	and adolescents, birth to 18 years.
6	And the measures of neurocognitive
7	development will be very consistent with those
8	addressed by other subcommittees. So, once again
9	we're trying to be very consistent in the work
10	that we're doing with this particular
11	subcommittee so that across the board our
12	subcommittees are focusing on those same
13	characteristics for neurocognitive development.
14	Okay, moving on to key confounders.
15	We are paying particularly close attention to
16	sources of confounding that will include child
17	age, sex, birth weight, gestational age, maternal
18	age, race, ethnicity, SES, anthropometrics,
19	parity, smoking, dietary patterns.
20	And components of the maternal diet
21	will include alcohol intake, dietary supplements,
22	particularly n-3 polyunsaturated fatty acids and

1	iron. And then we'll also be looking at non-fish
2	dietary exposure to n-3 polyunsaturated fat.
3	We're looking at parental education,
4	family history of neurocognitive disorders. And
5	we will be looking at key confounders that
6	include ADD, ADHD, anxiety, ASD and depression.
7	And then additionally we will be
8	looking at key covariates. And these are likely
9	to impact the relationship between seafood
10	consumption and health. And they include key
11	nutrients. For example, n-3 PUFAs, selenium,
12	environmental chemicals, mercury, PCBs for
13	example, and then blood or human milk biomarkers
14	of seafood intake, and infant feeding mode.
15	And then our second question will
16	focus on seafood consumption during childhood and
17	neurocognitive development. And the
18	intervention, exposure, and comparator here is
19	similar to the previous question.
20	And once again the boxes in red
21	include our population. We are going to be
22	focusing on seafood consumption from birth to 18

years of age, with neurocognitive endpoint
 outcomes assessed from age 2 years and older
 throughout adulthood.

And outcomes which reflect both neurocognitive development and neurocognitive health will also be considered, as you see here on this particular slide.

8 And then, again, key confounders and 9 key covariates are similar to our previous 10 question. However, infant feeding mode will be 11 considered as a potential source of confounding 12 rather than a key covariate.

And then our final seafood question 13 14 focuses on seafood consumption during childhood and risk of cardiovascular disease. And 15 16 intervention, exposure, and comparators are the 17 same as in our previous analytic framework. 18 Cardiovascular disease outcomes to be examined 19 near those across the rest of the project. 20 And once again we have here 21 population. Our focus here will be on seafood

consumption during childhood. We'll be assessing

Neal R. Gross and Co., Inc. Washington DC

22

intermediate outcomes in children, adolescents, 1 2 adults, and older adults, and then endpoint outcomes in adults and older adults as well. 3 And then key confounders and 4 5 covariates, we'll consider the relationship between seafood intake during childhood and 6 7 cardiovascular disease. This is going to be 8 similar to those I identified earlier, but it 9 will include family history of cardiovascular 10 disease. 11 And then very importantly, we will be 12 looking at inclusion/exclusion criteria. And the inclusion/exclusion criteria for seafood 13 14 questions are consistent with the standard 15 criteria as you've already seen in terms of the 16 committees' systematic reviews. As you can see, 17 we are including study design, publication 18 status, date of publication, language of 19 publication, country, and health status of 20 participants. 21 And more specifically here in terms of our subcommittee's role, there will be studies 22

1 that measure seafood consumption. Again, it is 2 important to keep in mind that there will be some 3 exclusions. So fish oil or n-3 PUFA, supplement 4 studies, and studies that only examine biomarkers 5 of seafood intake will not be included. And this 6 would include studies that evaluate infant 7 formulas with added DHA and EPA.

8 And now moving on to our dietary fats 9 questions, this is our second topic. The focus 10 on dietary fat consumption will be at each stage 11 of life. We'll be looking at neurocognitive 12 development and health, and risk of 13 cardiovascular disease, cancer, and all-cause 14 mortality.

Some key definitions. Saturated, monounsaturated, polyunsaturated fat types will be looked at. We'll be looking at omega-3 polyunsaturated fatty acids, EPA and DHA, and then omega-6 polyunsaturated fatty acids and cholesterol.

You might note here that we have not
included trans fats. And one of the reasons for

that is that some work was done to look at intake 1 2 since 2012. And intake was at about 1.5 grams per day. And trans fats are also not included in 3 4 federal food and nutrient databases, and they've 5 been not used in a lot of studies. So that's one of the reasons you do not see trans fats in that 6 7 list. 8 In key definitions, we feel -- and 9 certainly this is borne out in the literature -that sources of fat are very important as we talk 10 11 about dietary fats. So dairy, eggs, meat, and 12 plant sources will be important. 13 We'll be looking at amounts of 14 specific types of fat and proportions where we're 15 looking at ratios. And then replacement, where 16 saturated fat may indeed be replaced with 17 polyunsaturated fat, and then also carbohydrate 18 and protein replacement in terms of saturated 19 fat. 20 It's important I think here to note 21 that our committee was not tasked with looking at 22 overall amounts of dietary fat. And so we will

rather be focusing specifically on types of fat 1 2 and certainly amounts of types of fat. And so the first question that we are 3 looking at is the relationship between types of 4 dietary fat and neurocognitive development and 5 neurocognitive health. And this analytic 6 7 framework reflects our definition of types of fat 8 that will be used across the dietary fat 9 The neurocognitive endpoint outcomes questions. are consistent with previously presented analytic 10 frameworks on this particular outcome. 11 12 And then again, looking at those red 13 squares where we're identifying our population. 14 We will be evaluating studies conducted in infants, toddlers, children, adolescents, adults, 15 16 and older adults. 17 Key confounders will include sex, age, 18 race, ethnicity, socioeconomic status, BMI, 19 smoking, outcome. And age-specific key confounders will include neurocognitive 20 21 development, birth to 18 years, parental 22 education, neurocognitive health, 19-plus years,
education, ADD, ADHD, anxiety, ASD, depression,
Alzheimer's, a family history of neurocognitive
disorders. And we'll also be looking at mercury
in fat that originates from seafoods. And that
will be considered as a key covariate for this
particular question.

And then all-cause mortality, the 7 relationship of dietary fat to all-cause 8 9 mortality at each stage of life. The 10 intervention, exposure and comparators are the same as previously described for dietary fat 11 12 analytic frameworks. And all-cause mortality 13 outcome has already been described with several 14 of the other presentations. And we will be examining studies conducted in subjects 2 years 15 16 and older.

And then key confounders are similar to those considered previously: total energy and alcohol intake, physical activity and anthropometry, a family history of CVD, cancer, and diabetes.

22

Covariates will be considered also to

include carbohydrate and protein intake, and 1 2 other types of dietary fats and BMI. And then the next question involves 3 cancer. And here, in terms of the analytic 4 5 framework, we're describing examining the consumption of dietary fats and risk of certain 6 7 types of cancer. And so you see the different types of cancer on this particular slide. 8 9 Intervention, exposure, and comparators are basically what we've previously described. 10 11 And just important to keep in mind 12 that we did add liver to our list of types of 13 dietary cancer since we have been seeing that in 14 the literature recently. And then our population. We will be 15 16 evaluating studies that assess dietary fat in 17 subjects at each stage of life. And outcomes 18 will be assessed in subjects 2 years and older. 19 And then looking at types of cancer, 20 again one of the things to keep in mind is that

21 we will consider menopausal status as a 22 moderator. And key confounders listed on this

slide are similar to previous analytic 1 2 frameworks, except that there's the inclusion of family history of cancer outcome, a variety of 3 cancer-specific confounders that include hormonal 4 contraceptive use, the age of menopause for 5 breast and endometrial cancer, IBD for colon and 6 rectal cancer, lung disease and exposure to lung 7 8 carcinogens for lung cancer, and then viral liver 9 infection for liver cancer. And then our final analytic framework 10 11 addresses the relationship between types of 12 dietary fat consumption and risk of cardiovascular disease. 13 The intervention 14 exposure comparators, the target populations and the outcomes are consistent with what I've 15 16 described previously in terms of our analytic 17 framework. 18 And then key covariates. They are

19 similar to previous analytic frameworks 20 presented, except for the inclusion of family 21 history of CVD or diabetes, and the exclusion of 22 anthropometry which was considered to be a key

1

2	And then additional key covariates
3	include carbohydrate and protein intake, other
4	types of dietary fats, baseline CVD risk category
5	which might be high, moderate, and low, and
6	duration of intensity of the intervention, and n-
7	3 polyunsaturated fat supplement use.
8	And then as you see here, our
9	inclusion/exclusion criteria is consistent with
10	standard criteria across the subcommittees. I
11	think it's important to note here for our
12	specific subcommittee that studies that do not
13	assess the consumption of types of dietary fat,
14	so that might be studies that only include
15	biomarkers or that only assess total fat intake,
16	our overall macronutrient consumption will be
17	excluded.
18	And then next steps. The literature
19	database searches and screening for seafood and
20	neurocognitive outcome questions are complete,
21	and hand searches and data extraction will begin

22 shortly.

1	The literature search for seafood and
2	CVD will be conducted this summer. And the
3	subcommittee plans to begin work on the dietary
4	fats questions, starting with all-cause mortality
5	reviews.
6	And I want to again thank my
7	subcommittee and, also, in particular thank our
8	support staff who have done an incredible job in
9	terms of working with us on every single call.
10	The calls happen once a week and certainly have
11	been an incredible help to all of the work for
12	this particular subcommittee. And are one of the
13	reasons that we have gotten quite far along in
14	terms of the work that we have done so far. Many
15	thanks.
16	CHAIR SCHNEEMAN: So, I think we can
17	take some questions or discussion on the
18	protocol. Protocols. Yes?
19	MEMBER MATTES: Sorry if I missed it;
20	can you clarify what is outcome-specific key
21	confounders? Are they for a given outcome you'll
22	pick from that list which you use?

1	MEMBER SNETSELAAR: Say that again?
2	MEMBER MATTES: What is the definition
3	of outcome-specific key confounders?
4	MEMBER SNETSELAAR: They are just
5	specifically related to the work that we are
6	doing for the specific question we're asking.
7	MEMBER MATTES: So, for example, you
8	might pick ADD for one paper and ADHD for another
9	paper, or you would expect all of these in any
10	paper that you selected?
11	MEMBER SNETSELAAR: No. I think we
12	would certainly be looking at one at a time.
13	MEMBER MATTES: Okay. Otherwise, I
14	was going to say, you'd probably ding a lot of
15	papers if you had all of those in at once.
16	MEMBER SNETSELAAR: Yeah. And it's
17	important to keep in mind that confounders and
18	covariates aren't eliminating papers. So,
19	certainly, our exclusion criteria will do that.
20	But that's something to keep in mind.
21	MEMBER NOVOTNY: I don't know if you
22	know I wasn't aware of oh, this is Rachel

258

1	Novotny of freshwater fish being in the
2	seafood group. Do we know that the freshwater
3	fish have similar levels of mercury and other
4	or what is the rationale for including freshwater
5	fish with seafood?
6	MEMBER SNETSELAAR: I think the idea
7	is that we want to be sure that we are
8	generalizing to other populations. And, in the
9	Midwest, for example, that type of fish are
10	probably the kind of fish that would be consumed.
11	So, that's the reason.
12	I'm happy to have one of my
13	subcommittee members also maybe talk about that.
14	But we thought that there definitely was a reason
15	for including freshwater fish.
16	Linda, would you like to respond?
17	MEMBER VAN HORN: Linda Van Horn.
18	And, yes, as the person who probably glows in the
19	dark from all the Coho salmon we eat out of Lake
20	Michigan, you know, I think there are many
21	sources of freshwater fish across the country
22	that are consumed all the time. Freshwater fish

are potentially contaminated and, therefore, 1 2 definitely should be included, we think, in the fish and seafood category. 3 4 MEMBER SNETSELAAR: I quess the name, 5 I would prefer to call it fish and -- fish and seafood or something, or seafood and fish. 6 7 MEMBER BOUSHEY: And to add to that --8 this is Carol Boushey -- to add to that, of 9 course, we have fish that live in both, you know, that Coho salmon that you eat. 10 11 I think the CHAIR SCHNEEMAN: 12 important point is that it's captured and it's also identified as to whether it's fresh or 13 14 seafood. 15 Other questions or comments? Oh, 16 please. 17 MEMBER VAN HORN: Sorry. This is 18 Linda Van Horn again. And I'm on this 19 subcommittee, but when we were going through our 20 slides and you don't have any chance to put it 21 all in perspective, this is probably a parking 22 lot issue. But it occurred to me, especially

after all of what we've heard today, that, you
know, adverse pregnancy outcomes are a risk
factor for cardiovascular disease.

And what's of interest as I was 4 5 looking at all of this, realizing we're talking about the entire population now, if there are 6 7 dietary factors associated with adverse pregnancy outcomes -- as we were thinking earlier about 8 9 gestational diabetes, gestational hypertension, et cetera -- and maternal intake of these types 10 of foods, any of them -- I'm thinking fatty acids 11 12 but it could be any of them -- that relate to the 13 maternal risks, I also wonder if, because of the 14 adverse pregnancy outcomes, the child, the 15 offspring, is at greater risk for depression, 16 anxiety, you know, any other developmental 17 problems that still could stem from initial diet-18 related relationships maternally. I don't think 19 there's a whole lot of data that anybody's really 20 looked at those connections across the lifespan. 21 So, again, as I say, I think this is 22 way too much, you know, to try to expect us to do

within this particular environment and all these 1 2 questions that we're already trying to address. But I think, if it's possible on the basis of any 3 4 data that do exist that relate these connections, 5 we should recognize those as being potentially important as we go forward. Because if it all 6 7 starts with maternal nutrition, there's reason to 8 think, you know, we should be more mindful of 9 those relationships. 10 CHAIR SCHNEEMAN: Yeah, go ahead. 11 MEMBER ARD: Jamy Ard. So, one 12 question comes to mind related to fish and 13 seafood consumption. In thinking about the 14 definitions and the things that are considered in 15 analysis of type, source, amount, and frequency, 16 timing, one of the other things that comes to 17 mind from some data I can recall is the 18 preparation. So, a high proportion of seafood 19 consumption, especially fresh water fish and 20 seafood, is fried, right? 21 And so there are data that suggest

(202) 234-4433

22

Neal R. Gross and Co., Inc. Washington DC

that there's a different impact of seafood, or

maybe the beneficial impacts are not there when 1 2 the preparation is taken into consideration. MEMBER SNETSELAAR: And our committee 3 4 did definitely talk about that. And I was 5 thinking that it was still listed somewhere. But I will need to look at that again. 6 7 I don't know, Joanne, you may remember 8 more about that than I. But we have talked about 9 that, definitely. That's a good point. The subcommittee did 10 MS. SPAHN: 11 identify preparation. And we had said that that 12 would be an element of seafood we would extract 13 and would present in evidence tables for the 14 committee's evaluation during synthesis. 15 CHAIR SCHNEEMAN: So it's part of the 16 data extracted. 17 MEMBER SNETSELAAR: I remember that 18 specifically because it was something that I felt 19 strongly about. 20 CHAIR SCHNEEMAN: Other questions or 21 comments about getting the analytical framework down? 22

1	We do have we can move to the
2	committee discussion, just a general discussion.
3	And I think what we did the last time was just go
4	around and allow each of the committee members,
5	if you have comments at this point reflecting on
6	any one particular protocol, or just thinking
7	about the way forward from here, it would be
8	great to have as part of our closing comments
9	from today.
10	So I'm going to start with you, Elsie,
11	because I know you're going to pop out soon.
12	MEMBER TAVERAS: None that come to
13	mind at the moment.
14	MEMBER ARD: So, I'll steal Rick's
15	comment from earlier about sodium. And I wonder
16	if there might be some unifying concepts or ideas
17	or themes that go across the age span and
18	different questions that we might may not, you
19	know, sort of have all the data to, or specific
20	questions to address per se, but we might take
21	the opportunity to pose either areas for
22	additional work or at least speak to the idea

1	that, you know, A, this is what we were tasked to
2	look at, but, B, these are some other things that
3	we might need to consider that would modify the
4	effects that we're reporting out on. And sodium
5	would obviously be one of those that's measured.
6	CHAIR SCHNEEMAN: Heather?
7	MEMBER LEIDY: This is Heather Leidy.
8	Just a small comment. I really like the grid
9	idea. So, I think just that will help clear up
10	some of the inconsistencies I think that we have.
11	But something else that I had talked with a few
12	folks about, and that being it seems we're at the
13	stage now where, you know, as we start getting
14	the data, or summaries, there's going to need to
15	be, I think, a lot of crosstalk between a lot of
16	the different committees. And we haven't really
17	done that so much in our subcommittee calls.
18	And so I think I would just like to
19	see more where some of the chairs are sitting on
20	are able to call in on some of our
21	subcommittees, because I think the crosstalk
22	would be really helpful moving forward. So

that's something that came to mind today, that 1 2 there's a lot of things that I think now we can start being a little bit more integrative. 3 4 MEMBER NAIMI: Tim Naimi. Nothing to 5 add at this time. MEMBER MATTES: Rick Mattes. 6 I was 7 going to make that same point. I think that we 8 have to integrate more to avoid redundancies and 9 to make sure we capture everything, because a couple of new ideas came out. 10 11 This is Carol MEMBER BOUSHEY: 12 Boushey. And I have a similar comment to what 13 Jamy said, and Rick and everyone. I think we sometimes some of the 14 15 language needs to be harmonized a bit. We're 16 talking about the same thing but we use different 17 words, and I think -- which is fine because those 18 words are there, otherwise we wouldn't have 19 picked them out to use them, but it might be 20 easier for us to actually do comparisons if we're 21 using the same terms. 22 CHAIR SCHNEEMAN: Sharon.

1	MEMBER DONOVAN: Pretty much the same.
2	I was surprised, for example, like with the
3	beverages, that there's quite a bit related to
4	pregnancy and lactation. And so, in addition to
5	make sure the covariates are consistent, but also
6	how we're defining gestational weight gain,
7	postpartum weight retention. So I think we need
8	to kind of clean those up before we actually
9	start the systematic reviews.
10	MEMBER SNETSELAAR: I don't really
11	have a lot to add. I think that being consistent
12	across the subcommittees, which has already been
13	indicated. But one thing, for example, parity
14	was brought up as something that might certainly
15	be a part of many of the different subcommittee
16	questions. So, I could just see that there are a
17	variety of things that we might want to look at,
18	which I'm sure has probably been primed already
19	anyway.
20	MEMBER SABATE: Okay. Joan Sabate.
21	On the presentations before the break,
22	particularly the one on birth to 24 months, there

1	was quite a lot of discussion and presentations
2	on the specific nutrients and nutritional status.
3	I think this is quite interesting and very
4	important from the nutritional viewpoint.
5	But I'm a little bit surprised by this
6	emphasis, and particularly in the context of, if
7	this is the task of this committee, or is the
8	task of the Institute of Medicine, the one that
9	issues the dietary DRIs, you know our outcomes in
10	general is health, not nutritional studies. And
11	going into specific nutrients when they come from
12	different sources, that could be the nutrients in
13	foods, the foods that have been supplemented or
14	also taking independent supplements. See,
15	basically we are just focusing on nutrients
16	independent of the source.
17	And I don't know to what extent we are
18	going to once we get the nutritional status, I
19	mean, if we are going to make food
20	recommendations based on nutritional status or
21	based on health outcomes.
22	MEMBER NOVOTNY: Rachel Novotny.

Yeah, echoing most of what I heard. 1 In addition, 2 thinking about the analytic frameworks and harmonization in presentation that I think will 3 help our conversations to be more to the points 4 we are trying to make. 5 I think, even analytically, I think there may be some 6 7 commonalities on, of course, the classic "what to 8 do with energy" that is always going to be there, 9 particularly for some of our overweight outcomes. I think it could be useful to have some analytic 10 crosstalk as well. 11

12 MEMBER BAILEY: Regan Bailey. Just 13 echoing the -- and will be of no surprise to the 14 federal staff, who I keep talking about this with -- but harmonization and standardization of the 15 16 terms that we are using, things like, what is a 17 life stage? And that we're all on the same page 18 about the terms that we're using. What is a 19 covariate versus what is a confounder? How we 20 define nutrients of public health concern versus 21 shortfall nutrients. So, really having some clarify around those terms I think would be 22

helpful.

1

2	I really like, Jamy, your idea of the
3	grid for having consistent confounders and
4	covariates for each outcome. And, Heather, you
5	had some good ideas on that as well. And I think
6	that is mainly what I wanted to say. Thank you.
7	MEMBER VAN HORN: And, Linda Van Horn.
8	I've been pretty vocal, so I'll try to keep it
9	short. But I, likewise, agree with Jamy on the
10	sodium question for sure. That's got to be
11	something that we address because it's so
12	relevant to everything we're doing.
13	And also what Regan was just referring
14	to as far as nutrients of concern. In teaching,
15	one of the things that I use continually is the
16	wonderful slide that shows what are the
17	recommendations and what are the current American
18	eating behaviors. And I think that just sends
19	such an important message.
20	And one thing that was brought up
21	about beverages, I think it was Joan who said,
22	you know, is there a percentage of energy intake

from beverages that should be recognized as being 1 2 excessive in relation to obesity, weight control, things like that? I don't think we know the 3 4 answer to that. But I think, you know, I 5 remember an AJCN paper that once demonstrated that those who had higher intake of caloric 6 7 intake from beverages were more often overweight or obese. 8 9 And so, you know, practical questions

like that that are relevant to public health, you 10 know, I think beginning with the end in mind, you 11 12 know, it would be helpful if we could provide 13 some guidance and direction on that as well. 14 MEMBER BAZZANO: This is Lydia I don't have any additional comments at 15 Bazzano. 16 this time. Ron, come back to 17 CHAIR SCHNEEMAN: 18 you. 19 VICE CHAIR KLEINMAN: Yeah, I mean, I 20 think everyone's summarized my thoughts pretty I do think that our focus should be on 21 well.

health outcomes, just as Joan said.

Neal R. Gross and Co., Inc. Washington DC

22

1	And I think, in fact, it is. Where we
2	have focused on specific micronutrients, it's in
3	the context of ultimately understanding the
4	impact of that micronutrient status on health
5	outcome. So I think, in a way, that's an
6	intermediate step to health outcomes where that
7	comes up. But I totally agree that this has to
8	inform the public about how to improve their
9	health through what they eat. And I think that's
10	the goal.
11	I've been incredibly impressed with
12	the amount of information that is going to be
13	generated from this process. What Carol was
14	saying before, as we were chatting, when I
15	started this I couldn't have imagined the number
16	of questions that each of these topics would
17	generate. I thought they were fairly
18	straightforward. And, you know, 10 minutes, 15
19	minutes, we could go through at least a couple of
20	these topics. And they continue to expand.
21	So I would say that we have to keep in
22	mind that it's important to cover what's

1	important, but to keep in mind that expanding
2	this analytic framework means that we get an
3	extraordinarily expansive evidence base that
4	we'll then have to deal with.
5	And so, to some degree, I'm quite
6	comfortable with where we are now. I do think
7	sodium is an important consideration and we
8	should bring that in. And I particularly
9	appreciate that comment about a need for
10	longitudinal observations so that we can put diet
11	in context with these isolated aspects of diet.
12	So, those are two of the more
13	important things, I think, for us. And then we
14	have talked about creating a grid for some time
15	now. And I think that's a must. And that's
16	something that we can talk through as well with
17	the subcommittee chairs on one of those on our
18	regular calls. And I know that the staff, I
19	think, is currently working on that. So I think
20	we're on our way towards the next stage of this
21	process. Thank you.
22	CHAIR SCHNEEMAN: Great.

1	VICE CHAIR KLEINMAN: And I did want
2	to sorry, I did want to say that I really
3	appreciate all the work that those who presented
4	today put into the presentations. I thought they
5	were terrific. I've been sitting in on three
6	subcommittees now, and Barbara's been sitting in
7	on four. And I thought the summaries were
8	outstanding.
9	And I had some insight into the work
10	that went into putting those together, both by
11	the staff, as well as the members of the
12	committee and those who presented. And it's very
13	impressive, and it made a great difference today.
14	So, thank you all for that.
15	CHAIR SCHNEEMAN: Great. Thank you
16	for those comments. I think, Ron, you've
17	captured a lot of what has been going through my
18	mind. First of all, just to thank everyone for
19	the work that they've done on the subcommittees
20	and then in the presentations today.
21	And I hear what you're saying. I
22	think we've made some progress toward harmonizing

terminology, but I agree with everyone, that the discussion today shows that there's more we need And also the more we need to do to to do. 4 facilitate the crosstalk among the subcommittees, because I think that's going to be critical for the work going forward.

7 I'm going to just do some practical 8 I'll remind folks who are interested in things. 9 making comments, if the public is interested in making comments on the protocol, they will be 10 11 most useful to the committee if they could be 12 submitted by July 24th. You're welcome to submit 13 them any time, but to be most impactful, July 14 24th would be great.

And as the committee continues to move 15 forward with its work and it starts to implement 16 17 these protocols, there will be updates to the 18 web. So we want to be sure and encourage people 19 to stay on the listserv that USDA and HHS have, to visit the website, because that will be an 20 21 ongoing source of information. I think both departments have really committed themselves to 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

5

6

1 try and be as transparent as possible. And so 2 getting information out there is a key part of that. 3 We are prepared to adjourn at this 4 5 I would remind folks that we will point. 6 reconvene tomorrow morning. And tomorrow morning we start at 8:30. This morning we started at 7 8 So, we'll start a little bit early. And 9:00. we're looking forward to hearing the public 9 10 comments for the committee tomorrow. 11 And we, yes, we'll come right back 12 So, again, thank you. Thank you all for here. 13 attending and being here. And thank you to the committee for all your hard work. 14 15 (Whereupon, the above-entitled matter 16 went off the record at 4:13 p.m.) 17 18 19 20 21 22

Α a.m 1:10 3:2 139:6 A1c 70:7 86:2 118:21 150:16 ability 42:13 78:2 93:4 134:5 242:14 able 4:12.15 19:20 28:11 37:11 39:17 53:3 82:14 89:2 95:4 95:11 102:9 129:11 129:21 132:6 134:16 153:6 161:11.16 162:11 163:7 166:6 193:4,13,21 194:21 227:12 233:12,20 234:6 235:10.17 236:16 265:20 above-entitled 139:5 210:3 276:15 absence 31:20 97:15 absolute 91:18 absolutely 88:19 91:7,8 198:8 academic 67:18 176:8 Academies 31:5 Academy 30:9 acceptable 31:6 108:16 accepted 148:18 190:1 access 3:21 53:2 accolades 206:7 accomplish 92:19 account 238:16 239:5,8 accounted 145:5 accuracy 48:14 achieve 8:19 achieving 21:6 acid 35:3,5 141:13,16 148:4.21 149:5 150:4 150:6 151:3 152:10 155:7 157:9 158:7 164:19 186:2 203:5 203:10,20 acids 141:14 158:21 160:4 167:7 175:10 182:1 185:18,21 186:8 187:14 188:21 205:7 246:22 250:18 250:19 261:11 acknowledge 95:6 120:1 159:5 179:14 191:13 acknowledgment 198:1 acronym 31:7 acronyms 244:1 Act 178:21 182:16 active 48:10 49:18 72.15 activities 75:13 143:12

activity 65:11 67:11 68:10 69:7 70:1,14 112:2 114:10,14,18 230:15,16 253:19 actual 109:14 202:2 218:5 220:2 acutely 132:20 ad 133:8 add 8:10 38:2 45:15 64:10 83:17 88:17 95:18,21 114:21 116:7 120:11 135:5 137:9 192:17 203:14 218:1,1,4,5 226:18 247:6 253:1 254:12 258:8 260:7,8 266:5 267:11 added 2:12 10:8 18:10 21:5,16 33:13 36:7 37:21 40:20 50:12 51:12,14 107:6 114:9 115:6 116:10 117:10 118:11 150:10 153:10 157:11 189:16 210:15 212:12.16 215:1 224:16 226:1 250:7 adding 206:7 addition 5:4 6:1,4,6,17 30:19 35:4 60:1 74:3 74:15 75:1 150:4 151:15 158:2 180:12 185:3,15 233:8 267:4 269:1 additional 9:16 11:7 12:17 74:5 89:1 91:1 150:5 158:9 166:13 228:12 256:2 264:22 271:15 additionally 178:20 247:7 address 9:16 19:5,6 21:4 38:12,17 59:13 99:5,19 110:13 180:17 227:7 241:4 262:2 264:20 270:11 addressed 59:19,20 96:3 134:22 246:8 addresses 255:11 addressing 7:1 98:21 adequacy 21:15 31:20 adequate 31:18,21 33:10 76:7 195:20 adequately 100:5 109:7 128:4 ADHD 152:21 247:6 253:1 258:8 adherence 64:14,16,18 71:7

adiposity 220:8 adjourn 2:19 139:2 276:4 adjust 8:7 236:4 239:19 240:2 adjusted 28:8 adjustment 235:8 236:6 Administration 182:18 adolescence 176:12 180:19 adolescents 22:19 66:22 153:5 190:17 246:5 249:1 252:15 adopt 91:5 216:9 adult 43:19 195:4 adulthood 38:10 248:3 adults 22:20,21 27:17 28:2,12 29:18 34:21 35:3 44:17 45:5 65:3 66:22,22 67:6,7 68:2 69:1,20 70:11 104:10 134:16 178:3 204:8 249:2,2,3,3 252:15,16 advance 152:16 167:19 209:16 advancer 140:9 adverse 32:2,17 261:2 261:7,14 advertising 122:17 advice 226:8 **Advisory** 1:1,8 3:7,9 4:21 6:12 10:21 19:14 61:14 70:22 243:11 affect 42:1 115:1 129:2 afraid 223:14 afternoon 104:2 140:6 **age** 15:3 16:22 21:13,22 22:2 26:13,14,17,20 39:4 41:21 42:3,5,12 42:22 43:2,2 49:15 65:10 67:8 68:7 69:6 69:22 70:13 104:8,11 110:11 143:11 153:10 158:1,3 164:1 177:3,7 179:12,15 180:1,4,4 180:10 184:8 187:7 190:14,16,20 195:19 204:6,16 211:21 220:8 221:6,7,20 222:14 225:13 246:17 246:17,18 248:1,2 252:17 255:5 264:17 age- 28:7 age-adjusted 28:20 29:11 age-specific 252:19 agencies 6:9 agenda 3:16 8:17 17:21

18:12 19:13 57:17 ages 34:4 43:22 190:17 209:5,8 ago 104:21 105:19 agree 30:10 44:9 76:6 205:20 270:9 272:7 275:1 agreement 103:15 Agriculture 1:9 5:2,21 ahead 103:21 128:21 159:4,22 167:22 262:10 AI 31:18 aim 202:22 AJCN 140:22 271:5 alcohol 29:4,6 68:9 93:22 138:14 213:1 226:4 227:4 246:21 253:19 alcoholic 37:5 211:16 align 43:16 171:21 178:17 aligned 22:3 40:17 66:7 all- 109:18 113:16 all-cause 62:10 63:3,21 64:4.20 72:20 96:6 243:19 250:13 253:7 253:8,12 257:4 allergic 142:3 167:1 169:9 176:17 177:1 allergies 142:3 169:8 176:16 177:1 allergy 26:20 166:22 167:15 allocated 18:1 20:1 allow 219:11 264:4 allowed 1:10 allows 194:5 alluding 236:8 alphabet 31:9 **ALT** 29:1,3 44:19 45:10 alters 129:5 132:19 Alzheimer's 67:22 152:19 253:2 **AMDR** 31:9,12 33:13 72:3 America 23:7,14 25:7 33:21 American 97:8 151:10 238:2 270:17 Americans 52:2 59:16 59:17 244:15 amount 8:21 9:11 10:19 22:10 32:1 55:2 60:15 80:16 91:21 95:12 117:7 134:2 159:18 172:4 189:12 190:8 191:14,16 204:17

214:10 218:22 245:5 262:15 272:12 amounts 173:4,8 174:6 174:22 245:21 251:13 251:22 252:2 amplified 57:10 amplify 59:9 analyses 17:15 43:10 43:11 51:8 70:20 102:22 109:1,3 193:7 221:11 analysis 2:5 10:11 11:2 17:10,11 18:7 20:13 21:20 37:19 41:9,14 42:11 48:16 49:19 57:11 79:6 179:8,11 191:9 197:4 204:12 212:18 225:20 227:22 262:15 analytic 12:5 22:13,18 34:4 40:1 44:16 47:9 170:5 171:8,9 174:11 175:11 176:13 179:13 181:4 182:5,12,21 184:12 185:5 186:4 187:13 189:10 190:14 228:10.22 244:8 245:8,14 248:17 252:6,10 253:12 254:4 255:1,10,16,19 269:2,10 273:2 analytical 12:12,19 13:12,22 14:5,8 17:16 38:21 61:20 62:21 63:18,22 64:7,11 65:13 67:12,14 68:12 69:10 70:3 73:6 79:9 103:22 142:16 144:10 149:4 157:6 158:17 209:7 218:15 221:2 221:12 222:2,7 225:18 232:10,10 263:21 analytically 269:6 analyze 48:9 93:8 analyzed 23:9 135:8 and/or 11:5 13:16 15:1 64:14,16,18 65:3 66:9 67:1,7 68:2 69:2,21 70:12 71:7 73:10,12 97:12 116:2 147:19 149:15 168:9,14,17 169:7 170:1,9,13 171:12,19 173:1 175:22 177:11 183:3 183:11,15,20 184:14 185:18 186:12 188:12 anemia 156:19,20

184:3.22 animal 87:7 92:17 189:16,17 224:4 animals 244:17,19 animation 64:10 65:14 171.7 announced 7:15 announcement 139:17 answer 21:8 41:7 86:12 92:1 100:5 109:15 122:21 181:14 193:15 230:22 232:20 233:21 237:5,21 238:5 244:11 271:4 answered 62:12,19 168:5,21 answering 132:2 answers 51:2 92:2 antacids 23:17 anthropometric 211:17 220:6,10 anthropometrics 93:1 93:16 111:16 116:8 117:12 246:18 anthropometry 65:12 67:9 68:8 69:7 70:1 70:15 137:18 143:13 184:7 187:6 253:20 255:22 anticipate 52:20 anxiety 67:22 152:20 176:9 247:6 253:1 261:16 anybody 44:4 101:14 anybody's 261:19 anyway 165:18 209:14 267:19 apart 193:22 194:21 apologize 50:2 appetite 133:21 appetitive 132:20 **applied** 11:11 14:18 16:18 61:19 65:21 66:11 apply 9:8 70:18 71:2 appreciate 60:4,13 81:2 88:20 192:8 273:9 274:3 approach 11:9,17,19 30:11 33:7 53:20 54:14,17 130:10 181:14 203:18 227:18 227:19 approaches 9:17 11:1 11:13 71:9,13 130:14 193:17 approaching 213:8 **appropriate** 14:4 16:18

75:11 83:21 104:16 109:8 110:20 137:21 154:12 216:4 appropriately 75:9 179:9 approved 90:11,12 Ard 1:14 20:18 54:10,12 86:8,9,10,11 100:8 229:2,2 262:11,11 264:14 area 48:10 65:18 140:14 159:19 204:17 212:1,12 213:1 230:11 areas 10:4,6 61:7 95:10 96:1 140:11 141:9 166:15 167:4,11 211:15 243:13 264:21 argue 215:20 216:9 array 241:9 **article** 83:9 198:10 articles 12:8 14:14 62:7 74:4,15 articles/excluded 12:8 artificial 132:22 216:4.5 ASD 247:6 253:1 asked 105:13 107:13 119:15 165:3,18 asking 19:8 81:8,16 168:7 202:8,10 258:6 aspartame 216:8 aspect 111:3 206:16 aspects 100:20 112:14 115:3 129:17 160:6 205:15 273:11 aspirational 61:22 assess 24:12 76:14 99:22 103:2 125:13 146:2,3 234:6 254:16 256:13.15 assessed 39:16 211:18 248:2 254:18 assessing 191:10 228:20 248:22 assessment 13:3 26:7 114:17 125:8 assessments 111:8 119:18 127:16 assigned 148:13 assistance 22:7 associated 34:17 86:14 179:2 261:7 assume 207:19 232:14 assumed 31:19 assuming 48:21 assumption 33:5 48:2 assumptions 33:3 assured 195:21

AST 29:1.3 44:19 45:10 asterisk 96:12 212:9 asterisks 61:9 asthma 177:2,5 180:2,9 180:11 atopic 142:3 167:1 169:8 176:17 177:1 179:20 attempting 160:17 attend 3:11 attending 276:13 attention 67:19 176:9 246:15 audible 54:12 audience 49:4,6,9 97:7 168:2 auditorium 1:8 8:14 August 74:2,14 autism 67:20 152:21 176:10 availability 35:22 available 18:20 23:7 24:10 26:1,19 29:8,9 30:15 32:10 43:18 44:20 45:7,12,15,19 48:9 56:18 60:6 61:16 77:12 89:5 90:3 168:1 182:19 197:13,14 198:19 202:14 203:3 204:2,8 206:18 207:8 Avenue 1:9 average 24:22 25:9 31:13 37:9,11 40:4,12 53:11,11 averages 24:20 avoid 87:14 266:8 avoiding 5:16 aware 239:9 258:22 в **B** 26:11 39:20 42:19 89:15 226:13 265:2 **B-24** 153:1 B12 34:20 35:4 141:13 149:18 158:20 167:7 175:10 181:22 185:6 185:10,13 186:7 187:13 188:17 **B24** 22:17 40:16 47:7 48:7,15 49:20 52:15

52:17 193:18,20 205:9 B6 34:20 35:9 back 49:5 54:19 57:21 63:8 78:1 105:7,15 112:22 120:5 121:9 121:10 131:22 133:7 138:14 139:12 154:1

154:2 164:15 165:3 165:15 178:19 192:10 199:15 200:16 210:2 234:19 271:17 276:11 badge 3:20,21,21,22 badges 4:3 Bailey 1:14 2:5 20:12 20:15 42:10 43:4,7,13 44:6 45:1,14 46:4,14 46:22 47:12 48:5 49:17 51:9 54:3 56:10 59:11,13 125:6,6,17 127:2,20 128:1,7 201:14,17,18,18 202:9 237:8 243:8 269:12,12 bailiwick 234:13 balance 112:21 113:4 223:12 Barbara 1:10,13 2:4 8:5 197:7 209:14 226:10 230:4 243:10 Barbara's 274:6 base 46:17 51:5 72:8 98:13 273:3 based 5:13 18:14 21:10 22:1 28:17 35:21 50:16 51:2 58:9 65:22 72:3 84:19 106:11 109:7 116:4 121:16 128:12 132:15 144:5 150:14 196:9 214:21 221:16 268:20,21 baseline 69:7 111:8 116:1 117:3 124:14 144:1,19 157:5,13 184:8,9 187:6 222:10 235:17 236:12 256:4 basically 136:2 141:21 148:7 149:9 151:2,22 152:4,6,7,10,15 153:17 156:12,16 158:8 161:5 204:11 240:11,15 254:10 268:15 basis 217:19 262:3 batteries 63:4 battling 121:9,10 bazillion 51:8 Bazzano 1:15 56:21,21 135:11,11 238:13,14 271:14,15 bear 160:1 166:3 167:20 becoming 224:7 beer 37:6 before-pregnancy 149:12

began 141:5 244:13 **beginning** 63:14 130:4 192:16 271:11 begins 180:4 **behalf** 95:3 140:7 behavior 129:5 131:4 behaviors 124:4 270:18 belabor 213:4 believe 83:21 89:7 111:17 210:16 229:6 believes 217:7 beneficial 263:1 best 40:18 49:21 87:11 105:2 106:2 125:20 Beth 210:22 better 11:19 48:21 49:3 59:3 127:5 136:11 162:15 240:6 beverage 35:12 36:1,4 36:5,8,12 37:17,18 38:4 39:6 46:16,18 130:19 134:6,20 135:6 189:20 210:15 212:2 213:12 214:13 215:7 217:17,19 218:18,21,22 219:1 219:14 220:12,19,21 221:21 222:16 224:1 226:21 227:1 229:10 233:5,9,13,16 234:3 235:13,16,18,19 236:1,5,19 237:13 238:6,6,20 239:1 240:2,4,16,18 241:19 beverages 2:12 10:8 18:10 21:5 23:10 24:8 24:11 25:11 33:1 34:6 36:2,11,17,18,20,21 37:6,15 38:19 40:8,20 41:5 46:10 50:12 51:16 62:5 71:17 72:7 97:13 98:22 99:1 115:9 134:22 169:22 170:1,10,14 171:2 174:7 183:11 190:19 194:3 210:15 211:16 211:20 212:14 214:14 215:4,10 216:15,17 216:20,22 217:2,6 219:5,19 231:17 232:11,17,21 233:21 233:22 237:12 239:5 239:6,16,19,20 240:13,19 267:3 270:21 271:1,7 beyond 105:1 106:7 180:19 bias 13:3 111:21 119:18

228:19 biased 81:7 **big** 95:2 105:8 131:9 165:10 216:19 bilirubin 196:2 binder 36:15 binders 19:11 bio-marker 149:22 bioavailability 207:6 biochemical 30:17 54:5 113:10 203:1 **biological** 30:16 57:22 biomarker 56:14 202:13,14,21 biomarkers 34:8 66:2 188:2 201:21 202:2,5 202:7 203:12 204:22 247:13 250:4 256:15 birth 2:11 10:7 16:22 18:9 26:16,19 65:6 67:3 68:5 69:4 140:20 147:10 163:20 164:1 164:1 165:21 166:5 174:8 181:17 183:4 183:19 184:8,15 185:19 187:6 190:21 191:11 192:3 195:7 197:19 205:12 211:20 212:19 221:3,6 224:3 225:12 246:5,17 247:22 252:21 267:22 births 146:10 **bit** 23:2 24:4,15 25:21 29:6 31:8 38:16 42:7 60:5 88:12 103:20 107:14 117:11 119:8 125:3 126:13 147:1 152:12 166:10 171:6 174:19 179:5 213:7 214:14 215:11 227:16 230:3,9 266:3,15 267:3 268:5 276:8 black 109:21 143:4,19 blended 219:7 blood 34:14 35:2 69:15 149:19 151:6 180:14 203:22 247:13 blue 22:16 140:17 143:6 150:11 BMI 27:12 68:16 116:5 143:14 144:6 221:17 221:22 222:16 252:18 254:2 board 91:5 246:11 bobbing 85:17 **bodily** 138:17 body 62:17 68:14,16 73:5 74:13 96:7

113:22 115:2.22 122:6 143:22 166:20 167:9,13 168:10 171:13 173:20 174:10 174:18 179:19 182:4 186:10,16,18 187:16 199:20 205:7,11 206:3 218:16 223:11 232:12 bone 29:19 75:1 167:9 167:15 182:4 187:19 187:22 188:1,1,2,2,8 188:13,18,21 190:15 202:4 204:15 205:12 205:18,21,22 206:21 209:6 born 225:10,11 **borne** 251:9 bottle 173:9 175:3 217:12 bottled 37:3 **bottom** 35:8 75:10 150:3 172:20 174:3 174:19 Boushey 1:15 2:7 52:6 52:7 55:20 60:17.20 60:21 63:12 76:2.12 76:18 77:9 78:21 79:21 81:2 82:16 85:6 88:10,18 91:4,9 94:7 95:6 114:5 164:7,10 164:10 198:21,22 199:14 200:3,8,18 201:2,11 209:1,2 241:3 260:7,8 266:11 266:12 **box** 75:10 90:7 171:14 218:19 227:21 228:5 230:14,18 231:1 245:17 **boxes** 22:16 88:2 231:12 247:20 branching 87:6 brand 73:18 break 91:11 94:12 209:17 210:1 267:21 breakdown 242:4 breakfast 98:5 99:17,21 100:14,21 101:1,3 123:3 126:15 breast 48:10 49:15 53:6 145:13 169:16 173:8 175:2 193:9 194:7 222:18 227:3 255:6 breast-fed 49:16 breast-feeding 120:15 breastfed 195:14 breastfeeding 145:7,8

145:10,12 153:11,13 153:15 158:3 170:17 192:13 193:3,6 194:7 194:18 195:10.22 198:7 brief 8:16 bring 78:1 84:7 165:14 200:16 273:8 bringing 158:2 209:3 brings 131:16 Brittany 228:9 230:21 broad 22:5 82:2 broader 195:9 Broadly 22:19 broken 192:7 219:22 brought 10:1 41:21 62:22 127:9 135:22 267:14 270:20 building 3:22 **builds** 6:6 **bulk** 17:8 **bunch** 89:15 button 61:4 79:17 С **C** 34:19 37:21 C-O-N-T-E-N-T-S 2:1 **C-section** 206:14 cafeteria 4:6 caffeine 38:1 calcium 23:18 37:22 162:2 206:22 207:1,6 209:3 calculation 109:4,6 128:3 call 2:2 7:2,5 99:3 101:16 126:12 165:2 195:16 216:5 257:9 260:5 265:20 called 23:12 30:11 31:18 32:5 58:5 calling 153:14 215:17 217:5 calls 79:15 159:10 257:10 265:17 273:18 caloric 97:13 98:13 102:20 103:14 128:13 128:18 130:1 131:10 131:12 132:1,11 134:7 138:6 216:8 271:6 calorie 130:19 215:12 216:10,16 218:4 236:17 238:6,6 calories 36:20,22 38:5 94:6 129:16 130:8.9 131:16 134:2 233:22 239:6,6,18 240:9,13

cancer 26:9 74:21 243:19 250:13 253:20 254:4,7,8,13,19 255:3 255:6,7,8,9 cancer-specific 255:4 cancers 29:9 candy 134:10 capable 224:6 capture 48:14 74:6 81:13 92:15 101:19 102:2,10,12 107:11 107:17 121:17 124:11 124:12,19 125:9,22 126:7 129:11 131:2 133:5 153:7 198:6 266:9 captured 101:11,13,22 103:4 108:2 125:4 260:12 274:17 capturing 104:22 108:5 108:16 123:19 135:14 177:5 carb 72:1 77:5 78:4,5 carbohydrate 71:11,19 72:1,13 78:2,10,14 82:6 83:6,11,17 86:19 87:2,3 88:5,6 92:19 251:17 254:1 256:3 carbohydrates 37:21 80:13,17 92:10,11 carbonated 37:3 carcinogens 255:8 cardio-metabolic 180:15 cardiovascular 27:9 62:18 69:9,12,16,18 75:21 84:10 94:2 96:9 117:20 118:1.3 138:17 177:19 180:3 212:17 243:17,20 248:15,18 249:7,9 250:13 255:13 261:3 careful 56:1 carefully 242:10 caregiver's 172:1 caregivers 171:22 172:8 Carol 1:15 2:7 52:6 60:17,19,21 95:6 96:3 164:10 171:7 198:21 209:2 238:10 260:8 266:11 272:13 carotenoid 35:9 carotenoids 34:19 carried 197:20 235:13 carry 232:17 **carrying** 232:20 case 64:19,22 66:16

82:3 91:16 143:14 146:8 149:1,11 153:12 154:8 156:13 157:17 175:7 183:2 184:7,13,16 187:12 232:16 236:11 241:21 cases 22:3 149:13 cast 204:19 catch 74:9 categories 23:14 25:7 36:12 39:6 42:4 46:16 99:1 177:22 178:14 189:3 214:18 218:18 219:11 223:19 categorization 42:5 86:16 categorize 88:1 category 24:1,16 25:14 35:15 37:13 39:1,9,15 40:3,10 46:19 215:7 216:17 225:22 226:1 256:4 260:3 causality 146:5 cause 32:2 72:19 109:19 113:17 causes 64:6 73:1 113:18 **CDC** 214:6 **CDRR** 32:9 33:11 CE 35:9 cell 34:14 35:2 149:19 203:22 Center 3:5 certain 38:15 74:20 78:9 84:14 150:5 254:6 certainly 41:22 45:2,15 59:21 198:15 200:16 203:20 204:2 230:6 251:9 252:2 257:10 258:12,19 267:14 cetera 37:7 83:12 87:20 261:10 chaired 8:5 chairs 265:19 273:17 challenge 105:12 challenges 196:5 challenging 196:14 chance 260:20 **change** 9:13 18:14 37:11 38:14 107:7 111:11 115:22 120:22 124:4,16,17 130:17 143:22 144:18 218:5 220:12,21 222:10 223:11 233:13 235:17 235:18 241:12,12 changed 102:5 105:17

110:5 115:18 changes 6:7 21:9 24:3 24:17 25:5,12 27:7 38:9 42:20 48:12 74:8 74:9 84:20 113:10 114:2 116:14 117:2 218:3 219:20 231:19 changing 49:22 103:3 124:21,22 129:4 163:5 characteristic 28:17 characteristics 27:4 28:1 80:21 245:4 246:13 characterize 32:8 characterizing 26:15 26:22 27:18 29:5 charge 5:5 chart 12:6 **charter** 5:6 52:16 chatting 272:14 check 82:17 chemicals 247:12 child 152:14 153:10,13 158:2 170:3 180:18 200:21 201:4 246:16 261:14 childhood 38:10 174:8 243:16 247:16 248:14 248:22 249:6 children 22:19 26:19.21 27:10,13,17 34:8,18 44:8 45:7,21 47:15 65:2 68:1 69:1,20 70:11 104:9 133:20 133:22 134:3,15 153:5 154:21 178:2 190:16 191:11 246:4 249:1 252:15 chime 95:17 100:18 124:11 choice 214:11 choices 227:5 cholesterol 28:3 54:21 54:22 55:6 69:13 250:20 choose 227:4 chose 106:6 107:3,15 108:7.22 148:4 149:21 chronic 16:4 25:17,18 28:19,21 32:5,8 34:3 44:18 65:4 67:1,7 68:3 69:2,21 70:12 144:9 147:15 154:19 183:20 circadian 122:11 213:15

circumference 27:21 27:21 cirrhosis 28:21 **claim** 190:3 clarification 84:5 128:9 clarify 87:12 241:13 257:20 269:22 clarifying 95:16 clarity 127:3 classic 269:7 classified 147:3 clean 196:4,8 267:8 clear 198:12 201:5,13 201:20 211:10 265:9 clearly 70:18 216:11 217:9 clicker 166:1 clickers 171:16 clinical 30:22 33:22 54:6 56:22 58:1 202:21 203:1 237:1 close 139:1 144:19 246:15 closest 90:1 **closing** 264:8 cluster 214:19 co-founders 13:20 cobble 42:17 code 197:2 coffee 36:17 217:9 coffees 217:1 cognitive 67:20,21 176:5 Coho 259:19 260:10 cohort 105:10 106:18 241:20 **collect** 30:2 collected 34:12 197:12 collecting 53:10 205:1 collection 107:8,16 collectively 54:8 College 151:10 colon 255:6 coma 165:17 combination 61:15 149:7 170:8,12 combinations 36:10 combined 101:8 146:10 146:15 combining 145:13 come 26:14 48:16 51:13 55:9 58:7 63:7 82:10 101:10 120:5 129:15 138:14 140:1 155:15 164:14 191:18 195:9 216:14 240:13 241:1 264:12 268:11 271:17 276:11

comes 28:5 36:19 59:5 139:14 229:10,16 262:12,16 272:7 comfortable 273:6 coming 65:17 81:3 92:10,16 197:11 239:16,18 comment 18:16 20:3,6 43:22 54:12 55:20 89:9 90:4 92:6 129:15 136:6 165:5 197:16 198:20 206:20 228:6 264:15 265:8 266:12 273:9 comments 6:22 7:3,5 7:12 18:5 19:13,16,16 19:19 53:21 57:10 60:14 92:8 95:1 124:1 138:22 139:19 155:17 155:18 158:9 159:14 164:6,11 192:2,5 226:10 242:21 260:15 263:21 264:5,8 271:15 274:16 275:9 275:10 276:10 commercial 179:1 commercially- 169:19 committed 275:22 committee 1:1,8 2:17 3:7,9 4:8,9,21 5:5,17 6:2,12,13 7:1,2,12,20 8:4,11,21 9:3,14 10:1 10:17,21,21 11:4,15 11:20 12:1 13:5,8 18:5,17 19:10,14,22 20:8 21:11 29:2,10 40:19 41:12 42:8 43:17 49:20 52:18 53:15,20 58:13 59:21 60:14 61:14 69:3 70:22 75:21 88:13 89:12 92:12,22 95:5,8 95:17 100:18 104:14 107:10 122:18 140:7 141:15 151:22 159:6 165:1,14 168:2 178:8 192:3 205:5,16 210:7 210:21 218:12 237:1 238:9 243:10.11 251:21 263:3 264:2,4 268:7 274:12 275:11 275:15 276:10,14 committee's 6:8,14 7:4 7:6 20:4 39:19 263:14 committees 42:1 50:13 53:8 59:21 229:21 265:16 committees' 249:16

Neal R. Gross and Co., Inc.

Washington DC

common 50:10 162:13 196:18 commonalities 269:7 commonly 56:7 communicate 58:19 communicating 215:15 comparable 15:17 comparator 13:13 110:9 115:18 117:22 151:5 183:18 184:19 185:9,21 186:14 218:20 221:14 222:9 247:18 comparators 64:15 72:16 106:5 142:21 149:9 150:9 152:7 167:20 171:15 172:21 175:16,17 183:12 221:4 245:18 248:16 253:10 254:9 255:14 compare 24:13 39:17 39:21 41:4 56:13 163:7 219:11 229:6 compared 24:2 52:22 218:22 219:6,7 comparing 25:13 30:14 33:8 144:4 219:5 **comparison** 172:11,12 172:15 174:21 227:11 comparisons 171:18 171:21 172:2 173:3,3 173:6,12,18,21 174:16 175:3,20,21 176:20 177:15 266:20 compelling 31:16 compensation 234:4 **compile** 101:6 complement 223:22 237:20 complementary 38:19 39:13 51:11 167:12 169:22 170:9,13 171:2 174:7 191:6 192:12,16,21 193:1 193:12 194:2,22 196:15 complete 19:22 256:20 completed 166:13,14 167:12 completely 81:3 130:10 172:5 completing 68:6 complex 80:17 complexity 88:21 171:8 192:17 complicated 167:19 compliments 206:7 component 23:8 35:14

40:12 98:9 101:2 103:14 114:14,16 123:1 components 12:2,19 13:12 27:5 53:18 55:17,18 99:5 101:1 123:20 126:5 233:1 246:20 composition 48:11 62:17 68:14,16 73:5 74:13 96:7 113:22 115:2 118:14 122:7 151:20,21 152:4 154:10 155:21 158:14 166:21 167:9,14 168:11 171:13 173:20 174:18 179:19 182:4 186:10,16,18 187:16 199:20 205:8,11 206:4 212:5,10,21 218:16 225:21 232:12 compositions 78:17 comprehensive 83:14 83:18,22 comprise 77:14 comprised 20:17 compute 130:7 computer 63:6 concentration 35:7 216:3 concept 80:9 135:21 conception 157:2 concepts 97:20 199:9 213:15 264:16 conceptualizing 100:12 concern 30:6,8 32:13 38:2 53:17,19 54:1,9 55:1,22 56:6 57:15,19 57:21 79:20 80:6,14 83:5 133:17 207:2 269:20 270:14 concerned 236:14 concerning 212:18 concerns 161:20 212:1 conclusion 13:6 41:9 119:19 235:22 **concur** 164:7,8 concurs 164:11 condition 225:1,2 conditions 25:17,18 34:3 77:13 conduct 4:22 119:18 conducted 11:4 15:19 42:11 90:14 178:18 181:6,8 252:14 253:15 257:2 conducting 62:13 140:15 142:12

1	1		1
confirm 60:21 83:20	103:12 125:15 150:17	244:12 245:10.19.20	corpuscular 149:19
confounder 93:3.4.8.14	153:4 189:19 228:13	246:1 247:10.16.22	correct 47:19 85:16
93.21 110.17 19	228.17 19 248.6 11	248.14 22 250.1 10	90.9 128.6 163.14
111 14 19 19 22	253.5 18 22 255.22	254.6 255.12 256.13	227.18 231.2 8 235.3
112.1 12 113.13 14	262.14	256.16 262.13 19	236.10 21 241.16
11/-0 10 12/-0 133-/	considering 53:4 77:4	contain 36:21	correlational 123.3
137.15 138.10 10	220.1 246.3	contained 180:16	correspond 180.0
145.6 157.4 17	223.1240.3	containing 23:17	corresponding 72:15
195:16 100:11 21	106·4	170.19	couch 01:17
220:17 221:5 260:10	100.4	contains 26:20 217:7	coupt 120:10
230.17 231.3 209.19	90.19 00.19 04.4	contaminated 260:1	countries 15:15 155:14
69.7 60.6 22 70.12	09.10 90.10 94.4	contaminated 200.1	160.15 191.6 9
75:20 76:15 100:22	142.21 142.5 150.19	contemplate 70.1	207.10
10.22 110.10 111.17	142.21 143.3 130.10	442,9 420,4 422,4 5 7	207.19
109.22 110.10 111.17		113.0 130.1 132.1,5,7	Country 60.14 161.4
112:10 114:8,20	194:4 196:17 208:5		181.3 249.19 259.21
110.7,9 117.10,14	223.20 224.0 229.22	214.22 215.2 217.4	Couple 33.19 195.12
118:8,9,22 119:1,11	230:11 246:7,9	219:1	213:10 266:10 272:19
122:14,15 136:22	249:14 252:10 255:15	context 95:22 130:11	course 14:5 41:1 79:16
137:13,19 143:3	256:9 267:5,11 270:3	215:15 268:6 272:3	161:20 180:2 206:18
150:2,10 151:14	consistently 110:1	273:11	242:9 260:9 269:7
152:8 153:9 157:11	Consortium 66:2	contextual 125:10	covariant 230:15,16
174:3 184:5 185:1,14	constipated 160:22	continually 270:15	covariate 110:18
187:2,3 188:9 199:7	constituencies 58:3,5	continue 41:15 63:9	112:20 113:13 117:15
220:8 221:20 222:14	constituents 56:7	139:10 229:3 272:20	133:12 136:9 137:1,2
226:18 228:18,18	constructive 50:14	continues 192:5 275:15	137:6 248:12 253:5
229:6 232:13 246:14	consume 58:16 93:13	continuous 86:5	256:1 269:19
247:5 248:8 249:4	1/2:3,5	continuum 218:8,10	covariates 13:21 110:1
252:17,20 253:17	consumed 22:10 23:15	contraceptive 255:5	112:14 115:5 116:15
254:22 255:4 257:21	36:3 37:16 38:5 46:17	contribute 36:5 37:13	118:10 119:1,11
258:3,17 270:3	56:7 60:1 61:18 62:10	39:6 130:8,9 239:1	135:15 228:12 247:8
confounding 135:15	62:12 63:21 65:20	contributed 41:6 58:21	248:9 249:5 253:22
246:16 248:11	67:16 68:13 69:12	91:20 129:3	255:18 256:2 258:18
confusion 55:2 130:14	70:6 71:2,17 74:20	contributing 75:15	267:5 270:4
congratulate 159:17	75:1 85:21 142:9	contribution 233:5	cover 14:6 272:22
Congress 178:21	144:11 147:20 156:10	237:12	covered 73:2 110:8
conjunction 41:1 66:14	173:5,8 174:22 181:1	contributions 35:15	211:8
connect 93:5	181:16 183:4 184:15	39:10,15 47:14	covering 96:10 167:6
connection 93:17	195:5 239:17 245:22	237:17	cow's 52:22 170:10,14
connections 261:20	259:10,22	control 50:19 105:20,21	crab 244:22
262:4	consumers 216:11,20	106:5 138:16 146:4	created 11:15
consensus 51:13 66:3	consuming 36:3 102:15	236:16 240:10,14,17	creating 81:4 2/3:14
consequences 31:1	115:11 124:12 134:8	2/1:2	criteria 5:14 9:8 12:5,13
32:2 33:22 54:6 57:1	1/3:12,13 1/5:22	controlled 93:21,22	13:2 14:11,17,17,19
consider 30:16,20	consumption 29:4	117:6 154:4 222:13	55:8 64:3 /0:16,20
52:16 /5:22 /8:18	35:12 36:1,4 37:17	242:10	/1:3,14,22 /2:4 /3:3
120:6,14 137:1,14	53:12 64:14,15,17	controlling 190:12	81:19 82:8 84:19
138:1,10,20 163:5	/1:/ 94:1 99:12,13	237:14,18 240:15	103:17,18 104:7,13
190:22 196:15 206:15	129:6,9 133:9 168:10	converge 66:4	106:10 107:4 145:16
207:12 215:17 217:21	168:14,18 169:8,11	conversation 4:19	145:17,21 150:21
221:1 222:5 227:22	1/1:12,20 1/2:13,15	96:17 204:5 205:6	151:9 153:17,18
229:17 234:10 249:5	1/2:16 1/3:1 175:14	conversations 192:10	154:14 158:5 178:4,7
254:21 265:3	1/5:18 1/6:16 177:11	269:4	1/8:13 181:4 189:1,2
consideration 5:22	1/8:61/9:3,18	converse 48:2	189:3,6,8,11 190:7
25:19 80:19 161:6	180:18 181:5 183:9	conveys 216:11 219:15	203:16 208:3,21
195:19 235:12 263:2	183:12,13,15 184:2	copper 34:15 35:3	223:1,1,18 224:9,17
2/3:/	211:16 212:2 218:20	184:3	231:18 234:17 235:7
considered 5:2 37:4	220:13 224:1 233:14	core 12:20	241:18 249:12,13,15
45:2 / 1:12 / 4:6	234:4 238:5 241:19	coronary 28:8	256:9,10 258:19
1	I	I	I

criterial 154:17 criterion 181:3 critical 111:9 114:17 117:16 122:1,22 275:5 cross- 20:12 cross-cutting 10:10 40:16,19 191:9 cross-sectional 154:4 154:11 cross-talk 135:1 crosstalk 265:15,21 269:11 275:4 cultural 112:3 213:16 curious 199:8 202:18 current 5:1 6:3 23:20 30:14 35:11 59:22 60:5 74:10 90:19 175:6 270:17 currently 46:17 59:10 90:3 273:19 customarily 22:10 customary 220:19 cut-point 33:2,3 cut-points 30:18 cuts 10:12 cutting 20:13 CVD 73:8 74:13 244:4 253:20 255:21 256:4 257:2 cycle 136:8 cycles 27:16 D **D** 34:16 35:4 37:22 141:14 158:21 167:7 175:10 181:22 184:14 184:16,20,22 185:3,5 186:7 187:12 188:11 188:15 195:14 202:10 202:11 206:21 **D.C** 1:10 7:13 daily 32:1 37:17 38:4 40:7 96:19,21 128:9 233:6 239:18 dairy 47:3 207:4 214:20 215:2 251:11 Darcy 197:17 198:16 dark 259:19 DASH 71:9 77:5 162:3,5 data's 45:11 database 83:16 256:19 databases 48:9 251:4 date 7:16 73:16,19,22 74:11 89:13 90:1,1 104:13 141:2 179:5 223:4 249:18 dates 7:9 15:1 73:14

89:10 Davis 4:13 20:18 dawned 220:18 day 1:6 36:3 78:8 88:6 97:1,22 98:3 99:4,15 99:20 100:4,14 102:8 102:15 107:19 108:3 108:17 121:13 127:15 128:14,15,18 133:9 135:19 251:3 days 102:1 107:15 108:6,8 127:11 deal 50:22 92:12 165:11 273:4 dealing 19:3 deaths 64:5 113:18 debate 77:8 decades 242:16 December 6:19 **decide** 48:17 89:12 218:9 decided 55:12 65:5 67:2 141:15 149:12 154:3 155:10,20 158:19 165:14 175:2 223:7 231:3 deciding 150:15 decision 55:10,14 92:4 165:15 172:1 decisions 58:9 81:8 171:22 172:8 180:8 decline 67:21 decrease 93:4 deep 204:18 deeper 220:2 deficiency 156:19,19 184:3 deficit 67:19 176:9 define 53:22 58:14 66:4 78:16 86:18 97:5 98:17 126:16 187:21 214:14 269:20 defined 14:1 22:20 36:9 38:18 96:18 97:15 98:1 113:16 169:15 182:18 213:3 214:16 214:17 223:19 244:18 245:19 defines 12:19 64:4 142:22 defining 9:6 95:13 116:12 117:6 267:6 definitely 79:14 130:21 214:3 233:2 259:14 260:2 263:4,9 definition 21:22 36:19 37:5 44:3,4 46:11 55:8 61:12,19 62:1

65:21 66:11 71:4 98:10,12 102:6,19 103:9,11 131:9 132:9 132:14 142:14 148:6 148:7,15 170:14,22 171:3 182:14,17 190:1 192:21 193:3 194:2,5,6 195:10 197:18 213:12 214:5 214:8 223:22 239:22 244:13,16 252:7 258:2 definitions 21:19 30:7 31:2 36:11,14 66:6 96:14 104:5 128:13 148:5,18 169:14 170:4,16 182:6,10 192:12 198:3,9,12 213:10 244:15 250:15 251:8 262:14 degree 27:6 218:2,5 219:12 233:8 273:5 deliberations 4:16,17 7:4 delivery 116:3 144:3,3 144:20 153:11 158:3 174:9 206:10,14 219:14,16 dementia 67:21 demographic 23:1 27:4 27:12.22 demonstrated 271:5 demonstration 64:9 **density** 69:14,14 112:15 188:2 dentition 112:8 Department 1:9 departments 5:2,8,19 5:22 6:14 275:22 depend 195:2 dependent 98:2 depending 13:18 78:11 101:8 depends 101:5 124:14 236:20 depression 67:22 152:21 176:10 247:6 253:1 261:15 derived 71:13 77:16.17 80:17 131:13 dermatitis 177:2 describe 19:1 23:19 25:15 30:5 35:11 71:15 72:7 87:18 described 23:11 33:21 36:13 46:6 178:8 223:2 253:11,13 254:10 255:16

describes 17:13 describing 6:3 9:7 20:21 50:11 87:11 254:5 description 72:5,10 216:13 descriptions 198:4 descriptive 80:3 93:12 238:2 desegregate 81:12 desegregating 81:17 design 15:9 101:8 236:20 249:17 designated 3:6 16:17 designates 4:1 designed 97:9 designs 234:10 238:16 242:5 desirable 216:7 detail 17:3 24:15 25:21 125:10 213:7 214:15 244:7 details 10:14 11:10 17:14 detect 109:10 determine 233:13 235:17 determined 22:11 determining 242:11 develop 5:17,22 6:5 9:19 41:15 48:7 74:18 83:14 90:13 119:19 244:10 developed 62:1 83:18 160:14 167:17 181:11 developing 5:15 19:2 191:5,17 development 5:3 15:16 21:1 64:2 152:11 157:20 160:6 168:19 175:15 180:18 181:7 181:9 207:19 208:2 243:21 245:12 246:7 246:13 247:17 248:5 250:12 252:5,21 developmental 67:17 152:10,17 153:3 158:15 166:22 167:14 168:18 175:14 176:4 176:7 200:14 261:16 develops 17:12 devoted 21:3 Dewey 4:14 155:18 166:6 **DGAC** 75:6 **DHA** 244:4 250:7,18 diabetes 27:15 28:10 28:11 29:14 62:19

70:2,5,8,9 73:11,11 73:13 74:13 84:4,6,12 84:13,16,18 85:11,14 85:15,20,22 94:3 96:10 116:11 118:17 118:19,22 138:18 143:16 150:8,11,12 150:15 151:16,17 154:22 157:7,10,12 157:18 160:7 161:22 162:14 163:21 177:20 180:3 212:17 222:1 222:19 226:17 227:15 228:15 253:21 255:21 261:9 diagnosed 16:12,16 85:3,20,22 147:7,11 155:1 diagnoses 156:18 diagnosis 85:15 143:16 151:15 157:18 180:9 diagram 53:17 dictate 15:20 diet 12:20 36:11,17,18 36:19 48:3 78:2 82:6 83:6,11,16,17 88:14 92:19 97:8 112:15,16 112:18 113:1,2 115:6 125:8 142:3 162:4,5,9 162:16 174:8 185:16 189:18 215:10 232:15 233:1 240:2 246:20 273:10.11 diet- 261:17 Diet-related 14:21 DietaryGuidelines.gov 7:16,18,22 11:8 dietitians 126:19 diets 61:17 71:19 78:10 82:5 83:11 115:7,8 differ 22:1 difference 43:6 90:5 100:10 135:12 187:9 202:20 207:4 221:4 225:17 235:10 274:13 differences 27:3 38:22 39:2,5,9,17 109:11 117:13 124:7 129:22 154:13 206:13 212:15 different 21:21 36:10 39:2,7,10 40:8,11 42:3 44:9,12 51:2 52:21 58:16 61:15 64:16,17 73:16 76:13 78:11,15,17 79:3 80:22 82:15 87:17 88:14 91:17 92:2 95:21 99:9 103:20

104:20 105:21 112:14 117:11 126:5,7,13,20 128:17 130:10 134:15 144:13 147:5 149:9 152:12 154:16 167:20 172:13,15 173:3,7 174:21 176:1 179:3 183:14 192:18 199:9 207:5 211:17 213:14 213:17,18 218:21,22 219:1,2,2 221:10 226:2 227:2,5 245:22 254:7 262:22 264:18 265:16 266:16 267:15 268:12 differentiate 233:5 differentiates 80:22 differently 125:3 difficult 47:22 103:1 108:4 110:12 diligence 53:9 diluted 216:18 ding 228:1 258:14 dinged 111:1 dinner 99:17 dinner/supper 98:5 direction 271:13 directly 210:8 directs 13:2 disability 67:11 disagree 162:21 disappeared 228:6 230:19 discrete 36:12 38:5 46:16 214:16.18 discretely 220:1 discuss 29:7 40:14 48:6 140:12 166:11 191:10 222:20 discussed 5:9 9:15 65:21 79:15 88:13 92:9,21 118:18 150:14 152:1 165:2 182:11 183:22 189:21 191:4 203:22 discussing 7:21 19:18 53:10 121:10 140:18 discussion 2:17 9:3 10:1 11:22 12:10 18:4 18:15 19:9 22:19 40:16 49:18 53:14 54:20 59:10 63:9 79:19 80:5,8 82:3 98:20 133:19 153:21 155:9 217:14 222:6 257:17 264:2,2 268:1 275:2 discussions 40:20 45:4

232:1 disease 16:5,8,9 28:9 28:19,21 32:6,8 44:18 62:18 65:4 67:1,8,22 68:3 69:2,9,12,17,21 70:12 84:10 94:3 96:9 117:20 118:1 138:18 144:9 147:7,16 154:20 177:19 180:3 212:17 243:20 248:15 248:18 249:7,10 250:13 255:7,13 261:3 disease-related 69:18 118:4 diseases 142:4 167:1 169:9 176:17 179:20 183:21 disorder 67:20,20 176:9,10 disorders 68:11 73:9 151:4,8,18 157:15 163:22 247:4 253:3 disparity 50:21 displayed 75:9 distill 240:19 distinction 200:12 221:10 distinctions 219:10 distinguish 232:16 distinguishing 80:21 distribution 25:2 34:6 37:10 68:17 149:20 distributions 24:1.12 24:13 25:10 30:14 33:4 47:10 86:13 237:17 divided 171:15 174:16 doctor 85:2 document 119:20 132:6 228:10 documented 133:14 doing 23:21 36:13 51:11 59:17,18 60:9 70:21 75:2 79:6 121:12 146:7 161:2 238:3 246:10 258:6 270:12 dollars 22:6 domains 67:18 donor 169:18 **Donovan** 1:16 2:10 4:12 52:13,13 86:9 89:8,8 120:10 123:22 123:22 140:3,5,6 162:18,22 164:22 165:6 204:4,5 205:22 226:15,16 267:1

dosage 183:14 189:12 190:8 dovetail 52:4 downgrading 231:6 **Dr** 1:13,13,14,14,15,15 1:16,16,17,17,18,18 1:19,19,20 3:3,15 8:5 8:5 20:11,17,18,18,19 20:19 23:10 46:15 54:10 59:14 63:5 70:17 83:1 85:18 86:6 86:8,9,9 90:8,20 92:5 94:13 110:15 114:5 139:12 140:3 153:18 165:22 228:8 231:2,8 239:3 241:13,15,17 242:21 243:5 draft 40:22 41:9 drafted 9:21 11:22 dramatically 42:3 48:13 draw 132:22 218:9 235:22 drawing 237:1 drawn 214:6 **DRI** 32:17 42:6.22 56:12 drink 194:20 217:22 227:4 drinking 103:6,9 134:6 drinks 37:1,1,2 46:11 46:12,12 47:3 61:16 128:14 170:19 215:2 216:21,21 217:6 DRIs 32:5 53:11 268:9 drive 96:16 driven 114:10 119:14 driving 123:6 drops 170:18 **DrPH** 1:18 Drs 4:12,13 **Drug** 182:18 due 53:9 98:9 153:21 219:13 234:4 duplication 5:16 duration 15:3 117:15 120:13 122:5,8,10 123:5 126:7 153:13 166:19 168:8,13,17 169:6,10 171:11,19 172:20 174:13 175:13 175:18 177:10 223:7 256:6 durations 172:13,15 176:1 dynamic 42:20 Ε **E** 34:20 e.g's 77:9,10

eager 94:10 **EAR** 31:14,17,21 33:1,9 earlier 27:5 62:22 79:19 83:2,10 95:1,13 142:15 143:20 162:1 173:19 192:10 241:17 245:19 249:8 261:8 264:15 early 144:1 276:8 easier 266:20 eat 23:7,14 25:7 33:21 55:4 99:2,2 112:4 121:1 132:10,10 259:19 260:10 272:9 eats 80:15 echoing 269:1,13 eclampsia 151:12 161:21 educated 161:5 education 22:8 182:16 187:5 199:5,6,10,19 247:3 252:22 253:1 effect 56:16 137:5 205:2 220:12,21 236:19 238:7 239:21 240:3.16 effectively 47:19 126:1 effects 94:6 137:20 141:22 179:2 211:20 212:3 242:12 265:4 effort 196:17 210:8 efforts 75:14 eggs 55:4 251:11 eight 97:16 166:12 187:18 191:4 223:8 223:13 231:18 either 8:13 11:3 13:16 32:15 33:22 49:7 52:11 66:14 134:9 144:1,3 145:21 147:12 165:17 210:11 215:8 217:10 264:21 elaborate 42:7 58:18 elaboration 120:21 element 263:12 elemental 217:22 elements 9:6 12:20 245:14 elephant 98:8 elevated 35:5 eliminate 80:19 119:10 eliminating 258:18 Elsie 1:19 2:11 44:15 52:15 122:3 165:22 166:4 192:1 201:14 264:10 emotional 44:11 emphasis 268:6

emphasize 213:13 emptying 132:19 encompass 100:1 156:16 encompassing 82:14 100:19 119:7 encourage 8:1 19:18 57:9 275:18 endometrial 255:6 endpoint 66:19 69:16 70:8 84:5,12,17 85:1 85:5 114:4 117:2,22 118:19 157:8 177:21 178:1 248:1 249:2 252:9 endpoints 14:22 30:16 30:17 57:22 energy 31:10 33:16 36:6 37:2,14,18 39:7 39:10,12,16 40:7,11 65:12 67:9 68:9 69:6 69:22 70:14 71:22 72:2 91:20 93:2,11 98:13 110:11,16 112:15,15,16,17,19 112:21,21,22 113:1,2 113:4,4,6,6,7 114:18 129:2,3,8,9 131:3 132:8 134:12 137:15 137:17 138:15 170:3 192:22 220:10 232:14 232:14,17,20 233:6 233:11,16,21 234:5 235:9,12 236:4,5 237:13,15 238:17 239:16,19 240:4,10 240:14,17 253:18 269:8 270:22 energy-restricted 113:5 English 15:15 83:1,2 85:18,19 90:8,20 203:11,13,14 enhanced 37:3 217:12 enjoyable 139:10 enrichment 164:18,19 enroll 147:3,6,10,11 225:4,9,10,15,16 enrolled 224:21 ensure 31:19 195:20 enterprise 75:12 enthusiastically 75:7 entire 100:4 108:3 261:6 entirely 172:6 217:18 environment 112:3 262:1 environmental 247:12

enzymes 29:5 **EPA** 244:4 250:7,18 epidemiological 236:3 236:15 237:4 240:20 epidemiology 50:17 93:12 238:15 equal 239:20 error 238:18 escalating 206:12 especially 42:19 80:10 93:11 102:14 120:3 122:16 123:2 130:11 134:3 160:5 161:8 260:22 262:19 essence 112:4 121:12 essential 132:17 234:5 essentially 172:19 202:16 establish 31:17 55:12 established 4:22 14:11 21:13 31:5 145:19 151:9 178:22 establishing 82:11 estimate 31:14 47:22 48:1,20 49:3,14,21 estimated 31:13 estimates 237:16 et 37:6 83:11 87:19 261:10 ethnicity 23:4 26:17 65:10 68:8 143:11 220:9 221:20 222:15 246:18 252:18 European 66:3 evaluate 23:20 25:16 30:6 35:11,21 76:10 250:6 evaluated 125:3 144:16 evaluating 252:14 254:16 evaluation 263:14 Eve 2:2 3:3 8:7 232:4,7 evening 98:7 event 97:6,16 103:13 129:3,9 133:1 139:2 165:17 events 130:18 everybody's 96:5 everyone's 271:20 evidence 5:7 9:18 11:1 11:16 13:5 30:21 32:8 34:1 83:10 119:19 152:2 156:2 189:22 204:3,17 235:2 263:13 273:3 evidently 134:3 evoke 213:14 evolve 193:17

exact 202:13 exactly 121:21 230:8 exam 26:3 28:6 33:20 examination 44:17 174:12 examine 5:6 9:17 11:1 33:10 45:7 71:6,7,18 72:12 167:17 171:18 172:2 173:2,6,11,17 174:1 175:4 179:18 180:21 181:12 183:1 189:16 245:20 250:4 examined 12:21 13:16 62:5 71:16 72:11 102:8 176:12 178:2 178:18 191:1 248:18 examines 176:15 181:15 185:17 examining 27:22 63:2 63:20 65:19 67:15 71:1 169:18 172:22 182:21 184:12 185:22 189:21 253:15 254:5 example 35:18 42:13 51:12,16 71:8 82:3,4 83:16 101:20 107:21 128:12 134:6 137:17 173:15 188:10 203:20 219:4 227:5 229:7 240:8 244:20 247:11 247:13 258:7 259:9 267:2.13 examples 14:21 15:4 77:11,22 82:12 120:6 203:15 244:22 exceeds 33:11 exception 185:2 exceptions 30:3 34:10 excess 30:22 excessive 30:13 162:7 271:2 exciting 95:9 exclude 16:13 17:1 47:10 72:21 73:9,11 125:2 127:17 147:9 154:22 181:8 225:14 227:19 excluded 15:12 68:5 104:13 106:14 146:21 190:10 224:18 256:17 excludes 47:19 48:3 69:3 excluding 47:12,13,15 47:16 146:3,8,17 155:2 179:10 224:4 224:10 225:3 exclusion 12:13 14:11 14:17 64:3 70:16,20

(202) 234-4433

146:22 153:16 178:4 178:7,13 189:1,6 190:7 222:22 223:16 224:9,20 255:21 258:19 exclusions 73:8 250:3 exclusive 16:14 17:2 168:9,17 169:7,10 170:11,16 172:16 175:13 176:1 177:10 192:13 193:3,6 194:7 194:18 195:10,16,21 197:2,4 198:7 exclusively 120:15 145:12 147:10,11 172:10 195:14 225:4 225:15,16 exclusivity 120:14 153:14 198:13 exercise 112:6 114:14 114:15 exhausted 209:13 exhibit 56:16 exist 42:15 122:1 262:4 existing 11:5 24:2 39:4 62:2,20 74:1,7 140:19 168:22 169:2,5 177:9 178:17 180:6 208:5 208:22 exists 32:8 134:17 expand 153:6 272:20 expanding 157:22 273:1 expansive 273:3 expect 202:1 204:7 210:1 242:18 258:9 261:22 expelled 211:5 expenditure 113:7 114:18 experiencing 80:6 experimental 242:2 experts 62:2 198:1 explain 33:18 240:6 explicit 55:11 exploring 29:4 exposed 122:17 exposure 13:13 64:13 64:22 66:21 68:22 70:10 71:4 104:4 110:8 128:10 146:2,4 149:5,13 155:8 183:7 184:18 185:3,8,20 186:13,21 190:21 218:19 237:14 245:7 fasts 101:21 245:17 247:2,18 fat 33:14 48:12 68:17

71:3 72:4 73:3 103:17

107:4 145:16,20

exposures 14:22 81:18 142:20 156:13 172:21 174:13 175:17 198:11 221:4 expressed 169:16 extend 121:20 154:1 extended 121:14 extent 88:3,6 268:17 extra 209:18 extract 83:4,8 119:17 198:8 201:7,9 203:19 203:21 204:2 263:12 extracted 62:6 263:16 extracting 86:4 extraction 13:3 256:21 extraordinarily 273:3 extrapolate 53:12 eye 119:12 F facets 213:18 facilitate 275:4 fact 59:5 80:1,7 83:3 98:9 119:14 133:21 162:12 197:12 219:10 219:13 236:8 272:1 factor 241:1 261:3 factors 13:19 28:15.18 65:7 161:6 162:12 261.7 facts 22:12 51:20 failure 68:19 fair 78:6 fairly 187:8 272:17 fall 41:4 211:14 220:7 fallen 111:10 familiar 13:9 133:21 244:2 families 195:15 family 41:13 68:10 123:16 150:11 157:11 247:4 249:9 253:2,20 255:3.20 fantastic 199:1 far 58:2,15 89:6 92:9 104:2 105:21 108:20 159:21 232:9,10,19 257:13,14 270:14 farther 154:1 205:13 fasting 97:2,15,20 101:17 102:1,5,11 103:8,9,12 121:12 130:11 135:13,18,19 135:19,20 138:3

248:16 253:10 254:9

255:7,14

71:11,19 72:2,3,13 77:5 78:4 87:4,8,8,9 92:13 118:14 214:21 215:1 218:6 247:2 250:10,16 251:10,14 251:16,17,19,22 252:1,2,5,7,8 253:4,8 253:11 254:16 255:12 256:7,13,15 fat-free 68:17 fats 2:14 10:8 18:10 86:19 92:16 243:4,7 243:13,19 250:8,22 251:3,6,11 254:2,6 256:4 257:4 fatty 45:5 141:13 158:20 160:4 167:7 175:10 182:1 185:18 185:21 186:2,8 187:14 188:20 203:5 203:10,20 205:7 246:22 250:18,19 261:11 **FDA** 22:11 148:15 169:20 191:2 fed 49:15 52:19 169:16 172:7 173:9 198:4.13 federal 3:6 5:13,16 6:9 14:16 22:7 37:19 41:13 42:15 43:15 46:7 251:4 269:14 feed 53:6 172:2,9,10 feeding 120:15 125:15 145:13 166:17 167:12 170:4,7,8,11,12,22 171:1,3,4,22 173:14 173:15 176:2 184:7 187:5 189:17 191:7 192:13,16 193:2,5 194:7 196:16 198:10 205:9 207:20 222:18 227:3 247:14 248:10 feel 95:16 96:15 100:17 107:13 124:11 154:11 155:3 205:4 251:8 feeling 58:20 89:22 feels 230:1 felt 98:11,14,17 104:14 105:1 106:2 107:2 109:8 110:20 111:9 111:20 112:11 114:15 115:3,9 124:22 132:13 151:22 154:8 263:18 females 224:6 femoral 29:20 ferritin 34:13,22 fetal 174:8

fewer 128:3 138:7 179:10 fiber 80:14,16 field 120:8 215:20 Fifteen 4:10 figure 49:20 85:4 100:9 124:18 final 7:6 142:2 188:20 222:7 248:13 255:10 finalize 12:14 finally 21:14 22:9 30:20 32:12 38:4 58:13 174:2 177:8 180:20 181:2 185:17 187:17 188:19 224:19 226:3 find 48:20 49:13 52:9 53:20 89:2 95:12 99:19 102:16 138:11 241:3 findings 101:6 129:15 fine 266:17 finer 42:5 finish 225:19 finished 70:3 first 4:13 8:10 9:1,12 10:19 20:11.21 23:11 23:19 24:7 48:8 59:15 61:9 64:7 83:2 90:11 98:21 104:3,19 105:8 105:13 107:12 109:17 112:19 119:14 127:10 127:17 132:9 140:12 142:16 148:3,20 159:17 162:10 170:7 171:21 172:1 173:3 178:15 182:20 189:8 193:18 196:1 199:3,8 205:16 206:6 211:15 212:8 214:2 218:15 218:18 245:8,9,16 252:3 274:18 fish 250:3 259:1,3,5,9 259:10,15,21,22 260:3,5,5,6,9 262:12 262:19 fitting 216:13 five 6:11,17 17:9,18 20:22 28:15,18 40:15 46:2 75:4 140:15 141:19 149:2 159:1 163:9 166:13,15 167:11 flavor 214:22 217:12 flavored 46:10 47:3 214:22 flavoring 217:13 flow 12:6 fluid 223:12

fluids 170:21 **FNDDS** 23:10 focus 8:18,18 14:8 15:13 16:14,20 17:2 17:17 19:13 60:16 100:21 133:14 148:4 181:11 213:22 247:16 248:21 250:9 271:21 focused 15:18 17:7 272:2 focuses 68:12 221:3 248:14 focusing 104:10 116:22 141:5,12 144:14 147:22 148:11 149:9 152:4,13,14 160:13 225:20 226:3 245:16 246:12 247:22 252:1 268:15 folate 34:14,15 35:1 149:10,17,18,22 152:6 153:22 154:6 154:12 156:9 157:21 185:13 folic 35:3 141:13,16 148:4.21 149:5 150:4 150:6 151:3 152:9 155:7 157:9 158:6 164:18 folks 101:6 265:12 275:8 276:5 follow 4:19 8:1 35:19 77:21 81:22 85:14 86:11 136:5 162:5 202:18 follow- 52:18 follow-on 190:6 follow-up 189:19,22 followed 9:13 191:5 following 5:12,17 59:7 81:16 169:3 followup 128:2 food 2:5 10:11 11:2 18:7 20:13 21:6,9,10 21:12,14,20 22:6,7 23:4,13,14,20 24:1,1 24:16,19 25:4,6,7,13 26:20 35:15 37:13 38:22 39:2,4,9,15 40:3,4,5,10,17 49:19 56:7 57:18,18 58:2,5 108:10,14,17 121:4 125:9 126:1,6,10,16 126:19 127:4,12,18 129:17 134:9 135:5,6 135:6 136:10,19 137:2 142:3 153:22 154:7 161:8 166:22

167:14 169:8.21 176:16,22 182:18 189:20 191:9,10 193:1,13 194:20 219:5 251:4 268:19 food-based 59:2 food-oriented 72:9 foods 21:16 23:9,15,22 24:8,11 25:10 32:22 34:6 38:9,18,18,19 39:13 41:5 57:18 58:7 58:15,22 59:3 61:16 62:5 71:17 72:7 77:13 92:10,12,15 97:12 98:22 99:1,9,11 129:8 134:13 141:11 142:1 147:20 148:1,2,22 149:7,8 151:3 155:12 155:16 156:7 158:18 161:10 163:2 164:15 164:20 167:5 169:22 170:1,9,13 171:2 174:7 181:13,16 183:3,11,16 184:15 185:19 186:12 188:12 190:19 192:17.21 193:12 194:3 261:11 268:13.13 for-short 202:15 forbid 138:2 forego 160:19 forgot 139:16 form 129:17 219:3 formal 228:10 forms 68:16 87:17 formula 38:20 39:14 47:14 52:17 145:14 166:17,20 167:18 168:5,10,14,18,21 169:7,11,19,20 170:2 170:9,13 171:1,4,12 171:19 172:17 173:1 173:13,14,16,21 174:8 175:14 176:16 177:11 178:6,21 179:2,18 180:8,18 181:1,5 189:19,22 190:2,6 191:1 formula-fed 172:6 formulas 52:19 179:1 250:7 forth 58:4 121:10 fortification 148:14,16 148:19 153:22 154:7 182:17 189:13 190:8 fortified 21:16 141:11 142:1 147:20 148:2 148:22 149:7,8 151:3

155:11,15 156:6 158:18 161:9 163:2,2 164:15,20 167:5 181:13,16 183:3,11 183:16 184:14 185:19 186:12 188:12 189:20 fortunately 135:2 forward 53:21 57:15 65:13 74:17 89:1 91:16 119:13 214:4 223:4 231:10 232:6 262:6 264:7 265:22 275:6,16 276:9 found 7:22 51:18 81:19 105:12 foundation 12:22 64:1 66:1 75:12 four 5:14 25:2 26:19 27:5 62:15 75:4 102:1 140:19 156:4 158:22 167:6 181:20 182:2 186:6 187:17 212:8 213:6 274:7 **FPED** 23:12 fractures 188:3 frame 19:22 149:15 232:10 framework 12:5,12,19 13:12 14:5,9 17:10,13 17:17 22:13 32:20 38:22 62:21 63:18,22 64:7,12 65:16,19 67:12,14 68:12 69:10 70:3 73:7 87:22 88:7 95:14 104:1 109:20 142:17 144:10 149:4 157:7 171:8,9 174:11 175:11 176:14,15 177:8 182:12,21 184:12,22 185:6 186:4 187:13,14 199:19 209:7 218:15 221:2,7,12 222:7 228:22 232:11 244:9 245:9,14 248:17 252:7 254:5 255:10 255:17 263:21 273:2 frameworks 13:22 22:18 61:20 64:9 65:13 158:17 169:14 170:6 179:14 181:4 182:5 189:10 190:14 222:2 228:11 252:11 253:12 255:2,19 269:2 frankly 160:21 free 95:16 96:15 100:17 124:11

freezing 169:17 frequencies 129:11 131:11 frequency 2:8 10:9 18:8 21:5 40:22 50:11 61:17 84:7 94:14 96:2 96:6,18 98:19,22 99:8 99:12,12 102:15 104:22 105:5,17 107:2,18,21 108:10 108:14,18 109:18 110:21 111:5,8 112:11 113:10.21 114:13 115:8,13 116:17 117:19 118:16 120:12,19 122:6,15 124:5,7,16 125:9 126:1,6,11,17,19 127:4,12,18 129:1,12 131:2 132:15 135:6 136:9 137:20 166:19 168:8,13 171:11 172:22 174:13 175:19 176:19 177:13 183:15 213:18 229:9 231:20 245:6,22 262:15 frequent 129:6 130:5 131:17 frequently 9:10 fresh 169:17 260:13 262:19 freshwater 244:19 259:1,2,4,15,21,22 fried 262:20 front 18:19 47:1 95:14 102:4 122:16 fruit 36:17 37:1 46:12 170:20 215:9 216:21 219:6 full 4:9 9:3 10:1 12:1 33:6 198:6 225:10,11 full-term 16:21 fully 164:16 function 66:10 functional 217:6 fundamental 131:20,20 fundamentally 218:3 further 18:20 87:5 91:15 120:20 223:15 furthest 90:1 future 19:4 57:19 59:21 G gain 96:8 115:15,16,20 116:3,4,13 117:6,13 122:7 141:7 142:10

142:19 143:11,21

144:5 145:4 158:13

162:7 211:22 212:20 214:6,7 221:13,15,16 222:4,13,17 224:5 229:11,13,16 234:3 267:6 gains 116:13 game 78:6 gas 217:13 218:2 gastric 132:19 gather 90:2,18 gauge 52:11 Gene 182:8 general 14:7 16:5 20:2 24:21 32:18 58:15 87:14,22 88:7 89:9 168:2 208:21 212:15 224:22 225:20 242:8 264:2 268:10 generalizable 107:2 generalized 66:13 78:20 generalizing 259:8 generally 15:7 66:7 84:14 85:2 99:21 126:18 127:13 generate 272:17 generated 272:13 gestation 144:2 gestational 16:22 29:14 73:11 96:8 115:14,16 115:19 116:10,11,12 117:5,13 122:7 141:7 142:9,19 143:10,16 143:17,21 145:4 150:7 151:13,15,17 153:10 154:21 157:7 157:10,18 158:3,12 160:7 161:19,22 162:7,14 163:13,21 164:1 184:8 187:7 211:21,22 212:19 214:5 221:7,13,15 222:1,4,12,17,19 224:5 225:13 226:17 227:15 228:14 229:11 229:13,16 246:17 261:9,9 267:6 **getting** 47:21 127:5 139:1 263:21 265:13 276:2 GI 132:19 give 6:10 52:10 60:18 92:2 140:3 147:10 197:3 209:18 226:8 230:22 237:21 **given** 18:12 19:6 36:3 107:11 111:20 117:14 121:22 190:20 227:6

257:21 gives 10:13 13:7,11 14:21 23:12 89:1 **giving** 58:4 glad 88:22 gland 156:1 global 132:9 globally 208:9 glows 259:18 glucose 70:7 118:21 goal 8:20 12:13 19:20 101:9 216:12 272:10 goals 50:10 **God** 138:2 gotten 212:10 213:2,4 257:13 government 43:15 211:12 gradation 217:20 219:3 gradations 214:21 215:1 graded 119:19 grading 13:5 grams 88:6 251:2 granular 24:4 grapple 43:21 greater 72:1 97:16 261:15 grid 229:20 231:15,22 265:8 270:3 273:14 group 4:2 10:10 20:13 20:16 21:7 24:2 25:4 25:6,7 26:11 30:10 39:3,4 48:15,17 49:15 49:18 51:19 55:9 59:2 72:9 83:9 105:20,21 108:22 109:5 111:18 119:5 120:3 159:18 171:17 172:19 179:7 179:11 191:10,10 195:7 199:6,8,15 200:4 213:19,20 214:13 225:6 227:11 237:5 259:2 grouped 78:8,19 grouping 172:20 174:19 199:3 groupings 41:22 42:22 groups 15:2 21:22 22:3 23:13,20 24:19 40:4 42:12 57:18 66:4,6 171:16 174:17 214:15 220:5 223:21 226:14 227:17 230:17 growing 49:22,22 50:1 205:18 growth 62:17 68:13 73:4 74:12 96:7

113:22 166:20 167:9 167:13 168:10 171:12 173:19 174:9,18 179:19 182:4 186:10 186:15,18 187:16 199:20 205:7,11,15 205:18,21 206:3 218:16 232:11 guess 43:11 47:11,18 47:21 52:14 78:7 82:9 115:21 124:1 126:16 135:2 136:21 150:14 193:4 199:3 202:17 223:21 260:4 guidance 3:5 5:15 89:1 271:13 guide 58:15 guided 16:2 guidelines 1:1,8 3:7,13 4:21 5:4 6:1,4,17 16:3 32:15 33:15 39:20 54:20 58:2,10 148:17 162:8 218:12 244:15 guides 13:4 **Gungor** 197:17,18 198:18 199:18.22 200:6.9.12 201:6 Gynecology 151:11 н habits 107:18 194:20 habitual 107:17 108:7 111:4,12 113:9 124:2 124:8,19 127:5 habitually 61:18 111:10 124:12 half 80:15 halls 3:22 hand 36:21 256:21 handle 48:17 handled 212:14 handling 69:5 102:17 hands 43:18 hang 193:18 haphazard 230:1 happen 257:10 happening 91:6 happens 79:10 177:6 234:2 happy 95:17 206:9 259:12 hard 31:7 43:20 48:13 76:14 82:1 104:17 159:8 276:14 harmonization 227:16 269:3,15 harmonize 230:3 harmonized 266:15

Neal R. Gross and Co., Inc. Washington DC

harmonizing 89:3 274:22 HbA1c 84:14,15,20 85:3 HbA1c's 85:13 HDL 27:11 head 232:7 head's 85:17 headquarters 1:9 healthy 16:11 35:13,20 39:21 59:12,14 60:2 65:3 67:1,7 68:2,19 69:1,21 70:11 106:17 106:19 144:8 147:14 173:18 183:20 224:22 hear 17:3 49:5,6 50:3,4 52:5 53:14 60:3 95:1 274:21 heard 8:8 63:15 94:18 115:21 244:3 261:1 269:1 hearing 17:8 210:11 276:9 hearkening 54:19 heart 28:9 Heather 1:16 2:8 77:20 81:21 94:13,17 122:4 265:6,7 270:4 Heather's 86:11 heavily 57:3,5 161:9 **HEI** 37:9,10 39:17 Heidi 231:13 held 7:13 hell 43:9 help 52:8 59:9 96:16 100:9 138:4 139:20 162:16 191:20 195:15 231:15 257:11 265:9 269:4 helped 10:18 helpful 20:5 55:19 60:13 82:22 120:4 127:6 159:11 265:22 270:1 271:12 helps 64:1 91:16 152:16 210:10 hemoglobin 70:7 86:2 118:21 149:18 150:16 157:5,13 158:2 Heymsfield 4:14 95:4 HHS 5:12 6:5,16 7:7 8:11 10:16 275:19 **Hi** 135:11 198:21 hierarchy 51:3 58:8 high 15:16,16 19:8 26:12 27:11 28:3,3,4 29:1,5 44:19 45:10 53:6 59:16 69:14
71:11,19 72:2,13 77:5 78:4,5 82:5 92:15 155:13 165:9 181:6,7 207:18,22 208:12,13 208:15,20,21 215:13 215:18,20 216:6 256:5 262:18 high-income 155:14 higher 209:8 271:6 highest 107:10 125:20 highlight 114:2 highlighted 110:5 118:11 212:9 246:2 history 68:10 116:10,11 143:16 150:11 157:12 247:4 249:9 253:2,20 255:3,21 hitting 61:4 hold 63:8 164:21 209:20 holding 61:4 holiday 112:6 home 123:13,15 homework 230:10 homocysteine 149:21 hope 8:19 48:19 137:16 214:19 hopefully 139:9 209:17 232:5 hormonal 255:4 Horn 1:20 54:18.18 79:12,12,22 133:18 133:18 159:16,16 160:10 162:20 206:6 207:12 243:9 259:17 259:17 260:17,18 270:7,7 hospitalized 147:12 hospitals 224:13 hot 79:17 hour 108:6 hours 97:16 121:14 housekeeping 3:18 Houston 7:14 human 5:3,21 15:16 38:20 39:12,14 47:11 47:15,20 48:4,9 52:17 145:22 151:19,20 152:3,4,6 154:6,9,14 155:21 156:3 158:14 166:17,19 167:17 168:4,9,13,17,20 169:7,10,15 170:1,7,8 170:11,12 171:1,4,11 171:19 172:2,3,4,5,7 172:9,13,14,16,22 173:4,8,9,12,13,15,21 174:22 175:13,22

176:1,15 177:10 178:5 179:18 180:7 180:17,22 181:5,7,9 192:8 193:9 205:8 206:2 207:20 208:2 212:5,10 225:21 247:13 humans 15:19 224:4 hundred 215:8 hydration 112:8 195:19 195:20 hydroxy 34:16 202:11 hyperactivity 67:19 hypertension 27:11 28:5,8 29:17 71:9 116:11 143:17 151:13 154:22 161:20,22 162:6,14 261:9 hypertensive 73:9 151:4,8,17 157:15 163:22 hypothetically 77:17 i.e 77:10 IBD 255:6 idea 18:2 88:13 99:16 137:7 160:13 204:9 209:6 259:6 264:22 265:9 270:2 ideas 264:16 266:10 270:5 identical 114:7 176:21 177:15 identified 5:8.12 9:18 21:11 84:14 174:4 193:14 194:12,14 196:7 197:3 220:5 249:8 260:13 identify 38:1 51:10,12 54:8 77:13 218:11 224:11 263:11 identifying 14:13 51:22 96:14 97:1 252:13 identity 190:5 illness 147:13 illustrate 189:5 illustrated 189:10 illustrates 63:1,19 67:14 69:11 70:4 imagine 104:3 imagined 272:15 impact 5:16 13:19 65:8 129:7 134:11 138:8 156:3 161:12 180:18 212:20 217:8 219:19 220:3 226:20 232:21 233:10,13 234:1

235:18 242:14 247:9 262:22 272:4 impactful 275:13 impacting 152:3 impacts 129:12 138:17 263:1 impairment 66:10 67:21 implement 191:3 275:16 implemented 12:15,16 17:19 implementing 19:21 75:2 implications 56:8 132:21 importance 5:14 81:14 **important** 6:2 56:4 77:12 86:15,21 87:10 87:21 94:5 112:11 115:3,10 125:1 131:7 133:19 134:3 137:14 160:13 180:16,21 219:9 231:11 245:5 250:2 251:10,12,20 254:11 256:11 258:17 260:12 262:6 268:4 270:19 272:22 273:1 273:7,13 importantly 249:11 impressed 272:11 impressive 274:13 improve 272:8 in-person 1:11 3:12,19 4:11 8:12 inadequacy 30:22 31:15 inadequate 30:13 incidence 29:12 incidents 68:18 include 14:1 16:11,21 21:4 22:5 32:5 36:16 36:22 49:14 65:10 66:17 67:17 68:15,22 69:13,16 70:6 85:12 98:11 101:4 107:4 110:22 111:4,14 115:4 120:19 123:8 123:10 127:1 136:22 137:7 146:19 147:2,8 148:9 149:21 152:20 154:3,18,20 155:10 165:11 175:8,21 177:17 181:5 183:19 184:2,7 185:13 187:2 188:1 189:12,15 190:16 193:2 194:3 202:13,14 207:11

216:15 217:2,15,16 220:17,18,22 222:3 223:5 246:4,16,21 247:6,10,21 249:9 250:6 252:17,20 254:1 255:4 256:3,14 included 12:8 14:14 15:10,10,20 16:10 17:16 62:7 71:19 74:4 74:15 77:7 86:6 98:16 99:10 102:19,21 103:4,7 106:10,13,20 108:15,19 110:9 111:9,22,22 113:8 116:21 117:15 122:6 123:14 126:2,11 127:10,15 128:5 160:3 195:11 202:5 203:7,15 209:8 220:16 225:3 229:8 236:5 241:9 242:6 243:19 250:5,22 251:3 260:2 includes 13:19 26:2 66:21 67:6 68:1 69:20 70:10 97:9,12 131:10 215:12 244:16,20 245:17 including 6:22 7:21 16:7 44:7 46:10 62:5 79:15 109:3 115:7 152:11 156:5 166:8 168:19 175:15 176:5 176:8 177:18 178:15 179:6 180:1 184:2 198:17 211:17 224:21 225:5,8 229:15 241:20 242:1 243:22 249:17 259:4,15 inclusion 12:13 14:10 14:17 64:2 70:15,19 71:2,14,18 103:16 145:15,20 153:17 154:14,16 178:4,7,13 181:3 189:1,6,11 206:9 208:3 222:22 223:16,17 224:17,19 234:17 235:6 255:2 255:20 inclusion/exclusion 12:5 13:1 104:7 203:16 249:12,13 256:9 inclusions 72:15 73:1,6 inclusive 23:17 25:10 34:7 37:6 39:14 136:21 170:15 income 22:5,6 120:22

inconsistencies 265:10	inform 52:8 64:2 272:8
inconsistency 193:16	information 7:20 10:16
Incorporate 80:9	11:/ 12:17 18:21
161:16	23:16 26:9 28:12
incorporating 158:9	29:11,16,18 30:2
increase 100:4 109:9	38:13 41:3 52:2 62:3
increased 107.1	83.8 135.7 196.9
257·11	227.13 228.14 16
incredibly 272.11	227:13 220.14,10
incumbent 214.14	275.21 276.2
Independence 1:9	informed 6:7
independent 4:22	informs 13:1
268:14,16	infradian 213:15
index 35:14,20 39:21	ingested 131:5
59:14 60:2 174:10	ingestive 97:6 103:13
indicate 54:14	130:18 139:1
indicated 267:13	ingredients 148:11
indicates 59:15	initial 136:6 261:17
indicating 61:9 179:8	injury 147:13
Indicator 200:15	Input 5:13 6:8,21 131:1
individual 17:4 28:15	220.12 insecure 136:10
38.14 117.17 129.5	insecurity 136.10
239:17	inside 33:12
individuals 16:7,15	insight 274:9
106:16,19 225:5	instance 90:22 228:13
industrialized 161:4	228:14 236:3
inert 132:17	Institute 268:8
infancy 180:22 183:4	Institutes 66:1
infant 38:20 39:14	insulin 70:7 118:21
47:14 52:17 145:13	intakes 22:2 23:16,20
166:17,20 167:18	23:22 24:2,7,14,22
160.9,14,16 109.7,11	20.0,0 30.13,10 31.3
170.13 171.1 3 12 19	39.7 40.4 7 41.3 5
172:17 173:1.12.14	49:21 52:21 53:11
173:16.21 174:7	54:5 127:6 191:11
175:14 176:16 177:11	202:11
178:6,21 179:1,18	integrate 135:7 214:4
180:7,17 181:1,4	266:8
190:2 191:1 195:15	integrative 266:3
201:8 221:9 245:12	intended 8:17 50:14
247:14 248:10 250:6	174:01
30.11 15.21 16.2	intensity 215.13 18 20
47.10.13.20.49.15	256°6
65:5 67:3 68:5 69:3	intent 90:2.5 107:17
104:11,12 153:4	109:9 124:10
155:2 172:3,4,6,7,14	intention 198:5 201:7
173:5,9,18 175:1,8	intentional 50:5 217:4
176:12 180:14 183:19	intentionality 135:14
198:4 224:2 225:10	intentionally 177:4
225:11,15 246:4	Interest 3:13 13:15
202:10	14:22 10:17 64:14,19 64:21 65:1 9 66:20
influence 58.12 132.20	67.5 68.1 21 60.20
influencing 162:13	70:9 118:13 131:21

н

134:1 171:15 174:16 175:21 176:4,21,22 177:15,17 179:10 181:21 182:2,3 183:8 183:17 184:19,20,21 185:8,10,20 186:1,2 186:20 187:11 188:6 188:11,15,20 189:21 190:11 206:12,15,20 232:22 234:1 261:4 interested 26:22 27:18 47:7 53:19 138:2 203:6 275:8,9 interesting 78:22 80:1 82:17 105:4 106:11 110:14 134:19 136:7 138:12 163:11 214:10 227:1 268:3 intermediate 13:17 15:1 27:9 66:17 69:13 70:6 84:15,22 85:5 86:3 118:5,20 150:13 150:17 151:6 157:8 157:16 177:18,19,20 180:13 249:1 272:6 intermittent 97:20 101:16 102:5 121:12 130:11 135:20 international 62:2 169:21 191:2 interpretation 85:16 130:17 intervention 13:13 14:21 64:13,22 66:20 68:22 70:10 71:3 104:4 110:8 142:20 150:8 151:5 152:7 155:8 156:12 175:17 183:7 184:18 185:8 185:20 186:13,21 190:21 218:19 221:8 221:14 222:8 233:7 233:12,17 234:8,11 234:13 235:15,15 236:9 237:2 238:4,4 240:21 242:9 245:17 247:18 248:16 253:10 254:9 255:13 256:6 intervention/exposure 115:17 117:21 183:18 intervention/exposur... 189:9 interventional 239:11 interventions 65:2 174:12 241:6 Interview 26:4 28:7 introduced 60:21 193:9 193:10

introduction 38:9,18 60:11 172:17 investigating 143:8 investigation 48:10 involved 79:5 involves 254:3 iodine 35:7 141:14 158:21 175:9 **IOM** 214:8 iron 33:6,7 52:20 141:13,16 148:4 155:6,11,14,20 156:2 156:3,4,6,7,9,14,15 156:19,19 157:1,3,7 157:14 158:4 160:14 161:9,12 163:2,2 164:15,17,21 165:8 167:6 175:9 181:22 183:2,10 184:1,2,2 185:5 186:7,11,12 188:6 195:14 204:10 247:1 irrelevant 131:8 isolate 137:20 236:18 240:16 isolated 273:11 **issue** 76:8 91:14 137:12 137:14 195:7 196:3 204:16 216:19 233:3 260:22 issues 44:11 218:11 268:9 italics 110:12 items 3:18 15:7 216:22 230:9 iteration 24:9 iThenticate 211:4 J Jamie 20:18

Jamie's 20:17 Jamy 1:14 20:17 85:7 86:11 88:19 100:8 135:22 229:2 230:5 262:11 266:13 270:2 270:9 January 73:20 89:16 104:15 141:3 223:5 Jefferson 1:8 Joan 1:18 57:20 92:7 128:8 232:9 243:8 267:20 270:21 271:22 Joanne 263:7 job 201:15 226:6 257:8 ioin 4:12,15 juice 36:17 170:20 196:11 219:6 juices 215:8

290

	1	1	1
July 1:5 19:19 74:3.14	136:3,12 137:4.10	122:21 124:10 125:16	69:17 77:3 78:9 82:12
89:11.20 90:22	138:21 139:12.13.22	125:18 127:8.21	93:3 113:12 118:2.5
275:12.13	140:1 159:13 164:5.9	128:6.21 129:13	138:18 199:7.10
iumped 94.10 200.5	165 16 191 22 195 8	131.19 133.2 134.18	200.20 213.7 226.2
jumping 142.6	197.5 206.5 207.16	135.16 137.8 231.14	254.22 263.5
June 89:11 20 90:4	208.7 12 16 209.12	265.7 7	listing 93:3 133:16
223.6	271.10 271.1	Leidy's 94:13	lists 228.21
iustification 6:7	knowing 59:6 203:6	length 26:13 13 221:6	listery 7:17 18 275:10
justification 0.7	kilowing 59.0 205.0	lefight 20.13, 13 221.0	literature 12:7 13:2
Justify 09.19 179.15		167.16.240.0	32.17 00.15 101.11
к ————————————————————————————————————	label 22:12 56:1 72:6	lotting 164:12	124-4 179-15 10
	labeled 56:11	leukomia 27:14	134.4 170.13,19
Kay 155.10 100.0		level 10:9 22:7 29:1	259.12 251.9 254.14
KCal 37.4	laberatery 26:2 22:10		200.10207.1
Keep 3.22 19.0 02.1	laboratory 20.2 33.19	31.15,19 32.0 88.3	11111e 24.4, 15 25.21 29.0
100:6 119:12 139:20	lack 190.1 195.4 234.4	91.18 155.22 165.8	31.8 38:16 42:7 60:5
193:22 250:2 254:11	lactating 22:21 46:2	189:13 190:9 201:9	91:15 95:20 103:20
254:20 258:17,20	116:21 117:17 144:15		
269:14 270:8 272:21	140:15,16 224:16	1evels 64:17 85:3 86:5	117:11 126:3,13
	actation 2:9 10:7 18:9	149:10 259:3	152:12 166:10 174:19
keeping 144:2 145:1	73:10,12 116:18,19		209:2 213:7 215:11
226.6	117:1,15 120:13	librarian 83:19	218:1,2 230:3 266:3
ketogenetic 83:16	124:3 139:15 140:2	lies 220:3,3	268:5 276:8
key 9:6 13:11,19 14:1	140:10,13 142:10	life 21:20,22 38:8,15	live 244:19 260:9
21:18 61:12 65:7 68:7	144:12,15 145:9,22	39:2,7,11 40:8,11,13	liver 28:19,21 29:5
69:5,22 70:13 75:20	147:21 149:2,16	43:16 174:1 177:2	44:18 45:5 254:12
83:17 93:3,4,7,14	150:20 156:11,22	179:21 180:2 211:19	255:8,9
96:14 109:21 110:10	169:1 212:3,20	250:11 253:9 254:17	location 113:9
110:17 111:14,19,21	226:14,21 243:16	269:17	logic 164:20
112:10,12 113:12	245:11 267:4	lifespan 223:19 261:20	long 37:3 63:11 71:20
114:8,9,19 116:7	lactation-related 229:9	light 196:21	101:18 104:17 117:17
117:10 118:8,22	lacto-ovo 87:19	liked 65:15	155:9 172:9,9 191:1
			-
122:14 124:8 133:4	Lake 259:19	likewise 16:20 270:9	long-term 167:1 169:11
122:14 124:8 133:4 133:11 143:2 148:5	Lake 259:19 lakes 244:20	likewise 16:20 270:9 limit 241:5	long-term 167:1 169:11 177:11 179:20
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10	Lake 259:19 lakes 244:20 language 59:1 178:9	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Lind's 164:11 line 92:8 132:22 218:10 linked 32:17	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13 lay 97:7	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13 lay 97:7 LD 1:18,20	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8 124:6 126:4 132:7
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16 kinds 15:9 233:7	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13 lay 97:7 LD 1:18,20 LDL 27:11 28:4,4	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10 liquids 115:7	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8 124:6 126:4 132:7 141:22 145:3 155:21
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16 kinds 15:9 233:7 234:15 242:18	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13 lay 97:7 LD 1:18,20 LDL 27:11 28:4,4 lead 3:4	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10 liquids 115:7 liquor 37:6	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8 124:6 126:4 132:7 141:22 145:3 155:21 161:11 162:11 174:1
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16 kinds 15:9 233:7 234:15 242:18 Kingshipp 228:8,9	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laurel 86:12 203:13 lay 97:7 LD 1:18,20 LDL 27:11 28:4,4 lead 3:4 lean 66:8	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10 liquids 115:7 liquor 37:6 list 38:3 77:7 79:17	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8 124:6 126:4 132:7 141:22 145:3 155:21 161:11 162:11 174:1 179:17 181:11 186:5
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16 kinds 15:9 233:7 234:15 242:18 Kingshipp 228:8,9 231:2,8 241:13,15	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laurel 86:12 203:13 lay 97:7 LD 1:18,20 LDL 27:11 28:4,4 lead 3:4 lean 66:8 left 19:3 140:16 171:14	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10 liquids 115:7 liquor 37:6 list 38:3 77:7 79:17 119:3 156:18 160:2	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8 124:6 126:4 132:7 141:22 145:3 155:21 161:11 162:11 174:1 179:17 181:11 186:5 186:9 187:18 198:19
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16 kinds 15:9 233:7 234:15 242:18 Kingshipp 228:8,9 231:2,8 241:13,15 Kleinman 1:13 41:20	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13 lay 97:7 LD 1:18,20 LDL 27:11 28:4,4 lead 3:4 lean 66:8 left 19:3 140:16 171:14 Leidy 1:16 2:8 77:20,20	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10 liquids 115:7 liquor 37:6 list 38:3 77:7 79:17 119:3 156:18 160:2 203:9 210:21 228:12	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8 124:6 126:4 132:7 141:22 145:3 155:21 161:11 162:11 174:1 179:17 181:11 186:5 186:9 187:18 198:19 199:16 202:22 220:20
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16 kinds 15:9 233:7 234:15 242:18 Kingshipp 228:8,9 231:2,8 241:13,15 Kleinman 1:13 41:20 43:1,5,8 44:2 60:8	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13 lay 97:7 LD 1:18,20 LDL 27:11 28:4,4 lead 3:4 lean 66:8 left 19:3 140:16 171:14 Leidy 1:16 2:8 77:20,20 81:21 84:1 94:15,20	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10 liquids 115:7 liquor 37:6 list 38:3 77:7 79:17 119:3 156:18 160:2 203:9 210:21 228:12 228:17 251:7 254:12	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8 124:6 126:4 132:7 141:22 145:3 155:21 161:11 162:11 174:1 179:17 181:11 186:5 186:9 187:18 198:19 199:16 202:22 220:20 237:11 238:22 239:13
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16 kinds 15:9 233:7 234:15 242:18 Kingshipp 228:8,9 231:2,8 241:13,15 Kleinman 1:13 41:20 43:1,5,8 44:2 60:8 85:8 86:6 91:10 94:9	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13 lay 97:7 LD 1:18,20 LDL 27:11 28:4,4 lead 3:4 lean 66:8 left 19:3 140:16 171:14 Leidy 1:16 2:8 77:20,20 81:21 84:1 94:15,20 100:17 101:14 102:3	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10 liquids 115:7 liquor 37:6 list 38:3 77:7 79:17 119:3 156:18 160:2 203:9 210:21 228:12 228:17 251:7 254:12 257:22	long-term 167:1 169:11 177:11 179:20 longer 53:6 55:1 121:18 127:13 205:9,19 207:20 longer-term 152:20 longitudinal 38:12 154:9 238:3,16 239:13 240:20 241:4 241:9,22 242:15 273:10 look 12:2,18 24:21 30:12 31:11 33:9 36:2 37:11 38:15,22 45:3 46:4 54:10 59:1 65:14 79:3 84:10 93:11 99:9 102:9 105:15 108:6 110:17 114:3 115:8 124:6 126:4 132:7 141:22 145:3 155:21 161:11 162:11 174:1 179:17 181:11 186:5 186:9 187:18 198:19 199:16 202:22 220:20 237:11 238:22 239:13 242:14,19 245:21
122:14 124:8 133:4 133:11 143:2 148:5 148:12,12 150:2,10 151:14 152:8 153:9 157:4,10,17 169:14 174:3 182:6,10 184:5 185:1,14,15 187:2,3 188:9 199:7,21 220:8 221:19 222:14 228:18 229:7,12 230:15,16 230:16 231:5 232:13 243:22 246:14 247:5 247:8,10 248:8,9,12 249:4 250:15 251:8 252:17,19 253:5,17 254:22 255:18,22 256:2 257:20 258:3 276:2 kill 76:16 kinds 15:9 233:7 234:15 242:18 Kingshipp 228:8,9 231:2,8 241:13,15 Kleinman 1:13 41:20 43:1,5,8 44:2 60:8 85:8 86:6 91:10 94:9 95:7 101:15 135:4	Lake 259:19 lakes 244:20 language 59:1 178:9 215:19 249:18 266:15 language/communic 176:6 large 50:16 153:21 195:21 207:2 214:19 largely 212:13 larger 42:12 lastly 98:2 112:13 latest 89:12 Laughter 211:7 218:13 237:7 launch 162:9 Laural 83:1 85:18 90:8 Laurel 86:12 203:13 lay 97:7 LD 1:18,20 LDL 27:11 28:4,4 lead 3:4 lean 66:8 left 19:3 140:16 171:14 Leidy 1:16 2:8 77:20,20 81:21 84:1 94:15,20 100:17 101:14 102:3 102:18 103:11 121:6	likewise 16:20 270:9 limit 241:5 limitation 35:16 38:16 limitations 119:20 limited 35:13 39:13 59:7,12 60:5 170:17 limiting 121:16 Linda 1:19,20 2:15 54:18 55:20 79:6,7,12 79:13 133:18 135:9 159:15,16 160:9 206:5 243:9 259:16 259:17 260:18 270:7 Linda's 164:11 line 92:8 132:22 218:10 linked 32:17 lipids 180:14 lipoprotein 69:14,15 liquid 134:10 liquids 115:7 liquor 37:6 list 38:3 77:7 79:17 119:3 156:18 160:2 203:9 210:21 228:12 228:17 251:7 254:12 257:22 listed 40:9 61:8 62:8,15	$\begin{array}{r} \textbf{long-term} 167:1 \ 169:11\\ 177:11 \ 179:20\\ \hline \textbf{longer} 53:6 \ 55:1 \ 121:18\\ 127:13 \ 205:9,19\\ 207:20\\ \hline \textbf{longer-term} \ 152:20\\ \hline \textbf{longitudinal} \ 38:12\\ 154:9 \ 238:3,16\\ 239:13 \ 240:20 \ 241:4\\ 241:9,22 \ 242:15\\ 273:10\\ \hline \textbf{look} \ 12:2,18 \ 24:21\\ 30:12 \ 31:11 \ 33:9 \ 36:2\\ 37:11 \ 38:15,22 \ 45:3\\ 46:4 \ 54:10 \ 59:1 \ 65:14\\ 79:3 \ 84:10 \ 93:11 \ 99:9\\ 102:9 \ 105:15 \ 108:6\\ 110:17 \ 114:3 \ 115:8\\ 124:6 \ 126:4 \ 132:7\\ 141:22 \ 145:3 \ 155:21\\ 161:11 \ 162:11 \ 174:1\\ 179:17 \ 181:11 \ 186:5\\ 186:9 \ 187:18 \ 198:19\\ 199:16 \ 202:22 \ 220:20\\ 237:11 \ 238:22 \ 239:13\\ 242:14,19 \ 245:21\\ 251:1 \ 263:6 \ 265:2\\ \end{array}$

267:17 looked 14:15 105:7 154:6 155:5 205:6,8,9 229:7 250:17 261:20 looks 11:16 15:22 63:5 172:19,20 174:14 **lose** 138:4 losing 138:3 223:14 loss 66:13 96:9 116:18 120:12 122:8 141:8 142:11 144:12 212:4 212:22 222:8 224:15 225:7 226:22 lot 41:14,18,19 42:1,15 43:6,9,10 44:10 51:21 56:14 76:8 99:19 102:16 105:22 107:22 108:12 111:6 114:12 119:5 133:4 135:1,22 156:1 159:3 161:14 192:2,4 204:7 215:3 223:9 230:17 231:4,6 233:4 251:5 258:14 260:22 261:19 265:15 265:15 266:2 267:11 268:1 274:17 Lots 201:15 loud 77:19 **Louder** 49:4 loudly 57:13 139:18 love 52:4 low 16:22 26:12,15 27:11 28:3 29:19 34:14,14,15,15,15 35:1 66:7,8,9,14,15 66:17 69:14 71:10,18 72:1,12 77:5 78:1,4,5 78:9,14 80:14 82:6 83:6,11,16 92:19 130:19 215:12 216:10 216:15 218:4 225:12 225:12 256:5 lower 86:19,19 87:1 109:7 120:21 181:9 216:3 lowest 32:6 lumbar 29:20 lumped 196:19 lumping 81:10 87:14 lunch 4:6 91:12 94:10 94:12 98:5 99:22 101:3 139:10 lung 255:7,7,8 Lydia 1:15 56:21 135:10,11 166:8 238:13 271:14 Μ

ma'am 51:20 macro 62:6 macro- 78:3 80:20 88:8 macro-nutrient 78:11 78:17 86:13 87:13 macro-nutrients 80:10 macronutrient 72:11 113:8 132:7 256:16 macronutrients 31:10 36:6 91:15 macros 83:7 magnesium 23:18 37:22 main 140:11 143:21 213:1 majorly 239:10 making 55:16 58:9 94:18 135:9 230:7 237:3 239:20 275:9 275:10 MALE 48:22 mammary 156:1 management 16:8,15 **mandate** 6:16 manipulation 235:16 manner 111:2 manners 96:19 manuscripts 156:17 March 6:13 19:15 marine 244:16,18 marker 203:1 204:11 markers 149:17 204:7 204:15 mass 29:19 66:8,13,18 68:17,17 174:10 188:1 material 18:18 maternal 115:22 142:2 143:22 174:9 185:16 221:20 222:14 246:17 246:20 261:10,13 262:7 maternally 261:18 mathematical 239:22 matter 139:5 210:3 276:15 Mattes 1:17 2:13 50:7,9 50:9 56:5,5 75:19,19 76:6,17 91:13,13 95:7 101:9 128:22 130:16 130:22 132:16 136:5 210:18,20 211:8,13 218:14 227:9 228:3 230:21 231:3,9 233:2 234:2 235:14 236:22 237:9,20 240:7 241:7 241:14 257:19 258:2 258:7,13 266:6,6

maximum 32:1 Mayer-Davis 4:14 **MD** 1:13,14,15,17,18,19 2.11meal 97:2 99:16 100:10 100:15 106:1 107:21 123:6 135:13,21 217:3 meals 97:11 98:2 105:19 107:1 121:2 125:14 128:18,18 134:8,12 mean 21:21 23:22 24:12,22 37:17,18 39:2 43:8 58:13,16 82:10 85:8,15 87:12 89:5 92:14,15,17,18 93:5,13 98:13 120:20 121:21 123:15 130:7 131:1,13,14,14 132:18 145:7 149:19 162:4,18 165:8 195:8 196:6 201:11,12 232:16 233:22 235:11 236:3 238:7 242:3,9 268:19 271:19 means 6:18 16:7 35:14 50:5 55:11 58:4 237:17 273:2 meant 55:3,13 208:8 measure 76:21 223:10 250.1measured 71:12 76:3 265:5 measurement 76:7 238:18 measurements 220:10 measures 86:5 153:2 211:18 220:7 246:6 measuring 219:13 meat 251:11 mechanism 220:3 234:3 mediating 93:10 mediator 93:8,15 110:19 113:15 137:15 mediators 137:13 medical 85:2 medical-izes 216:6 medication 114:21 medications 115:1 Medicine 268:8 medicines 170:19 Mediterranean 83:11 88:14 medium 35:6 181:9 meet 6:16 71:20 191:8 meeting 1:3,10 3:9,11

3:14 4:8.13 6:13 7:10 7:11,13,15,16 8:4,20 9:1,1,9,12 10:19 11:21 23:11 25:4 40:6 49:11 59:15 70:4 158:10 169:20 meetings 4:9 6:12 7:9 75:8 meets 39:4 191:1 members 1:12 4:10,16 4:17 8:12 10:14 13:8 30:10 41:11 42:8 53:15,20 61:2 75:7 120:1 140:7 159:6 191:14 210:7,22 259:13 264:4 274:11 membership 7:3 membrane 203:22 menopausal 111:16 254:21 menopause 255:5 menstruating 33:5 mention 122:14 206:22 mentioned 25:4 27:5 32:13 37:9 40:2 86:7 141:6 143:20 173:19 180:9 191:17 223:18 242:13 mercury 247:12 253:3 259:3 MeSH 83:15 message 270:19 messages 215:16 messenger 60:7,8 met 1:8 9:10 81:19 metabolic 28:13,15,17 metabolism 138:8 188:3 196:2 method 33:2,3 methodology 11:11 104:19 methods 104:22 170:5 methylmalonic 35:5 methylmercury 244:5 mic 125:7 210:21 Michigan 259:20 micro-nutrients 62:6 80:11 microbiome 206:12.15 micronutrient 99:6 156:11 158:15 166:21 167:13 168:15 174:14 175:5,8 272:4 micronutrients 36:6 152:2 272:2 microphone 139:18 201:19 210:9,19 microphones 8:8 50:2

micros 83:7 mics 94:21 midday 98:6 middle 49:7 Midwest 259:9 milestones 152:11 153:3 158:15 166:22 167:14 168:19 175:15 176:5 200:14 milk 36:16 38:20 39:12 39:14 46:11,17 47:2,3 47:3,4,11,15,22 48:4 48:10 52:17,22 99:12 145:13 151:19,21 152:3,4,6 154:6,9 155:21 156:3,7 158:14 166:17,19 167:17 168:9,13,17 169:7,10,15,16,18 170:1,7,8,10,11,12,14 171:1,4,11,19 172:2,3 172:4,5,7,9,13,16,22 173:5.8,9,10,12,13,15 173:21 174:22 175:13 175:22 176:2.15 177:10 178:5 179:18 180:7,17 181:1,5 192:8 193:10 194:7 205:8 206:2 207:4.20 212:5,10,21 214:19 214:21 215:4 225:21 247:13 milk- 215:3 milk-- 47:20 milk-fed 172:14 milk/infant 168:4,20 milks 190:4 207:5 214:22 mind 76:9 100:6 207:8 232:3 250:2 254:11 254:20 258:17,20 262:12,17 264:13 266:1 271:11 272:22 273:1 274:18 mindful 262:8 mindset 102:4 mineral 188:1.2 minerals 155:22 170:18 minimalist 227:19 minimum 71:16 107:15 121:19 127:15 223:8 223:13 minor 200:19 minus 117:9 214:12 minute 100:2 187:21 minutes 18:1 209:19 245:15 272:18,19 mirror 150:21

misaligned 122:11 missed 20:10 91:2 257:19 missing 235:20 mister 51:20 mixed 120:15 145:12 170:22 201:3,3,4 mixed-fed 173:5 175:1 mobility 66:9 mode 174:9 206:9 247:14 248:10 model 116:15 117:20 modeled 136:15 modeling 2:5 10:11 11:2 18:7 20:14 21:9 21:14,21 40:18 49:19 50:15 191:9 models 225:18 228:5 moderate 256:5 moderator 254:22 moderators 13:21 modifier 137:5 modify 265:3 moment 3:17 79:17 209:14 264:13 momentarily 222:21 moms 207:3 Monitoring 26:7 monounsaturated 250:16 month 7:15 68:6 121:1 121:22 124:1 195:7 monthly 120:19 136:8 months 2:11 10:8 18:10 65:6 67:3 69:4 108:13 140:21 149:14 157:1 165:22 166:5 181:17 183:5,19 184:15 185:19 190:22 191:12 197:19 205:12 267:22 moot 84:21 morning 3:3 20:15 98:6 153:19 214:2 276:6,6 276:7 mortality 29:12 62:10 63:3,22 64:5,20 69:19 72:19,20,21,22 96:7 109:19 113:17 118:4 243:19 250:14 253:7 253:9,12 257:4 mother 152:13 221:8 mother's 169:15 mothers 26:17 147:3,6 154:19,21 225:9,11 225:16 **mouth** 95:2 **mouthful** 172:18 move 52:22 74:17

Neal R. Gross and Co., Inc.

Washington DC

103:21 165:21 226:1 264:1 275:15 movement/physical 176:6 moving 89:1 155:3 246:14 250:8 265:22 **MPH** 1:14,15,17,17,19 MUFAs 244:4 multiple 6:21 129:2 130:18 146:10,12 149:6 181:18 223:2 224:12 muscle 29:21 66:8,9,13 66:14,15,17 must-include 228:2 Ν n-256:6 n-3 244:4 246:22 247:2 247:11 250:3 **N-6** 244:4 Naimi 1:17 4:12 20:19 77:2,2 93:19,19 137:11 230:13,13 234:12 236:7,11 242:7 266:4.4 name 4:18 44:14 77:15 139:19 164:9 190:3 210:8 260:4 National 26:3.5.18 28:6 28:22 30:8 31:5 66:1 nationally 22:15 237:10 nature 13:18 18:14 near 144:3 248:19 necessarily 51:17 56:17 87:15 148:1 158:19 193:6 204:15 228:1 237:18 238:19 neck 29:20 need 3:20 6:18 14:1,19 15:4 18:15 20:10 42:18 48:16 51:7 53:9 55:22 56:12,13 81:12 84:2 98:11 100:3 120:20 126:9,16,22 130:1 133:6 140:8 150:18 159:20 201:20 204:12 227:21 235:16 235:21 263:6 265:3 265:14 267:7 273:9 275:2,3 needed 21:10 226:7 242:21 needs 18:20 44:11 57:5 59:19 121:13 166:1 197:12 266:15 NESR 9:7 11:2,5 62:2 62:13,20 73:18 82:1,8

101:6 103:17 106:9 109:15 145:17 158:6 213:9 net 204:19 neurocognitive 62:16 67:13,16 68:11 73:4 74:2 94:1 152:11 153:7 157:19 160:5 168:19 175:15 243:16 243:20 245:11 246:6 246:13 247:4,17 248:1,5,5 250:11 252:5,6,9,20,22 253:2 256:20 neurodevelopmental 153:8 neurological 74:7 never 62:14 102:7 172:5 175:22 new 32:3 52:15 73:17 73:18,19 89:15 90:11 90:11 95:10 140:15 141:5 142:12 145:6 152:8 157:4,10,17 164:3 165:12 168:5 171:10 175:12 192:2 192:17 266:10 NHANES 22:1 23:8 24:9 24:21 26:1,14 27:2,14 27:16,20 28:2,6 29:1 30:1 33:20 38:11 42:6 42:6 **NHIS** 26:4,19 28:20 nice 63:6 77:3 104:1 105:14 119:9 138:9 night 105:7 nine 215:22 nodding 232:7 nominations 7:2 non 53:5 non- 146:15 211:15 238:5 non-alcoholic 211:19 212:2 215:6 non-beverage 236:17 non-caloric 97:14 102:20,21 103:14 216:8 non-fish 247:1 non-lactating 227:8 nonpurposeful 125:14 noon 100:16 norm 49:3 note 76:19 108:9 116:20 202:2 250:21 251:20 256:11 notebook 18:18 noted 30:3 34:11,17

35:16 38:11 61:11 181:20 notice 3:19 4:3 176:3 176:11 noticed 89:10 161:3 179:12 220:15 Novotny 1:18 47:6,6,18 48:19 49:2,8,12 57:12 57:12 58:17,17 102:13,13 103:8 120:17,18 136:14 192:6 194:11,15 197:1 205:3 207:17 207:17 208:2,10,14 208:18 227:14,14 258:21 259:1 268:22 268:22 number 64:5 77:11 92:21 96:19 102:7 113:17 128:9,15,16 128:19 130:5,7 131:16,22 132:10,15 133:8 146:7 166:7 167:20 177:18,20 178:12 207:3 211:16 220:5 272:15 numerical 128:20 nutrient 21:6,15 23:9 23:16 24:6 25:8 30:7 30:13,18,21 32:15,22 33:6,20 34:8 39:7 40:7 41:3 48:11 49:21 52:21 55:1,21 56:3,11 80:21 88:9 155:5 167:8 178:22 180:21 182:3,21 183:2,5,9,13 183:14,16 184:9,13 184:16,19 185:6,9,12 186:6 187:10,19 188:6,7,11,14,19 190:9,11 191:11 201:20 213:16 217:4 219:1 251:4 nutrients 23:21 24:7,17 25:12,14 30:6,19 31:20 32:11,12 33:1,8 37:19 38:1 39:1 40:9 47:17 48:12 53:16,18 53:22 54:8 56:6 57:14 57:22 58:6,10,14,20 61:16 72:8 78:4 79:19 80:5,10,13 83:5,7 91:19,20,22 99:6 131:3 141:12,18 147:19 148:1,3,10,12 148:12 167:4,6 170:3 181:12,15,21 182:2 182:21 189:14,17

190:10.19 192:18.22 205:10 206:3 219:16 219:17 247:11 268:2 268:11,12,15 269:20 269:21 270:14 nutrition 3:4,5 5:1 6:3 22:12 44:12 45:20 262:7 nutrition-related 25:16 25:18 34:3 nutritional 31:19 217:2 238:15 268:2,4,10,18 268:20 nutritionist 3:4 nutritionists 126:19 0 o'clock 139:2 obese 106:18 147:4 271:8 obesity 27:1,2,3,7,7,19 27:20.22 46:1 62:18 68:15,20 73:5 93:2,6 93:10 94:2 96:8 114:1 114:12 115:2 134:1 147:8 154:19 162:7 218:17 225:5,17 232:13 238:7 271:2 obesity-related 231:19 object 209:18 **objective** 11:16 14:12 observation 20:2,9 observational 241:2,22 242:22 observations 273:10 observe 174:15 177:13 Obstetrics 151:10 obviously 15:18 97:4 98:8 114:4 115:19 145:9 216:19 221:5 224:17 265:5 occasion 22:11 97:5,10 97:12 102:20 103:6 108:1,2 113:9 123:12 126:14 131:17 occasionally 195:22 occasions 96:20,21 97:1,22 98:7,15,16 99:15 100:3,14 106:1 107:16 127:19 128:10 128:16 129:16 130:6 131:11,12,22 132:8 138:7 occur 24:17 42:20 occurred 74:10 260:22 **odd** 84:22 odor 218:1 Off-mic 165:5 198:20

Office 148:7 Officer 3:6 offspring 158:1 224:7 225:13 261:15 oftentimes 242:15 oil 250:3 old 216:1 older 22:20,21 29:18 34:5 37:15 38:10 39:3 39:15,18 43:3,19 44:17 65:3 66:22 67:6 68:2 69:1,20 70:11 104:10 178:2 209:5 248:2 249:2,3 252:16 253:16 254:18 olds 44:7,7 45:10 52:22 omega- 163:8 omega-3 141:13 158:20 167:7 182:1 185:18 185:21 186:7 187:14 188:20 205:7 250:17 omega-3s 163:8 203:21 omega-6 203:21 250:19 omega-9 203:21 omission 199:17 230:19 on-line 12:16 once 7:6 38:1 79:9 129:14,20 210:6 221:22 234:20 246:8 247:20 248:20 257:10 258:15 268:18 271:5 ones 9:22 58:11 61:21 70:18 106:13 108:12 109:21 110:2 117:11 118:9,11 119:2 126:21 127:12 130:7 130:8 140:17 141:16 143:4,6,18 145:18 150:5 154:22 164:3 184:6 212:8 231:21 232:18 ongoing 7:4 275:21 online 3:12 8:15 11:18 18:20,21 182:19 203:17 209:22 210:12 open 4:9 20:3,6 75:17 81:11 139:20 159:14 192:1 opening 8:16 operationalize 71:4 operationally 66:4 opinions 52:5 opportunities 6:21 **opportunity** 7:11 76:9 79:7 82:7 120:2,7 215:11,19 217:17 264:21

opposed 122:8 236:19 240:20 options 29:4 156:18 oral 7:12 170:20 order 3:21 9:18 18:6,11 19:1 20:22 56:12 81:6 158:20 235:22 238:20 Order/Opening 2:2 Organization 170:15 194:5 organized 159:19 orientation 9:5 213:13 original 11:4 62:13 151:20 163:3 165:13 168:6 181:18 originally 127:3 originates 253:4 osteoporosis 29:19 ought 221:1 outcome 14:22 16:13 16:17 44:21 64:19 70:8 84:5,9,15,17 85:1,11 118:12 143:7 146:2,3,3 147:21 150:18 152:5,8,9 157:20 161:13 179:9 179:15 184:17,21 186:2,21 187:15,19 188:13 202:7 205:2 219:12 221:5,9 233:10 239:2 240:5 252:11,19 253:13 255:3 256:20 257:21 270:4 272:5 outcome-specific 257:20 258:3 outline 19:7 outlined 5:6 70:16,18 224:9 outlines 5:18 outside 7:13 33:13 outstanding 226:6 274:8 over-consumed 32:16 over-control 240:11 over-controlling 240:14 overall 16:2 17:14 138:6 153:16 158:6 251:22 256:16 overfeed 113:3 overlap 30:1 50:10 51:22 52:4 190:2 overly 120:4 overnight 135:19 overview 3:16 overweight 27:1,19 46:1 62:18 68:14,20

73:5 93:2,5,10 94:2 96:8 106:17 114:1 218:17 232:12 269:9 271:7 overwhelming 191:14 oysters 245:1 Ρ P-R-O-C-E-E-D-I-N-G-S 3:1 **p.m** 139:7 210:4,5 276:16 page 46:21 54:1 63:17 96:5 269:17 pair 129:21 panel 62:1 Pannucci 20:20 23:10 46:15 59:15 paper 76:15,16 146:18 204:10 258:8,9,10 271:5 papers 83:20 89:2 101:13 144:22 223:5 223:14 227:11 231:4 231:6 233:4 258:15 258:18 paradigm 97:3 parallel 212:13 parameters 33:18 66:7 198:3 parent 199:4,6,10,19 200:20 201:3,9 parental 187:5 247:3 252:21 parentheses 84:11 parity 143:13 229:8,8 229:16 246:19 267:13 parking 260:21 part 4:2 8:20 16:2 19:20

46:18 77:1 79:9 95:7 95:10 104:4 112:19 119:9 138:14 140:20 153:21 163:18,19 164:18,19 165:13 175:19 176:19 177:14 192:9 200:1 223:3 228:10 231:12 238:19 239:7,12 243:10 263:15 264:8 267:15 276:2 PARTICIPANT 48:22 participants 15:3 16:1 16:10 104:9 106:9 108:22 109:2 154:15 166:8 178:10,11 179:7,11,13 180:1,4 190:15 223:17 224:21 225:4 249:20

participating 75:8 210:11 particular 15:22 16:13 17:2 64:19,22 66:16 86:5 87:13 93:1 165:8 229:14,18 233:9 234:21 243:12 246:10 248:7 252:11 253:6 254:8 257:7,12 262:1 264:6 particularly 38:8 44:18 52:20 82:21 196:1 202:4 226:12 246:15 246:22 267:22 268:6 269:9 273:8 partly 208:4 partnership 6:5 parts 64:11 79:10 partum 222:12 pass 48:8 passed 178:21 patient 44:4 pattern 2:5 10:11 11:2 18:7 20:14 21:9,14,20 35:19 36:8 40:18 48:3 49:14.19 59:7 64:15 64:17,18 71:10,11,12 71:16,18 72:6,6,8,13 77:14,15 78:14,20 80:5 87:13 100:13 101:21 111:11.13 129:9 131:10,15 143:5 162:16 191:9 193:13 213:12,14,20 patterning 57:18 91:14 138:16 patterns 2:6 10:7 18:8 21:10,12 35:12,18,21 37:8 38:8,14 59:6,22 60:17,22 61:11,13 62:4,10,11 63:3,21 65:20 66:21 67:13,16 68:13 69:11 70:5 71:1 71:5,8 74:20,22 77:4 77:6,11,17,18 78:6,9 79:1 80:2,8,20 81:1 82:15 85:21 86:14,17 87:16,18 88:16 93:1,5 93:9,13,15 97:22 105:5,17 106:4 107:7 111:12 114:6 119:6 120:22 121:18,21 124:3,20 129:19 135:5,6 140:12 142:7 142:8,10,14,18,22 143:1 144:11,16,17 145:18,19 158:11 163:13 164:2 193:8

213:20 246:19 pause 63:7,11 171:6 187:21 paying 246:15 PCBs 247:12 pediatric 44:4,22 pediatrician 44:3 PedNSS 45:19 peer 83:19 peer-reviewed 15:13 people 3:10 33:12 38:13 61:6 75:9 85:2 86:18 93:12 128:3 131:14 161:4 164:22 209:21 210:11 225:1 275:18 people's 52:5 percent 25:4 31:10 33:16 36:3,17 37:16 37:18 38:4 39:3 40:5 68:17 71:20,22 72:2 88:4 215:8,22 239:18 240:8 percentage 53:6 270:22 percentages 72:12 perfect 60:11 perfectly 22:3 30:1 performance 66:9,15 66:18 67:19 176:9 period 20:3 91:3 97:17 97:17 102:11 108:6 108:17 113:19 117:4 117:8 121:11,19 124:19 180:22 214:11 222:6,11 236:18 periodically 101:21 periods 124:5,7 permit 170:17 person 201:19 236:17 239:17 259:18 perspective 239:14 241:16 260:21 phase 204:12 **PhD** 1:13,14,15,15,16 1:16,17,18,19,20 2:2 2:4,5,7,8,10,13,15 phone 159:10 phosphorus 37:22 phrase 21:19 32:14 physical 26:2 28:6 65:11 67:10,11 68:10 69:7 70:1,14 112:2 114:10,14,17 143:12 219:3 230:14,16 253:19 physiological 112:19 132:21 217:8 physiology 129:4

phytochemicals 56:9 58:3 phytonutrients 56:15 **pick** 82:15 201:12 227:12 257:22 258:8 picked 200:1 266:19 picking 213:17 piece 98:18 105:3 110:7 192:8 pieces 12:4 14:7 64:11 79:10 piggyback 88:12 pitched 137:18 plagiarism 211:6 plain 47:2 216:1 217:11 **plan** 11:12 17:14,18 34:4 40:1 41:2,8 44:16 47:9 83:12 169:3 191:8 202:14 plans 257:3 plant 251:12 plant-based 207:4 215:3 play 36:19 205:15 241:1 played 122:19 please 3:22 4:4 7:8,17 47:5 50:13 56:20 75:18 139:17 166:3 210:7 241:14 260:16 **plenty** 94:13 pluck 238:19 **plus** 128:14 131:13 point 11:20 19:15 21:2 45:6 55:7 56:22 60:5 64:10 65:13 78:7,18 78:22 80:1,18 83:2,10 84:21 85:19 86:2,12 92:20 99:14 102:10 110:15 115:22 116:2 117:4,16 121:7 122:21 123:21 125:19 132:12 133:3,16,19 134:14,19 135:1,17 144:21 146:6 164:15 195:1,3 200:7,11 204:20 207:15 217:17 222:11 227:10 229:3 230:6,12 235:21 237:2,3 238:14 241:8 242:8 260:12 263:9 264:5 266:7 276:5 pointed 59:5 214:2 pointing 209:11 points 98:20 100:6 108:19 135:8 163:1 230:6 269:4 pole 136:22 policy 3:5 14:16

polyunsaturated 246:22 247:2 250:16 250:18,19 251:17 256:7 pooled 146:20 poorly 76:3 **pop** 264:11 population 13:14 15:17 16:6 22:14,14 24:20 25:2,9 31:14 32:18,19 33:11 37:11 40:4,5,12 49:22 64:21 65:1 66:20 67:5 68:1,21 69:19 70:9 107:3 110:9 115:11,18 116:6,20 136:17,17 144:7 156:21 157:22 176:13 183:17 185:10 185:22 186:20 208:3 208:8 212:15 215:15 221:18 224:22 225:20 238:2 247:21 248:21 252:13 254:15 261:6 populations 44:20 45:16 76:9 147:15 229:5 246:3 255:14 259:8 portion 113:8 214:1 pose 196:5 264:21 posed 54:11 **positive** 193:15 possibility 136:8 **possible** 14:18 90:10 94:6 136:22 151:1 161:15,17 162:11 191:19 209:21 262:3 276:1 possibly 137:1 160:6 210:9 post- 222:11 post-bariatric 106:14 106:16,21 post-ingested 165:17 **post-partum** 214:9,11 post-prandial 166:3 posted 11:18 203:16 postpartum 96:9 116:18 117:2,3,4,5,7 117:8 120:12 122:8 124:17 141:7 142:11 144:12,19,21 145:3 146:14 158:13 196:2 212:3,22 222:8,11 224:15,16 225:7 226:19,21 227:1 267:7 potassium 32:4,11 37:22 118:14

potency 216:6 potential 5:15 94:5 109:22,22 110:18 111:17,19 112:1,10 112:13 113:13 114:20 115:5 116:9,15 117:14,14 118:8,10 118:22 119:1,10,11 122:14 138:19 159:2 190:1 197:4 248:11 potentially 123:6 137:5 138:11 148:10 160:15 260:1 262:5 poverty 22:6 power 109:3,6,10 128:3 179:8,11 powered 109:7 128:4 179:9 practical 271:9 275:7 practices 112:3 153:15 184:7 187:5 196:18 **PRAMS** 26:6 29:15 pre-28:10 70:7 118:21 150:11 221:16 222:15 pre-diabetes 27:15 157:12 pre-eclampsia 151:12 pre-energy 234:6 pre-period 220:11 pre-pregnancy 116:5,8 117:9,12 124:13 143:14 144:1,6 149:14 214:12 221:21 221:22 222:16 pre-term 147:10 155:2 225:15 predominant 170:16 193:2,5 194:6 196:13 197:2 198:7,13 preeclampsia 161:21 prefer 34:9 260:5 pregnancies 224:12 pregnancy 2:9 10:7 18:9 26:7 73:10,12 89:15 112:9 115:14 115:16,19 116:1,2,6 116:14 124:3 139:14 140:2,10,13,20 142:9 142:19 143:10 144:8 145:21 146:9 147:4 147:20 149:2,15 150:7,20 151:4,9,18 156:10,22 157:15 162:10,13 163:19,19 163:22 165:7 169:1 197:19 211:20 212:18 214:8 221:17 222:16 224:14 226:13 243:15

245:11 261:2,7,14 267:4 pregnancy-229:8 pregnancy-induced 29:16 pregnant 22:21 29:13 35:6 46:2 124:15 162:4 221:19 224:6,7 preload 97:9 preloads 97:11 prenatal 184:8 preparation 262:18 263:2,11 prepare 119:18 prepared 37:20 41:14 159:11 169:20 276:4 prescribed 106:22 present 1:12 39:22 76:14 94:14 104:15 106:3 137:16 166:1 178:16 198:15 213:7 228:16 263:13 presentation 10:15 18:3 57:11 64:10 70:17,19 71:5 77:3 94:11 165:20 210:17 211:4 269:3 presentations 5:10 9:6 17:22 18:6 106:12 139:4 210:14 253:14 267:21 268:1 274:4 274:20 presented 53:15 59:15 61:10,21 64:7 66:6 71:5 75:4 114:5 142:15 146:12 153:18 185:11 198:18 201:8 241:17 252:10 255:20 274:3,12 presenting 95:3 140:7 141:17 166:4,16 presents 228:13 presiding 1:10 pressure 69:15 151:7 presumably 192:22 pretty 86:6 95:9 155:4 214:6 230:22 267:1 270:8 271:20 prevalence 25:16 26:12 26:15,20,22 27:3,10 27:18 28:4,8,9,13,14 29:14,21 30:12 33:10 33:12 44:19 45:22 51:15 68:18 237:16 prevention 134:1 previous 6:6 32:21 40:9 74:16 96:4 114:21 116:9 117:11 118:9

163:16 174:17,20 176:18,21 177:16 184:11 185:1,4,7,11 185:14 186:1,6,22 187:3,18 188:22 190:14 247:19 248:9 248:17 255:1,19 previously 89:6 118:18 119:2 150:14 152:18 252:10 253:11,18 254:10 255:16 primarily 130:18 204:22 213:22 220:7 233:7 234:13 236:9 237:1 primary 99:7 211:14 216:12 221:18 primed 267:18 prior 4:18 7:15 146:2,4 157:1 172:16 177:6 233:12,17 priori 81:8,12 prioritized 5:13 priority 58:5 probability 33:7 probably 10:4 42:21 86:20 88:15 90:6 94:4 105:4 107:13 111:5 119:13 121:3 123:19 133:7,20 136:18 137:2 213:11 216:11 223:13 230:3.9 231:11 240:5 244:3 258:14 259:10,18 260:21 267:18 problem 8:9 54:16 105:16 problematic 160:15 problems 162:13 261:17 process 5:12 6:11,22 13:1 75:15 79:5 272:13 273:21 products 189:16 214:20 217:3 program 45:20 programs 22:7 progress 10:19 274:22 progressive 66:12 project 66:2 140:21 197:20 248:19 projected 18:12 prolonged 102:11 promised 9:11 promoting 16:5 Promotion 3:6 pronged 30:11 **prongs** 54:4 property 219:2,15

proponents 155:19 proportion 59:16 72:11 91:19 262:18 proportions 36:9 58:16 61:15 173:4,7 174:22 242:4 251:14 propose 178:6,15 179:6 189:2 190:13 proposed 51:8 54:15 181:2 proposing 109:12 130:15 131:8 190:18 prospective/retrospe... 241:20 protein 37:21 67:10 78:5 82:4,5 87:4,6,7,7 92:13,16 217:4 218:7 251:18 254:1 256:3 proteinuria 151:7 protocol 11:10,14 12:4 15:5,8,22 17:12 21:1 48:7 90:6 234:18 257:18 264:6 275:10 protocols 7:21 9:7,8,19 9:21 11:12,15,18,21 12:3,14,16 16:19 17:4 17:5,7,19 18:17,19 19:2,4,10,17,21 20:4 22:17 40:15,21,22 74:18 75:3 90:12 96:11 166:10,12,13 167:17 168:1 181:11 191:4,6,17 203:17 224:10 231:13 244:10 257:18 275:17 provide 9:5 16:3 51:14 72:5,10 170:3 192:21 271:12 provided 62:3 169:16 170:2 182:11,16 198:9 provides 63:22 providing 52:1 71:17 226:7 pubertal 112:9 **public** 1:3,11 4:10,13 5:13,15 6:9,21 7:2,3,9 7:12 8:13,19 11:18 19:14,16 20:3 30:6,8 32:13 38:2 49:11 53:16,18,22 54:9 55:3 55:22 57:14,19 58:15 58:19 80:15 137:22 138:2,11 139:16 181:21 269:20 271:10 272:8 275:9 276:9 publication 15:2 73:19 74:11 89:10 104:14

109:5 178:9.9 179:5 249:17,18,19 publications 15:14,14 73:14,22 91:2 published 15:14 74:4 89:16 90:21 140:22 178:16 PubMED 83:15 **PUFA** 250:3 PUFAs 244:4 247:11 pull 79:10 193:5,21 194:21 202:3 204:11 228.16 pulled 194:16 198:14 pulling 197:9 235:5 **punt** 46:14 purely 64:8 purpose 16:2 36:14 101:18,19 purposeful 125:13 **put** 43:14 76:5,15 81:15 88:2 123:1 128:12 131:21 200:13 215:16 218:18 231:5 232:6 237:8 239:15 260:20 273:10 274:4 putting 75:13 81:4 133:13 233:15 274:10 Q qualifiers 84:11 qualifying 124:14 quality 100:4 107:11 109:9 123:5 125:2,20 235:2 quantified 124:21 quantify 133:5 quantities 36:9 61:14 170:17 quantity 151:21 152:3 158:14 212:6,11,21 214:1 225:21 questioning 95:11 questionnaire 126:14 126:17,20 127:4 questionnaires 108:10 108:14,18 125:9,13 126:1,3,6,11,15,22 127:12,18 quick 4:20 75:19 77:21 84:1 138:13 206:8 quickly 95:12 119:4 155:4 187:8 206:6 quite 13:8 23:2 48:12 52:21 55:13 104:3,20 119:8 121:2 145:1 147:1 219:4 257:13 267:3 268:1,3 273:5

quorum 4:16 R RACC 22:9 36:19,20,22 37:4 race 23:3 26:16 65:10 68:7 143:11 220:9 221:20 222:15 246:18 252:18 race/ethnicity 110:11 174:5 187:4 200:19 Rachel 1:18 47:5,6 52:14 57:12 58:17 102:13 120:18 192:5 194:2 207:16,17 227:14 258:22 268:22 Rachel's 136:6 raise 18:5 96:15 raised 120:5 162:1 220:15 **raising** 57:13 ran 63:4 randomized 50:19 52:10 range 31:12 73:19,22 74:11 86:18 173:22 176:8 ranges 73:16 ranked 181:6,8 ranking 227:20 rapidly 49:22 206:11 rarely 76:6 rating 126:2 127:14 ratio 22:6 rationale 12:9 95:18 164:16 192:12 207:18 223:9 229:14,22 233:14 259:4 ratios 251:15 **RCTs** 242:2 **RD** 1:14,16,17,19 **RDN** 1:15,18,20 re-think 55:5 react 219:21 read 10:4 21:2 25:19 36:16 134:4 182:7,8 244:7 ready 20:11 210:13 real 48:14 52:7 84:1 132:21 230:22 reality 55:21 realize 10:4 47:21 50:4 55:21 77:18 realizing 119:4 261:5 **reason** 55:9 56:10 73:15 75:10 101:17 107:5 127:9,15 179:4 206:1 259:11,14

262:7 reasons 104:17 193:21 224:13 250:22 251:6 257:13 recall 39:18 125:12 127:16 204:5 262:17 recalls 125:22 127:5 receive 158:9 received 9:16 19:15 189:13 190:9 receiving 39:12 47:11 47:20 recognize 16:6 55:16 56:16 134:14 262:5 recognized 189:22 271:1 recognizes 80:2 recollection 123:10 recommend 45:11 recommendation 51:13 recommendations 5:19 16:4 21:7 24:3 25:5 33:15 39:5 40:6 43:15 51:5 52:3 53:4 91:22 108:4 116:4 119:21 144:5 162:9 195:13 196:18 221:16 268:20 270.17recommended 31:9,11 53:7 80:16 106:22 160:21 161:7 reconsider 205:17 reconvene 276:6 record 139:6 210:4 211:10 232:8 276:16 recording 144:20 rectal 255:7 recurrent 177:6 180:11 red 34:14 35:2 110:5 118:11 149:19 171:17 203:22 247:20 252:12 reduce 162:6,16 reduced 29:21 86:21 88:8 138:6 reducing 16:4 reduction 32:6,9 redundancies 266:8 redundancy 51:6 reference 18:18 22:2.10 24:14 30:15 31:3,4 56:13 referring 270:13 reflect 49:16 248:4 reflecting 264:5 reflects 252:7 refreshments 4:6 refrigeration 169:17 Regan 1:14 2:5 20:12

41:20 59:4.12 60:12 125:6 201:16,18 202:8 214:1 243:8 269:12 270:13 regard 89:5 224:20 regarding 21:9 180:13 regardless 232:22 regards 29:3 registered 3:10,11 registration 7:14 registry 26:9 regular 273:18 regulate 134:7 regulated 155:22 regulation 133:22 rehydration 170:21 reinforce 52:7 reiterate 52:14 58:22 relate 21:6 41:5 60:2 92:22 93:9 166:16 167:4,12 173:20 175:18 180:15 191:6 261:12 262:4 related 21:15 40:21 54:21,22 112:14 114:12.22 123:4 128:19 143:10 160:5 160:6 162:9,14 163:12 164:1 178:5 181:12 207:2 212:16 258:5 261:18 262:12 267:3 relates 59:9 92:20 133:20 142:2 161:19 185:9 206:9 relating 128:11 192:10 relation 144:5 175:4 179:19 221:16 271:2 relationship 12:20 13:20 30:21 62:9,11 63:2,20 65:8 67:15 74:19,22 109:18 113:21 115:13 116:4 116:17 117:19 118:16 142:8 147:18 148:21 168:8,12,16 169:6,9 171:10 175:12 177:9 183:1 245:10 247:9 249:5 252:4 253:8 255:11 relationships 21:11 51:22 122:20 261:18 262:9 relative 29:5 32:16 33:9 52:2 91:21 211:4 218:21 219:14 221:6 release 6:16,18 32:3 relevance 5:14

relevant 14:16 88:2 130:13 131:18 136:18 161:16 175:4 184:1 217:14 222:3,20 230:10 231:6 237:3 242:17 270:12 271:10 religious 101:17 remainder 96:3 **remaining** 7:9 21:3 191:5 remains 117:8 214:10 remarks 2:2 8:16 19:8 Remarks/Agenda 2:3 remember 61:6 105:7 165:4 205:5 263:7,17 271:5 **remembers** 230:20 remind 10:5 19:12 142:13 210:7 275:8 276:5 reminded 57:8 reminder 4:20 10:20 15:6 54:3 reminds 12:3 reminiscent 79:18 removed 212:21 rep 243:11 repeat 143:18 replaced 86:22 87:3,3,4 88:9 251:16 replacement 217:3 251:15,18 replaces 92:9 replacing 92:14 **report** 5:18,20 6:8,15 7:6 20:11 30:9 32:3 60:12,18 72:21 83:6 91:11 138:9 139:14 140:1,4 **reported** 83:4,8 86:4 120:16 146:19 152:18 156:17 195:3 203:19 204:1 233:18 reporting 20:12 72:20 77:1 204:10 265:4 reports 9:2 42:15 139:11 151:16 repository 26:9 represent 23:2 31:4 32:15 60:22 75:11 173:22 180:10 representative 22:15 115:10 208:8 237:11 represented 22:12 representing 20:16 represents 75:16 request 6:14 42:14 43:19

requesting 41:16 require 42:4 requirement 31:13 requirements 33:4 53:12 178:22 190:4 requires 195:22 research 5:1 97:19 99:18 103:20 105:6 105:14 109:5 110:4 110:21 111:6,20 118:15 119:21 125:21 131:20 198:10 resources 46:7 respond 259:16 response 134:15 responses 123:6 rest 12:22 95:17 96:16 100:18 107:3 108:3 208:14 248:19 restaurant 123:13 restricted 97:3 100:13 125:15 restriction 113:2 result 189:17 resulting 182:5 results 17:16 34:2 41:9 87:11 119:17 resumed 139:6 210:4 retained 174:21 212:19 212:22 retention 117:5.7 145:4 158:13 214:9 222:12 226:20 267:7 return 137:11 reverse 146:5 review 4:22 5:17,18 8:17 12:22 14:14,20 17:7 18:22 19:4 41:8 63:1,20 64:1 65:9,19 65:22 66:12 68:7 69:11 70:5 73:18 74:7 74:16 109:15 156:6 171:10 175:12 177:9 182:22 244:9 reviewed 83:19 **reviews** 11:3,3,4,6 15:11,12 17:11 21:12 34:1 51:10 61:14 62:3 62:13,20 71:1 73:20 74:1,12 81:5,6 89:13 140:15,19 141:6,22 142:12 159:3 163:18 168:6,22 169:1,2,5 178:17 179:16 180:7 181:19 208:5,22 213:9 249:16 257:5 267:9 rhinitis 177:1

rich 125:10 Richard 1:17 2:13 **Rick** 50:7,8,9 56:5 75:19 91:13 95:6 125:5 134:19 210:16 241:13 242:13 266:6 266:13 Rick's 264:14 rickets 188:3 risk 13:3 16:4,7,12 26:7 27:21 28:15,18 31:15 32:6,9 62:17 65:3 67:1,7 68:3,14 69:2 69:21 70:12 111:21 114:1 118:17 119:18 144:8 147:15 154:19 162:6 180:15 183:20 212:16 218:16 228:19 232:12 248:15 250:12 254:6 255:12 256:4 261:2,15 risks 162:17 261:13 ritual 170:21 rivers 244:20 road 82:10 200:13 rocking 63:13 role 6:3 55:5 211:15,19 236:1 249:22 rolling 63:13 **Ron** 95:7 139:22 166:8 271:17 274:16 **RONALD** 1:13 room 98:8 210:12 round 54:20 row 71:21 rule 79:2 rules 81:16 ruling 89:17 run 195:6 211:3

<u>S.W</u> 1:9

Sabate 1:18 57:20,20 92:6,7,7 110:15 128:8 128:8 130:3,20 131:6 232:9,9 233:20 234:7 234:20 235:3,8 236:2 236:10,21 238:1 239:3,9 243:8 267:20 267:20 Sabate's 242:21 salient 45:6 salmon 244:21 259:19 260:10 salt 170:21 sample 29:8 109:8 samples 34:11 sampling 22:1

sarcopenia 62:12 65:17 65:18,20,22 66:2,5,11 66:18,19 67:6 73:1,2 saturated 33:14 87:8 250:15 251:16,18 save 7:9 saw 122:4 206:16 saying 60:4 78:13 81:11 100:12 130:12 130:13 131:7,8 195:5 237:19 240:1 272:14 274:21 says 47:2 56:6 215:13 schedule 112:6 122:4,9 209.20 scheduled 209:17 schedules 112:7 Schneeman 1:10.13 2:4 3:16 8:5,5,6 20:19 44:13 46:20 47:2 50:6 53:13 54:10,13 55:15 56:20 57:8 59:4 60:10 75:18 76:20 82:18 86:8 89:21 90:17 91:7 92:5 94:17 139:8.16 153:18 160:9 164:14 197:7,8,15 198:16 201:16 202:17 203:4 209:15 210:6,19 211:11 226:9 230:4,5 231:10 232:4 234:16 235:1.4 238:10 239:3 240:22 241:17 242:20 243:10 257:16 260:11 262:10 263:15.20 265:6 266:22 271:17 273:22 274:15 Schneeman's 70:17 school 112:5 science 6:4 51:3,4 76:10 Science's 30:9 science-based 5:18 **scientific** 6:6.8 7:6 11:13,17 30:20 31:16 **scope** 17:14 65:6 67:4 238:8 scores 35:14 37:9,10 37:12 40:12 screen 122:15,17 123:9 123:17,21 126:4 140:16 screening 12:7 90:16 119:17 256:19 screens 122:18 125:10 scrutiny 159:20 se 264:20 sea 244:19

seafood 2:14 10:9 18:11 99:13 243:4,8 243:13,14,15 244:6 244:11,13,16,18 245:3,10,19,20,21 246:1 247:9,14,16,22 248:13,14,21 249:6 249:13 250:1,5 256:19 257:1 259:2,5 260:3,6,6,14 262:13 262:18,20,22 263:12 seafoods 253:4 search 12:6,7 13:2 74:5 82:1,5,8,9,14,21 83:13,14,18,21 90:13 90:13,14,15,22 101:11 103:5 119:17 129:14 135:17 136:2 163:6 165:11 257:1 searched 141:2 searches 141:4 154:1 256:19,21 searching 85:10,10 103:6 seasonal 112:7 213:16 second 3:9 6:11 8:19 25:15 63:7,10 71:21 83:19 92:20 96:20 99:14 105:3 141:9,10 144:10 172:11 179:6 199:6 212:12 221:2 234:9 243:18 247:15 250:9 secondary 90:22 138:5 **Secretaries** 5:20 7:7 security 4:2 22:6 23:5 121:4 137:2 seeing 132:4 254:13 seen 45:9 64:8 140:22 249:15 SEER 26:8 27:14 29:10 selected 37:19 95:19 129:8 258:10 selenium 247:11 self-selected 35:17 semi-vegetarians 160:18 sends 270:18 sensations 132:20 sense 6:10 89:4 108:20 162:15 226:18 sensitive 88:21 97:18 133:7 sensory 219:2,17 sentence 63:16 separate 78:3 80:4 101:7 108:19 122:10 131:15 132:3 134:17

136:1 167:8 245:14 separately 130:2 146:13,19 series 186:5,9,17 188:5 188:7 serum 34:14,15,15 35:2 35:4 202:11 served 112:12 serves 12:21 service 139:17 Services 5:3,21 SES 121:22 136:9 246:18 session 171:5 173:14 set 30:7 31:4 49:3 51:2 63:8 97:21 100:13 142:17 147:18 149:3 149:14 158:10,16 162:8 181:14 182:12 182:22 183:8 189:6 190:14 196:8 223:8 sets 53:2 186:22 setting 194:15 223:4 settling 165:17 **seven** 128:14 severe 27:1.7.19 66:19 147:12 sex 23:3 29:11 65:10 67:8 68:7 69:6,22 70:13 110:11 153:10 158:2 187:4 211:21 220:8 221:7 246:17 252:17 shakes 215:4 217:5 share 8:20 100:2 209:5 229:20 shared 90:13 Sharon 1:16 2:10 50:7 50:8 52:13 89:8 123:22 140:3,6 165:19 166:8 191:16 204:4 224:9 226:16 266:22 shedding 196:20 shellfish 244:22 shift 112:8 123:1 223:12 shifting 187:19 shoot 60:7 short 52:7 94:21,21,22 125:7 201:19 238:4 270:9 short-term 242:11 shorter 44:5 shortfall 269:21 shortly 61:21 256:22 show 188:7 showed 174:17

showing 183:10 186:11 244:8 shown 62:22 63:18 65:9 69:9 70:13 73:6 140:16 143:3,6 150:2 184:6 185:2 189:3,8 228:11 shows 156:2 166:15 167:3 171:17 185:5 186:11 188:5,10 270:16 275:2 **shrimp** 244:22 shutting 63:6 side 116:20 140:16 141:20 215:11 sign 7:17 significant 9:11 similar 24:19 27:17 32:20 34:21 40:2 101:12 109:20 114:4 116:9 118:6,9,18 152:17 155:7 156:9 157:21 168:22 171:7 174:4,11 176:18 184:6,11 185:4,7,14 186:5.22 187:3.18 190:13 229:4 247:19 248:9 249:8 253:17 255:1,19 259:3 266:12 similarly 25:8 193:11 194:21 simple 152:5 239:15 Simultaneous 45:13 single 98:22 99:11 107:19 149:6 171:4 173:14 202:7 224:11 257:9 singleton 146:9,11 sitting 82:20 211:2 265:19 274:5,6 **six** 61:9 75:4 148:12 149:13 157:1 161:2 size 15:2 62:17 68:13 73:4 74:12 96:7 108:21 109:8 113:8 113:22 166:20 167:9 167:13 168:10 171:13 173:19 174:18 179:19 182:4 186:10,15,18 187:16 199:20 205:7 205:11 206:3 214:1 218:16 232:12 sizes 29:8 skeletal 66:7,13 **skip** 100:14 skipping 97:2 99:17,17 99:21 100:10,15,21

101:1,3 106:1 107:21 121:1 123:3 125:14 126:15 135:13,21 sleep 112:7 122:4,5,22 123:4,5,5 slide 6:20 13:7 15:6 21:3 35:8 38:21 40:10 46:21 47:1 61:8 62:9 62:16,22 63:15,19 65:9 69:10 73:2 75:16 77:18 84:3 92:20 103:18 128:2 140:8 152:16 166:15 167:3 174:2,17,20 175:6 176:3,18,21 181:20 182:16 184:11 185:1 185:5 186:11,22 188:10,13,14,20 189:4 206:17 214:20 223:20 245:16 248:7 254:8 255:1 270:16 slides 9:4 24:5 25:21 33:19 54:2 61:1.3 73:7 94:16 95:15 174:5 177:16 183:8 185:4,8,11,15 186:1,5 186:9,17 187:4,9,10 187:15,17 188:5,7,22 189:4 209:16 234:14 241:17 244:2 260:20 small 16:22 128:18 209:2 212:14 225:13 265:8 smaller 42:14,16,22 107:1 174:20 smoking 65:12 68:9 69:8 70:1,15 93:21 111:15 143:13 174:9 221:22 222:17 246:19 252:19 smoothies 217:1,3 snacking 98:9 105:20 snacks 97:11 98:11,17 Snetselaar 1:19 2:15 88:11 243:5,6 258:1,4 258:11,16 259:6 260:4 263:3,17 267:10 social-emotional 176:7 sociodemographic 220:9socioeconomic 22:4 23:4 65:11 67:9 68:8 111:18 121:4 136:20 143:12 174:6 187:4 200:1,3 221:21 222:15 252:18 soda 240:9

sodium 32:4,10,11 75:22 76:22 79:16 118:13 162:1 264:15 265:4 270:10 273:7 soft 37:1 46:11 216:21 sole 101:19 solely 72:8 solid 219:5 solutions 170:21 somebody 84:18 109:5 128:13,17 217:6 239:15 240:8 somebody's 84:20 111:10 113:5 240:12 someone's 80:3 somewhat 192:11 soon 90:10 196:15 264:11 sooner 20:5 **sorry** 49:2,12 59:12 91:12 94:20,22 112:22 115:15 127:8 131:11 139:21 152:15 160:10,11 161:18 162:17 175:16 182:8 184:13 188:16 201:18 208:1 212:4 213:5 225:22 257:19 260:17 274:2 sort 53:4 55:10 87:14 100:9 130:12 147:5 160:8 197:20 198:6 200:13 215:4 216:6 217:21 220:15,18 229:5 230:1 237:14 242:2 264:19 sorts 220:6 sounds 55:15 78:5 197:11 226:11 240:22 **soup** 31:9 source 47:16 94:6 131:1,3 173:10 207:6 245:5 248:11 262:15 268:16 275:21 sources 23:6 24:1,16 25:14,22 33:17 37:13 39:1 40:3,10 45:18 50:22 190:19,20 207:1 213:21 215:7 245:21 246:16 251:10 251:12 259:21 268:12 **SPAHN** 263:10 span 174:1 177:2 179:21 211:19 264:17 **speak** 57:9,13 79:13 83:4 134:10 139:17 139:18 210:8 264:22 speaking 4:18 45:13

80:7.12 special 41:13 217:7 219:18 specialized 115:6 189:18 specialty 216:22 **specific** 5:7 9:15,20 11:11 13:15 14:2,20 15:5 18:13 19:17 20:4 29:12 35:19 42:6 43:10,22 64:6 86:16 87:18 104:17 113:18 118:12 119:7 123:20 129:22 131:16 143:7 143:15 147:21 149:22 150:20 167:4,6 171:18 172:21 181:12 181:15 183:2,5,9,14 184:19 186:6 187:18 188:5,7,11,14,19 189:14 190:9 200:15 203:15 205:6,10 206:2 217:4 251:14 256:12 258:6 264:19 268:2,11 272:2 specifically 5:5 37:20 38:17 40:21 48:18 56:6 99:11 110:3 123:11 134:22 175:9 189:11 192:14 238:20 243:15 249:21 252:1 258:5 263:18 specifications 69:17 specifics 72:17 specified 67:18 71:14 71:20 72:12 specify 189:12 190:8 specifying 213:11 spectrum 31:22 67:20 89:4 176:10 198:6 **speed** 66:10 spent 95:12 233:3 spine 29:20 split 81:20 sport 46:12 sports 37:1 216:21 spring 7:5 squares 252:13 staff 4:4,5 10:16 41:12 82:19 85:16 90:3,15 120:1,3 159:6,8 165:15 191:15,20 197:9,16 199:17 228:4 232:6 241:15 257:8 269:14 273:18 274:11 staff's 226:5 stage 21:19,22 250:10

253:9 254:17 265:13 269:17 273:20 stages 38:15 39:2,8,11 40:8,11,13 43:16 standard 9:7 14:16 56:13 98:10 103:17 106:9 142:14 145:15 145:16 153:18 158:5 178:7 181:3 189:2 203:18 204:7 208:21 223:1 234:18 241:18 249:14 256:10 standardization 98:15 269:15 standardize 215:19 232:2 standardized 15:8 148:18 211:21 standards 169:21 191:2 Stang 4:14 20:18 staple 105:19 start 19:20 52:11 63:14 79:6 96:13 100:16 121:1 139:19 141:15 158:16 159:21 169:13 182:20 227:4 264:10 265:13 266:3 267:9 276:7.8 started 90:10 139:9 142:4 166:9 272:15 276:7 starting 24:11 70:21 148:20 177:3 257:4 starts 262:7 275:16 state 4:18 6:3 112:16 113:1,5,6 stated 130:4 133:10 statement 51:13 54:22 56:18 76:10 123:20 190:5 215:17 statements 41:10 119:20 statistics 26:5,10,18 28:22 29:15 status 16:1 22:4 23:4,5 27:12 30:18 34:8 65:11 67:9 68:8 106:8 111:16,18 112:9,9,9 114:18 115:2 121:4,4 121:22 136:20 143:12 147:1 149:18 150:1 156:11,15 158:16 166:21 167:8,13 168:15 174:6,14 175:5,8 178:9,10 180:21 182:3,22 183:6 184:2,3,4,10,16 184:22 185:6,12,13

186:2 187:5 200:1.3 201:20,22 202:10,15 202:15,21 203:1,5,20 204:11,21 220:9 221:21 222:15,18 224:20 249:18,19 252:18 254:21 268:2 268:18,20 272:4 stay 275:19 stayed 152:22 steal 264:14 stem 261:17 step 272:6 steps 19:7 40:14 74:17 75:2 119:16 158:8 191:3 225:19 256:18 Steve 95:4 stevia 216:5 Stoody 2:2 3:3,4 63:5 stop 71:9 226:8 straightforward 214:7 272:18 strategy 12:6 13:4 83:15 90:13,14 129:14 133:10 136:2 stratified 23:3 stratify 136:20 strength 29:21 32:7 66:8,15,18 strict 194:17 stricter 107:14 stroke 28:9 69:17 118:3 stronger 51:4 strongly 263:19 struck 50:10 structure 81:5 structuring 10:22 struggle 195:15 stuck 160:1 studied 93:15 study 15:2,2,3,9 16:1 16:14 17:2 77:1 99:7 100:4 101:8,19 102:2 104:8 106:9 109:10 111:1 113:3 125:2,3 128:2 178:10 179:8 179:13 180:4 190:15 223:7,17 228:1,13 234:10 235:4,6,15 236:3,15,18,20 238:3 240:20,21 242:5,15 249:17 studying 220:11 stunting 68:19 **stupid** 205:4 subcommittee 2:9,11 2:12,14 8:22 9:5 10:3 10:13,15 17:22 18:3,8

18:22 60:11,16,18 61:1,3,7,12,20 64:4 65:5,21 67:2 68:4,6 69:5 75:7 91:6 94:14 95:10 134:20 139:11 140:2,11 142:22 144:17 166:5,7 182:11 184:1 189:21 191:13 203:22 210:14 210:16 211:1 212:7 220:16 224:10 239:10 243:2,7,12 244:10 246:11 256:12 257:3 257:7,12 259:13 260:19 263:10 265:17 267:15 273:17 subcommittee's 249:22 subcommittees 9:2.9 10:6,18 11:22 12:11 14:2,7 18:2 50:17,18 110:2 118:6 213:17 214:3 230:8 246:8,12 256:10 265:21 267:12 274:6,19 275:4 subdivided 217:11 **subaroup** 32:19 40:16 41:2 42:19 **subgroups** 23:2,13,22 27:12 40:5 42:14,16 subject 18:14 109:1,2 subjects 16:11 106:14 253:15 254:17,18 submit 5:20 7:7 19:19 275:12 **submitted** 275:12 subsequent 17:15 99:20 129:6 134:7,12 172:8 180:15 substance 114:22 substances 115:1 substantial 95:12 substitutes 47:4 215:3 subtraction 233:9 success 75:15 sucrose 215:22 sufficient 32:7 sugar 36:7 134:10 216:1 229:10 231:16 sugar-sweetened 51:15 sugared 240:9 sugars 2:12 10:8 18:10 21:5,17 33:13 37:21 40:20 50:12 51:12,14 210:15 212:12 226:1 sugary 134:6 suggest 262:21 suggested 72:14 123:4

suggesting 126:12 suggestion 49:13 94:8 122:12 summaries 265:14 274:7 summarized 271:20 summer 257:2 sun 185:3 supplement 24:10 149:6 160:20,20 161:7 165:8 182:15 184:9 195:13,17 250:3 256:7 supplemental 45:20 160:14 161:12 163:1 228:9 supplementation 148:19 156:2 157:1 supplemented 268:13 supplements 21:16 23:17 25:11 34:7 41:4 41:7 58:21 141:10 142:1 147:19 148:3,6 148:8,22 149:5,7 151:3 155:11,15 156:6.14 158:5.17 167:5 181:13.16 182:14 183:3,10,13 183:15 184:13,14 185:18 186:12 188:12 246:21 268:14 supply 153:22 154:7 161:9 support 40:18 41:12 54:14 75:9 120:1,3 159:6,8 191:15 257:8 supported 10:17 20:19 supporting 75:13 **suppose** 196:6 supposed 49:10 188:16 surgery 106:15,17,22 surplus 113:2,6 surprise 50:20 269:13 surprised 206:21 227:10 267:2 268:5 surrogate 30:17 surrounding 125:7 surveillance 45:22 survey 22:15 23:7 26:4 27:16 28:7 34:9,12,16 237:11 surveys 50:16 suspect 195:6 196:14 sweetened 36:21 37:17 46:10,18 170:20 215:12,13 216:20 217:10 219:18 229:10 231:16

sweetener 216:10 218:4,6 sweeteners 215:18 216:16 sweeter 215:22 216:1 sweetness 216:2 219:21 switch 181:10 switching 147:17 symmetrical 33:4 syndrome 28:14,16,17 synonymous 136:1 synthesis 83:10 119:19 263:14 synthesizing 13:4 syrups 170:18 system 26:6,7 28:22 29:15 109:15 219:14 219:16 systematic 11:3,5 12:22 15:11,12 17:7 17:11 21:12 34:1 51:10 62:3,13,20 63:1 63:19 64:1 65:9,19 66:12 70:4 71:1 73:18 73:20 74:1.12.16 81:6 89:13 140:15 141:22 142:12 156:5 159:3 163:18 168:6,22 169:5 171:10 175:12 177:9 178:17 180:7 181:19 182:22 213:9 244:9 249:16 267:9 т tables 263:13 tackle 95:11 tackling 20:22 tailor 190:18 tailored 14:6,8,20 15:5 19:5 179:5 223:3 tailoring 15:22 178:13 181:2 189:5 190:13 taken 212:19 218:17 241:8 244:14 263:2 takes 223:10 talk 17:6 24:14 48:22 56:8 59:2 76:2 91:18 91:19,21 100:9 123:11 220:22 251:10 259:13 263:4 273:16 talked 29:2 89:14 101:16 132:13 136:9 136:12 147:1 215:14 263:8 265:11 273:14 talker 41:19

Neal R. Gross and Co., Inc. Washington DC talking 22:17 42:2,18

52:18 58:20 81:13

136:17 205:12 228:15 233:3 261:5 266:16 269:14 talks 204:14 tall 201:19 tap 37:2 217:12 target 135:20 225:6 255:14 targeted 225:2 targeting 119:9 task 268:7,8 tasked 61:8 251:21 265:1 Taveras 1:19 2:11 44:15,15 45:9,16 46:9 122:3,3 165:22 166:2 166:4 194:1,13 195:1 197:14 199:12,16,21 200:10,22 202:1,12 203:2,8,12 205:20 207:10,14,22 208:4 208:20 209:10 264:12 tea 36:17 217:10 teaching 270:14 team 37:20 41:14 198:1 198:2 200:17 teas 170:20 196:12 217:1 teleconference 9:10 television 122:19 telling 51:19 166:10 template 13:7,10 temporal 213:19 temporality 146:1 ten 29:9 128:16,16,17 131:12 209:18 214:16 214:18 218:18 tend 132:17 tended 200:2 tendency 105:6 tentative 18:12 Teresa 20:18 term 22:4,5 23:1 32:4 32:12 43:19 44:8 127:13 216:4 225:10 225:11 terminology 14:4 216:10 275:1 terrific 139:13 159:21 274:5 test 83:20 tested 62:4 71:16 Texas 7:14 thank 3:12 8:6 41:16 55:18 60:12,20 63:12 92:5 128:7 139:3 140:5 159:13 164:11 165:19 191:20,22

192:6 197:5 209:10 210:18 226:5 242:7 243:1,6,9 257:6,7 270:6 273:21 274:14 274:15,18 276:12,12 276:13 thanks 41:13 75:6 77:2 120:10 127:2 209:2 257:15 theme 137:12 225:9 themes 264:17 theoretically 77:16 106:19 things 15:4,19 21:21 37:1 40:2 56:15 57:2 58:19 59:1 78:19 95:19 97:5 103:19 117:21 120:6 130:12 138:10 152:19 160:1 160:7,12 193:8,22 195:13 196:11 206:8 215:22 217:22 226:11 227:19,21 240:18 254:20 262:14,16 265:2 266:2 267:17 269:16 270:15 271:3 273:13 275:8 third 30:5 94:11 161:18 173:11 212:1 213:1 221:12 228:5 thought 46:5 77:22 84:7 94:3 104:17 122:18 127:10 129:1 180:16,20 192:16 199:3 208:10 230:2 259:14 272:17 274:4 274:7 thoughts 76:4 102:17 271:20 three 10:22 30:11 53:18 54:4,6 55:16,18 66:3 73:16 75:4 105:19 107:15 108:8,17 125:22 127:11,15 131:10,13 140:11 160:1,5 167:3,8 168:4 168:6 171:17 172:21 182:2 187:10 211:14 243:14 244:11 274:5 threshold 85:13 threw 226:11 thrive 68:19 thrombosis 69:18 118:3 throw 220:17 tied 43:18 tier 127:21 228:21 tightly 155:22

tilapia 244:21 Tim 20:18 77:2 93:19 136:4 137:10 230:12 230:13 266:4 time- 100:12 125:14 time-period 64:6 time-restricted 97:19 97:21 100:11,22,22 102:6 times 4:1 18:13 74:10 99:5 107:22 128:14 128:15 223:2 timing 96:20,22 98:3,13 125:10 132:1,5,15 245:6,22 262:16 **Timothy** 1:17 240:5 tiny 174:2 tireless 75:12 today 3:14 4:11,15 7:22 8:17 10:2 12:1,11 13:10 17:6,17 19:18 20:21 22:17 61:10 64:8 95:4 96:11 140:18 141:6,17 166:6,11,16 191:4 244:4 261:1 264:9 266:1 274:4,13,20 275:2 today's 4:16 5:10 9:1 17:21 toddler 190:4 toddlerhood 180:22 183:4 toddlers 39:11 52:19 65:5 67:3 68:5 69:4 104:12 153:5 173:18 175:9 180:14 183:19 224:2 246:4 252:15 tomorrow 3:15 7:10 8:18 276:6,6,10 tomorrow's 19:13 **top** 110:7 171:17 172:19 topic 10:3.6 19:6 30:3 61:7 79:14 95:13 96:4 140:11,14 159:19 162:1 166:15 167:3 167:11 192:2 209:13 211:15 212:1,12 243:18 250:9 topical 65:18 topics 5:7,8,11 6:22 9:20 40:22 96:1 167:18 181:12 243:13 272:16,20 topping 171:3 173:15 175:3 total 25:11 28:3 32:22

33:16 34:7 35:15 37:14 41:5 64:5,20 67:9 68:9 69:6,13 70:14 93:2,11,17 110:11,16 112:21 113:17 128:15 129:2 129:10 137:14,17 138:15 191:5 220:9 232:13,14 233:5 235:9 236:4 237:13 238:17 239:19 240:10 240:12,14 253:18 256:15 totality 80:3 105:15 129:20 totally 272:7 touch 83:3 touched 104:5 track 38:8 144:2 145:1 215:11 226:6 training 9:17 trans 250:22 251:3,6 transcript 44:14 transcription 210:10 transferrin 34:13,22 transient 177:6 180:10 223:12 transit 132:19 translates 82:13 transparent 14:13 276:1 treated 130:2 treatment 16:9,15 tremendous 8:21 10:18 55:2 60:15 159:18 trend 161:3 trial 225:3 trials 50:19 52:10 224:4 237:4 241:21 tried 150:19 triglycerides 28:3 69:15 trouble 160:11 trout 244:21 true 88:15 121:7 242:1 truest 132:14 truly 113:14 223:13 trumps 51:17 try 14:3 42:16 43:15 45:11 94:16 95:18,21 209:20 215:19 261:22 270:8 276:1 trying 12:14 14:6 53:1 58:14,14 85:4 90:18 93:7 97:18 98:4 101:4 102:11 110:18 112:8 112:17 119:12 121:17 124:18 131:2 135:20

136:15 148:17 150:22 understand 11:19 57:6 153:6 196:21 204:19 78:13 84:13 86:21 239:4,13 240:16 89:17 137:19 144:22 246:9 262:2 269:5 192:11 195:16 207:3 tuna 244:21 226:19 227:2,6 241:7 turn 8:3 54:15 139:11 understanding 8:7 88:8 209:14 206:13 239:4 272:3 turning 58:21 understood 127:3 164:16 twice 65:15 undertaken 221:11 two 21:13 37:15 39:3,15 39:18 42:13 44:16 underweight 27:1,19 50:18,22 54:5 62:8 68:18 147:4 72:22 75:4 77:20 unfortunate 161:11 90:10 92:8,18 96:19 unfortunately 60:7 98:20 100:6 104:11 unifying 264:16 104:16 107:16 108:18 unique 70:20 107:9 112:18 130:14 131:10 111:5 131:1 140:17 141:9,9 142:7 uniquely 224:11 148:3 154:13 158:12 unit 123:16 160:12 162:10 168:20 universally 55:13 169:3,4 171:15 unmetabolized 35:3 174:17 177:3,7,16 unsaturated 87:8 160:4 180:4,10 185:4,7 unsweetened 217:10 190:17 199:9 204:6 up-front 14:12 205:16 206:8 210:13 upcoming 24:4 25:21 239:20 243:13 273:12 189:4 type 27:15 28:10 37:2 update 73:18 74:1.12 56:17 59:8 62:19 70:2 164:3 169:3 177:8 70:5,8 73:10,12 74:13 updated 12:17 17:20 84:3,5,12,13,16,18 32:11 151:11 169:4 85:11,13,15,20 96:10 updates 7:18 168:22 118:17,19 134:2,9 275:17 212:17 218:21 231:14 updating 11:5 62:19 235:2,6 245:4 259:9 141:1,3 169:5 262:15 upper 223:3 upside 61:5 types 15:11,19 36:2,5 38:5 74:20 79:4 86:17 urbanization 27:6 28:1 88:16 97:20 99:9 urinary 35:7 114:16,22 153:20 **USDA** 3:5,21 4:6 5:12 174:6 192:18 242:5 6:5,15 7:7 8:11,14 245:21 250:16 251:14 10:16 20:20 191:15 252:1,2,4,7 254:2,7,8 275:19 254:12,19 255:11 use 17:9 21:15 22:5 256:4,13 261:10 23:1 29:3 31:14 33:2 typical 203:18 33:14 34:9 53:11 93:7 94:16 112:20 114:22 typically 98:4 135:18 192:15 122:15 123:9 133:4 148:17 154:18 171:18 U 184:9 216:12 255:5 256:7 257:22 266:16 **U.S** 1:9 14:16 15:17 266:19 270:15 22:14 26:10,16 80:15 97:8 useful 53:20 194:21 229:4 269:10 275:11 **UL** 31:22 33:11 usual 23:22 24:12,13 ultimately 58:7 272:3 25:10 34:5 47:10 uncertainty 180:12 under-consumed 32:16 101:20 underneath 96:21 usually 95:1 undernutrition 147:12 utilized 46:8

V vaginal 206:14 valid 153:2 238:7 **validated** 30:16.18 56:14 108:12 125:12 127:13 204:15 valuable 134:16 value 129:8 values 31:4 Van 1:20 54:18,18 79:12,12,22 133:18 133:18 159:16,16 160:10 162:20 206:6 207:12 243:9 259:17 259:17 260:17,18 270:7.7 variability 179:15 variable 98:12 145:1 variation 190:5,12 225:8 variations 36:4 88:15 varies 179:13 235:2 varieties 36:10 variety 61:15 71:13 255:3 267:17 various 9:8 12:4 16:19 68:15 70:20 161:10 209:22 220:7 vary 18:13 73:15 190:10 vegan 71:10 77:5 87:19 185:16 vegetable 87:7 215:9 219:7,7 vegetables 92:16 vegetarian 35:18 71:10 77:5 87:16,17 vegetarians 160:17 vehicle 217:21 219:20 venous 69:17 118:3 **ventured** 214:16 versus 58:6 85:22 97:1 110:8 111:12 113:14 114:3 115:18 117:22 120:15 123:13 125:4 125:13 130:8,19 131:11,15 132:10 137:13 173:9 175:3 175:22 198:13 202:20 206:14 224:12 232:17 232:21 233:21 235:11 238:6 239:17 245:18 269:19,20 Vice 1:13 41:20 43:1,5 43:8 44:2 60:8 85:8 91:10 94:9 101:15 135:4 136:3,12 137:4 137:10 138:21 139:13

139:22 159:13 164:5 164:9 165:16 191:22 195:8 197:5 206:5 207:16 208:7,12,16 209:12 271:19 274:1 view 11:19 viewing 1:11 122:19 viewpoint 92:18 268:4 violated 33:5 viral 255:8 viscosity 219:3 viscous 218:8 visible 4:1 231:12 visit 275:20 visual 63:9 Vital 26:5,18 28:22 29:14 vitamin 34:16,19,19,20 35:4,8 37:21 141:14 149:18 158:21 167:7 167:7 181:22,22 184:9,14,16,20,22 185:3,5,6,10,13 186:7 186:7 187:12,13 188:11,15,17 195:14 202:10 206:21 vitamins 170:18 175:10 vocal 270:8 volume 36:4 47:22 149:19 166:19 168:9 168:13 171:11 172:22 174:13 175:19 176:19 177:14 W waist 27:20,21 wait 139:15 waiting 79:7 waking 97:17 walking 66:10 wanted 52:7 56:22 88:11,17 90:9 93:20 95:6 96:13 100:1 107:10 111:14 112:20 119:22 135:12 137:11 154:1 164:14 179:14 182:8 203:14 270:6 wants 197:16 warn 167:18 Washington 1:10 7:13 wasn't 50:4 107:2,19

109:4 201:4 239:9 258:22 wasting 68:19 watching 8:14 209:22 water 37:2,5 102:14,15 102:17,21 103:2,8,10 128:14 129:7 130:9

130:18.22 131:14 132:16 133:5,9,14 134:9 170:19,20 192:14,22 193:2,12 194:3,6,9,10 195:5,10 195:22 196:7,9 198:17 216:18 217:11 217:13,15,18,20,21 262:19 water-based 170:19 waves 34:12 105:6 way 8:1 10:20 43:11 46:15 53:15 56:1 61:5 80:4 89:4 94:4 110:22 125:11 127:3 128:20 136:20 198:15 212:13 213:8 261:22 264:7 272:5 273:20 ways 54:7 79:18 80:8 91:17 92:18 110:22 112:18 113:12 129:2 129:12 132:18 178:12 192:18 209:22 weakness 66:8 web 1:11 168:3 275:18 website 17:20 36:15 275:20 Wednesday 1:5 19:19 weeds 199:2 week 97:1 108:13 121:15 257:10 weekend 97:2 weekly 75:8 96:22 159:10 weeks 95:13 196:1 223:8,13 231:18 weigh 57:3,5 weight 16:22 26:13,13 26:16 68:15,16,20 96:8,9 115:14,16,20 116:1,3,4,13,13,18 117:3,5,5,7,8,9,13 120:12 122:7,8 138:3 138:4 141:7,7 142:9 142:11,19 143:11,21 143:22 144:5,12,19 145:4,4 158:13,13 162:7 164:1 174:8 211:21,22 212:3,19 212:20,22 214:5,7,9 214:10,12 217:19 221:3,6,13,15,15 222:4,8,10,12,12,17 223:11 224:3,5,15 225:7,12 226:19,22 229:11,13,16 234:3 242:15 246:17 267:6 267:7 271:2

weight-related 223:10 weights 22:1 weird 107:5 welcome 3:8 4:11 8:10 275:12 went 89:16 90:6 105:7 111:3 125:20 139:6 208:11 210:4 223:15 274:10 276:16 wheeze 177:6 180:11 whispering 49:10 who've 16:15 whoops 115:12,15 213:5 225:21 WIC 45:19 wide 77:12 86:18 190:5 widely 204:20 width 149:20 wine 37:6 Wing 4:7,7 woman 116:13 117:17 221:8,19,19 woman's 117:9 214:12 women 22:22 29:13 33:6 34:22 35:6 45:20 46:1.2 53:5.6 115:19 116:6.19.21.22 120:14 124:4 144:7 144:14,15 145:21,22 146:16 147:10,11 156:21 160:16,19 162:5 214:7,7 224:12 224:16 227:3,8 wonder 57:15 122:4,5 193:12 207:20 261:13 264:15 wondered 122:13,18 207:18 wonderful 26:8 139:3 159:8 233:18 270:16 wondering 44:21 84:9 84:16 102:14 197:8 woohoo 55:4 word 215:21 word-for-word 182:7 words 31:8 83:17 214:11 237:18 266:17 266:18 work 8:1,22 9:2,12 10:17,22 14:9 18:14 19:1,22 20:4 21:11 39:19 40:18 43:17 47:8 52:9 53:8 60:15 61:5 94:18 110:6 112:5,8 159:3,18 161:1,14 191:14,16 192:2,5 206:8 214:3 232:6 246:9 251:1

257:3,11,14 258:5 264:22 274:3,9,19 275:6,16 276:14 worked 14:3 212:7 workers 123:2 working 10:10 20:13,16 22:15 30:9 34:2 48:17 49:18 51:19 66:3 87:22 95:14 120:2 159:9 191:10 192:4 228:4 257:9 273:19 works 119:8 World 170:15 194:5 worldwide 196:18 worms 76:1 worth 213:11 worthwhile 82:19 wouldn't 51:16 87:15 127:10 162:4,15 191:19 199:10 227:10 228:1,17 231:4 266:18 wrestled 84:6 write 56:2 wrong 61:4 227:18 Х Y vear 6:13 30:2 44:7.7 45:10 52:22 53:7 101:22 178:20 years 6:18 21:13 25:2 26:20 29:22 30:3 34:10,11,17,18 38:15 44:17 104:21 105:18 105:18 108:13 158:1 161:2 162:10 177:3 180:5 190:17 204:6 205:16 242:16 246:5 248:1,2 252:21,22 253:15 254:18 yesterday 99:3 121:9 yielding 129:9 young 170:2 younger 44:5 Ζ zero 204:6 239:16 zinc 34:15 35:4 175:9 184:3 0 **04** 37:12 1 1,000 3:10 **1.5** 251:2

1:02 139:7 **10** 1:5 33:15 272:18 **100** 36:16 88:5 240:8 **11:40** 139:6 **11:45** 91:11 94:12 **12** 182:5 190:17 12:30 3:15 13 54:1 92:21 **140** 2:10 1400 1:9 **15** 84:3 108:22 128:3 272:18 15/'16 25:13 166 2:11 **18** 42:13 44:7 158:1 206:1 246:5 247:22 252:21 19 22:20 26:21 34:18 44:7 46:21 19-plus 252:22 19-year-old 44:10 1950s 105:9 **1980** 74:4,16 154:2 178:16,19,20 179:3 **1994** 182:15 2 **2** 1:6 22:20 26:21 27:15 28:10 49:6 62:19 70:2 70:5.8 73:10 74:13 84:3,5,12,13,16,18 85:11,13,15,20 96:10 118:17,19 128:14 212:17 248:2 253:15 254:18 2-year-old 44:9 **2:21** 210:4 2:30 209:17 2:45 210:2 2:47 210:5 20 2:5 4:10 22:20 35:1 43:2 44:17,21 45:17 88:4 159:2 2000 73:20 104:15 105:1 106:2,7 154:2 223:5 2000s 105:22 2003 34:18 37:12 2006 34:18 2007/'08 27:8 2009 214:8 2009/'10 25:13 2012 251:2 **2013** 25:3 27:13 28:12 29:1 74:14 2013/'14 35:5 2014 74:3,5,16 2015 35:20 39:17

	1
148:16	6 34:18
2015-2020 244:14	60 2:7 43:2.20
2015/'16 25:1 27:8	64 22:20
37.12	65 22:21 43:2 20
2015/16 24.21	
2015/2020 33:14	7
2016 25:3 26:10 27:13	7 20·17
28.12 29.1 10	7 000 19.15
2017 26:4 6 28:20 89:17	700 3.12
141.3	70s 105:11
2019 1:5 73:21 74:3 14	71 43·20
151.11 223.6	11 10.20
2020 1 1 3 7 4 20 6 15	8
6.19 7.5 61.13 70.22	8 2.4 45.10
210 2.13	8·30 3·15 276·7
24 2.11 10.7 18.9 26.11	0.00 0.10 27 0.7
39.20 42.19 65.6 67.3	9
68.6 69.4 89.15	9.00 1.10 3.14 276.8
140.21 165.22 166.5	9.01 3.2
181.17 183.5 19	90s 105·12
184.15 185.19 190.22	94 2·8
191.12 192.3 195.7	VT 2.0
197.19 205.12 226.13	
267.22	
24- 108:5	
24-hour 97.17 121.11	
121.19 125.11	
243 2:15	
24th 19:19 275:12.14	
25 34·16 202·11	
25 34:16 202:11 257 2:17	
25 34:16 202:11 257 2:17 276 2:19	
25 34:16 202:11 257 2:17 276 2:19	
25 34:16 202:11 257 2:17 276 2:19 3	
25 34:16 202:11 257 2:17 276 2:19 3 3 4:7 24:16 49:9 128:14	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11	
25 34:16 202:11 257 2:17 276 2:19 3 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9	
25 34:16 202:11 257 2:17 276 2:19 3 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 .	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 42:2 7:11,13	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 2:2 7:11,13 4:13 276:16	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17 36:20,22	
25 34:16 202:11 257 2:17 276 2:19 3 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17 36:20,22 45 18:1 71:22	
25 34:16 202:11 257 2:17 276 2:19 3 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17 36:20,22 45 18:1 71:22 48 121:14	
25 34:16 202:11 257 2:17 276 2:19 3 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 42:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17 36:20,22 45 18:1 71:22 48 121:14 49 35:1	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17 36:20,22 45 18:1 71:22 48 121:14 49 35:1	
$\begin{array}{r} \textbf{25} 34:16\ 202:11\\ \textbf{257}\ 2:17\\ \textbf{276}\ 2:19\\ \hline \\ \hline \textbf{3}\\ \textbf{3}\ 4:7\ 24:16\ 49:9\ 128:14\\ 256:7\\ \textbf{30}\ 109:1\ 141:21\ 179:7\\ 179:11\\ \textbf{300}\ 3:11\\ \textbf{35}\ 17:6\ 72:2\\ \textbf{3s}\ 163:9\\ \hline \\ \hline \textbf{4}\\ \textbf{4}\ 2:2\ 7:11,13\\ \textbf{4:13}\ 276:16\\ \textbf{4:30}\ 3:15\\ \textbf{40}\ 11:21\ 17:6\ 19:17\\ 36:20,22\\ \textbf{45}\ 18:1\ 71:22\\ \textbf{48}\ 121:14\\ \textbf{49}\ 35:1\\ \hline \\ \hline \textbf{5}\\ \hline \textbf{5}\ \textbf{47}\ 07.5\\ \hline \end{array}$	
$\begin{array}{r} \textbf{25} 34:16\ 202:11\\ \textbf{257}\ 2:17\\ \textbf{276}\ 2:19\\ \hline \\ \textbf{3} \ 4:7\ 24:16\ 49:9\ 128:14\\ 256:7\\ \textbf{30}\ 109:1\ 141:21\ 179:7\\ 179:11\\ \textbf{300}\ 3:11\\ \textbf{35}\ 17:6\ 72:2\\ \textbf{3s}\ 163:9\\ \hline \\ \textbf{4} \ 2:2\ 7:11,13\\ \textbf{4:13}\ 276:16\\ \textbf{4:30}\ 3:15\\ \textbf{40}\ 11:21\ 17:6\ 19:17\\ 36:20,22\\ \textbf{45}\ 18:1\ 71:22\\ \textbf{48}\ 121:14\\ \textbf{49}\ 35:1\\ \hline \\ \textbf{5} \ \textbf{5}\ 4:7\ 37:4\\ \hline \\ \textbf{5}\ 4:1\ 4:12\\ \textbf{5}\ 16:1\ 4:12\ 16:1\ 4:12\ 4:1$	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17 36:20,22 45 18:1 71:22 48 121:14 49 35:1 5 5 4:7 37:4 50 104:21 105:18,18 20212	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17 36:20,22 45 18:1 71:22 48 121:14 49 35:1 5 5 4:7 37:4 50 104:21 105:18,18 239:18	
25 34:16 202:11 257 2:17 276 2:19 3 4:7 24:16 49:9 128:14 256:7 30 109:1 141:21 179:7 179:11 300 3:11 35 17:6 72:2 3s 163:9 4 4 2:2 7:11,13 4:13 276:16 4:30 3:15 40 11:21 17:6 19:17 36:20,22 45 18:1 71:22 48 121:14 49 35:1 5 5 4:7 37:4 50 104:21 105:18,18 239:18 6	
$\begin{array}{r} \textbf{25}\ 34:16\ 202:11\\ \textbf{257}\ 2:17\\ \textbf{276}\ 2:19\\ \hline \textbf{3}\\ \textbf{3}\ 4:7\ 24:16\ 49:9\ 128:14\\ 256:7\\ \textbf{30}\ 109:1\ 141:21\ 179:7\\ 179:11\\ \textbf{300}\ 3:11\\ \textbf{35}\ 17:6\ 72:2\\ \textbf{3s}\ 163:9\\ \hline \textbf{4}\\ \textbf{4}\ 2:2\ 7:11,13\\ \textbf{4}:13\ 276:16\\ \textbf{4}:30\ 3:15\\ \textbf{40}\ 11:21\ 17:6\ 19:17\\ 36:20,22\\ \textbf{45}\ 18:1\ 71:22\\ \textbf{48}\ 121:14\\ \textbf{49}\ 35:1\\ \hline \textbf{50}\ 104:21\ 105:18,18\\ 239:18\\ \hline \textbf{6}\\ \hline \end{array}$	

CERTIFICATE

This is to certify that the foregoing transcript

In the matter of: 2020 Dietary Guidelines Advisory Committee Meeting

Before: USDA

Date: 07-10-19

Place: Washington, DC

was duly recorded and accurately transcribed under my direction; further, that said transcript is a true and accurate record of the proceedings.

near A ans f

Court Reporter

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

www.nealrgross.com

(202) 234-4433